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Abstract 
This research explored in-vitro and in-vivo performance of three salbutamol metered dose 
inhalers (MDIs): Ventolin Evohaler (Evo), Airomir (Airo) and Salamol. In the in-vitro studies, 
critical quality attributes of the MDI using an Andersen cascade impactor (ACI) were examined 
and included measurement of fine particle dose (FPD) and total delivered dose (TDD). 
Bioequivalence studies were conducted in humans using the urinary pharmacokinetic method. 
Post-inhalation urinary excretion of salbutamol in the first 0.5 hour (lung deposition, USAL0.5) 
and over 24 hours (total systemic bioavailability, USAL24) were compared to determine the 
bioequivalence of the MDIs. The spacers recommended for use with these inhalers were also 
studied, and charcoal block studies were performed to assess the extent of USAL0.5. 
The three MDIs had FPD (µg) of 78, 91 and 89, respectively; the latter pair was equivalent. 
Their USAL0.5 (6, 7 & 7 µg) was however not bioequivalent. These MDIs delivered equivalent 
dose (177, 174 & 180 µg) which reflected on their USAL24 (101, 84 & 97 µg). Nevertheless, 
USAL24 was inequivalent between Evo and Airo. 
The FPD of Evo with Volumatic (VOL), AeroChamber Plus (AERO) and Able spacer was 78, 
68 and 74 µg, respectively. The AERO treatment method was not equivalent to the MDI while 
VOL and Able were equivalent between them. Spacer USAL0.5 (16, 15 & 14 µg) was not 
bioequivalent to the MDI but to each other. The spacer in-vitro TDD (95, 85 & 92 µg) was 
inequivalent to the MDI treatment method. In contrast, their USAL24 was bioequivalent (97, 85 
& 90 µg). 
The FPD of Airomir with AERO (95 µg) was in-vitro equivalent while USAL0.5 (15 µg) of this 
treatment method was bio-inequivalent to the MDI alone. On the contrary, the TDD (110 µg) 
and USAL24 (84 µg) of AERO were respectively in-vitro inequivalent and bioequivalent to the 
MDI alone.  
The FPD (µg) of Salamol MDI alone and with VOL (84) and AERO (86) as well as between the 
spacers was equivalent. However, the USAL0.5 of the MDI was not bioequivalent to spacers 
(20 and 18 µg) despite being equivalent between the spacers. In contrast, the respective TDD 
(103 and 95 µg) of spacer treatment methods were in-vitro inequivalent to the MDI alone albeit 
having bioequivalent USAL24 (86 and 87 µg). 
The variations in the in-vitro performance of the three MDIs are most likely due to differences 
in their formulations and designs. As the performance metrics of the MDI influence lung 
deposition, substituting one MDI with another can have clinical implications. 
Although the spacers reduced in-vitro TDD of the MDI to about half, their use increased lung 
deposition by over two folds, the magnitude of which varied with the MDI and spacer type. 
Despite significant decrease in dose delivery, the total systemic bioavailability with the spacers 
was similar to that with the MDI alone. This systemic bioequivalence is more likely due to 
greater USAL0.5 with the spacers. The results of the charcoal block studies reinforced this 
outcome. 
The present study is unique as it used a clinically relevant salbutamol MDI dose (two puffs), 
assessed results for equivalence and analysed ACI deposition data further as stage groups. The 
deposition on adjacent ACI stages were grouped together as coarse, fine and extra-fine particle 
masses to identify their more likely deposition sites in the human respiratory tract. Moreover, 
this thesis describes highly sensitive and novel HPLC and SPE methods, developed and 
validated to quantify salbutamol in urinary and aqueous matrices. 
As the clinical effects of MDIs are related to their lung deposition, the current work emphasizes 
the importance of spacer use. Nevertheless, differences in dose delivery between spacers may 
have clinical consequences. Hence, only the specific spacer recommended for use with the MDI 
should be used. 
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1 Chapter 1: Introduction 
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1.1 Overview 
Inhaled drug delivery is the mainstay of managing respiratory ailments such as asthma 
and COPD. The inhalation route is a fast and effective way of delivering drugs to the 
site of action for a localised effect which leads to a rapid clinical response, particularly 
for inhaled β-agonist therapy (Dolovich and Dhand, 2011; Cheng, 2014; Lavorini et al., 
2014; Bonini and Usmani, 2015; Lewis, 2015; Ivey et al., 2015). This route of drug 
administration enables delivery of low doses directly to the airways which minimises 
systemic side-effects while also avoiding the first-pass metabolism with minimum 
reduction of bioavailability. The large surface area and highly permeable air-to-blood 
barrier of the respiratory system make it a highly receptive site for drug delivery 
(Demoly et al., 2014). 
Respiratory drug delivery can be achieved by a number of devices such as Metered 
Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), Soft Mist Inhalers (SMIs) and 
nebulisers. These methods of delivery are diversifying with technological development 
and changing patients’ needs. The MDI has been in use for 60 years and presently 
represents the most common method of drug delivery to the lungs (Ivey et al., 2015). 
The clinical effects of an asthma treatment have been shown to be directly correlated 
with the drug’s lung deposition (Newman, 2000). Pulmonary drug deposition of an 
inhaled drug is influenced by the aerodynamic particle size distribution of the emitted 
aerosol (Seale and Harrison, 1998; Darquenne, 2012). Therefore, in-vitro measurements 
of critical performance parameters of an MDI will reflect on the likely success of drug 
delivery and targeted deposition (Lewis, 2015). These include assessing the total 
quantity of drug emitted from the MDI and therefore available to the patient, and the 
respirable dose and aerodynamic size of the particles that make up the emitted aerosol. 
These performance metrics impact the proportion of the total dose that reaches the lungs 
during inhalation, along with its regional intrapulmonary deposition, and hence clinical 
effects. 
These in-vitro MDI performance metrics are measured using cascade impactors such as 
ACI (Mitchell et al., 2007). These equipments simulate particle deposition in the human 
airways (BP, 2005; USP28-NF23, 2005; Ph. Eur, 2011; Cheng, 2014) (Figure 2.3.1). 
They provide information on how formulation and device variables affect MDI 
performance besides estimating its dose delivery efficiency. Hence, ACI has been used  
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in this research project to evaluate and compare in-vitro performance of salbutamol 
HFA MDIs.  
Spacer used with an MDI assists patients in circumventing the problem of coordination 
in press and breathe manoeuvres of the discharged dose. Hence, the effects of this 
treatment method on the performance metrics of salbutamol MDIs will also be explored.  
Lung deposition and total systemic bioavailability of salbutamol MDIs can be 
effectively determined and compared with urinary pharmacokinetic (PK) studies in 
healthy volunteers (EMA, 2009 & 2010). The method developed by Hindle and 
Chrystyn (1992) will be used for this purpose (see Chapter 3 Methodology). Each study 
is complemented by charcoal blockade element to identify the proportion of the dose 
delivered to the lungs. 
Regulatory authorities require that in-vitro studies are to be carried out to assess any 
claims of equivalence between MDIs. These authorities recommend using cascade 
impactors to identify similarity in their performance metrics. If these MDIs are not 
found in-vitro equivalent, EMA (2006, 2009) allows proving equivalence in PK studies. 
Nevertheless, both in-vitro and in-vivo equivalence studies will be carried out in this 
project to explore if their outcomes are co-related. 
1.2  Aims and objectives 
1.2.1 Aims 
 To evaluate in-vitro and in-vivo equivalence of salbutamol HFA MDIs without and 
with spacer. 
1.2.2 Objectives 
I. To develop and validate HPLC methods for the determination of salbutamol in 
aqueous samples collected from in-vitro studies with ACI and in human urine 
samples collected following inhalation. 
II. To undertake in-vitro characterisation of salbutamol HFA MDIs using ACI. 
III. To investigate the relative lung and total systemic bioavailability of salbutamol 
HFA MDIs in healthy volunteers using urinary pharmacokinetics. 
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1.2.3 Framework 
The aims and objectives of the research will be achieved in three parts (Figure 1.3.1): 
I. Analytical Method Development and Validation 
a. To develop and validate efficient, robust and reliable solid phase extraction 
(SPE) methods for the separation and concentration of unhydrolysed and 
hydrolysed salbutamol from human urine samples collected post-inhalation. 
b. To develop and validate a sensitive and robust HPLC method for quantifying 
salbutamol in aqueous samples collected from in-vitro studies with ACI and 
residual dose in the MDI components and spacers following administrations to 
human subjects. 
II. Determination of In-Vitro Equivalence 
a. This study will have two components- 
(i) In-vitro characterisation of salbutamol HFA MDIs used alone. MDIs 
included in this study are Ventolin Evohaler
®
, Airomir
®
 and Salamol
®
. 
(ii) In-vitro characterisation of salbutamol HFA MDIs used with spacer. The 
spacers selected for this project are Volumatic, AeroChamber Plus and 
Able spacer. 
III. Determination of Bioequivalence 
These studies will have two components, each of which will have two parts- 
a. Determination of bioavailability of salbutamol MDIs used alone. 
b. Determination of bioavailability of salbutamol MDIs used with spacers. 
(ii)  
 
1.3 Thesis Structure 
This introductory chapter is followed by review of previous work and, current and 
ongoing issues related to this research project in Chapter 2. The rationale for 
methodological approach is highlighted and discussed in Chapter 3. 
Development and validation of HPLC and SPE methods have been described in Chapter 
4. 
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The in-vitro and in-vivo equivalence studies have been put together for each treatment 
method evaluated in this project. Hence, these equivalence studies for salbutamol MDI 
alone, Ventolin Evohaler without and with spacers, Airomir without and with spacer 
and Salamol without and with spacers have been separately explored in Chapters 5, 6, 7 
and 8, respectively. 
General discussion and overall conclusions drawn from this project and direction for 
future work are included in Chapter 9. 
The organogram of the thesis is shown in Figure 1.3.1. 
 
 
Figure 1.3.1. Thesis structure. 
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2.1 Overview 
Asthma and COPD are amongst the most prevalent respiratory diseases (GINA, 2017; 
GOLD, 2018). Inhalation therapy is the mainstay of providing relief from these ailments 
(NICE, 2010 & 2017). The pulmonary route allows drug delivery directly to their target 
sites which can result in a rapid onset of their activity. This is highly desirable, for 
instance when delivering bronchodilators for the treatment of asthma. Additionally, this 
localised delivery minimises systemic exposure and, thus, potential side-effects (Roche 
et al., 2013). This targeted drug delivery is achieved by a number of inhalation devices 
which include inhalers and nebulisers. Selective β2 agonists and corticosteroids are the 
cornerstone of treatment for these diseases. MDI remains the delivery device of choice 
(Lavorini et al., 2011), and salbutamol is the most widely prescribed β2 agonist (GINA, 
2017).  
MDIs originally contained chloroflourocarbons (CFCs) as propellants. However, due to 
their deleterious effects on the ozone layer (Molina and Rowland, 1974), these were 
gradually replaced with hydrofluoroalkane (HFA) propellants in compliance to the 
Montreal Protocol (UNEP, 2017). Pharma industry faced great challenges during this 
phase-out period (Smith, 1995; Atkins, 1999; Bowman and Greenleaf, 1999; 
Cummings, 1999) which incurred significant investment in research and development 
(Leach, 2005; Stein and Thiel, 2017). Nevertheless, this was in disguise an opportunity 
to develop and modify MDI device components and reformulate drugs in HFA 
propellants. 
Many patients have difficulty in coordinating MDI actuation with inhalation which can 
be overcome with a spacer. Nonetheless, the combination of MDI with a spacer 
produces a different and new dose delivery system, the efficiency of which is likely to 
be determined by the characteristics of its component two devices. It has been shown 
that the delivery of MDI dose is governed by device design and formulation (Ross and 
Gabrio, 1999; Gabrio et al., 1999, Cripps et al., 2000; Stein et al., 2014; Myrdal et al., 
2014) and spacer characteristics, such as geometry, volume and construction material, 
can significantly influence this (Barry and O’Callaghan, 1995a, 1996 & 1997; Lipworth 
and Clark, 1998a; Mitchell et al., 1999; Rau et al., 2006; Oliveira et al., 2015 & 2016). 
Therefore, the technologically modified and reformulated salbutamol HFA MDIs are 
likely to have intrinsically varied drug delivery to the lungs when used alone or with a 
spacer. Most of the previous in-vitro and in-vivo studies compared salbutamol HFA  
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MDIs to those of CFC MDIs during their transition period. Later in-vitro studies were 
conducted to assess the suitability of marketed spacers for salbutamol HFA MDIs 
(Mitchell et al., 1999; Hatley et al., 2014; Slator et al., 2014; Johnson et al., 2016) or to 
explore their plume characteristics (Brambilla et al., 2011; McCabe et al., 2012; 
Hautmann et al., 2013; Kunda et al., 2017). The present work focuses on three 
differently formulated and designed salbutamol HFA MDIs, vis-à-vis: Ventolin 
Evohaler
®
, Airomir
®
 and Salamol
®
 (Table 2.2.1). To the knowledge of this author, these 
HFA MDIs have not been compared in-vitro with each other independently, in 
particular with spacers, and that studies on these MDIs have not been complemented by 
in-vivo studies. Nevertheless, in-vitro studies for HFA MDIs alone and with a cardboard 
spacer have recently been reported by Johnson et al. (2016). 
In this chapter, a brief backgrounder is followed up with a review of in-vitro studies on 
salbutamol HFA MDIs. While these studies encompass broad areas, primary focus 
remains on salbutamol HFA MDI when used alone and with a spacer. Further, review of 
in-vitro studies centres on particle size characterisation using Andersen Cascade 
Impactor (ACI) and Next Generation Impactor (NGI) due to their similarity with each 
other (Mitchell et al., 2003; Kamiya et al., 2004) and because ACI will be used in this 
project. In-vivo pharmacokinetic studies have been reviewed in Chapter 3 
(Methodology). An overview of literature on HPLC and SPE method development for 
salbutamol quantitation in urine post-inhalation has been provided in Chapter 4. 
2.2 The Rejuvenated MDI 
The MDI has now been available for over 60 years. The technology has evolved 
significantly over these years particularly since transition from CFC to HFA containing 
formulations. However, this transition was not straightforward as HFAs could not 
directly replace CFC propellants due to incompatibility of HFA formulations with 
previously used excipients and MDI device components (Myrdal et al., 2014). As a 
result, significant efforts were put to develop new device components which were 
complemented with varying formulation approaches. Notable modifications to the MDI 
device components ( 
Figure 2.2.1) included development of new elastomers, redesigned valves, changes in 
nozzle diameter and metered dose volume, coated canisters and actuator (Leach, 2005; 
Bell and Newman, 2007; Roche and Dekhuijzen, 2016; Stein and Thiel, 2017). 
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Two general approaches were applied for CFC to HFA transition vis-à-vis: to reproduce 
the similar dose delivery characteristics of the original MDI or to overhaul the existing 
ones (Table 2.2.1). The first approach is mirrored in the preservation of Ventolin CFC 
characteristics into Ventolin Evohaler to give patients the same feel of their ongoing 
salbutamol treatment (Cripps et al., 2000). This approach was extended to salmeterol 
xinafoate (Seretide Evohaler) (Peyron et al., 2005) and fluticasone propionate (Flixotide 
Evohaler) (Gabrio et al., 1999). The second approach metamorphosed salbutamol CFC 
MDI into Airomir (Ross and Gabrio, 1999; Gabrio et al., 1999). Nevertheless, during 
this transition to HFA MDIs, the aim was to provide similar drug delivery and 
demonstrate their comparability in efficacy and safety with their predecessor CFC MDIs 
in simple clinical trials to limit expenses (Cipolla et al., 2010). 
 
 
Figure 2.2.1. Schematics of an MDI. 
Adapted from Ivey et al. (2014). 
 
Table 2.2.1. Formulation and device design of salbutamol HFA MDIs. 
Modifications 
Ventolin Evohaler 
(Ventolin HFA) 
Airomir (Proventil HFA) 
ProAir, Salamol 
(HFA) 
Formulation 
HFA 134a Yes Yes Yes 
Ethanol No Yes Yes 
Oleic Acid No Yes No 
Device Design 
Actuator Mouthpiece Rectangular (oval) Round Rectangular (oval) 
Actuator orifice 
diameter 
0.50 mm
a
 0.25 mm
b
 - 
Metered dose volume 63 µL
a
 25 µL
c
 25 µL
d
 
a 
Brambilla et al., 2011; 
b 
Cheng et al., 2001 and Kunda et al., 2017;
 c
 Ross and Gabrio, 1999;
 d
 Salamol 
PIL (Teva, 2015) 
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2.3 Aerosol Particle Deposition Dynamics and Clinical Effects-ACI Vs 
HRT 
Drug delivery characteristics of an MDI are assessed with cascade impactors which 
include widely recommended ACI, NGI and Multi-Stage Liquid Impinger (MSLI) (BP, 
2005; USP28-NF23, 2005; Ph. Eur., 2011). ACI (Mark II) consists of a stack of eight 
stages attached to an Induction Port and mimics human respiratory tract (HRT) (Figure 
2.3.1). Each succeeding stage has increasing number of nozzle jets with progressively 
decreasing diameter, and a collection plate underneath (and the back-up filter to the last 
stage). When an aerosol is drawn with the air through the equipment (Figure 2.3.2), the 
impaction of progressively smaller particles occurs in the succeeding stages due to 
differences in inertia - a function of particle aerodynamic diameter and velocity. The 
velocity increases as particles travel through the impactor resulting in increased particle 
inertia (Mitchell and Nagel, 2003). At an airflow rate of 28.3 L/min, the particle 
fractionation ranges from >10.0 to 0.4 µm diameter. Particles <0.4 µm are collected on 
the backup filter. The impactor separates the discharged dose from an inhaler (the total 
emitted dose (TED)) into defined size fractions deposited onto individual stages, which 
are then quantified to generate Aerodynamic Particle Size Distribution (APSD) profile. 
The APSD is characterised by attributes such as mass median aerodynamic diameter 
(MMAD) and geometric standard deviation (GSD) (Newman and Chan, 2008; Stein et 
al., 2014; Myrdal et al., 2014). Within APSD, the Fine Particle Dose (FPD) consists of 
particle having aerodynamic diameter <5 µm (EMA, 2006). TED, APSD and FPD of an 
MDI are its Critical Quality Attributes (CQA) (ICH-Q8(R2), 2009) and key factors 
affecting its functionality (Sandell and Mitchell, 2015). 
Researchers have shown that aerodynamic particle diameter determines deposition in 
the HRT (Hickey et al., 1996; Howarth, 2001; Pritchard, 2001; Mobley and Hochhaus, 
2001; Heyder, 2004; Newman and Chan, 2008). APSD governs pulmonary drug 
deposition (Darquenne, 2012) and the dose deposited in lungs has been found to be 
correlated to clinical effects (Laube, 1996; Newman, 1998, 2000). FPD represents the 
amount of the drug that is considered respirable (Chrystyn et al., 2015). Both FPD and 
APSD are critical in-vitro performance metrics (Stein et al., 2014; Myrdal et al., 2014) 
that are linked to the efficacy and safety (Clark and Lipworth, 1996a & b; Lipworth, 
1996; Newman, 1998, 2000; Newman et al., 2000; Weda et al., 2002 & 2004; Usmani et 
al., 2003 & 2005; Usmani, 2008; Moore et al., 2017). These studies emphasize that  
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aerodynamic particle size appropriately describes particle dynamics within the HRT. 
 
Figure 2.3.1. Schematic comparison of ACI and Human Respiratory Tract. 
Adapted and modified from: ACI user manual 1985; Rudolf et al., 1994; Gulak et al., 2009; Ph. 
Eur. 7.0, 2010; Hussain et al., 2011; Cheng, 2014; https://basicmedicalkey.com/pulmonary/. 
Accessed 27 Dec 2017. 
 
 
Figure 2.3.2. Schematics of impaction mechanism in ACI. 
Adapted and modified from USP 34-NF 29, 2010; Hickey et al., 1996; Hinds, 
W.C., 1999; Nagao et al., 2005; Mostafa et al., 2015; Elmes and Gasparon, 
2017. 
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The deposition of inhaled drug particles in the HRT takes place by three principal 
mechanisms (Figure 2.3.3): inertial impaction, gravitational sedimentation and 
Brownian diffusion (Newman et al., 1982; Schulz, 1998; Hinds, 1999; Zeng et al., 2001; 
Carvalho et al., 2011; Darquenne, 2012; Tena and Clarà, 2012). Deposition by 
impaction mainly occurs in the first 10 bronchial generations representing the upper 
airway (oropharynx, larynx), large, more central, conducting airways and at airway 
bifurcations (Figure 2.3.1 and Figure 2.3.3). The air velocities are relatively high in 
these airways and the swift changes in flow direction leads to aerosol particle 
deposition. Deposition by sedimentation predominates in the last 5 bronchial 
generations representing the small airways (smaller bronchi and bronchioles) and 
alveolar regions. Deposition by diffusion primarily takes place in the lung periphery and 
alveoli, where the airway dimensions are small and air velocities are low. In general, 
larger drug particles (>10 μm) deposit in the oropharynx, particles of >5 μm in the 
central airways and particles of 1–5 μm in the small airways and alveoli. Deposition by 
impaction and sedimentation increases with increasing particle size. In contrast, 
deposition by Brownian diffusion increases with decreasing particle size and therefore 
particles <0.5 μm in diameter mainly deposit by this mechanism. Nevertheless, any 
particles that remain airborne during the respiratory cycle are exhaled, and this occurs 
most frequently with very small particles (<0.5 μm) (Zeng et al., 2001). However, 
deposition of inhaled particles can be enhanced by breath holding which is regarded as 
one of the critical steps of inhalation from an MDI (Section 3.4.4). 
Deposition of particles in ACI occurs mainly by inertial impaction under constant 
airflow (Figure 2.3.2). In HRT (Figure 2.3.3), where the respiratory cycle produces 
continuously varying airflow, the movement of drug particles in the size range of 
interest 0.5-10 μm is largely influenced by inertia, to a lesser extent by gravitational 
sedimentation and least by diffusion (Rudolf et al., 1990).  
During inhalation ( 
Figure 2.3.4), the TED of an inhaler is either deposited into the airways or impacts onto 
the oropharyngeal region and is swallowed (Chrystyn, 2001; Sakagami, 2006; Laube et 
al., 2011; Chrystyn et al., 2015). A small fraction of the drug that is deposited into the 
airways is removed by mucociliary clearance and is also swallowed. The swallowed and 
inhaled portions of the emitted dose reach the systemic  
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Figure 2.3.3. Schematics of inhaled drug deposition mechanisms in HRT. 
Adapted and modified from: Chrystyn, 1999; Carvalho et al., 2011; Hussain et al., 2011; 
Demoly et al., 2014; http://bronchiectasis.com.au/wp-content/uploads/2015/09/Particle-
size.png. Accessed 03 Jan 2018. 
 
circulation through the gastrointestinal and pulmonary routes, respectively. The APSD 
of the drug, measured in-vitro with a cascade impactor, provides an insight into the 
amount of drug that will impact onto the oropharyngeal region and the distribution of 
the inhaled fraction in the lungs which includes the FPD. Thus, the information obtained 
from the APSD profile may predict the likely deposition of the drug particles in the 
HRT (Newman, 1998). The TED, being a surrogate marker for systemic delivery is 
therefore considered an indicator of systemic safety, while the FPD and its distribution 
depict lung deposition, hence regarded as a marker for efficacy (Labiris and Dolovich, 
2003; Tena and Clarà, 2012; Chrystyn et al., 2015). Thus, in-vitro data can be helpful in 
estimating the efficacy and safety of inhaled drugs (Olsson et al., 1996; Newman, 2000; 
Howarth, 2001; Weda et al., 2004; Usmani et al., 2003 & 2005; Usmani, 2008). Further, 
these in-vitro metrics have also been shown to predict pharmacokinetic (PK) and 
pharmacodynamics (PD) outcomes (Hindle and Chrystyn, 1992; Chrystyn et al., 1998; 
Chrytyn, 2001; Tomlinson et al., 2003; Mazhar et al., 2008; Mazhar and Chrystyn, 
2008; Abdulrahim et al., 2011; Moore et al., 2017). Hence, both in-vitro and in-vivo 
studies have been carried out in this project to investigate the presence or absence of 
this link between them for salbutamol HFA MDIs.   
 14 
 
 
 
Figure 2.3.4. Fate of inhaled drugs in humans. 
Adapted and modified from: Newman, 2000; Chrystyn, 2001; Derendorf et al., 2006; Hochhaus 
et al., 2015; de Pablo et al., 2017. 
 
2.4 Spacer (Valved Holding Chamber) 
Spacer is a chambered add-on device for an MDI which receives the emitted dose to be 
inhaled (Figure 2.4.1). Spacer use helps patient overcome problems of poor 
coordination between actuation and inhalation (Lavorini and Fontana, 2009; Dolovich 
and Dhand, 2011; Nikander et al., 2014). It also retains the ballistic portion of the 
emitted dose containing large non-respirable particles (>5 µm) thereby significantly 
reducing the oropharyngeal deposition and local side-effects. The total amount of drug 
that reaches the patient is also reduced. 
Spacers are available in different sizes, volumes, shapes and designs with varying 
construction material (Hess, 2008; Nikander et al., 2014) and therefore differ in their  
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drug delivery characteristics (Barry and O’Callaghan, 1995a, 1996 & 1997; Newman, 
2004). Large volume spacers provide for greater lung deposition than those with small 
volumes which may affect the amount of drug available for inhalation (Newman and 
Newhouse, 1996; Barry and O’Callaghan, 1996; Lipworth and Clark, 1998). However, 
this varies with drug type and characteristics (Barry and O’Callaghan, 1996). 
Even though spacer allows for few seconds to inhale the discharged dose into it 
(Dolovich et al., 2000), however, it has also been shown that inhalation should take 
place immediately (Barry et al., 1993). This is because the delayed inhalation may cause 
the emitted particles to deposit on spacer walls under gravitation and/or electrostatic 
pull (Wildhaber et al., 1996a; Newman, 2004; Rau, 2006; Rau et al., 2006; Lavorini and 
Fontana, 2009; Slator et al., 2014; Nikander et al., 2014). If not inhaled immediately, 
the suspended emitted dose particles remain susceptible to the gravitation force and are 
also under sustained electrostatic attraction from the spacer walls. Study by Clark and 
Lipworth (1996a) further substantiates this wherein they observed a two-fold decrease 
in plasma levels of salbutamol (Ventolin CFC) in healthy subjects following a delay in 
inhalation compared to no delay. Moreover, patient information leaflets (PIL) of 
salbutamol MDIs recommend simultaneous press and breathe manoeuvres for inhaling 
the puff. Further, the inhalation technique using a spacer can only be simulated to MDI 
alone if the dose discharged in the spacer is immediately inhaled as per PIL 
recommendations (also see Section 3.4.3). Hence, in this project, no inhalation delay 
methodology has been applied for in-vitro and in-vivo studies. On the same grounds, 
tidal breathing and breathing simulation profile through spacer has not been considered 
here. 
2.4.1 Spacer Electrostatic Charge  
Studies have shown that electrostatic charge in a spacer can affect the delivered dose of 
an MDI (Wildhaber et al., 1996b; Clark and Lipworth, 1997), which is pronounced if 
inhalation is delayed (Barry and O’Callaghan, 1995b; Clark and Lipworth, 1996a; 
Wildhaber et al., 1996a & b; Rau et al., 2006). This electrostatic charge in the spacer 
can be reduced by priming shots of the placebo or drug (Table 2.4.1, Figure 2.4.1), or by 
washing with ionic detergent aqueous solution. However, differences exist whether the 
spacer should be rinsed with water before drip-drying (Table 2.4.2; Option I) or not 
(Table 2.4.3; Option II). These respective differences are also reflected in the spacer  
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manufacturer’s PILs for Volumatic (GSK, 2018) and AeroChamber Plus (TMI, 2008; 
Blake et al., 2012; Dissanayake et al., 2018). Further, the approach of regional National 
Health Service (NHS) also differs; for example, NHS Greater Glasgow and Clyde 
(2013) and NHS North Tees and Hartlepool (2017) recommend final rinsing with water 
while NHS Cambridgeshire and Peterborough (2016) and NHS University College 
London Hospitals (2011) do not suggest this step. 
Intriguingly, differences in PIL also exist between the Continents and countries. In 
USA, the FDA requires manufacturers of spacers to recommend that patients rinse them 
in clean water after washing in detergent, to avoid patient contact with detergent-coated 
surfaces, which could result in contact dermatitis (Mitchell and Nagel, 2007; Mitchell et 
al., 2007a; Hess, 2008; Dolovich and Dhand, 2011). This is evident when Rau et al. 
(2006) highlighted that they followed the manufacturer’s United States instructions to 
pre-treat the seven spacers (including anti-static AeroChamber Max) used in their in-
vitro study. Kelly et al. (2001) also rinsed AeroChamber Plus with water after detergent 
treatment as per the USA manufacturer’s PIL. These findings re-affirm the existence of 
different regional approaches for spacer pre-treatment. 
 
 
Figure 2.4.1. Schematics of emitted dose aerodynamics of an MDI attached to a spacer. 
Adapted from Sheth et al., 2014, 2015 & 2017. 
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Table 2.4.1. List of studies using various options for priming spacers. 
Investigators Methodology MDI Spacer Spacer Treatment 
Barry and 
O’Callaghan, 1995b 
MSLI Budesonide* Nebuhaler Anti-static lining ✣ 
Clark and Lipworth, 
1996a 
Plasma PK Study, healthy volunteers 
(mean age 20.5 years), n=10 
Salbutamol 
(Ventolin) CFC 
Volumatic (VOL) Two VOL coated with antistatic wash resistant 
polyurethane dispersion✣. All VOL spacers washed in 
warm water and left to drip dry. 
Barry and 
O’Callaghan, 1997 
MSLI Ventolin CFC, 
Airomir 
AeroChamber, 
Nebuhaler 
Nebuhaler coated with static dissipative paint (U-100)✣ 
Kenyon et al., 1998 MSLI, scintigraphy in asthmatic 
patients (19–66 years), n=10 
Budesonide* (radio 
labelled) 
Volumatic, Nebuhaler, 
Nebuchamber
⚓
 
20 placebo doses 
Fowler et al., 2001 Plasma PK Study Salbutamol HFA 
(Airomir) 
AeroChamber, 
cardboard tube 
Detergent drip drying and 50 puffs of the MDI 
Lipworth et al., 
2002 
Plasma PK, stable mild asthmatic 
children (5-12 yr), n=25 (out-patient) 
Salbutamol HFA 
(Ventolin Evohaler) 
Volumatic Benzalkonium chloride (0.05%) coating and drip 
drying 
Land et al., 2014 DUSA Ventolin Evohaler Volumatic 20 doses of Ventolin (HFA) 
MSLI = Multi Stage Liquid Impinger; DUSA = Dosage Unit Sampling Apparatus; PK = Pharmacokinetic; * Pulmicort; 
⚓ 
Metallic; ✣ Static Safe Ltd, UK. 
 
  
  
1
8
 
 
 
 
 
Table 2.4.2. List of studies using detergent coating of spacers with option I: Wash with soapy water, rinse with water and drip dry. 
Investigators Methodology MDI Spacer 
Dewsbury et al., 1996 MSLI Salbutamol CFC (Salbulin) Volumatic 
Finlay et al., 1997 ACI (delay: 1 sec) Ventolin CFC and 
Beclomethasone (Beclovent) 
Space-Chamber, AeroChamber 
Finlay and 
Zuberbuhler, 1999 
ACI (tidal breathing) Airomir AeroChamber, OptiChamber, E-Z Spacer, Vent170, NES 
spacer
†⚓
 
Silkstone et al., 2002a  ACI Ventolin CFC Volumatic 
Rau et al., 2006 ACI (delay: 2 and 5 sec) Ventolin HFA AeroChamber Max, Vortex (metallic), OptiChamber 
Advantage, ProChamber, Breathrite, PocketChamber, ACE
‡
 
Goncalves et al., 2013 NGI Beclomethasone+Formoterol⁑ Able Spacer, AeroChamber Plus, Vortex
⚓
 
Hatley et al., 2014 NGI (flow rates: 15 and 30 L/min) Salbutamol HFA (ProAir), 
Beclomethasone (QVAR) 
AeroChamber Z-Stat, AeroChamber Plus, OptiChamber 
Diamond  
Slator et al., 2014 Collected on filter; (delay: 0, 5, and 10 
sec; flow rates: 5, 15, and 30 L/min) 
ProAir AeroChamber Z-Stat, AeroChamber Plus, OptiChamber 
Diamond  
ACI = Andersen Cascade Impactor; NGI = Next Generation Impactor; 
†
 Nebuchamber; 
‡
 Aerosol Cloud Enhancer; ⁑ Innovair 
Other notations explained as for (Table 2.4.1). 
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Table 2.4.3. List of studies using detergent coating of spacers with option II: Wash with soapy water and drip dry; no rinse with water. 
Investigators Methodology MDI Spacer 
Wildhaber et al., 1996a MSLI; (also with delay: 1, 5 and 20 sec in two 
spacers)** 
Ventolin CFC Babyhaler**, Nebuchamber**
⚓
, Babyspacer, 
AeroChamber, Nebuhaler 
Wildhaber et al., 
1996b 
MSLI Ventolin CFC Volumatic 
Piérart et al., 1999 MSLI and healthy volunteers (25–42 years), n=8 Ventolin CFC (radio labelled) Volumatic 
Anhøj et al., 1999 Plasma PK Study, children (7–12 years), n=5 Salbutamol HFA (Sultanol) Babyhaler, AeroChamber 
Mitchell et al., 1999 ACI Ventolin CFC, Airomir Volumatic 
Wildhaber et al., 2000a PD Study, FEV1, asthmatic adults (18-65 years), 
n=20 
Ventolin CFC AeroChamber, Volumatic 
Wildhaber et al., 
2000b 
MSLI, Radioactivity measurement, stable 
asthmatic children of age <48 (n=8)^ months 
and >48 months (n=10) 
Ventolin CFC (radio-labelled) ^Babyhaler (with mask), Volumatic 
Dompeling et al., 2001 PD Study, PEF, asthmatic children (4–8 years), 
n=90 
Ventolin HFA AeroChamber, Volumatic, Nebuchamber
⚓
 
Chuffart et al., 2001 MSLI, PD Study, FEV1, asthmatic children (13–
17 years), n=12 
Ventolin CFC, Airomir AeroChamber, Nebuhaler, Volumatic 
Barben et al., 2003 PD Study, FEV1, stable asthmatic children (7–18 
years), n=50 
Ventolin HFA Volumatic 
Dubus et al., 2003 PD Study, Methacholine challenge, FEV1, 
asthmatic young children (3-6 years), n=64 
Ventolin HFA Babyhaler (static and non-static) and 
Nebuchamber
⚓
, both with their own facemasks. 
Notations explained in Table 2.4.2 and Table 2.4.3. 
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Interestingly, the clinical evidence is conflicting with regards to spacers that were 
treated with detergent only (Table 2.4.3). Anhøj et al. (1999) observed that the plasma 
concentration of salbutamol HFA (Sultanol
®
) in children increased by over two-fold 
with non-electrostatic Babyhaler as compared to non-conducting Babyhaler and 
AeroChamber. Wildhaber et al. (2000a) recorded improved bronchodilator response 
(FEV1) to salbutamol (Ventolin CFC) in asthmatic adults with detergent treated 
Volumatic. Wildhaber and colleagues (2000b) also found higher lung deposition of 
radio-labelled salbutamol (Ventolin CFC) in children using Babyhaler (with mask) and 
Volumatic. Moreover, Chuffart et al. (2001) reported increase in FEV1 at 5 min post-
inhalation in asthmatic children when salbutamol HFA (Airomir) was used with non-
static Nebuhaler as compared to static Nebuhaler attached to Ventolin CFC. In contrast, 
Clark and Lipworth (1996a) found significant increase in Cmax of Ventolin CFC inhaled 
by healthy adults from the untreated Volumatic compared with the antistatic treated 
Volumatic (both prewashed with warm water only) and no other differences were seen 
in average plasma salbutamol levels (Cave) or systemic β2 responses (Table 2.4.1). They 
concluded that washing a Volumatic with water was as effective as coating it with an 
antistatic spray in reducing the effects of static charge on salbutamol delivery in-vivo. 
Besides, Dompeling et al. (2001) could not observe significant differences in peak 
expiratory flow rate (PEF) of asthmatic children when they inhaled salbutamol 
(Ventolin HFA) with Volumatic and AeroChamber (static and non-static), and 
Nebuchamber (metallic) (Table 2.4.3). They concluded that electrostatic charge on 
plastic spacers did not decrease the efficacy of bronchodilator therapy in their subjects. 
These observations are also supported by Barben et al. (2003) who could not find a 
clinical benefit of detergent-coated Volumatic after a single dose of salbutamol 
(Ventolin HFA) in asthmatic children. There was no difference in FEV1 and maximal 
mid-expiratory flow (MMEF) at 10 and 20 min after inhalation from either coated or 
non-coated Volumatic. However, they noticed a small statistically significant difference 
in PEF at 10 min, which disappeared after 20 min. Further, Dubus et al. (2003) also 
found no difference in methacholine challenged bronchodilation with salbutamol 
(Ventolin HFA) administered to asthmatic young children using Babyhaler (static and 
non-static) and Nebuchamber, all equipped with their own facemasks.  
Nevertheless, it is noted that these studies have shortcomings. Wildhaber et al. (2000b) 
did not provide any data for static spacers to show the actual difference in lung  
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deposition of radio-labelled salbutamol in children. Chuffart et al. (2001) measured 
FEV1 at 5 min while EMA (2009) requires this be measured at 15 min. Further, there is 
an inherent bias in this study as two different delivery systems have been compared with 
(Airomir + non-static Nebuhaler Vs Ventolin CFC + static Nebuhaler). Consequently, 
the results may have been affected by a number of varied factors originating from 
differently formulated MDIs (Table 2.2.1) and differently treated spacers. The results 
therefore cannot be reliably linked to the potential benefit of detergent treatment of 
spacer. Discussing their apparently out of trend results, Dompeling et al. (2001) 
explained that the difference between coated and non-coated spacer may have been 
masked by either a good inhalation technique of children or the dosage used may 
already have been at the higher part of the dose-response curve. However, these 
researchers used a different outcome measure PEF and therefore their results may not be 
comparable to studies using FEV1. Nevertheless, Barben et al. (2003) used FEV1, PEF 
and MMEF as outcome measures and reached the same conclusions as those of 
Dompeling and co-workers. It is interesting to note that in study by Dompeling et al., 
the two non-conducting plastic spacers were considered electrostatic after washing these 
with water only and this was shown with the significant difference in their measured 
electrostatic charge. However, Clark and Lipworth (1996a) also pre-washed both static 
and anti-static spacers with warm water. Although they did not measure the electrostatic 
charge on Volumatic, their conclusions are in agreement to those of Dompeling and 
colleagues. Intriguingly, the data of in-vitro study by Dubus et al. (2001) shows similar 
FPD (<5.8 µm) of Airomir from non-conducting (AeroChamber-Infant and Babyhaler) 
and conducting (NebuChamber, metallic) spacers, all of which were washed with 
lukewarm water only (Table 2.5.2). Their reported FPD of Airomir with AeroChamber-
Infant (68 µg) is also similar to that of Mitchell et al. (1999) (62 µg) for this 
combination, the apparent difference in FPD is more likely due to the latter’s FPD being 
<4.7 µm. This is despite Mitchell and co-workers prewashed and drip dried the spacer 
with ionic detergent to minimize the influence of electrostatic charge. These 
contradicting in-vitro findings raise questions and may suggest that spacer preparation 
method may not be of significance or perhaps irrelevant in this case. 
Further, it can be noticed that most of these clinical studies were performed in children 
except those of Clark and Lipworth (1996a) and Wildhaber et al. (2000a). However, the 
former used Ventolin CFC while it is not clear if Ventolin HFA was used in the latter  
  
 22 
study. Nevertheless, Anhøj et al. (2000) found that lung deposition (plasma 
concentration) of inhaled budesonide (Pulmicort) administered with Nebuchamber 
increased with age in mild stable asthmatics aged 2–3 and 4–6 year and adults older 
than 18 year. It is also known that children have different breathing patterns, respiratory 
anatomies and capacities, volume of distribution and clinical response than those of 
adults (Labiris and Dolovich, 2003; Rubin and Fink, 2005; Venegas et al., 2013). 
Therefore, extrapolating the results of one age group to a different one is difficult to 
justify (EMA, 2009). Also, experiments with one spacer (similarly or differently 
treated) or a specific drug cannot be extrapolated to others (Barry and O’ Calaghan, 
1997; Liworth and Clark, 1998). In addition, studies using different methodologies, 
outcome measures, subjects (patients or healthy), ages, types and dosages are difficult 
and inappropriate to compare. Further, given that the clinical evidence in children is 
conflicting, and that the clinical evidence in adults is scarce, the effects of rinsing or not 
rinsing spacers with water after detergent treatment on salbutamol dose delivery 
efficiency remains obscure (Lavorini and Fontana, 2009; Laube et al., 2011). 
The foregoing literature review reveals lack of consensus on whether spacers should be 
rinsed after cleaning with detergent. Besides, the PK and PD evidence is conflicting and 
insufficient for HFA salbutamol MDI delivery with these spacers. Hence, the 
conclusion drawn from salbutamol CFC MDIs studies cannot be representative of those 
of HFA MDIs (Liu et al., 2017) due to differences in their formulation and device 
design (Table 2.2.1) and where different spacers were used. Therefore, based on the 
information extracted from the literature, PILs and FDA recommendations, the spacers 
used in this project have been treated with aqueous detergent solution followed by water 
rinsing and drip-drying (Section 3.3.2). 
2.5 In-Vitro Particle Size Characterisation Studies 
A summary of in-vitro studies for Ventolin Evohaler, Airomir and ProAir is given in 
Table 2.5.1, Table 2.5.2 and Table 2.5.3, respectively. The studies conducted during 
transition from CFC to HFA propellant were carried out either by pharmaceutical 
companies themselves or sponsored by them. Parallel in-vitro studies were also carried 
out by the manufacturers of spacers which are ongoing with the introduction of newer 
MDIs and/or spacers. 
These in-vitro studies were carried out using Andersen Cascade Impactor (ACI) with a 
USP induction port operated at a flow rate of 28.3 L/min. When Next Generation   
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Impactor (NGI) was in use, this was operated at 30 L/min. Airflow duration varied 
between studies from 8 to 30 seconds while in one study, it was timed to allow 4 L of 
air to pass through the instrument (McCabe et al., 2012). In general, 5 to 10 puffs of the 
MDI were used for each experiment (with 3 to 6 replicates), even though the clinically 
relevant dose of salbutamol MDI is upto 2 puffs (BNF, 2017). In most studies, ACI 
impaction plates or NGI impaction cups were not coated. Where spacers were used with 
the MDI, some researchers chose to pre-treat these with a detergent while others did 
not; also pre-treatment procedure varied between them as discussed earlier (Section 
2.4). Further, one study did not provide spacer identity (Ross and Gabrio, 1999). APSD 
data analysis and reporting of full profiles was selective and not all studies provided 
data on TED (and TDD ex-spacer), FPD, MMAD and GSD. Statistical comparisons 
were not provided in some studies (Ross and Gabrio, 1999; Cripps et al., 2000). The 
ambiguity in the experimental details, the lack of availability of essential MDI 
performance data (including stage- or stage-group wise comparisons) and the use of 
clinically relevant doses represent the main areas where improvements are needed in 
future studies. A review of full and detailed publications on in-vitro studies follows. 
Ross and Gabrio (1999) described the development of Airomir (Table 2.5.2). These 
researchers compared Airomir with Ventolin CFC used alone and with unspecified 
small and large volume spacers using ACI. Based on the results, they suggested that 
FPD (<4.7 µm), fine particle fraction (FPF), MMAD and Induction Port (IP) (throat) 
deposition of the two MDIs with these spacers was comparable and that these spacers 
had similar effects on both MDIs. However, these claims were not substantiated with 
the statistical evidence. Their data shows an increase in FPD with the spacers as 
compared to MDI alone and the differences in the magnitude of this increase by the two 
unspecified spacers were not highlighted. Interestingly, a closer look at their data for 
Airomir shows that FPDs obtained with small and large spacers are greater than MDI 
alone, having ratios of 1.30 and 1.56, respectively. Further, it is also not clear how many 
puffs were used (although 20 puffs were used in their temperature cycling study on 
these MDIs), whether ACI plates were coated to prevent the particle bounce and re-
entrainment (Nasr and Allgire, 1995; Nasr et al., 1997; Kamiya et al., 2004), and what 
was the airflow duration. Also, APSD graphic profile in their manuscript does not show 
salbutamol deposition on the filter stage and no explanation was provided for this 
omission. Further, it is not elaborated whether spacers were neutralised for electrostatic 
charge.   
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Cripps et al. (2000) reported the seamless pharmaceutical transition of Ventolin CFC to 
Ventolin Evohaler (Table 2.5.1). These researchers used ACI fitted with a small volume 
metal induction port (IP) which is likely to have different dimensions and volume than 
the IP of USP/Ph. Eur. It was concluded from the results that particle size distribution 
profiles of the two MDIs were similar, albeit without providing the statistical evidence.  
Comparing Ventolin HFA MDI alone and when attached to Babyhaler and Volumatic, 
Cripps and co-workers concluded that spacers did not significantly affect APSD; again 
without supporting the claim with statistical data. However, assessment of their 
available data reveals that FPD of Ventolin HFA with Volumatic is considerably higher 
(ratio) than both MDI alone (1.27) and with Babyhaler (1.30). These researchers did not 
coat the ACI plates. Hence, the reported particle bounce and re-entrainment on uncoated 
plates (Nasr and Allgire, 1995; Nasr et al., 1997; Kamiya et al., 2004) was evident from 
a high capture of particles on the filter. Also, it is not clear if the spacers were pre-
treated to minimise electrostatic charge. Further, these researchers defined FPD to 
consist of deposition on stages 2 to 6 of ACI.  
Mitchell et al. (1999) compared Ventolin CFC and Airomir without and with 
AeroChamber and Volumatic (Table 2.5.2). Spacers were treated with detergent and 
drip dried. ACI was stacked with glass collection plates. Their data shows a greater 
magnitude of increase in FPD of Ventolin CFC when used with Volumatic than 
AeroChamber, albeit both FPDs being greater than that of the MDI alone. They also 
observed significantly larger FPD of Airomir with these spacers, however, the 
differences of FPD between these spacers were smaller even though approaching 
statistical significance (p = 0.056). They inferred from these results that increase in 
spacer volume between ~140 and 750 mL may have only small impact on FPD of 
salbutamol HFA MDIs. However, this inference should have been qualified to Airomir 
only since Hall et al. (2011) have reported an increased FPD of Ventolin HFA with 
Volumatic than Breath-a-Tech with a ratio of 1.29. Although Volumatic is not 
recommended for use with Airomir, it is not clear as to how Mitchell and co-workers 
connected the round actuator mouth piece was connected to the roughly rectangular 
(oval) inhaler port of the spacer. If a rectangular shaped actuator was substituted for 
Airomir canister (as shown in the manuscript), it can have implications for TED and the 
resultant APSD profile may not be representative of the original Airomir actuator. On 
the other hand, if the inhaler port of Volumatic was changed to a round hole, it can also   
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influence APSD profile besides this being impractical and irrelevant. Further, these 
investigators estimated MMAD from the log normal plots of cumulative mass % less 
than stated size for both spacer combinations. In contrast, MMAD for MDI alone was 
deduced by separating the IP depositions from the impactor mass. This approach was 
adopted since the cumulative mass % less than stated size could not exceed 50% cut-off 
point; a plateau was observed at ~40% for Ventolin CFC MDI and at ~50% for Airomir. 
Nevertheless, the reported MMAD of >9 µm remains questionable. 
Mitchell and co-workers also reported %FPF of >96% for both MDIs and spacer 
combinations and suggested their similar FPD delivery efficiency (Table 2.5.2). 
However, FPD for Ventolin CFC with AeroChamber and Volumatic was 45.4 µg and 
63.8 µg, respectively, which is significantly different. Their respective TED was 47.2 
µg and 66.1 µg. On the other hand, FPD of Airomir with these spacers was 62.0 µg and 
67.9 µg, respectively, which are comparable. Their respective TED was 64.2 µg and 
69.7 µg. It is clear that for both MDIs, FPD was conspicuously larger with Volumatic 
than AeroChamber. However, because this magnitude of increase was not observed 
with their TEDs, %FPF was similar thereby suggesting their apparent similarity in dose 
delivery efficiency. Although the scale of error of using the derived data (%FPF) 
reported in this study is more with Ventolin CFC than Airomir, the use of this outcome 
measure has high potential of misleading and jeopardising objective decision making 
(also see Section 6.2.7.5).  
Dubus et al. (2001) reported particle size characterisation of four salbutamol MDIs 
(Airomir, Ventolin CFC and two French generics) used alone and with three spacers 
(AeroChamber-Infant, Babyhaler and metallic NebuChamber) (Table 2.5.2). These 
spacers were treated by washing with lukewarm water only. ACI impaction plates were 
used without coating. Higher FPD (<5.8 µm) is reported for Airomir than Ventolin CFC 
(ratio 1.34). FPD of both MDIs increased with spacers as compared to MDI alone, 
however, the magnitude of this increase for Ventolin CFC was lesser with 
AeroChamber than the other two spacers. The FPD of Airomir obtained from the 
conducting NebuChamber was only slightly larger (ratio) than non-conducting 
Babyhaler (1.08) and AeroChamber (1.07) while it was similar between the non-
conducting spacers (0.99). The corresponding FPD ratios for Ventolin CFC obtained 
from these spacers are 1.03, 1.27 and 1.23. Further, FPD with spacers reflected on their 
respective delivered dose for both MDIs. Although more salbutamol dose was delivered 
from NebuChamber as compared to the other two spacers, the data suggest that the   
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formulation and plume ballistic characteristics of the two MDIs, along with the spacer 
volume, had more contribution to this than the conducting material or the spacer 
washing method. It is also noted that %FPF was calculated with TED obtained from 
Emitted Dose Uniformity (EDU) tests performed separately rather than the TED 
obtained from same ACI data. MMAD and GSD for MDI alone were not provided to 
assess the impact of spacer on them. 
Johnson et al. (2016) compared APSD of Ventolin HFA, Proventil HFA and ProAir 
HFA alone and with LiteAire spacer. The salbutamol amounts have been reported as 
sulphate (see base equivalent conversions underneath Table 2.5.1-Table 2.5.3). The 
FPD of Ventolin HFA MDI alone is atypically very small while IP deposition is large as 
compared to other inhalers. The TED for MDI alone meets mass balance requirement 
(±25% of the labelled claim) for ProAir HFA only. Spacer deposition could not be 
reported due to its cardboard construction. With spacer, FPD for Ventolin HFA and 
Proventil HFA increased while it decreased for ProAir. The TDD and FPD of Ventolin 
HFA with LiteAire are significantly lower than those reported by Hall et al. (2011). 
Also, there seems to be issues with the sensitivity of the analytical method as some 
stage depositions could not be quantified. 
McCabe et al. (2012) performed comparative APSD of Ventolin HFA and ProAir HFA 
using NGI at a flow rate of 28.3 L/min and flow volume of 4 L (~8.5 seconds) (Table 
2.5.1 and Table 2.5.3). The flow rate used in their study is not pharmacopoeia 
recommended. The NGI collection cups were not coated. Their reported FPD for 
Ventolin HFA is out of trend.  
Hall et al. (2011) have reported spacer only studies with Ventolin HFA and therefore 
cannot be related to MDI alone performance. They have reported an insignificant 
increase in TDD from large-volume (>500 mL) than small-volume (<250 mL) spacers. 
The TDD was averaged for these two groups of three spacers each (Table 2.5.1). Their 
data does not reveal any linking trend for spacer volume and shape to TDD and FPD. 
Although these metrics are atypically low and out of trend for Space Chamber, the 
%FPF suggests similarity of dose delivery efficiency to other spacers which is grossly 
erroneous as discussed above.  
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Table 2.5.1. In-vitro studies on Ventolin HFA without and with spacers. 
Ventolin MDI or 
MDI+SP
1
 
TED / 
TDD
2
 
SP
3
 SP
3 
Vol 
(mL) 
SP
3
 
Treat
ment 
IP
4
 FPD
5
 FPF
6
 
(%) 
MMAD
7
 
(µm) 
GSD
8
 ACI 
Plate 
Coating 
Flow 
Time 
(sec)  
No. of 
puffs 
Reference 
Ventolin
§
 82 N/A N/A N/A 39 34
#
  42
#
 2.1 ? No ? 5 Cripps et al., 2000; 
n=6 + Volumatic
§
 90 (TED) 
53^ (TDD) 
37 750 No 1.3 43
#
  48
#
 (TED); 
82
#
 (TDD)^ 
? ? 
+ Babyhaler
§
 93 (TED) 
39^ (TDD) 
54 350 No 0.7 33
#
 36
#
 (TED); 
85
#
 (TDD)^ 
? ? 
+ Volumatic 40.8 ? 750 Yes
a
 ? 37.2 91.2 ? ? No** 10; 
20 sec 
last puff 
10 Hall et al., 2011; 
n=6 + Breath-a-Tech 32.8 ? 218 Yes
a
 ? 28.9 88.2 ? ? 
+ Space Pod 30.7 ? 800 Yes
a
 ? 29.5 96.2 ? ? 
+ Space Chamber 16.6 ? 225 Yes
a
 ? 15.6 93.6 ? ? 
+ e-Chamber 37.2 ? 510 Yes
a
 ? 33.7 90.6 ? ? 
+ LiteAire 33.4 ? 160 N/A ? 31.3 93.8 ? ? 
Ventolin; NGI; 
28.3 L/min 
85 N/A N/A N/A ? 26 31 2.4 2.0 No 4 L 10 McCabe et al., 
2012; n=6 
Ventolin HFA
‡
 86.5
‡
 N/A N/A N/A 61.6
‡
 20.9
‡
 24.2 2.48 1.77 No 30 5 Johnson et al., 2016; 
salbutamol as 
sulphate, n = 6 
+ LiteAire
‡
 26
‡
 (TDD) 
91
‡
 (TED)^ 
62
‡
^ 160 
cc 
N/A 2.8
‡
 25
‡
 94 (TDD);  
27 (TED) 
2.08 1.71 
1 
MDI with spacer; 
2
 Total Emitted/Delivered Dose; 
3
 Spacer; 
4
 Induction Port; 
5
 Fine Particle Dose; 
6
 Fine Particle Fraction; 
7
 Mass Median Aerodynamic Diameter; 
8
 Geometric 
Standard Deviation; N/A = Not Applicable; ? = data/information not provided. 
a 
Option II: Washed with soapy water and drip dried (Table 2.4.3). 
# FPD < 5.8 µm (stages 2-6) 
* Calculated by this author from the data in the manuscript. 
** Personal communication 
^ Value estimated by this author from the data in the manuscript. 
§ FPD (stages 3-F) and FPF (%) estimated by this author (Cripps et al., 2000): Ventolin FPD (37), FPF% (46); Ventolin+ Volumatic FPD (47), FPF%TED (52), FPF%TDD 
(~88); Ventolin+ Babyhaler FPD (35), FPF%TED (38), FPF%TDD (~91). 
‡ Salbutamol base equivalent (calculated by this author) (Johnson et al., 2016): Ventolin HFA TED (72.2), IP (51), FPD (17.4), FPF% (24.03); Ventolin HFA+ LiteAire TDD 
21.8 (ex-SP), TED (75.7) (ex-actuator)^, spacer deposition (51.2)^, IP (2.3), FPD (21). 
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Table 2.5.2. In-vitro studies on Airomir without and with spacers. 
Airomir MDI or 
MDI+SP
1
 
TED / TDD
2
 SP
3
 SP
3 
Vol 
(mL) 
SP
3
 
Treat
ment 
IP
4
 FPD
5
 FPF
6
 
(%) 
MMAD
7
 
(µm) 
GSD
8
 ACI 
Plate 
Coating 
Flow 
Time 
(sec)  
No. of 
puffs 
Reference 
Airomir 99.4* N/A N/A N/A 44.0 49.8 50.1 2.23 ? ? ? ? 
20
C
 
Ross and Gabrio, 
1999; n=3 + small volume SP
1
 74.4* (TDD) ? ? ? 2.9 64.5 86.7 2.50 ? 
+ large volume SP
1
 89.0* (TDD) ? ? ? 1.9 77.7 87.3 2.67 ? 
Airomir 81.3 N/A N/A N/A ~43* 38.7 47.6* > 9 ? ? (Glass 
plates) 
30 5 Mitchell et al., 
1999; n=3 + AeroChamber 64.2 (TDD) ? 145 Yes
a
 ? 62.0 96.6* 2.6 ? 
+ Volumatic 69.7 (TDD) ? 750 Yes
a
 ? 67.9 97.4* 2.4 ? 
Airomir;  85.3† N/A N/A N/A ? 54.1֍ 63.5* ? ? ? 30 5 Dubus et al., 2001; 
n=6 + AeroChamber 69.9† ? 145 Yesb ? 68.3֍ 97.7* 2.78 1.47 
+ Babyhaler 68.5† ? 350 Yesb ? 67.5֍ 98.5* 2.68 1.39 
+ NES-spacer
⚓
 80.2† ? 150 Yes
b
 ? 73.2֍ 91.3* 2.77 1.47 
Proventil HFA
‡
 75.04
‡
 N/A N/A N/A 34.3
‡
 40.1
‡
 53.4
♦ 
 2.22 1.57 No 30 5 Johnson et al., 2016; 
salbutamol as 
sulphate, n = 6 
+ LiteAire
‡
 53.8
‡
 (TDD) 
87.1
‡
 (TED) 
29.1
‡
^ 160 
cc 
N/A 4.78
‡
 52.5
‡
 98 (TDD); 
60 (TED)^ 
2.26 1.41 
b 
Washed with lukewarm water only. 
C
 Temperature cycling study. 
† TED (TDD) obtained separately from sampling tube experiments (EDU); n=30, Flowrate = 28.3 L/min for 10 seconds. 
‡ Salbutamol base equivalent (calculated by this author) (Johnson et al., 2016): Proventil HFA TED (62.3), IP (28.5), FPD (33.3), FPF% (53); Proventil HFA + LiteAire TDD 
(44.7) (ex-SP), TED (72.3) (ex-actuator)^, spacer deposition (25)^, IP (4.0), FPD (43.6) 
♦ (58% in the manuscript; more likely a typo error) 
⚓ Nebuchamber 
֍ FPD = < 5.8 µm (stages 2-7 and F) (Dubus et al., 2001) 
Other notations explained as for Table 2.5.1. 
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Table 2.5.3. In-vitro studies on ProAir HFA without and with spacers. 
ProAir MDI or 
MDI+SP
1
 
TED / TDD
2
 SP
3
 SP
3 
Vol 
(mL) 
SP
3
 
Treat
ment 
IP
4
 FPD
5
 FPF
6
 
(%) 
MMAD
7
 
(µm) 
GSD
8
 ACI 
Plate 
Coating 
Flow 
Time 
(sec)  
No. of 
puffs 
Reference 
ProAir; 
NGI, 28.3 L/min 
93 N/A N/A N/A ? 53 57 2.3 1.6 No 4 L (~8.5 
sec)^ 
10 McCabe et al., 
2012; n=11 
ProAir, 90 µg
✤
 90.7
✤ N/A N/A N/A 29.7 57.8✤ 63.7 2.35 ? No 20 sec 
(last puff 
30 sec) 
(Hatley 
et al.) 
10 Hatley et al., 2014 
and von Hollen et 
al., 2011a & b, 
2012 & 2013; 
NGI, 30 L/min; 
MDI n=12, 
MDI+SP n=6 
+ AeroChamber 
Plus; 90 µg✤ 
68.5✤ (TDD) 
89.2^ (TED) 
20.7^ 
 
149 Yes
d
 ? 58.1✤ 84.8 (TDD) 
65.1^ (TED) 
2.39 ? 
+ AeroChamber 
Plus Z-Stat; 90 µg✤ 
72.3✤ (TDD) 
88.5^ (TED) 
16.2^  149
e
 Yes
d
 7.6 61.1✤ 84.4 (TDD) 
69.0^ (TED 
2.40 ? 
+ OptiChamber 
Diamond; 90 µg✤ 
69.7✤ (TDD) 
89.5^ (TED) 
19.8^  140 Yes
d
 4.6 61.2✤ 87.8 (TDD) 
68.4^ (TED 
2.41 ? 
ProAir
‡
 106.7
‡
 N/A N/A N/A 38.9
‡
 64.4
‡
 61 2.4 1.53 No 30 5 Johnson et al., 
2016; salbutamol 
as sulphate, n = 6 
+ LiteAire
‡
 63.2
‡
 (TDD) 
108.6
‡
^ (TED) 
42.9
‡
^ 184 
cc 
N/A 3.07
‡
 61.4
‡
 97 (TDD); 
56.5^ (TED) 
2.33 1.48 
d 
Option I: Washed with warm soapy water, rinsed with deionised water and drip dried (Table 2.4.2). 
✤ Salbutamol base equivalent rounded to 100 µg (ex-valve dose) (Hatley et al., 2014 and von Hollen et al., 2011a & b, & 2012): ProAir HFA TED (100.8), FPD (64.6); ProAir 
HFA + AeroChamber Plus TDD (76.1), TED (99.1), spacer deposition (23), FPD (64.6); ProAir HFA + AeroChamber Plus Z STAT TDD (80.3), TED (98.3), spacer deposition 
(18), FPD (67.9); ProAir HFA + OptiChamber Diamond TDD (77.4), TED (99.4), spacer deposition (22), FPD (68.0). 
‡
 Salbutamol base equivalent (calculated by this author) (Johnson et al., 2016): ProAir HFA TED (88.6), IP (32.3), FPD (53.7) ProAir HFA + LiteAire  TDD (52.5) (ex-SP), 
TED (90.2) (ex-actuator)^, spacer deposition (35.6)^, IP (2.6), FPD (51.0). 
e
 Li et al., 2008 
Other notations explained as for Table 2.5.1. 
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2.6 The effect of Spacer on FPD of Salbutamol HFA MDIs 
The data reported by Ross and Gabrio (1999) shows significantly greater ratios of FPD 
of Airomir when used with unspecified small (1.30) and large volume (1.56) spacers as 
compared to MDI alone. Mitchell et al. (1999) also reported that FPD of Airomir with 
both AeroChamber (small volume) (1.60) and Volumatic (large volume) (1.75) was 
significantly higher than the MDI alone. On the other hand, Cripps et al. (2000) could 
not find any significant difference in FPD of Ventolin HFA between MDI alone and 
when attached to Babyhaler (0.97) or Volumatic (1.27), although it was greater with the 
latter spacer. Studies on ProAir reveal similar FPD with small volume spacers 
(AeroChamberPlus, AeroChamber Z-stat and OptiChamber Diamond) as compared to 
the MDI alone (von Hollen et al., 2011a & b, & 2012; Hatley et al., 2014). To the 
knowledge of this author, no studies have been reported with large volume spacers for 
ProAir or Salamol.  
Formulation and MDI device design influence the dose delivery characteristics (Stein et 
al., 2014; Myrdal et al., 2014). The differences in salbutamol HFA MDI formulations 
have been shown to be affected differently with the spacer volume and the magnitude of 
this effect varied with each type of spacer. Cripps et al. (2000) reported greater FPD 
(ratio) when Ventolin HFA was attached to Volumatic than Babyhaler (1.30). Hall et al. 
(2011) also found similar trend between Volumatic and Breath-a-Tech (1.29) for 
Ventolin HFA. Greater FPD has also been reported by Ross and Gabrio (1999) for 
unspecified large spacer than the small one (1.21) for Airomir. However, this magnitude 
of increase in FPD of Airomir was lesser between Volumatic and AeroChamber (1.10) 
in the study by Mitchell et al. (1999). Interestingly, ProAir HFA has been shown to have 
similar FPD between the three spacers (von Hollen et al., 2011a & b, & 2012; Hatley et 
al., 2014). 
These findings do not reveal any general trending in FPD of either salbutamol HFA 
MDI alone and when used with a spacer. Further, this trend was also not clearly evident 
with the spacers used with these MDIs. 
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2.7 Summary and Conclusions – Literature Review 
The review of in-vitro studies reveals high variability in FPD amongst and within each 
of the three salbutamol HFA MDIs when used alone. This is expected since these HFA 
MDIs are differently formulated and dispensed with differently designed devices (Table 
2.2.1). Further, differences amongst in-vitro studies conducted by different investigators 
for the same MDI are of a common occurrence. This is because APSD measurements 
using ACI are a very sensitive technique with many potential sources of variability. 
Moreover, spacers can introduce additional sources of variability, in particular due to 
their handling technique and experimental set-up. The addition of a spacer to an MDI 
creates a new drug delivery system which can change APSD profile; the extent of which 
depends on a number of spacer-related factors. Differences in spacer characteristics 
(construction material, size, volume and dimensions, valve type and design) coupled 
with pre-treatment and handling methods (new, water washed, detergent washed 
without or with water rinsing, antistatic coating, priming) have been reported to have 
influenced APSD to a varied degree (Table 2.4.1 to Table 2.5.3). Hence, the APSD data 
would reflect on these differences.  
It has been reported that both large and small volume spacers attached to Airomir 
provide for larger FPD than the MDI alone; the degree of this increase is greater with 
the large volume spacer. However, difference in FPD of Ventolin Evohaler was 
identified as not significant with both large and small spacers as compared to MDI 
alone. Comparative studies on ProAir did not report any difference in FPD obtained 
with small spacers and MDI alone. 
It is also noted that 5 or more MDI puffs were used in all previous in-vitro studies while 
the recommended dose for patients is 1 to 2 puffs. Besides, the cascade impactor 
experimental procedure has not been reported clearly in most studies and where a 
pharmacopoeia method was used, it was not referred to. Further, selective data has been 
reported which makes it difficult to analyse the results independently and 
retrospectively review the trend over time. These shortcomings are compounded by the 
use of derived data (such as %FPF) to interpret the results which has a considerable 
biasing tendency in addition to masking the actual performance of the delivery system. 
Further, statistical analysis has not been reported in many studies while comparison of 
stage- or stage-groups has altogether been missing. Hence, comprehensive data analyses 
for in-vitro equivalence in the light of current regulatory requirements have been 
presented in this thesis.   
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Flow duration of 30 seconds at 28.3 L/min has been used in most studies. This is 
equivalent to 14.15 L of air passing through ACI. However, in this project, airflow for 
8.5 seconds has been used to allow passage of 4 L through ACI so as to reflect on the 
inhalation volume of a healthy human adult (Hall et al., 2011).  
In most reported studies, ACI impaction plates were not coated to prevent particle 
bounce and re-entrainment. However, this shortcoming has been addressed to in this 
project.  
The recommended technique for inhalation from an MDI alone or with spacer requires 
press and breathe in the discharged puff simultaneously. Since in-vivo studies have been 
based on this inhalation manoeuvre; therefore, no inhalation delay methodology has 
been applied for in-vitro studies. Pursuant to this approach, tidal breathing and 
simulation profiles through spacer has not been considered in this project. 
Different methods have been used to pre-treat spacers with divergent in-vitro findings, 
to which many outcomes of in-vivo studies are at variance. Further, the divergence in 
spacer pre-treatment method is also noted in PILs for the same spacer in different 
regions and between countries. Interestingly, FDA advises to wash spacer with water 
after detergent treatment. Because of conflicting evidence and the lack of consensus on 
pre-treatment method, the spacers used in this project have been treated with aqueous 
detergent solution followed by water rinsing and drip-drying. 
2.8 Statements of Purpose 
In-vitro dose delivery characteristics of Ventolin Evohaler
®
, Airomir
®
 and Salamol
®
 
HFA will be investigated for equivalence in the light of the current regulatory 
requirements using clinically relevant dose of 2 puffs. Spacer studies will also be 
conducted using Volumatic, AeroChamber Plus and Able spacer. The round actuator 
mouth piece of Airomir does not fit into Volumatic, therefore, these studies will not be 
undertaken. 
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3 Chapter 3: Methodology 
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3.1 Overview 
In Europe, regulatory authorities apply a step-wise approach for establishing 
equivalence between MDIs; starting from in-vitro comparisons, followed by 
pharmacokinetic (PK) studies and then pharmacodynamics (PD) studies (EMA, 2009; 
Dissanayake, 2010; Evans et al., 2012; Forbes et al., 2015; Lee et al., 2015). If 
equivalence is established at in-vitro level, no further studies are required; otherwise PK 
studies are to be conducted. If PK studies could not prove similarity between 
comparator MDIs then PD studies are to be carried out. Nevertheless, regulatory 
authorities may require further studies beyond in-vitro comparisons as they may deem 
necessary on reasonable grounds. On the other hand, FDA requires all of these studies 
to be performed and the comparator MDIs are considered equivalent only on the weight 
of evidence basis. 
The current project will explore in-vitro and in-vivo equivalence of salbutamol MDIs. 
This chapter outlines the methods, techniques and procedures to be used to carry out the 
research work. Analytical, in-vitro, in-vivo and statistical methodology have been 
outlined separately. 
3.2 Analytical HPLC Methodology 
The development and validation will be carried out in compliance to ICH guidelines 
Q2(R1) (2005). Details of HPLC methods for aqueous and urine samples are provided 
in Chapter 4. 
3.3 In-Vitro Methodology 
Aerodynamic particle size distribution (APSD) profile of an MDI provides information 
on its dose delivery characteristics which may predict the likelihood and whereabouts of 
aerosol particle deposition in the respiratory tract. APSD profiles are generated using 
cascade impactors (BP, 2005; USP28-NF23, 2005; Ph. Eur., 2011; Mitchell and Nagel, 
2003 & 2004; Christopher et al., 2007). An eight-stage Andersen Cascade Impactor 
(ACI) is widely used for the in-vitro determination of the APSD.  
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3.3.1 Materials and Methods 
3.3.1.1 Materials and Equipments 
Andersen Cascade Impactor Mark II, Copley Scientific Ltd., UK. 
Critical Flow Controller Model TPK, Copley Scientific Ltd., UK. 
GAST 1023 Pump Brook Crompton, UK. 
Air Flow Meter  Model PR 4000, MKS Instruments, MA, USA. 
GF 50 filter Copley Scientific Ltd., UK. 
Silicone spray Releasil B silicone spray, Dow Corning Ltd., U.K. 
Parafilm M Laboratory film Pechiney Plastic Packaging, USA. 
3.3.1.2 MDIs 
Ventolin Evohaler™, GlaxoSmithKline, UK 
Airomir™, Teva, UK 
Salamol™, Teva, UK 
These MDIs deliver 100 µg ex-valve (metered dose) and 90 µg ex-actuator (emitted 
dose) per puff as salbutamol base equivalent. Their nominal strengths as salbutamol 
sulphate are 120 µg and 108 µg, respectively. 
3.3.1.3 Spacers 
Volumatic Spacer™, Allen & Hanburys Ltd., UK. 
AeroChmaber Plus™, Trudell Medical International Europe Ltd., UK. 
Able Spacer™, Clement Clarke International Ltd., UK. 
The spacer images are shown in Figure 3.3.1 (not to scale). 
 
 
(a) Volumatic Spacer 
 
(b) AeroChamber Plus 
 
(c) Able Spacer 
Figure 3.3.1. Images of spacers. 
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3.3.2 In-Vitro Study Design 
A designated ACI will be used to minimise variability from different lots (Stein and 
Olson, 1997; Stein, 1999). ACI experiments will be conducted with MDI alone and with 
a spacer, both randomly selected. Studies with Airomir will be performed with 
AeroChamber Plus only since its round mouthpiece does not fit in the oblong inhaler 
port of Volumatic. All MDIs will be stored on their sides while being used to reflect 
normal storage. All experiments to be performed under ambient environmental 
conditions. However, temperature and humidity in the laboratory is maintained between 
18-23 
°
C and 40-60 %RH, respectively. All MDIs, spacers, equipments and solvents are 
to be acclimatised to ambient conditions for 1 hour before use. Each experiment will be 
performed five times using two separate actuations on each occasion. 
3.3.2.1 ACI Procedure 
Pharmacopoeial methods (BP, USP, Ph. Eur.) are to be applied to determine the in-vitro 
particle size distribution of MDI alone and when used with a spacer. Clinically relevant 
dose of 2 puffs of salbutamol MDIs are to be used in this study. Protocol 3.3.1 describes 
procedures for preparing an MDI and spacer before testing and details of ACI testing 
are provided in Protocol 3.3.2. A summary of the testing procedures follows underneath. 
Pre-Test Preparation: 
Salbutamol MDIs are to be primed by discharging puffs to waste; 5 shots from new un-
used MDI and 4 shots from in-use MDI. This is to minimise the probability of firing 
low content puff (Ross and Gabrio, 1999) and to comply with instructions in the patient 
information leaflet (PIL). 
Canister valve and actuator are to be cleaned with deionised water and dried with 
methanol followed by air (Sheth et al., 2015). 
Before each test, the spacer is to be washed in lukewarm mild detergent solution, rinsed 
with deionised water and left to drain and air dry. This pre-treatment minimises the 
electrostatic charge on the spacer (Table 2.4.2). 
Impaction plates are to be coated evenly with silicone oil spray to minimise particle 
bounce and re-entrainment effect (Nasr and Allgire, 1995; Nasr et al., 1997; Mitchell, 
2003; Mitchell and Nagel 2003; Guo et al., 2008; Sheth et al., 2015). The plates are to  
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be left for 15 minutes and then assembled. The assembled plates are to be used for 
testing in 30 min post-spray coating. 
Test Procedure: 
Previously cleaned, washed and dried ACI is to be assembled with silicone oil spray 
coated metal plates using designated stages (Protocol 3.3.1). The stages are to be 
stacked in reverse order of stage number, starting from placing back-up filter in the 
filter stage at the bottom ( 
Figure 3.3.2). A steady airflow through ACI is to be maintained at 28.3 ± 0.5 L/min (in-
house limits) at the Induction Port (IP) using flow meter. Flow duration is to be set at 
8.5 seconds on critical flow controller to allow 4 L of air to pass through. Primed MDI, 
shaken immediately before the experiment, are to be inserted into the IP using a 
designated adapter. The puff is to be discharged while simultaneously starting flow 
through the ACI (Chambers and Ludzik, 2008). Second puff is to be discharged as 
before after shaking for 5 sec, keeping a gap of 30 sec between the two puffs. After 
completing the flow duration, ACI is to be dismounted. The drug contents are to be 
recovered from the MDI and ACI components, stages and filter with deionised water 
and made up to volumes as shown in Table 3.3.1.  
This experiment is to be repeated with pre-treated spacer attached to IP. The MDI puff 
is to be discharged into spacer at its inhaler port (Protocol 3.3.2). Aqueous washings, 
including that from the spacer are to be collected as mentioned earlier. 
3.3.2.2 Sample Analysis 
The sample solutions are to be assayed for salbutamol contents on HPLC using a 
validated method (Chapter 4). 
 
  
 38 
 
 
 
Figure 3.3.2. Schematic representation of ACI experimental set-up for Aerodynamic Particle Size 
Characterisation of an MDI without and with spacer. 
Modified from USP (2005). VOL = Volumatic; AERO = AeroChamber Plus; ABLE = Able spacer 
 
 
 
Table 3.3.1. Washing volumes used for various 
components and stages of ACI. 
MDI and ACI Components / 
Stages 
Volume 
(mL) 
MDI Canister Valve (atomising 
nozzle) 
50 
MDI Actuator 50 
Spacer & mouthpiece adapter 250 
ACI Throat (no spacer used) 200 
ACI Throat (spacer used) 50 
ACI S-0 10 
ACI S-1 10 
ACI S-2 10 
ACI S-3 50 
ACI S-4 50 
ACI S-5 50 
ACI S-6 10 
ACI S-7 10 
ACI Filter 10 
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3.3.2.3 Protocol 3.3.1: Preparing an MDI, spacer and impaction plates for ACI 
testing 
I. Priming of an MDI 
Prime the new un-used MDI with 5 and in-use MDI with 4 shots to waste as follows: 
1. Shake MDI for 5 seconds. 
2. Uphold the MDI vertically and discharge 1st shot inside a card box (with paper towel 
covered inner walls) placed in the fume hood.  
3. Repeat for 2nd and remaining shots as above allowing 30 seconds between shots. 
4. Clean canister valve and actuator with de-ionised water and dry with methanol 
followed by air. 
 
II. Preparation of spacers for testing 
Before each test, wash the spacer in lukewarm mild detergent (1mL of detergent in 2L 
of deionised water), rinse with deionised water and leave to drain and air dry. 
III. Preparation of ACI for Testing 
1. Washing of Impaction Plates: Before (or after) each test, rinse all impaction plates 
with hot water. Then soak them in warm 1% detergent solution in water (e.g., 
10:1000 mL) for 15 minutes. Rinse thoroughly with hot water, followed by 
deionised water and methanol and leave to dry.  
2. Coating of Impaction Plates: 
a. Using tweezers, place previously washed and dried ACI stage plates on the 
designated shelved stand which holds plates vertically. Place this stand in fume 
hood. 
b. Coat plates uniformly by using silicon oil spray. 
c. After coating, lay the shelved stand horizontally outside the fume hood and 
leave for 15 minutes. 
d. Using tweezers, assemble coated plates into ACI stack. 
e. Place the entrance cone on top of assembled stages and hold these together 
with three spring clamps. 
f. Attach the Induction Port to the entrance cone. 
  
 40 
3.3.2.4 Protocol 3.3.2: ACI Testing Procedure 
I. ACI Experiment-MDI alone 
1. Switch on pump, attach flow meter at Induction Port (IP) using adapter and 
adjust flow rate to 28.3 ± 0.5 L/min (in-house limits). Use parafilm if required. 
Make sure all tubing connections and adapter junctions are airtight and airflow is 
consistent. 
2. Set time on Critical Flow Controller to 8.5 seconds to allow for 4 liters of air to 
pass through the ACI. 
3. Shake the MDI for 5 seconds. 
4. Attach the MDI to the IP using designated mouth piece adapter. 
5. Fire 1st shot into ACI and start timer on Critical Flow Controller at the same 
time. 
6. Remove MDI after 8.5 seconds of the shot. 
7. Shake MDI for 5 seconds. 
8. Attach MDI again to Induction Port via the adapter. Allow 30 seconds between 
1
st
 and 2
nd
 shots. 
9. Fire 2nd shot into ACI and start timer on Critical Flow Controller 
simultaneously. 
10. Switch off pump after 8.5 seconds of the last shot. 
11. Recover the dose deposited on MDI components and ACI assembly using de-
ionised water as described below. Collect each washing into separate volumetric 
flasks and make up the volume as shown in Table 3.3.1. 
a) Remove MDI from IP. Take out MDI canister from the actuator. Wash them 
separately. 
b) Release three spring clamps from ACI stages and remove IP assembly 
(entrance cone, IP and MDI mouthpiece adapter). Wash each component. 
When used, collect spacer washings separately (See Section 3.3.2.4, Method 
II). 
c) Using stainless steel tweezers, transfer each impaction plate and the final 
stage filter into designated glass petri-dishes, add about 9 mL of de-ionised 
water and immerse completely. Place designated glass cover on each petri-
dish and gently shake on a flat-bed shaker for 5 min. Wash impaction plates 
of stages S3, S4 and S5 with two additional lots of de-ionised water (~10 ml 
each). 
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12. After completing a single test run, wash ACI equipment and all its components 
with mild hot water paying special attention to stage jet holes. Rinse with de-
ionised water followed by methanol and leave to air dry. Rinse impaction plates 
as described in Protocol 3.3.1 (see Section 3.3.2.3: III (1)). 
 
II. ACI Experiment-MDI with attached spacer 
Use Method I (Section 3.3.2.4) with the following additional adjustments for spacer: 
1. Measure the air flow at Induction Port (IP) and adjust flow rate to 28.3 ± 0.5 
L/min. 
2. Attach spacer to IP with an adapter. If required, use parafilm to make connection 
of spacer to IP inlet airtight. Use an appropriate support such as a stand to keep 
spacer horizontal and flush with Induction Port inlet.  
3. Follow the procedure as described in Method I from Nos. 2 to 12. In brief, after 
shaking MDI for 5 seconds, park it into the inhaler port of spacer. Fire the puff 
into spacer while simultaneously starting the Critical Flow Controller timer to 
allow airflow through ACI. Remove MDI from spacer after 8.5 seconds, shake it 
again for 5 seconds, and repeat as above. Recover dose deposited in MDI 
components and ACI assembly as described in Method I. Disband the spacer, 
wash each part and collect all rinsing into a volumetric flask (Table 3.3.1). 
3.3.3 CQAs, Deposition Profiles and Data Analysis 
EMA quality guideline (2006) enumerates in-vitro tests for MDIs to measure their 
Critical Quality Attributes (CQAs) (ICH Q8, 2009). EMA (2006 & 2009) also requires 
provision of full profiles of APSD and the amount of drug deposited on each stage or 
their justified groupings. The CQAs are described hereunder: 
Total recovery: This is the sum of active drug amounts recovered from the canister 
valve (orifice), the MDI actuator, induction port (IP), spacer (when used), ACI stages 
and back-up filter. The amount recovered from IP includes the amounts recovered from 
the mouth piece adapter and the ACI entrance cone (Figure 2.3.1 and  
Figure 3.3.2). This parameter provides information on the system suitability 
(Christopher et al., 2003) although not required by regulatory authorities. 
Mass balance: This is the amount of active drug delivered from the canister valve, i.e., 
ex-valve, or the metered dose, and includes the amount recovered from the MDI   
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actuator, spacer (when used), IP, ACI stages and back-up filter. Mass balance serves as 
system suitability check (Christopher et al., 2003; EMA, 2006). 
Total emitted dose (TED): This is the dose of active drug that is discharged ex-actuator 
(or ex-mouthpiece) i.e., the amount of active drug deposited in spacer (when used), IP, 
ACI stages and back-up filter.  
Total delivered dose (TDD): For an MDI with attached spacer, this is the amount of 
active drug delivered ex-spacer and includes deposition on IP, ACI stages and back-up 
filter. For an MDI without spacer, TDD = TED. 
Impactor mass (S0toF): This is the amount of active drug recovered from all ACI stages 
and back-up filter. 
Fine particle dose (FPD): This is the amount of active drug deposited on stages 3 to 7 
and back-up filter. FPD (or respirable dose) consists of particles of aerodynamic size < 
5 µm in diameter. The effective cut-off diameter size of ACI stage 3 is 4.7 µm at the 
flow rate of 28.3 L/min (BP; USP; Ph. Eur.). 
Fine particle fraction (FPF): This constitutes the fraction of the active drug having 
aerodynamic particle size <5.0 µm. FPF is calculated as the ratio of FPD to TED and/or 
TDD. Both parameters are also expressed as percentage. 
Aerodynamic diameter (D) and Mass median aerodynamic diameter (MMAD): The D is 
the diameter of a sphere of unit density having the same terminal settling velocity as the 
particle at issue (EMA, 2009). MMAD corresponds to the diameter that divides the 
particle size distribution into two halves with respect to mass (Smyth, 2003; BP; USP; 
Ph. Eur.). MMAD can be derived by plotting the cumulative percentage of mass less 
than the stated cut-off aerodynamic diameters on probability scale versus aerodynamic 
cut-off diameter on log scale.  
Geometric standard deviation (GSD): It is the ratio of median diameter to the diameter 
at ±1 SD from the median diameter (Laube et al., 2011). GSD can also be calculated 
alongside MMAD by using the following equation (BP; USP; Ph. Eur.): 
GSD =  √
D84.13%
D15.87%
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3.3.4 APSD and ACI Stage Grouping  
EMA guidelines (2006 & 2009) also offer options for comparing APSD either as per 
impactor stage or as justified grouped stages. APSD profile obtained from ACI provides 
information on particle size of aerosolized drug. Individual stages are linked to specific 
particle size or a size-range and correlate to human respiratory tract (HRT) deposition 
sites (Pritchard, 2001). The amount of inhaled drug which deposits in HRT or in certain 
regions of HRT is related to clinical effects (Weda et al., 2004; Usmani et al., 2005). 
However, it is difficult to distinguish the role of individual stages for efficacy and 
safety, since underlying physiological and pharmaceutical phenomena (such as 
differences in breathing patterns, patient’s age, gender, disease state, HRT morphology, 
inhalation technique, aerosol velocity in entering the airways and plume geometry) play 
a critical role in lung deposition (Lipworth and Clark, 1997; Labiris and Dolovich, 
2003; Rubin and Fink, 2005; Venegas et al., 2013). On the other hand, stage groups 
include a broad range of particle sizes and relate lung deposition to regions (Pritchard, 
2001). Therefore, inhaled particles from a broad range of sizes may be involved in 
clinical effects. Hence, it is more likely that a group of stages rather than a specific 
single stage represents clinical efficacy and safety. The three salbutamol HFA MDIs 
under study are polydisperse suspensions and generate aerosol clouds that contain a 
range of particle sizes. Therefore, comparison of grouped stages as opposed to 
individual stages is more predisposed to predict clinically relevant in-vitro differences 
between them. 
Thus, ACI components and stages are to be pooled into groups to mimic the likely 
regional deposition in HRT (Table 3.3.2). Similar stage groups were reported by others 
(Heyder et al., 1986; Pritchard, 2001; Asmus et al., 2003; Heyder, 2004; Dunbar and 
Mitchell, 2005; Guo et al., 2008 & 2013; de Boer et al., 2015; Nagel and Suggett, 2017; 
Hillyer et al., 2018). 
ACI has traditionally been used to predict deposition in HRT. Induction Port (IP) (along 
with spacer when used) represents oropharynx. Higher IP (or combined spacer and IP) 
deposition may predict higher oropharyngeal deposition which is largely swallowed and 
absorbed from gastrointestinal tract (GIT). This may lead to salbutamol related systemic 
side effects. Group 1 stages (CPM) represent upper respiratory tract, in particular the 
laryngeal region. Group 2 stages (FPM) represent trachea, bronchi and bronchioles, i.e., 
upper and central airways and deposition in this region is linked to bronchodilation.   
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Group 3 stages (EPM) represent alveolar region (peripheral airways). EPM reaching to 
alveoli is largely exhaled if breath is not held for few seconds. Absorbed EPM may 
contribute to systemic effects. 
 
Table 3.3.2. ACI Stage Grouping. 
ACI Components / 
Stage Groups 
ACI Components / 
Stages 
Particle Size 
(µm) 
Likely Respiratory Tract 
deposition sites 
Induction Port Mass 
(IPM) 
SP (when used), IP, 
Entrance Cone, IP 
(& SP) Adapter(s) 
≥ 10  Oropharyngeal region 
Group 1: Coarse Particle 
Mass (CPM) 
S0 + S1 + S2 < 10 to ≥ 4.7  Pharyngeolarynx region; trachea  
Group 2: Fine Particle 
Mass (FPM) 
S3 + S4 + S5 < 4.7 to ≥ 1.1*  
Trachiobronchial region 
* < 2 µm Alveolar region 
Group 3: Extrafine 
Particle Mass (EPM) 
S6 + S7 + Filter <1.1 to ≥ 0.43 Alveolar region 
 
Further, FPD comparison of MDIs is also to be carried out to determine in-vitro 
equivalence. Since, TDD ex-spacer contains high proportion of FPD, this provides a 
common ground for performance comparison between MDI alone and with a spacer 
(EMA, 2006). Not surprisingly, published work on salbutamol HFA MDI performance 
provides only selective CQAs data while APSD assessment as either individual stages 
or group of stages is altogether lacking. Hence FPD would be a common criterion to 
compare this work to others’. Also in this thesis, these comparisons are centred on data 
generated from ACI and NGI techniques due to their similarity (Mitchell et al., 2003; 
Kamiya et al., 2004).  
3.3.5 Statistical Analyses - In-Vitro Studies 
For in-vitro equivalence determination, data are to be logarithmically transformed. 
Mean ratio and 90% Confidence Interval (CI) are to be generated which are then to be 
exponentially reverted to numerals. The MDIs are to be considered in-vitro equivalent if 
the mean ratio of a CQA (performance parameter) is between 0.85 and 1.18, i.e., within 
±15% of the reference product (EMA, 2006 & 2009). Mean difference at 95% CI is to 
be calculated from non-transformed data (normal scale). ANOVA tests are to be 
performed using Bonferroni corrections for post-hoc pair-wise multiple comparisons; p 
< 0.1 and p < 0.05 are to represent significant differences for ratios and mean 
differences, respectively. Statistical analyses are to be performed using SPSS (SPSS 
Inc., USA).  
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CQAs and derived parameters are to be calculated from ACI components and stage data 
using MS Excel (Microsoft Corporation). MMAD and GSD are to be determined using 
Copley Inhaler Testing Data Analysis Software (CITDAS, Copley Scientific, UK). 
3.4 In-Vivo Methodology 
Pulmonary deposition and systemic bioavailability of an inhaled drug can be 
characterised by pharmacokinetic (PK) studies (EMA, 2009). PK methods are indirect 
measurements from serum and urine (Chrystyn, 2001; Lu et al., 2015). These methods 
are useful in crossover studies to investigate the equivalence between inhaled products, 
inhalation treatment methods, devices and techniques. 
It has been shown that 10-20 % of inhaled salbutamol from an MDI reaches the lungs 
while the remaining dose impacts on the oral cavity and oropharynx (Lipworth, 1996; 
Chrystyn, 2001). Since salbutamol is only negligibly absorbed from buccal mucosa 
(Lipworth et al., 1989a), most of it is eventually swallowed and subsequently absorbed 
through the GIT (Newman et al., 1981). The swallowed fraction undergoes pre-systemic 
metabolism in the intestine and first-pass degradation in liver (Ward et al., 2000). Only 
a small fraction (8%) of salbutamol is protein bound (Martin et al., 1971; Goldstein et 
al., 1987). 
Following inhalation, salbutamol is delivered to the lungs within 1-3 seconds and is 
instantly absorbed (Shenfield et al., 1976). Since there is no first-pass conjugation in the 
lung (Shenfield et al., 1976; Ward et al., 2000), active (unchanged) salbutamol rapidly 
appears in the systematic circulation and is eliminated in the urine very quickly. 
However, GI absorption of salbutamol is noticeably delayed as compared to lung 
absorption. It has been shown that following oral administration there were negligible 
amounts of salbutamol excreted in the urine within the first 30 min post-dosing (Hindle 
and Chrystyn, 1992; Silkstone et al., 2000). Further, Du et al. (2002) found two plasma 
peaks after inhaled salbutamol, 1
st
 at 15 min and the 2
nd
 at 2 hours when the mouth 
rinsing water was swallowed after inhalation. They attributed the 1
st
 peak to lung 
deposition and 2
nd
 peak to GI absorption of the swallowed mouth rinsing water. This is 
in line with the findings that 60% of systemic bioavailability of inhaled salbutamol was 
from the swallowed fraction (Ward et al., 2000) and that 50% of orally administered 
dose was absorbed from the gut reaching a peak at about 2 hours after intake (Goldstein 
et al., 1987).  
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It is clear that differences in the rate of absorption exist between the two absorption 
pathways. Hence, this lag time between quick lung absorption and delayed oral 
absorption of salbutamol has the potential to differentiate between lung deposition and 
systemic bioavailability (Hochhaus et al., 2015). Monitoring salbutamol in the urine 
over the first 30 min post-inhalation indicates how much salbutamol entered the 
systemic circulation through pulmonary absorption (Hindle and Chrystyn, 1992). 
Therefore, the first 30 min post-inhalation of salbutamol dose is considered as a 
sensitive index of the lung dose and indicates the relative bioavailability to the lungs 
(Hindle and Chrystyn, 1992). Pharmacokinetic studies using plasma differentiate 
between them by determining partial area-under-the-curve (AUCs) such as AUC(0–0.5), 
Cmax and tmax(0-0.5) (Singh et al., 2011; Moore et al., 2017). A number of investigators 
used first 20 min to represent this index (Lipworth and Clark, 1997, Anhøj et al., 1999, 
Mobley and Hochhaus, 2001; Du et al., 2002). However, tmax(0-0.5) is measured at pre-set 
time points and therefore may not be a true tmax which may fall between those times 
(Weber et al., 2010; Evans et al., 2012). 
Total systemic bioavailability of salbutamol is estimated by comparing plasma AUC 
data or urinary drug excretion (to infinity). Hindle and Chrystyn (1992) collected urine 
up to 24 h post-inhalation to assess total systemic delivery.  
Salbutamol is a polar and basic molecule (The Merck Index, 2003) and therefore 
unaffected by changes in the urine pH (Chrystyn, 2001). Because of these 
physicochemical properties, its passive tubular reabsorption in the kidney is prevented 
which obviates the need to control urine pH. 
Comparisons of relative lung and total systemic bioavailability give some indication of 
relative efficacy and safety, respectively, of different inhalation methods or products in 
crossover studies. 
Urinary excretion of drug following the oral administration of charcoal identifies the 
total effective lung dose (Borgstrom and Nilsson, 1990). The charcoal block technique 
separates systemic delivery via the gastrointestinal and pulmonary routes by preventing 
GI absorption. The systemic exposure from this study serves as a surrogate for the local 
lung absorption and exposure. When GI absorption is prevented, the differences in the 
AUCs indicate differences in the dose reaching the airways. Further, EMA (2009) 
requires two PK studies for drugs with significant GI absorption such as salbutamol. 
One study is performed in the absence of charcoal to prove “safety equivalence” as the   
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total systemic exposure from both the lung and gut absorptions is measured. The second 
PK study is performed in the presence of activated charcoal to prove “efficacy 
equivalence” and only measures the “lung absorption exposure” as the absorption from 
the gut is inhibited by the charcoal. The charcoal blockade method therefore assesses 
the potential differences in pulmonary delivery. Hence, charcoal blockade studies have 
been often used in PK studies (Thorsson et al., 1994; Ward et al., 2000; Daley-Yates et 
al., 2001; Silkstone et al., 2000 & 2002b; Mazhar and Chrystyn, 2009; Abdelrahim et 
al., 2011; Singh et al., 2011; Said et al., 2012; Moore et al., 2017). 
The application of plasma pharmacokinetic methods to inhalation studies is difficult. 
The small doses in large volume of distribution result in low systemic concentrations 
(Hindle and Chrystyn, 1992), which keep decreasing over time and present challenges 
for drug assay accuracy and reproducibility (Rogers and Ganderton, 1995). Also, 
sophisticated and costly analytical equipment may be required to quantify low plasma 
levels. Administering high doses may have implications for systemic effects (Lipworth 
et al., 1989; Fowler and Lipworth, 2001; Du et al., 2002) while not being clinically 
relevant. Hence, in these circumstances EMA (2010) would accept urinary excretion 
data as a surrogate for a plasma concentration-time profiles. In contrast, the 
concentrations of drugs in urine are much higher and can be assayed with simple 
analytical instruments using clinically relevant doses. 
Further, plasma pharmacokinetic (PK) methods are invasive and require involvement 
and supervision of health care personnel which is not always feasible. Besides, these 
methods make it difficult to recruit healthy volunteers and patients. On the other hand, 
urinary PK methods are non-invasive and simple to carry out. 
The PK method proposed by Hindle and Chrystyn (1992) uses urine concentrations to 
estimate the amount of inhaled drug. The amount of salbutamol excreted in the first 30 
min identifies the relative lung bioavailability, and the cumulative amount of salbutamol 
and its metabolite excreted over the 24 hour post-inhalation identifies relative systemic 
bioavailability. This method has demonstrated linearity of dose-response relationship of 
inhaled salbutamol (Tomlinson et al., 1995; 2003) and inhaled terbutaline (Abdelrahim 
et al., 2011), and is reproducible (Hindle and Chrystyn, 1994; Tomlinson et al., 2003; 
Abdelrahim et al., 2011; Said et al., 2012). This method has been shown to be useful to 
compare inhaled salbutamol from MDI with oral salbutamol administration (Hindle and 
Chrystyn, 1992; Silkstone et al., 2000), spacers used with MDI (Chege and Chrystyn,   
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1994; Hindle and Chrystyn, 1994; Silkstone et al., 2002a; Mazhar and Chrystyn, 2008), 
DPIs (Hindle et al., 1995; Hindle et al., 1997; Chege et al., 1998) and nebulisers 
(Silkstone et al., 2000; Silkstone et al., 2002b; Mazhar et al., 2008). Moreover, this 
method can also differentiate between inhalation techniques (Hindle et al., 1993; 
Tomlinson et al., 2005) and formulations (Chege and Chrystyn, 2000). This method has 
also been useful to verify the correlation between lung deposition and improved 
spirometry (Chrystyn et al., 1998; Tomlinson et al., 1999 and 2005; Mazhar et al., 
2008). 
Further, this method has also been extended to other inhaled drugs, such as sodium 
cromoglycate (Aswania et al., 1999; Aswania and Chrystyn, 2001 & 2002), nedocromil 
(Aswania et al., 1998), gentamicin (Nasr and Chrystyn, 1997; Al-Amoud et al., 2005), 
formeterol (Nadarassan et al., 2007), terbutaline (Abdelrahim et al., 2011) and 
beclometasone (Said et al., 2012).  
In the current project, this urinary PK methodology is being applied to salbutamol HFA 
MDIs and will be extended to spacers used with them. 
3.4.1 Bioequivalence and regulatory requirements 
There is ongoing debate on acceptable methodology and bioequivalence (BE) limits for 
PK studies of inhaled drugs (Parameswaran, 1999; Daley-Yates and Parkins, 2011; 
Fuglsang, 2012; Garcia-Arieta and Gordon, 2012; Evans et al., 2012; Hochhaus et al., 
2015; Al-Numani et al., 2015; Lee et al., 2015; Lu et al., 2015). In addition, there are 
differences in the approach of regulatory bodies in Europe and other continents. EMA 
guideline (2009) states that PK studies be conducted in patients, while FDA 
recommends these studies are performed in healthy volunteers. Interestingly, EMA 
guideline (2010) suggests that the model of healthy volunteers is adequate in most 
instances to detect formulation differences and to extrapolate the results to other 
populations (e.g., the elderly, children). However, the rare instances where the 
extrapolation is not adequate are not identified. Therefore, in the present situation, it can 
be assumed that the model of healthy volunteers is applicable (García-Arieta and 
Gordon, 2012). It may be that those with asthma may have different airway deposition. 
Nevertheless, it has been shown that the only difference between healthy volunteers and 
those with asthma is that lung deposition is related to airway calibre (Lipworth and 
Clark, 1997) and therefore bioequivalence studies are often conducted in healthy   
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subjects (Daley-Yates and Parkins, 2011). Furthermore, Hochhaus et al. (2015) report 
that EMA is currently accepting these studies in healthy volunteers. 
Healthy volunteer PK studies are likely to be at least as, or more, sensitive than patient 
studies to detect differences between different treatment methods, inhalation techniques 
and formulations (Dissanayake, 2010). Also, the model of healthy volunteers avoids the 
influence of variable airways obstruction across study periods in asthma and COPD 
patients. Besides, the urinary salbutamol pharmacokinetic method has been shown to be 
more sensitive to detect a difference in relative lung deposition than the methacholine 
challenge method recommended by Regulatory Authorities (Tomlinson et al., 2003). 
Hence, it is reasonable to preferentially undertake PK studies in healthy volunteers. 
Therefore, healthy volunteers will participate in the current study. Further, EMA 
recommends the conduct of the BE study with and without the use of spacers.  
3.4.2 Bioequivalence criterion 
Regulatory limits for the bioequivalence of inhaled products are that the 90% 
confidence limits should be between 0.80–1.25 for Cmax and AUC (EMA, 2009 & 
2010). However, it has been suggested that when comparing relative potencies these 
limits should be between 0.67 and 1.50 (EMA, 2009; Parameswaran, 1999). Hence, the 
urinary PK data in this project will be assessed in line with both these limits. 
Much larger numbers of subjects may need to be studied to make firmer conclusions to 
suggest comparability between inhaled products. However, most of the studies that were 
included in a meta-analysis comparing different inhalation methods used a low number 
of subjects (Brocklebank et al., 2001), and were designed to show equivalence. Hence, 
in this project, a minimum number of 12 evaluable subjects will be included which is in 
compliance to EMA (2010) recommendations for any BE study.  
3.4.3 Subject selection 
EMA requires that subjects should be ≥18 years of age and preferably have a Body 
Mass Index (BMI) between 18.5 and 30 kg/m
2
, and that they could belong to either sex.  
Healthy and non-smoking volunteers from either sex will be selected for the PK study. 
Smokers will be excluded as they may introduce variability due to having an altered 
mucociliary clearance and local microenvironment (Scott, 2004) and induced   
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metabolism (Kroon, 2007; Olsson et al., 2011). Besides, pregnant women will be 
excluded.  
This study is to be conducted in accordance with Good Clinical Practice and the guiding 
principles of the Declaration of Helsinki (World Medical Association (WMA), 2013). 
3.4.4 Subject training 
Training of the subjects for correct and consistent inhalation technique is essential to 
minimise variability in the dose delivery that is not related to the treatment method. All 
healthy volunteers will therefore be trained to use the following inhalation technique 
(Hindle et al., 1993; Laube et al., 2011; PILs): 
3.4.4.1 MDI alone inhalation technique 
1. Take the cap off. 
2. Shake the primed MDI for 5 seconds (see Protocol 3.3.1 (3.3.2.3) for priming). 
3. Exhale slowly, as far as comfortable (to empty the lungs). 
4. Hold the inhaler in an upright position. 
5. Immediately place the inhaler in the mouth between the teeth, with the tongue 
flat under the mouthpiece. 
6. Ensure that the lips have formed a good seal with the mouthpiece. 
7. Start to inhale slowly, through the mouth and at the same time press the 
canister to actuate a puff. 
8. Maintain a slow and deep inhalation for 5-10 seconds, through the mouth, until 
the lungs are full of air. 
9. At the end of the inhalation, take the inhaler out of the mouth and close the 
lips. 
10. Continue to hold the breath for as long as possible, or up to 10 seconds before 
breathing out slowly. 
11. Breathe normally. 
12. Repeat steps 2–10 for the second puff after 30 seconds. 
3.4.4.2 MDI with the attached Spacer 
1. Take the cap off. 
2. Shake the primed MDI for 5 seconds (see Protocol 3.3.1 (3.3.2.3) for priming). 
3. Insert the mouthpiece of the MDI into the open end of the spacer (MDI port) 
and ensure a tight fit.  
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4. Exhale slowly, as far as comfortable (to empty the lungs). 
5. Place the mouthpiece of the spacer in the mouth with the teeth over the 
mouthpiece and the lips sealed around it. 
6. Actuate one puff into the spacer and simultaneously start to inhale slowly 
through the mouthpiece.  
7. Maintain a slow and deep inhalation for 5-10 seconds through the mouth, until 
the lungs are full of air. 
8. At the end of the inhalation, take the spacer out of the mouth and close the lips. 
9. Continue to hold the breath for as long as possible for up to 10 seconds before 
breathing out slowly. 
10. Breathe normally. 
11. Repeat steps 2–9 for the second puff after 30 seconds. 
3.4.5 In-Vivo Study Design 
This bioequivalence single dose cross-over open study has been approved by Bradford 
University Ethics Committee. Initially, 14 non-smoking healthy volunteers (7 females) 
older than 18 years with an average FEV1 > 90% of predicted participated after giving 
informed written consent. However, one male volunteer discontinued due to illness 
which was not study-related. 
All volunteers are to be trained in optimal inhalation technique (Sections 3.4.4.1 & 
3.4.4.2) and are to be refreshed on the standard technique on the day of study before 
inhaling the dose. 
All salbutamol MDIs are to be primed immediately before each study and detergent pre-
treated spacers are to be used (Protocol 3.3.1 (3.3.2.3)).  
The PK study is to consist of two parts. In Part 1, each volunteer is to inhale 2 puffs 
from the primed salbutamol MDI in two separate manoeuvres. In Part 2, each volunteer 
is to repeat this study with the concurrent administration of activated charcoal by 
swallowing 100mL of charcoal slurry immediately before and after two inhalations 
(Activated Charcoal 25g in 200mL of water; Carbomix
TM
, Penn Pharmaceuticals, UK) 
(Silkstone et al., 2000; Mazhar and Chrystyn, 2009). Volunteers are to swish around 
charcoal slurry in the mouth before swallowing all of it. Each study is to be separated by 
7 days to allow for wash-out of salbutamol. 
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Urine samples are to be collected 0.5 hour before and after inhalation, the post-dose 
sampling time to start after inhaling the 1
st
 puff. Thereon total urine is to be pooled for 
24 hours. Volume and pH of all urine samples is to be recorded. All urine samples are to 
be stored at –20°C till extracted and assayed. 
The residual dose in MDI actuator and spacer (when used) is to be assayed after 
inhaling two puffs (Protocol 3.3.2 (3.3.2.4)). 
3.4.5.1 Bioequivalence of Salbutamol HFA MDI alone 
This is a six way study in two parts. Each part of this study consists of three sub-sets 
involving three different salbutamol MDIs, vis-à-vis: Ventolin Evohaler
®
, Airomir
®
 and 
Salamol
®
. Each volunteer is to inhale 2 puffs in two separate manoeuvres (as detailed in 
Section 3.4.4.1) from one of the randomly selected primed MDI.  
3.4.5.2 Bioequivalence of Ventolin Evohaler without and with spacer 
This is two parts eight way study. Each part of this study consists of four sub-sets 
involving four treatment methods of salbutamol inhalation from either Ventolin 
Evohaler alone (Evo) or attached to one of the three pre-treated spacers: Volumatic
®
 
(VOL), AeroChamber Plus
®
 (AERO) or Able
®
 (ABLE). 
Each volunteer is to inhale 2 puffs in two separate manoeuvres (as described in Section 
3.4.4.2). Each single dose discharged into a spacer is to be inhaled within the first 
second of discharge into one of the randomly selected spacer. 
3.4.5.3 Bioequivalence of Airomir Without and with AeroChamber Plus 
This is a four way two parts study. Each part of this study consists of two sub-sets 
involving two methods of salbutamol inhalation, vis-à-vis: Airomir alone (Airo) and 
with AeroChamber Plus (AERO). Volunteers to inhale 2 puffs as narrated in Section 
3.4.4.2. 
3.4.5.4 Bioequivalence of Salamol without and with spacer 
This is a six way study split in two parts. Each part of this study consists of three sub-
sets involving three treatment methods of salbutamol inhalation from either Salamol 
(Sala) alone or attached to VOL and AERO. Every volunteer to inhale 2 puffs as 
explained in Section 3.4.4.2.  
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3.4.6 Sample Analysis 
Urine samples are to be processed and assayed for salbutamol using validated SPE and 
HPLC methods described in Chapter 4. 
3.4.7 Statistical Analysis – In-Vivo Studies 
Statistical comparisons are to be made between all treatment methods; i.e., MDIs, MDI 
alone and MDI with spacer, and between spacers. For in-vivo equivalence 
determination, data are to be logarithmically transformed. Mean ratio and 90% 
Confidence Interval (CI) are to be generated which are then to be exponentially reverted 
to numerals. Two tier assessment of bioequivalence of the treatment methods is to be 
carried out, one at ±20% (0.80 – 1.25) and the other at ±33% (0.67 – 1.50). The 
comparative treatment methods are to be considered in-vivo equivalent if the mean ratio 
of parameters under study (USAL0.5 and USAL24) is within one of these limits (EMA, 
2009). Mean difference at 95% CI is to be calculated from non-transformed data 
(normal scale). ANOVA tests are to be performed using inhalation method as fixed and 
volunteers as random factors. Bonferroni corrections are to be applied for post-hoc pair-
wise multiple comparisons; p < 0.1 for mean ratios and p < 0.05 for mean differences 
are to represent significance.  
A paired t-test with 95% CI is to be used to compare recoveries of inhaled salbutamol 
without and with charcoal blockade and p < 0.05 is to be considered a significant 
difference. 
The delivered dose to the volunteers is to be estimated by subtracting the dose that is 
retained in the MDI components and spacer (UDD) from the nominal dose (ND) (200 
µg) [ND – UDD]. 
Statistical analyses are to be performed using SPSS v22 (SPSS Inc., Chicago, USA).  
3.4.8 Summary of Methodology 
The research in this project will have three components vis-à-vis: analytical method 
development for inhaled salbutamol, in-vitro characterisation of salbutamol MDIs 
without and with spacer, and their in-vivo equivalence. Analytical method development 
will be carried out as per ICH guidelines (Q2R1) while in-vitro and in-vivo equivalence 
will be assessed in line with EMA guidelines (2006, 2009 & 2010).  
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4 Chapter 4: Development and validation of salbutamol 
HPLC assay 
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4.1 Overview 
Salbutamol is a widely prescribed 
2
-agonist for relieving bronchospasm in patients 
with asthma and Chronic Obstructive Pulmonary Disease (NICE, 2010 & 2017; 
Moxham and Costello, 1997; Pride, 1987). Salbutamol is first-pass metabolised to an 
inactive sulphate conjugate in the liver and possibly in the gut wall (Morgan et al., 
1986). It is rapidly absorbed from the gastro-intestinal tract and excreted in the urine as 
an unchanged drug or metabolites. On inhalation, about 10 to 30 % of the salbutamol 
dose is absorbed from the lung and most of the remaining inhaled dose is swallowed 
and absorbed from the gut (Chrystyn, 2001). It is suggested that salbutamol does not 
metabolise in the lung (Hindle and Chrystyn, 1992). The amounts of salbutamol 
recovered as unchanged or metabolite fraction determines the proportion of inhaled 
salbutamol relative to the proportion swallowed. Since only unchanged salbutamol is 
effective in relieving the acute attacks of bronchospasm rapidly, it is therefore rational 
to quantify the amounts of both unchanged and metabolised salbutamol so as to identify 
its relative lung deposition. Relative lung deposition is used as a yardstick in inhalation 
bioequivalence studies. 
A urinary salbutamol pharmacokinetic method has been identified to compare the 
relative lung and systemic bioavailability of different inhaled products and inhalation 
techniques (Hindle and Chrystyn, 1992). Although several reversed phase high 
performance liquid chromatography (HPLC) methods have been reported to determine 
salbutamol in biological fluids for studying its pharmacokinetics in healthy volunteers 
and patients (Rejeev et al., 1982; Hutchings et al., 1983; Morgan et al., 1986; Miller and 
Greenblatt, 1986; Ong et al., 1989; Lipworth et al., 1989; Hindle and Chrystyn, 1992; 
He and Stewart, 1992; Gupta et al., 1994; Clark et al., 1996; Mohamed et al., 1999; 
Murthy and Hiremath, 2004), only three have used a urine matrix (Morgan et al., 1986; 
Clark et al., 1996; Hindle and Chrystyn, 1992). Since urine matrix has more endogenous 
interfering peaks as compared to plasma/serum, it was not possible to use assay methods 
developed for plasma/serum matrix. In addition, collection of blood from healthy 
volunteers and patients require invasive techniques which limits their participation in 
the clinical trials. Morgan et al. (1986) worked at low sensitivity because of the 
presence of interfering peaks in urine while Clark et al. (1996) did not hydrolyse urine 
samples to assay the salbutamol ester metabolite. Both methods do not use an internal 
standard. 
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The analysis method of Hindle and Chrystyn (1992) has been widely used to identify 
the relative lung and systemic bioavailability following an inhalation (Chrystyn, 2001). 
However, the run time of this assay is long (>50 min) because of the need to split some 
interferences with the salbutamol and the internal standard (bamethane) peaks which 
frequently could not be baseline resolved. Also, the SPE method produced variable 
recoveries of salbutamol and bamethane. Further, these recoveries were very low (≤30% 
and ≤40%, respectively) from the hydrolysed urine samples. The aim of this study was 
therefore to overcome these difficulties. Hence a new HPLC method with a reasonably 
short run time and two new solid phase extraction (SPE) methods have been developed, 
optimised and validated using terbutaline as the internal standard. The first SPE method 
uses mixed-mode cationic cartridges but can only be used for unchanged salbutamol. 
The second method uses polymeric cartridges and can be used for both unchanged and 
total salbutamol (unchanged plus metabolised). Since many studies only use data for 
unchanged salbutamol in the first 30 min then the first method is recommended because 
the extraction cartridges are much cheaper and the sample preparation time is shorter. 
The application of the assay to quantify salbutamol excreted in urine from participants 
of an inhaler study is reported. 
4.2 Experimental 
4.2.1 Materials and Reagents 
All solvents used for chromatography and SPE were of HPLC grade (BDH, UK). 
Reagent grade orthophosphoric acid (H
3
PO
4
, 85%, specific gravity 0.85), 7 N 
hydrochloric acid (HCl), ammonia solution (35%, specific gravity 0.88), sodium 
dodecyl sulphate (Biochemical; SDS), potassium dihydrogen phosphate (KH
2
PO
4
) and 
potassium hydroxide pellets (KOH) were also obtained from BDH (UK). Ultra-purified 
(Deionised) water was prepared in-house using a Milli-Q Reagent Water System 
(Millipore). Salbutamol base, terbutaline hemisulphate, bamethane and other drugs and 
compounds tested for method specificity and selectivity were purchased from Sigma-
Aldrich (UK). 
4.2.2 Preparation of Reagents for SPE 
Stock solution of KH
2
PO
4
 (0.5 M, pH 7.0) was prepared, pH adjusted with KOH (10 M) 
and filtered (0.45 m). Working buffers of 100, 60, 45, 30 and 15 mM were prepared 
from the stock buffer solution. Another aliquot of 0.5 M KH
2
PO
4
, pH 13.0 was   
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prepared for use in post-hydrolysis SPE. All buffers were stored at ambient temperature 
(25-27C) and used within 3 months. 
Stock solution of HCl (1 N, ±0.2%) was prepared by diluting HCl (~7 N, BDH Convol) 
in water to make 1 L. Working HCl strengths (0.00001 N, pH ~5.0; 0.005 N, pH ~2.50; 
0.01 N, pH ~ 1) were made from diluting 1 N HCl in purified water. All dilutions were 
used within 6 months and the stock solution (1 N) in one year. 
Aqueous solutions (v/v) of methanol (MeOH, 5%), acetonitrile (ACN, 2%), 
tetrahydrofuran (THF, 0.25%) and acetic acid (CH3COOH, 2%) were prepared fresh 
every week. Ammoniacal methanol (6% v/v, pH ~12.0) was prepared fresh on the day 
by adding ammonia solution (6 mL) to HPLC grade methanol (25 mL). 
4.2.3 Preparation of Urine and Aqueous Standards 
Blank urine was obtained from 14 (7 females) volunteers to prepare stock and working 
standard solutions. Stock aqueous solutions of 10,000 g/L for salbutamol base and 
5000 g/L for terbutaline sulphate were prepared. Stock salbutamol urine standard 
(1000 g/L) was prepared by diluting appropriate volume of the aqueous stock solution 
with urine. From this urine stock solution working urine standard solutions containing 
salbutamol concentrations of 750, 500, 300, 250, 200, 150, 100, 75, 50, 25, 15, 10 and 5 
g/L were prepared by serially diluting urine standards with urine. Quality Control 
(QC) standards (200, 100 & 50 g/L) were prepared from a separate stock solution. All 
urine standard solutions and blanks were transferred to polypropylene tubes (25 mL) 
and frozen at −20ºC. Previous studies have shown that when prepared and frozen at 
−20ºC, these standards were stable for 12 months (Tomlinson, 2000). All standard 
solutions were therefore frozen and used within 12 months. Terbutaline sulphate 
aqueous solution (500 g/L) was used as the internal standard in situ during the SPE. 
Salbutamol aqueous standards were prepared in parallel concentrations each containing 
500 g/L terbutaline sulphate. All aqueous standards were stored at 5ºC. 
4.2.4 Solid-phase extraction methods 
Varian Vac Elute workstations (10 cartridge ports) with on-line laboratory vacuum were 
used for extraction. Eluates were dried under nitrogen (N2) in the fume hood using a  
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Techne Dri-Block DB-3A sample concentrator, reconstituted with 1 mL mobile phase, 
thoroughly mixed and transferred to autosampler vials (screw-capped with air-tight 
seals) for injection onto the HPLC system. 
4.2.4.1 SPE Pre-Hydrolysis (USAL METHOD) 
Solid phase extraction (SPE) of unchanged salbutamol was carried out using mixed-
mode cationic-exchange Isolute Confirm HCX 130 mg cartridges with a 10 mL capacity 
(IST, UK). The extraction procedure is described in Table 4.2.1. To each urine sample 
(1 mL), internal standard terbutaline (1 mL) was added. Similarly, in the blank urine 
sample, purified water was added instead of the internal standard. The samples were 
allowed to run through under gravity. Care was taken not to let the cartridges dry in any 
step before sample application. 
4.2.4.2 SPE Post-Hydrolysis (USALMET METHOD) 
Oasis HLB 30 mg in 1 mL (Waters, UK) polymeric cartridges were used for the 
extraction of total salbutamol (unchanged plus metabolised) and the internal standard. 
To each cartridge, a 25 mL reservoir (IST, UK) was attached at the top using an adapter 
(Supelco, UK). The flow rate of sample application and elution was maintained between 
1-2 mL/min using vacuum while low vacuum was applied throughout the SPE. 
The urine samples were first hydrolysed to convert all metabolised salbutamol back to 
the free salbutamol. The hydrolysis procedure consisted of boiling for 1 hour in a water 
bath a solution of 1 mL urine sample and 1 mL internal standard terbutaline in a glass 
test tube to which 8 mL of 0.1 N HCl was added and vortex mixed (10 mL). The test 
tubes were covered with kitchen foils and it was ensured that the meniscus of the test 
tube solution was well dipped into the boiling water. Blank urine was treated similarly 
except that 1 mL of purified water was added instead of the internal standard. After acid 
hydrolysis, the samples were left to cool and then 1 mL of 0.5 M KH2PO4 (pH: 13.0) 
was added and vortex mixed. The pH of the neutralised hydrolysate (11 mL) was 
checked randomly. The extraction procedure is described in Table 4.2.2. 
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Table 4.2.1. Sample pre-treatment and SPE method for salbutamol and 
terbutaline from un-hydrolysed urine (USAL METHOD). 
SPE Pre-Hydrolysis (USAL METHOD) 
Sample/Blank Pre-Treatment 
1 mL Sample/Blank urine 
1 mL Internal Standard/1 mL H2O in Blank urine 
2 mL 30 mM KH2PO4 (pH: 7.0) 
Mix and check final pH if necessary and randomly 
Total Volume: 4 mL 
Vol. 
(mL) 
SPE PROCEDURE 
Solvents/Reagents 
1.0 MeOH 
1.0 15 mM KH2PO4 (pH: 7.0) 
4.0 Pre-treated Sample/Blank 
2.0 15 mM KH2PO4 (pH: 7.0) 
2.0 HCl (0.00001 N, pH: 5.0) 
 Dry for  2 min under full vacuum 
1.0 HCl (0.005 N, pH: 2.50), apply low vacuum 
 Dry for  5 min under full vacuum 
1.50 MeOH:H2O (75:25) 
 Dry for  5 min under full vacuum 
 Insert glass test tubes for eluate collection 
1.0 
NH3:MeOH (06:94), apply low vacuum for 2-3 min when all 
eluted 
 Concentrate at 60
0
C under N2  for 15 min 
1.0 
Reconstitute with mobile phase, mix and transfer to 
autosampler vials, screw-capped with air-tight seals, for 
injection onto the HPLC system 
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Table 4.2.2. Sample pre-treatment and SPE method for salbutamol and 
terbutaline from hydrolysed urine (USALMET METHOD). 
SPE Post-Hydrolysis (USALMET METHOD) 
Sample/Blank Pre-Treatment 
1 mL Sample/Blank Urine 
1 mL Internal Standard/1 mL H2O in Blank urine 
8 mL 0.1N HCl, vortex mix, cover with kitchen foil, make sure sample 
meniscus is well dipped in boiling water, boil for 1 hour, cool 
1 mL 0.5 M KH2PO4 (pH: 13.0), vortex mix 
Check final pH if necessary and randomly: 6.5 - 7.2 
Total Volume: 11 mL 
Vol. 
(mL) 
SPE PROCEDURE 
Solvents/Reagents 
2.0 MeOH 
2.0 45 mM KH2PO4 (pH: 7.0) 
11.0 Pre-treated Sample/Blank 
2.0 15 mM KH2PO4 (pH: 7.0) 
 Dry for  2 min under full vacuum 
1.0 MeOH:H2O (05:95 
 Dry for  1 min under full vacuum 
1.0 ACN:H2O (02:98) 
 Dry for  1 min under full vacuum 
1.0 THF:H2O (0.25:99.75) 
 Dry for  2 min under full vacuum 
 Insert glass test tubes for eluate collection 
2.0 
CH3COOH: H2O (02:98), apply low vacuum and continue for 
2-3 min when all eluted 
 Concentrate at 120
0
C under N2  for 35 min 
1.0 
Reconstitute with mobile phase, mix and transfer to 
autosampler vials, screw-capped with air-tight seals, for 
injection onto the HPLC system 
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4.2.5 Optimised HPLC Method 
The HPLC system and optimised HPLC method are detailed in Table 4.2.3. 
Table 4.2.3. HPLC system and chromatographic conditions. 
1. HPLC System 
Pump Gilson 307 
Degasser Membrane Degasser, Thermal Separation Products 
Column Thermostat Column Chiller Model 7950, Jones Chromatography, UK. 
Autosampler SIL-9A Autosampler, Shimadzu, Japan. 
Column Zorbax, ODS 5 m, 25 cm x 0.46 mm ID; Phenomenex, UK. 
Guard Column Security Guard cartridge, ODS 4 mm x 3 mm ID; 
Phenomenex, UK. 
Detector Spectroflourometric Detector RF-551 (Ver. 2.4, 12 L flow 
cell); Shimadzu, Japan. Detector settings: Response time 1.5, 
Range x 128, Sensitivity High, Gain 1 and signal output at 
1mV full scale 
Integrator Shimadzu Chromatopac CR-6A with attenuation set on 8 
using Method 2061, Format 0.0 (zero) and signal input from 
the detector at 1 mV 
2. Chromatographic conditions 
Mobile Phase (MP) Acetonitrile:Tetrahydrofuran:Methanol:Buffer (B) with 
respective ratio of [10:08:14:68 (% v/v/v/v)] 
Buffer (B) KH
2
PO
4
, 5 mM, pH 2.50 
Ion Pairing Agent Sodium Dodecyl Sulphate 25 mM (Dissolved in B) 
Filtration and 
Degassing 
The mobile phase was filtered (0.45 m, Millipore) and 
degassed by sonication (Decon FS200 B) under vacuum for 10 
min. 
Excitation: 
Emission 
269:312 (nm) 
Injection Volume 100 L using 200 L loop 
Flow Rate 1 mL/min 
Temperature 30
º
C 
Working Pressure 145-150 Bar 
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4.2.6 Validation 
The efficiency of chromatographic separation and solid-phase extraction was evaluated 
and validated according to criteria described in the literature (Szepesi et al., 1989; Buick 
et al., 1990; Causey et al., 1990; Shah et al., 1992; CDER, 1994 & 2013; EMA, 2012; 
ICH-Q2(R1), 2005). 
4.2.6.1 Validation of HPLC 
Selectivity was determined by injecting:  
a) blank mobile phase, Milli-Q water and blank urine collected from volunteers 0.5 
hour before a salbutamol inhalation,  
b) aqueous and urine standards, and  
c) volunteers’ urine samples collected 0.5 and 0.5-24 hour after salbutamol 
inhalation. Both un-hydrolysed and hydrolysed urine specimens were extracted 
and assayed. 
Intra-day accuracy and repeatability (RSD of peak height ratio) were determined by 
injecting three salbutamol concentrations (50, 100 and 200 µg/L; QC Standards) in 
triplicate. The accuracy and precision of the calibration curves to measure the unknown 
concentrations or QC standards were determined by drawing calibration curves 
excluding these concentration points and expressed as mean measured concentrations 
(with their respective biases) and RSD. 
The inter-day accuracy and precision were determined for all concentrations of the 
standard calibration curve. Inter-day accuracy (n=6) was determined as mean measured 
concentration of each calibration point, which was obtained using a linear regression 
equation of each calibration curve and reported as bias. Inter-day precision (n=6) was 
expressed as the RSD of the peak height ratios of individual calibration points. 
Limits of Detection (LOD) and Quantitation (LOQ) were calculated using the data 
obtained from linear regression equations (n=6) (ICH-Q2(R1), 2005). LOD and LOQ 
calculated by linear regression were subsequently validated by the repeated analysis of 
three salbutamol aqueous and urine standards prepared at concentrations near the LOD 
(5, 10 and 15 g/L) and the RSD was calculated (ICH-Q2(R1), 2005). 
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The ruggedness of the assay was estimated by day-to-day variability of the 
chromatographic response of three salbutamol urine QC standards and one unknown 
sample (volunteer KA24) evaluated in duplicate on 5 different days. Robustness was 
estimated by varying various HPLC conditions such as the mobile phase constituents, 
temperature, buffer strength and molarity of the ion-pairing agent. 
4.2.6.2 Validation of extraction recovery, precision and accuracy 
Intra-day recovery of salbutamol was determined by repeated SPE (n=3) of three 
urinary salbutamol QC standards selected at high, mid and low points of the calibration 
range (50, 100 and 200 µg/L). The inter-day extraction recovery (n=6) was determined 
using the extraction and assays of the whole calibration curve standards. The peak 
heights of salbutamol urine extracts were compared to the peak heights obtained with 
the direct injections of salbutamol aqueous standards assuming 100% recovery in order 
to provide an estimate of the extraction recovery. The intra- and inter-day accuracy and 
precision were determined as the percent relative recovery and RSD, respectively. 
The study to optimise the conditions for the SPE when more than 1 mL of urine sample 
was used, consisted of extracting and injecting 8 replicates of hydrolysed salbutamol 
urine standards (50 g/L) and a volunteer’s 0.5-24 hour urine sample (NK24) for each 
test volume (1-5 mL) after the volunteer had inhaled 5 puffs of salbutamol from an MDI 
(Ventolin Evohaler™). The results were expressed as the recovered amount, bias and 
RSD. 
4.2.6.3 Stability studies 
Two stability studies were carried out, one for establishing the stability of salbutamol 
and terbutaline urine concentrates in the mobile phase post-reconstitution and post-SPE, 
and the other for concentrated urine extracts frozen at ─20C for up to 40 days for later 
reconstitution. 
The first study involved determining the stability of urine concentrates in the mobile 
phase over 0-38 hour after reconstitution at ambient temperature (25-27C). This was 
assessed by repeated (n=5) HPLC determinations of three urine and aqueous salbutamol 
QC standards (50, 100 and 200 g/L), a volunteer’s urine sample containing no 
salbutamol (blank) and a 0.5-24 hour post salbutamol inhalation urine sample. 
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The second stability study was carried out to determine the recovery of extracted 
salbutamol and terbutaline in frozen urine concentrates for a period of 10-40 days post-
SPE using the same QC standards and samples and the frequency of SPE as mentioned 
in the first study. The concentrated urine extracts collected as SPE eluates in glass test 
tubes were sealed with parafilm, further enveloped in polythene bags and frozen at 
─20C till defrosted and assayed. The first set of samples was considered as reference 
day-1 with no freezing.  
The urine salbutamol QC standards, volunteer’s 0.5-24 hour post-inhalation samples 
and blanks were all extracted the same day in duplicate using the SPE USAL 
METHOD. Accuracy (recovery) and precision were determined against aqueous 
standards to establish the stability at each test point. 
4.2.7 Volunteer Study 
This study was conducted as enumerated in Section 3.4.5 (Chapter 3 Methodology). In 
brief, fourteen healthy volunteers (7 females) participated in two parts of the study. In 
Part 1, on separate study days (one week apart), each volunteer inhaled 2 puffs (200 g) 
from one of the randomly selected salbutamol MDIs, vis-à-vis: Ventolin Evohaler™, 
Airomir™, Salamol™ and AirSalb™ (Sandoz Ltd., UK). The MDI was randomly 
selected. In Part 2, each volunteer repeated this study with charcoal intake immediately 
before and after the two inhalations. All volunteers inhaled salbutamol from all MDIs. 
On all occasions urine samples were collected 0.5 hour before and after inhalation and 
thereafter pooled their urine for 24 hours. The volume and pH of all urine samples were 
recorded. Aliquots of each urine samples were stored at –20C till extracted and 
assayed. Urine samples collected at 0.0-0.5 hour post inhalation were assayed for 
unchanged salbutamol (USAL0.5) using the USAL METHOD. Pooled urine samples 
collected during 0.5-24h were assayed for their unchanged salbutamol (USAL24) using 
the USAL METHOD and for their salbutamol plus metabolite concentration 
(USALMET24) using the USALMET METHOD. 
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4.3 Results and Discussion 
4.3.1 Validation of HPLC method 
4.3.1.1 Wavelength Scanning 
A decrease in sensitivity and eventual loss of response was noted at excitation:emission 
wavelengths (Ex:Em) 276:609 nm (Hindle and Chrystyn, 1992) with different 
combinations of solvents for mobile phase. To accommodate solvent effects, 
wavelength scans for salbutamol using HP 1100 Series with HP ChemStation for LC 
(Rev. A.06.01 [403]) revealed various Ex:Em combinations vis-à-vis: 220:312; 
270:312; 220:614 and 270:614. These Ex:Em wavelengths are comparable to those 
found by other researchers (Gupta et al., 1994; Koh, 2003). At 220:312 baseline was 
noisy while at 220:614 and 270:614 the response decreased by 30% and 40% 
respectively when compared to 270:312. After multiple salbutamol injections around 
270:312, the optimised Ex:Em combination of 269:312 was selected using Shimadzu 
Spectroflourometric Detector. 
4.3.1.2 Representative Chromatograms 
The representative HPLC chromatograms of un-hydrolysed and hydrolysed blank and a 
0.5-24 hour volunteer’s urine samples are shown in Figure 4.3.1 and Figure 4.3.2, 
respectively. Salbutamol eluted after ~24 min (RSD 0.31%; range 24.2-24.5 min) and 
terbutaline in ~27 min (RSD 0.26%; range 26.9-27.1 min) (n=50) with baseline 
resolution (Rs=1.8, RSD=3.3%, n=5). 
4.3.1.3 Specificity and Selectivity 
Commonly used adjuvant drugs, and salbutamol structural analogues were injected (as 
aqueous or dilute methanolic solutions unless otherwise specified) onto HPLC system to 
ascertain specificity and selectivity of the method for salbutamol and to find an 
appropriate Internal Standard (IS). These chemical entities included bamethane, 
fenoterol HBr, eformoterol, salmeterol, metapropterenol, synephrine (dissolved in dilute 
HCl), isoetharine, methoxyphenylamine HCl, pirbuterol, ±-phenylpropanolamine HCl 
(norephedrine), ephedrine HCl, isoprenaline sulphate, norphenylephrine (norfenefrin), 
de-oxyepinephrine, DL-metanephrine, prenalterol, L-phenlyephrine HCl, clenbuterol, 
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ii: 0.0-0.5 h urine sample 
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iii: 0.5-24 h urine sample 
 
Figure 4.3.1. Specimen chromatograms of un-hydrolysed blank and salbutamol containing 
urine samples – USAL METHOD 
B=salbutamol, C=terbutaline, A & D=unknown peaks; samples of a male volunteer 
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Figure 4.3.2. Specimen chromatograms of hydrolysed blank and 
salbutamol containing urine sample – USALMET METHOD 
B=salbutamol, C=terbutaline, A & D=unknown peaks; sample of a 
female volunteer. 
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methoxamine HCl (Vasoxine Inj. GlaxoWelcome), metaraminol tartrate (Aramine Inj. 
MSD), ipratropium bromide, pindolol, timolol, ±-metoprolol, nadolol, oxpremolol, 
atenolol, labetolol, aspartame, oxamniquine, caffeine, amphetamine, warfarin, 
naproxen, ketoprofen, fenbufen, acetanilide, sulindac, dopamine, tyramine HCl, 
beclomethasone dipropionate, estrone, ethyl paraben, methyl paraben and 4-benzyl 
biphenyl. Of the tested compounds none interfered with salbutamol. Terbutaline and 
bamethane were also fully resolved and were the only candidates for the internal 
standard ( 
Figure 4.3.3). However, the retention time of bamethane was very long (>45 min). 
 
 
 
 
 
 
 
Figure 4.3.3. Structural formulae of salbutamol, terbutaline and bamethane. 
 
4.3.1.4 Linearity and Range 
The mean (n=6) regression equations using peak height ratios of salbutamol to 
terbutaline for aqueous standards (SAS), un-hydrolysed (USAL) and hydrolysed 
(USALMET) urine standards were y = 0.00488x + 0.00372, y = 0.00482x + 0.0000166  
HO
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H
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and y = 0.00448x+ 0.01455, respectively (Figure 4.3.4). The corresponding RSD of 
their slopes were 2.72, 1.56 and 1.68 % with respective standard deviation (SD) of the 
intercepts at 0.00299, 0.0058 and 0.0065. These slopes were not different from each 
other indicating that urine matrix had a minimal effect on the method (Brun and 
Veuthey, 1996). This could be due to effective clean-up of samples during extraction. 
The mean intercept (SD; 95% confidence interval) of USAL and USALMET at the 
lower limit of quantitation (LLOQ, 25 g/L) was 0.05% (4.8; –0.022, 0.019) and 11.9 % 
(5.8; –0.010, 0.039), respectively. 
 
Figure 4.3.4. The Calibration lines of SAS, USAL and USALMET METHODS. 
 
The regression lines were linear over the range 25 g/L – 300 g/L. The mean r2 (RSD) 
values for SAS, USAL and USALMET were 0.9992 (0.1002%), 0.9983 (0.06%) and 
0.9976 (0.202%), respectively. The calibrations were also found linear over the range 5 
g/L – 1000 g/L. Since a smaller range is reported to tolerate larger deviations from 
linearity and make the method more rugged to non-linearity (Mulholland and Hibbert, 
1997), a small concentration range with more close points spanned over the intended 
use of the method was selected. 
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4.3.1.5 Accuracy and Precision 
The intra- and inter-day accuracy and precision (Table 4.3.1, Figure 4.3.5) for both 
USAL and USALMET urine standards were within acceptable limits of ±15% (FDA, 
1994 & 2013; EMA, 2012). The results also depict the accuracy of the HPLC assay in 
precisely measuring unknown concentrations. 
 
 
Figure 4.3.5. The graphic representation of reproducibility of accuracy and precision. 
Light broken lines - RSD of recovered concentrations measured from individual 
regression curves. Bold broken lines - reproducibility of peak height ratio. 
 
4.3.1.6 Limit of Detection and Quantitation (LOD and LOQ) 
The calculated LOD for salbutamol aqueous (SAS), USAL (1 mL sample) and 
USALMET (1 mL sample) standards was 2.0, 4.0 and 4.8 µg/L, respectively, and the 
LOQ was 6.1, 12.1 and 14.6 µg/L. Repeated assays of three salbutamol concentrations, 
5, 10 and 15 µg/L using the SAS method produced RSD values (n=10) of 4.1, 2.7 and 
1.3 % respectively while the same concentrations using the USALMET METHOD gave 
RSD values (n=7) of 10.6, 3.9 and 3.9 %. The HPLC method is therefore highly  
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Table 4.3.1. Intra- and inter- day HPLC accuracy and precision (repeatability and reproducibility). 
Nominal Concentration 
(µg/L) 
USAL METHOD USALMET METHOD  
USAL METHOD USALMET METHOD Mean Measured Concn* 
(RSD%) 
Mean Bias 
(%) 
Mean Measured Concn* 
(RSD%) 
Mean Bias 
(%) 
a) Intra-Day Accuracy (n=3) a) Intra-Day Repeatability (n=3) RSD (%) 
  50 50.11 (5.72) 0.23 52.70 (0.92) 5.40 6.69 3.13 
100 105.16 (4.62) 5.16 100.04 (3.24) 0.04 5.30 1.03 
200 201.46 (3.96) 0.73 207.04 (1.66) 3.52 4.90 1.70 
b) Inter-day Accuracy (n=6)  b) Inter-Day Reproducibility (n=6) RSD (%) 
  25 24.30 (15.03) -2.81 24.81 (11.04) -0.78 5.68 5.59 
  50 49.03 (5.36) -1.94 52.12 (3.31) 4.25 4.77 2.80 
  75 73.92 (5.43) -1.44 74.57 (2.47) -0.57 6.42 2.37 
100 104.10 (4.12) 4.10 99.28 (2.80) -0.73 6.28 2.01 
150 147.64 (3.62) -1.58 150.03 (3.05) 0.02 4.21 3.47 
200 200.36 (3.05) 0.18 205.87 (1.50) 2.94 5.84 1.98 
250 252.88 (2.07) 1.15 244.66 (2.99) -2.14 3.41 2.11 
300 297.47 (1.73) -0.84 302.05 (1.80) 0.68 3.41 2.83 
*Concn = Concentration 
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sensitive for quantifying salbutamol extracted in urine after inhalation. Specimen 
chromatograms of hydrolysed salbutamol urine standards 5, 10 and 25 µg/L containing 
terbutaline (500 µg/L) are shown in Figure 4.3.6. 
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Figure 4.3.6. Specimen chromatograms of hydrolysed salbutamol urine standards (USALMET 
METHOD). 
Salbutamol urine standards with terbutaline (i) 5 (ii) 10 and (iii) 25 µg/L 
B=salbutamol, C=terbutaline, A & D= unknown peaks. 
 
4.3.1.7 Robustness 
The influence of different chromatographic parameters upon separation was evaluated 
by systematically varying the chromatographic conditions (ICH Q2(R1), 2005). Only 
one condition was changed while the others were kept constant. Slight variations in 
mobile phase constituents may change the width of the window for salbutamol and 
terbutaline which, however, remained fully resolved with respect to each other. The 
change in operating temperature by ±5C did not affect resolution except back pressure. 
An increase in phosphate buffer molarity of up to 10 mM and of the ion-pair agent 
sodium dodecyl sulphate in the mobile phase up to 30 mM decreased the retention time 
with sharp peaks. However, this reduced resolution of salbutamol and terbutaline in 
hydrolysed urine samples and the width of the window squeezed by the unknown matrix 
peaks “A” and “D” (Figure 4.3.1 and Figure 4.3.2). Increasing molarity of the ion-pair 
agent also increased back-pressure. 
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4.3.2 SPE recovery, accuracy and precision 
The results (obtained using peak heights of both un-hydrolysed and hydrolysed urine 
standards compared to direct aqueous injections) of intra- and inter-day SPE recovery, 
accuracy and precision are presented in Table 4.3.2. The pooled mean (RSD) intra-day 
percentage relative recoveries (%RR) of salbutamol using USAL and USALMET 
samples was 91.3 (0.05%) and 92.5 (2%) and the pooled mean precision RSD of % RR 
was 4.4 and 2.6 %, respectively. The pooled mean (RSD) inter-day %RR of salbutamol 
using USAL and USALMET samples was 90.8 (2.3%) and 91.5 (3.0%) and the pooled 
mean precision RSD of % RR was 2.9 and 3.3 %, respectively. The parallel %RR of 
terbutaline, added as the internal standard, was 90.2 (2.9%) and 96.4 (1.8%) with 
precision RSD of 4.9 and 3.9 %. 
The USAL METHOD reported here is the mixed-mode SPE which is based on a control 
of the pH and thereby ionisation of the analyte(s) (Hennion, 1999; Fritz, 1999). The 
previously reported SPE method (Hindle and Chrystyn, 1992) lacked this control. The 
mean intra- and inter-day recoveries were within the accepted value of ±15% (Shah et 
al., 1992) indicating that the USAL METHOD was efficient, accurate and precise. 
Extracting salbutamol from hydrolysed urine posed difficulties in controlling the pH, 
osmolarity and ionic strength of the analytes in the urine sample optimally with 
consequent variable and decreased recoveries of salbutamol and terbutaline. However, 
the pH of the acidified samples was raised and controlled in the region of pH ~7.0 with 
phosphate buffer (0.5 M, pH 13). The mean adjusted pH of 14 volunteers’ hydrolysed 
samples was 6.80 (RSD 2.36; range 6.44-7.17; n=45). The mean adjusted pH of a 
female volunteer sample was 6.85 (RSD 1.97; range 6.58-7.06; n=24). The mean 
adjusted pH for 18 salbutamol urine standards was 6.73 (RSD 1.40, range 6.47-6.86). 
All these samples and standards contained terbutaline as internal standard. The pH 
control with KH2PO4 was precise and reproducible making the method robust. 
Nevertheless, this strong buffering of hydrolysed urine samples resulted in high 
osmolarity and ionic density of the sample, which decreased recovery of salbutamol and 
terbutaline from HCX cartridges to less than 50% and 30%, respectively. Since 
polymeric cartridges are reported to possess a higher retaining capacity of analytes 
(Brun and Veuthey, 1996; Fritz, 1999; Masqué et al., 1998), Oasis HLB cartridges were 
used for extracting hydrolysed urine samples using the USALMET METHOD. Oasis   
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HLB were chosen instead of Oasis MCX (polymeric cationic) cartridges as the latter did 
not produce clean extracts. The USALMET METHOD gave reproducible recoveries of 
both salbutamol and terbutaline, which were comparable to USAL METHOD. This also 
indicates that the drying of eluates at 120ºC under a gentle stream of nitrogen in 
USALMET METHOD did not affect the integrity of the analytes. Besides, Mälkki-
Laine et al. (1995) have reported virtually no decomposition of salbutamol on 
autoclaving for 20 min at 120ºC in solutions buffered at pH 3–5. 
Table 4.3.2. Intra- and inter- day SPE accuracy and precision. 
Nominal 
Concentration 
(µg/L) 
% Relative Recovery (RR) of salbutamol 
USAL METHOD USALMET METHOD 
% RR RSD % RR RSD 
a) Intra-day (n=3) SPE Recoveries of salbutamol 
  50 91.32 4.72 94.09 2.03 
100 91.39 3.40 90.47 4.32 
200 91.30 5.21 92.83 1.47 
b) Inter-day (n=6) SPE Recoveries of salbutamol 
  25 93.15 4.32 96.02 4.76 
  50 90.99 3.50 92.95 2.66 
  75 87.77 2.22 87.86 3.43 
100 88.89 3.19 89.49 3.05 
150 92.70 3.26 93.95 2.32 
200 89.30 3.65 92.22 1.34 
250 93.37 2.18 90.04 3.89 
300 90.37 1.02 89.80 4.87 
 
Acid hydrolysis of salbutamol has been used to free it from its glucuronide conjugate 
(Evans et al., 1973; Hindle and Chrystyn, 1992; Forsdahl and Gmeiner, 2004). This is 
the first work where an internal standard has been used during acid hydrolysis to study 
the effect of any degradation of salbutamol itself in addition to freeing it from its 
glucuronide conjugate. Terbutaline, being a structural analogue, possesses similar 
physico-chemical properties as that of salbutamol (McDowall, 1989; The Merck Index, 
2003; Ehrhardt et al., 2005). It was therefore added to the samples to reflect the stressful 
conditions salbutamol undergoes during acid hydrolysis. Forsdahl and Gmeiner (2004) 
have reported decomposition of salbutamol at 60ºC for 1 hour and could recover only 
63% of intact salbutamol. This may be because they used 6 M HCl with the final  
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concentration of the acidified urine at 2 M. Evans et al. (1973) used 1 M HCl and 
reported that salbutamol remained unaffected by hydrolysis in a boiling water bath for 1 
hour. The results of this work are in agreement with the findings of Evans et al. (1973). 
The samples were acidified to give a final concentration of 0.01 N HCl. The similarities 
and consistencies in recoveries of salbutamol and terbutaline indicate that both 
remained stable during acid hydrolysis for one hour at boiling temperature. 
Although Oasis HLB cartridges could also be used for unchanged salbutamol when the 
samples were not hydrolysed they are more expensive than Confirm HCX cartridges. 
Also the preparation time when using Oasis HLB cartridges is longer because more 
steps are involved with the extraction. Thus on grounds of economy it is recommended 
that the Confirm HCX cartridges are used for unchanged salbutamol and when urine 
samples are hydrolysed for their salbutamol plus metabolite amounts then Oasis HLB 
cartridges are used. 
4.3.3 Use of increased/multiple sample volume 
The urine output of individuals is difficult to control over a set collection period. This is 
particularly important when patients are unable to inhale salbutamol dose correctly and 
completely from an MDI with resultant low levels excreted in urine. In such 
circumstances, a large output of urinary volume may necessitate the use of more than 1 
mL of urine sample for the SPE to ensure consistent chromatographic response. The 
optimised and validated SPE conditions (based on the inhalation of two puffs of 
salbutamol (200 µg) by volunteers from an MDI) using 1–5 mL of the urine sample are 
shown in Table 4.3.3. Table 4.3.4 shows the results of the volunteer study using 1–5 mL 
of sample volume for the SPE. The individual and mean RSD values were within the 
acceptable limits (Shah et al., 1992) for both salbutamol and terbutaline which indicates 
that the extraction remained accurate and reproducible with the use of different sample 
volumes (1–5 mL). This may help in further increasing the sensitivity of HPLC by using 
multiple sample volume where appropriate. It was found that with higher urine volume 
in a given period the inherent urinary interferences were diluted which presented little 
concern for the resolution of salbutamol or terbutaline when more than 1 mL of sample 
was used for SPE to concentrate the sample. 
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Table 4.3.3. Sample preparation and pre-treatment methods before SPE. 
Total Urine Output (mL) 
in the Sampling Period 
(hour) 
Volume 
of Urine 
Sample 
to be 
taken 
(mL) 
Volume 
of 
internal 
standard 
to be 
used 
(mL) 
Pre-treatment of un-hydrolysed urine sample 
(USAL METHOD) 
Pre-treatment of urine samples for hydrolysis and of hydrolysed 
urine (USALMET METHOD) 
Molarity 
of Buffer 
KH2PO4, 
pH 7.0 
(mM) 
Volume 
of 
Buffer 
to add 
(mL) 
Total 
Volume 
of Treated 
Sample 
(mL) 
Final 
Molarity 
of Treated 
Sample 
(mL) 
Normality 
of HCl to 
be added 
to sample 
(N) 
Volume 
of HCl to 
be taken 
(mL) 
Final 
Normality 
of Treated 
Sample 
(N) 
Volume of 
KH2PO4, 
pH 13.0 to 
be used 
(mL) 
Total 
Volume of 
Treated 
Sample 
(mL) 
0-0.5 0.5-24 
Upto 75 Upto 750 1 
1 
30 2.0 4.0 15.00 0.10 
8 0.01 1 
11 
75-150 750-1500 2 60 2.0 4.0 15.00 0.11 12 
150-225 1500-2250 3 100 0.7 4.7 14.89 0.12 13 
225-300 2250-3000 4 100 0.9 5.9 15.25 0.13 14 
300-400 3000-4000 5 100 1.1 7.1 15.49 0.14 15 
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Table 4.3.4. Recovery and reproducibility of SPE (USALMET METHOD) with increasing volume of hydrolysed salbutamol urine standard and a volunteer’s 
urine sample (USALMET24). 
Sample 
Volume 
(mL) 
Accuracy and Precision with increasing volume of hydrolysed salbutamol urine standards and samples (n=8) 
Salbutamol urine standard (50 g/L) Volunteer’s 0.5-24 hour urine sample (NK24) 
Concn.* found  
(g/L) 
Recovered amount  
(g) 
Bias  
(%) 
RSD  
(%) 
Concn.* found  
(g/L) 
Recovered amount  
(g) 
RSD  
(%) 
1 43.9 43.87 -12 5.93 114.6 189.55 6.63 
2 88.2 44.09 -12 2.03 220.71 182.53 3.51 
3 134 44.69 -11 3.36 326.44 179.98 3.10 
4 183 45.68 -8.6 2.64 419.38 173.41 7.19 
5 217 43.32 -13 2.89 492.68 162.98 5.23 
Mean  44.33 -11.3 3.37  177.69 5.13 
SD  0.90 1.8 1.51  10.05 1.82 
RSD  2.03    5.66  
*Concn = Concentration; Salbutamol urine standard = 50 g/L; Volunteer’s urine sample = 0.5-24 hour 
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4.4 Stability Study 
Analysis of a large number of samples over a prolonged period of time (overnight) 
makes it necessary that stability of the analyte(s) and internal standard in the carrier 
solvent for injection onto the automatable HPLC system be assured (Shah et al., 1992; 
ICH Q2(R1), 2005). Mälkki-Laine et al. (1995) have reported slowest decomposition of 
salbutamol in phosphate buffer (0.067 M, pH 5.2) over three days. Mälkki and 
Tammilehto (1990) also found maximum stability of salbutamol in aqueous solution at a 
pH of about 3.5 at 65
º
C. The results of this study are summarised in Table 4.4.1 and 
Table 4.4.2. This study shows that the mean (n=5) salbutamol and terbutaline recovered 
from the urine standards and the volunteer’s sample (dissolved in the mobile phase) left 
at room temperature for up to 36 hours were consistent (>91% and ≥94%) and precise 
(RSD≤2% for both), respectively. The mean (n=10) salbutamol and terbutaline 
recovered from the urine standards and the volunteer’s sample extracted concentrates 
frozen at –20C for up to 40 days were also consistent (>88% for both) and precise 
(RSD≤4% and ≤3%), respectively. The mean (RSD) recovered amount of salbutamol 
over 0-36 hours (n=5) and over 40 days (n=10) from the 0.5-24 hour urine sample of the 
volunteer (KA24) was 210.5 g (2.0%) and 187.6 g (8.1%), respectively. The 
differences in recovery over the specified period were within the acceptable limits of 
±15% (Shah et al., 1992). The mean (SD) percent change in measured concentration of 
salbutamol and terbutaline with subsequent injections (n=4) as compared to the 1
st
 
injection was ≤3% (3.1) and ≤2% (2.7), respectively. The mean (SD) percent change in 
measured concentration of salbutamol and terbutaline after freezing and defrosting 
(n=8) was ≤ −2% (1.2) and ≤ −3% (3.3), respectively. These variations may be 
considered due to inherent assay variability rather than a reflection of any instability of 
salbutamol or terbutaline. Also, the chromatograms of urine standards and the 
volunteer’s sample did not show the appearance of any interfering or additional peaks 
over the test time-frame and no changes in chromatography were observed. 
Nevertheless, the peaks at position “A” (Figure 4.3.1, Figure 4.3.2 and Figure 4.3.5) 
grew in height over time in some of the SUS which, however, did not interfere with 
salbutamol peak at position “B”. These stability studies indicate that salbutamol and 
terbutaline left at room temperature for up to 36 hours (dissolved in the mobile phase) 
and their extracted concentrates frozen at –20C for up to 40 days did not show any 
significant variation of the measured concentration and recovery. The results of the two 
stability studies also demonstrate that the HPLC method is ruggedly robust.  
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Table 4.4.1. Stability indicating recovery of salbutamol and terbutaline. 
Nominal 
Concn  
g/L 
Stability indicating Mean % Relative Recovery (%RR) 
Stability in mobile phase over 0-36 
hours at ambient temperature (n=5) 
Stability of extracted concentrates after 
freezing at –20°C for up to 40 days (n=10) 
Salbutamol Terbutaline Salbutamol Terbutaline 
% RR RSD %RR RSD % RR RSD %RR RSD 
50 90.82 5.04 94.61 2.45 88.99 3.65 89.39 2.20 
100 93.38 3.36 97.13 1.83 84.67 4.51 89.68 1.42 
200 91.46 2.13 94.41 2.51 90.72 1.92 90.43 4.14 
KA24   93.67 2.90   85.76 5.57 
Mean 91.89 3.51 94.96 2.42 88.12 3.36 88.82 3.33 
SD 1.33 1.46 1.50 0.44 3.12 1.32 2.08 1.88 
RSD 1.45  1.58  3.54  2.35  
 
Table 4.4.2. Stability indicating percent change in recovery of salbutamol and terbutaline. 
Nominal 
Concn  
g/L 
Mean % Change (C) in Recovery 
with subsequent injections as 
compared to 1
st
 injection (n=4) 
Mean % Change (C) in Recovery after 
freezing and defrosting as compared to 1
st
 
day (n=8) 
Salbutamol Terbutaline Salbutamol Terbutaline 
%C SD %C SD %C SD %C SD 
50 7.15 4.93 2.33 2.62 0.91 4.22 -3.17 1.86 
100 2.60 3.72 2.34 1.78 -3.28 4.78 -2.10 1.19 
200 2.63 2.12 1.11 2.87 -1.80 1.97 -4.97 3.81 
KA24 -0.46 2.27 0.94 3.33 -2.39 3.98 -1.78 6.27 
Mean 2.98 3.26 1.68 2.65 -1.87 3.71 -3.00 3.28 
SD 3.13 1.33 0.76 0.65 1.98 1.22 1.44 2.28 
 
4.5 Volunteer Study 
The applicability of the method was demonstrated by determining urinary salbutamol 
concentration post inhalation using doses (two) equivalent to normal clinical practice (). 
In the past larger doses have been used to overcome assay sensitivity issues (Clark et 
al., 1996; Hindle and Chrystyn, 1992). 
Figure 4.5.1 shows the average of the urinary concentrations for each of the 14 
volunteers and the overall mean values (n=56) following the MDI inhalations (Part 1 
Study). Similar values following inhalation from the MDIs with the co-administration of  
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oral charcoal (Part 2 Study) are shown in Figure 4.5.2. For each individual the USAL 
and USALMET data from the four study doses has been averaged. Following inhalation 
from the MDIs (Part 1 Study) the range of salbutamol concentrations was 22.1-501.3, 
36.7-315.4 and 49.3-512.4 µg/L, respectively, for USAL0.5, USAL24 and 
USALMET24. Similar ranges for the MDI inhalations with the co-administration of oral 
charcoal (Part 2 Study) were 33.5-302.4, 12.1-94.8 and 37.0-195.7 µg/L. The range of 
urine volumes for all 0-0.5 and 0.5-24 hour collection periods was 15-580 and 370-2805 
mL, respectively and the pH of all samples ranged from 4.7-8. 
 
Figure 4.5.1. Mean urinary salbutamol concentration of individual volunteers 
following inhalation from MDIs (Part 1 Study). 
The bold line indicates the mean of all the volunteers’ samples. 
 
The mean (n=56) amount of salbutamol dose (unchanged and metabolite fraction) 
recovered in the urine samples after the inhalation of 2 puffs (200 g) from four 
different MDIs (Part 1 Study) and with the co-administration of oral charcoal (Part 2 
Study), by the 14 volunteers, are shown in Table 4.5.1. 
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Figure 4.5.2. Mean urinary salbutamol concentration of individual volunteers 
following inhalation from MDIs (Part 2 Study). 
The bold line indicates the mean of all the volunteers’ samples. 
 
The percentage of salbutamol dose recovered in urine in the first 0.5 hour (USAL0.5) 
post-inhalation from an MDI, without and with the co-administration of oral charcoal, is 
consistent with that reported earlier (Hindle and Chrystyn, 1992 & 1994; Hindle et al., 
1997; Clark and Lipworth, 1996b; Silkstone et al., 2002a; Tomlinson et al., 2003). The 
amount of salbutamol excreted unchanged in urine in the first 0.5 hour after inhalation 
is believed to be mainly derived from the lung and is used as an index of relative 
bioavailability (Hindle and Chrystyn, 1992; Chrystyn, 2000 & 2001). The recovery of 
salbutamol dose in the first 30 min post-inhalation is considered to elicit the rapid 
bronchodilation and hence clinical effectiveness of an MDI as measured by spirometry. 
This index of relative bioavailability of salbutamol is used to identify the correlation of 
its pharmacokinetics and pharmacodynamics. The total amount of salbutamol and its 
metabolite excreted in the urine in the 24 hours post inhalation reflects the systemic 
delivery and is considered an indicator of the relative bioavailability of salbutamol to 
the body following an inhalation (Hindle and Chrystyn, 1992; Chrystyn, 2000 & 2001).  
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Table 4.5.1. Mean salbutamol dose recovered in the urine samples of healthy volunteers after inhaling two puffs of salbutamol from MDIs 
without and with charcoal co-administration. 
 Urinary recovery of salbutamol dose (µg) in the given period (hour)  Total Recovered 
Dose (µg)  
0.0-24 hour 
Total Delivered 
(emitted) Dose 
(µg)  USAL0.5
a
 USAL24
a
 
Metabolite 
fraction 0.5-24
c
 
USALMET24
b
 
MDI alone (Part 1 Study)       
Mean (SD)
d
 6.44 (3.36) 48.09 (17.06) 37.42 (15.89) 85.51 (21.7) 91.94 (22.43) 156.18 (9.92) 
% of Nominal Dose (SD) 3.22 (1.68) 24.04 (8.53) 18.71 (7.94) 42.75 (10.85) 45.97 (11.21)  
Range 15.30-1.10 98.90-14.90 75.18-2.87 161.93-25.42  177.68-136.71 
% of Recovered Dose (SD) 4.13 (2.16) 30.71 (10.45) 24.11 (10.47) 58.96 (14.49)   
MDI + Charcoal (Part 2 Study)      
Mean (SD) 6.57 (3.23) 19.99 (8.01) 12.82 (6.81) 32.81 (11.04) 39.38 (11.72) 151.75 (13.12) 
% of Nominal Dose (SD) 3.28 (1.61) 10.00 (4.00) 6.41 (3.41) 16.41 (5.52) 19.69 (5.86)  
Range 16.93-2.53 38.43-6.83 31.31-3.62 67.38-17.88  172.67-121.72 
% of Recovered Dose (SD) 17.38 (8.11) 50.71 (11.98) 31.91 (13.19)    
a
 assayed using the USAL METHOD and 
b
 assayed using the USALMET METHOD 
c 
obtained from USALMET24 minus USAL24 
d
 SD = Standard Deviation 
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In Part 1 Study, this amount was similar to that previously reported (Morgan, 1990; 
Hindle and Chrystyn, 1992). Hence approximately 46% of the nominal inhaled dose 
was delivered to the body via the pulmonary and gastro-intestinal routes. As a large 
proportion of the inhaled dose is swallowed (Pauwels et al., 1997), the salbutamol dose 
recovered in urine in 0.5–24 hour contains both unchanged and metabolised fractions. 
Since only unchanged salbutamol is effective in relieving bronchospasm, it is therefore 
necessary to ascertain the proportions of these fractions. 
Charcoal blockage is used to separate absorption via the pulmonary and oral routes 
(Borgström and Nilsson, 1990; Silkstone et al., 2000; Ward et al., 2000) and to identify 
the total effective lung dose after inhalation (Chrystyn, 2001). Hence there was a 
difference between the amounts excreted in the urine in the 24 hour collections between 
the MDI inhalation without and with the co-administration of oral charcoal. The amount 
excreted over 24 hours with the co-administration of charcoal represents the amount that 
was deposited into the lungs and delivered to the systemic circulation. This was found 
to be 20% of the nominal dose. This value compares well with Olsson et al. (1996) and 
Chrystyn et al. (1997) and suggests that approximately 26% of the nominal dose was 
delivered to the systemic circulation and excreted in the urine. 
The total inhaled bioavailable amount of salbutamol was 59% of the delivered (emitted) 
dose (lung + oral, Table 4.5.1) and 26% of this was due to pulmonary absorption. The 
undelivered dose varied from 21.91% (SD 4.96, range: 31.64-11.16%) to 24.12% (SD 
6.56, range: 39.14-13.67%) for inhalation without and with charcoal respectively. 
Hindle et al. (1995) have reported similar results. About 20% of the delivered dose is 
un-accounted for in our studies. Of this, about 10% of the delivered dose drug could not 
be recovered during solid phase extraction (Table 4.3.2). The role of buccal absorption 
of salbutamol is not clear (Lipworth et al., 1989a; Lipworth, 1996; Spina et al., 1997; 
Valenzuela et al., 2001). The oesophageal absorption of salbutamol is still unknown. 
Therefore, the remaining 10% of the delivered dose would probably have excreted in 
the bile and/or in the faeces (Evans et al., 1973). Thus the mass balance of recovery of 
inhaled salbutamol from urine for 24 hour demonstrates the effectiveness of using 
urinary excretion as a measure of effective lung dose, relative bioavailability and total 
bioavailable dose. 
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4.6 Conclusion 
The HPLC method was linear (over the range tested), precise, accurate and sensitive for 
determining salbutamol concentrations in human urine following the inhalation of 
normal doses. Two SPE methods for extracting salbutamol from un-hydrolysed and 
hydrolysed urine were efficient, reproducible and robust. A method using Confirm HCX 
cartridges is recommended for unchanged salbutamol and a different method using 
Oasis HLB is recommended for total salbutamol (salbutamol plus its metabolite). These 
methods were reliably applied to urinary pharmacokinetic studies using 14 volunteers 
after the inhalation of two 100 µg doses of salbutamol. The concentrations of unchanged 
and total salbutamol were within the sensitive range of the assay. This volunteer study 
revealed that about 20% of the nominal dose is delivered to the lungs and 46% to the 
systemic circulation following inhalations from a metered dose inhaler. 
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5 Chapter 5: In-Vitro and In-Vivo Equivalence of 
Salbutamol HFA MDIs 
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5.1 Overview 
In-vitro studies on MDIs provide critical information on their dose delivery 
characteristics and aerodynamic particle size distribution (APSD) profiles. 
Pharmacopoeias recommend Andersen Cascade Impactor (ACI) to obtain this 
information (BP, 2005; USP28-NF23, 2005; Ph. Eur., 2011). 
Physical properties of inhaled drug molecules, their APSD and aerodynamic particle 
diameter define in-vivo lung deposition (Hickey et al., 1996; Harrison et al., 1997; 
Howarth, 2001; Guo et al., 2008). These characteristics of aerosol particles influence as 
to where they will deposit in the human respiratory tract (HRT) (Chrystyn, 2000 & 
2001; Mobley and Hochhaus, 2001) to produce therapeutic and systemic effects 
(Pritchard, 2001; Weda et al., 2004; Usmani et al., 2005). 
With the phase-out of CFC propellants under the Montreal Protocol agreement (UNEP, 
2017), replacement salbutamol metered dose inhalers (MDIs) containing HFA 
propellant are since then available. Development, transition, and comparative in-vitro 
studies on salbutamol HFA MDIs were carried out by manufacturers of MDIs (Ross and 
Gabrio, 1999; Cripps et al., 2000; McCabe et al., 2012) and add-on devices (Mitchell et 
al., 1999; Hatley et al., 2014; Sanders and Bruin, 2015; Johnson et al., 2016). However, 
these studies employed 5 to 10 puffs. It has been reported that firing multiple puffs of 
salbutamol MDI results in the loading effect in ACI measurements and leads to aerosol 
particle entrainment (Nasr and Allgire, 1995; Nasr et al., 1997). In addition, multiple 
puffs mask the emitted dose variations. Consequently, the resultant APSD does not 
represent the true particle size distribution. Hence, in the current study, a clinically 
relevant dose (2 puffs) has been used. Further, the present in-vitro studies are 
complemented by in-vivo pharmacokinetic studies. 
This chapter is organised into separate sections comprising of in-vitro and in-vivo 
equivalence studies on salbutamol HFA MDIs. 
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5.2 In-Vitro Equivalence of Salbutamol HFA MDIs-Aerodynamic 
Particle size Characterisation 
The aim of this study is to determine APSD using ACI to investigate in-vitro 
equivalence of salbutamol HFA MDIs. 
5.2.1 Materials and Methods 
5.2.1.1 Materials and Equipments 
Details provided in Section 3.3.1.1 (Chapter 3 Methodology).  
5.2.1.2 Test MDIs 
Ventolin Evohaler
™
 (Evo), Airomir
™
 (Airo) and Salamol
™
(Sala).  
5.2.2 Study Design 
Protocols 3.3.1 and 3.3.2 (Sections 3.3.2.3 & 3.3.2.4; Chapter 3) describe the study 
design as per pharmacopoeial requirements. In brief, one puff of a randomly selected 
primed salbutamol HFA MDI was discharged into ACI operated at a flow rate of 28.3 
L/min for 8.5 seconds to allow 4L of air to pass through it. The second puff was 
similarly discharged after 30 seconds. The amount of salbutamol deposited on ACI 
components and stages was quantified using validated HPLC method (Chapter 4). 
5.2.3 Results: In-Vitro Equivalence of Salbutamol HFA MDIs 
The mean amount (n=5) of two actuations of salbutamol deposited on various 
components and stages of ACI recovered from Evo, Airo and Sala are shown in Table 
5.2.1. Their individual run data is provided in Appendices 5.2.3.1 to 5.2.3.3, 
respectively. Figure 5.2.1 and Figure 5.2.2 respectively show complete APSD profiles 
and cumulative particle size deposition of the three MDIs. Summaries and comparisons 
of various CQAs are provided in Table 5.2.2 to Table 5.2.6 and Figure 5.2.3 & Figure 
5.2.4. Results of statistical analysis and in-vitro equivalence of MDI performance 
metrics are given in Table 5.2.7 to Table 5.2.9. 
The mass balance and total emitted dose (TED) of Ventolin Evohaler, Airomir and 
Salamol were within 5% and 25% of labelled metered dose (100 µg) per actuation 
(Table 5.2.1). This confirms system suitability. Hence, the results generated are valid 
and accurate (Christopher et al., 2003).   
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Table 5.2.1. APSD of Salbutamol HFA MDIs. 
Identity 
Ventolin Evohaler Airomir Salamol 
µg SD RSD µg SD RSD µg SD RSD 
MDI Canister Valve 5.0 0.5 9.9 19.6 2.7 13.8 20.0 2.2 10.8 
MDI Actuator 36.2 2.9 8.1 21.0 1.9 9.1 28.8 5.3 18.4 
ACI IP (Throat) 88.8 7.4 8.3 69.7 2.1 3.0 80.1 3.1 3.8 
ACI S-0 2.1 0.2 8.8 3.5 0.8 24.3 2.7 0.6 22.4 
ACI S-1 2.8 0.3 12.5 4.0 1.1 27.5 3.8 0.8 21.3 
ACI S-2 4.6 0.6 12.1 5.8 1.4 23.7 4.1 0.5 11.9 
ACI S-3 18.4 2.2 12.1 25.1 3.4 13.5 19.0 2.5 13.4 
ACI S-4 35.2 2.6 7.3 35.7 1.8 4.9 35.8 4.3 12.1 
ACI S-5 19.9 1.9 9.7 21.0 1.4 6.8 24.0 3.8 15.8 
ACI S-6 3.4 0.3 8.3 5.2 0.5 8.7 5.8 1.0 16.9 
ACI S-7 0.6 0.1 13.2 2.1 0.0 1.5 2.3 0.5 21.5 
ACI Filter 0.9 0.2 19.9 2.3 0.4 17.8 2.6 0.8 31.7 
Total Recovery (µg) 217.8 8.9 4.1 214.9 3.4 1.6 228.9 7.4 3.2 
% Recovery
a
 108.9 4.4 4.1 107.5 1.7 1.6 114.4 3.7 3.2 
Mass Balance
b
 (µg) 212.8 8.6 4.0 195.3 3.5 1.8 208.8 6.2 3.0 
% Recovery  106.4 4.3 4.0 97.7 1.8 1.8 104.4 3.1 3.0 
TED
c
 (µg) 176.6 7.6 4.3 174.3 1.7 1.0 180.0 5.2 2.9 
% TED 88.3 3.8 4.3 87.2 0.8 1.0 90.0 2.6 2.9 
a = % Recovery calculated with respect to Nominal Dose (ND), i.e., two actuations of 100 µg per 
puff. 
b = Mass Balance = Ex-Canister Valve recovery. Recovery calculated with respect to Nominal 
Dose (ND) excluding deposition on Canister Valve but including deposition on Actuator (mouth 
piece). 
c = TED (Total Emitted Dose Ex-Actuator). Recovery calculated with respect to Nominal Dose 
(ND) excluding deposition on Canister Valve and Actuator (mouth piece). 
 
 
Figure 5.2.1. Mean APSD profiles of salbutamol HFA MDIs. 
Can = MDI Canister; Actu = MDI Actuator 
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Figure 5.2.2. Mean percent cumulative particle size deposition profiles of 
salbutamol HFA MDIs. 
 
 
 
 
Figure 5.2.3. Dose delivery characteristics of salbutamol HFA MDIs. 
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Figure 5.2.4. Stage group deposition of salbutamol HFA MDIs. 
 
 
TED of three salbutamol MDIs was both statistically similar and in-vitro equivalent 
(Table 5.2.2 & Table 5.2.7). 
IP deposition was neither statistically similar nor in-vitro equivalent amongst the three 
MDIs (Table 5.2.2 & Table 5.2.9). Impactor mass (S0toF) was both statistically similar 
and in-vitro equivalent between Airomir and Salamol only. With Ventolin Evohaler, 
TED was evenly distributed between IP and ACI plates (S0toF). This IP deposition was 
higher than both Airomir and Salamol. With Airomir, ~60% of TED entered ACI 
assembly (S0toF); with Salamol, TED was ~11% more than its IP deposition. 
S0toF deposition was statistically similar and in-vitro equivalent only between Airomir 
and Salamol. Their S0toF as %TED was also in-vitro equivalent, albeit with a 
statistically significant difference. 
FPD and %FPF were significantly lower for Ventolin Evohaler as compared to Airomir 
and Salamol (Table 5.2.3, Table 5.2.4 & Table 5.2.7) which rendered it in-vitro 
inequivalent to them. On the other hand, Airomir and Salamol MDIs had both 
statistically similar and in-vitro equivalent FPD and %FPF. 
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Table 5.2.2. Dose delivery and deposition in ACI of salbutamol HFA MDIs. 
Treatment 
Method 
TED IP IP+CPM S0toF IP (%TED) 
IP+CPM  
(%TED) 
S0toF  
(%TED) 
µg SD µg SD µg SD µg SD % SD % SD % SD 
Ventolin* 176.63 7.55 88.78 7.36 98.21 7.40 87.85 6.77 50.25 3.48 55.59 3.31 49.75 3.48 
Airomir 174.33 1.69 69.68 2.10 82.94 1.66 104.65 3.24 39.98 1.42 47.58 0.57 60.02 1.42 
Salamol 180.03 5.21 80.07 3.07 90.62 2.39 99.96 7.11 44.52 2.54 50.38 2.36 55.48 2.54 
 * Ventolin Evohaler 
Table 5.2.3. FPD, Stage groups, MMAD and GSD of salbutamol HFA MDIs. 
Treatment 
Method 
FPD FPM EPM CPM MMAD GSD 
µg SD µg SD µg SD µg SD µm SD 
 
SD 
Ventolin* 78.42 6.28 73.49 6.46 4.93 0.51 9.43 0.68 2.68 0.03 1.56 0.02 
Airomir 91.38 0.75 81.87 0.89 9.51 0.72 13.27 3.08 2.77 0.13 1.60 0.06 
Salamol 89.41 6.58 78.71 7.10 10.70 1.74 10.55 1.60 2.56 0.07 1.62 0.05 
 * Ventolin Evohaler 
Table 5.2.4. FPD and stage groups as %TED of salbutamol HFA MDIs. 
Treatment 
Method 
FPF (%TED) FPM (%TED) EPM (%TED) CPM (%TED) 
% SD % SD % SD % SD 
Ventolin* 44.41 3.31 41.62 3.49 2.79 0.26 5.34 0.28 
Airomir 52.42 0.57 46.96 0.51 5.46 0.43 7.60 1.71 
Salamol 49.62 2.36 43.67 2.84 5.95 1.05 5.86 0.88 
 * Ventolin Evohaler 
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FPM deposition shows that only Airomir and Salamol met in-vitro equivalence criterion 
although the three MDIs were statistically equivalent in this respect (Table 5.2.3 & 
Table 5.2.9). On the other hand, CPM and EPM depositions did not meet in-vitro 
equivalence criterion. Statistical similarities of CPM were found between Ventolin 
Evohaler Vs Salamol and Airomir Vs Salamol. However, EPM deposition showed 
statistical similarities only between Airomir Vs Salamol. 
 
Table 5.2.5. FPD and stage groups as %S0toF of salbutamol HFA MDIs. 
Treatment 
Method 
FPD (%S0toF) FPM (%S0toF) EPM (%S0toF) CPM (%S0toF) 
% SD % SD % SD % SD 
Ventolin* 89.25 0.60 83.59 1.41 5.65 0.87 10.75 0.60 
Airomir 87.38 2.59 78.28 2.22 9.10 0.80 12.62 2.59 
Salamol 89.44 1.52 78.70 3.37 10.74 2.02 10.56 1.52 
 * Ventolin Evohaler 
 
Table 5.2.6. FPD and S0toF delivery efficiency of salbutamol HFA MDIs. 
Treatment 
Method 
FPD / IP FPD / IP+CPM S0toF / IP 
Ratio SD Ratio SD Ratio SD 
Ventolin* 0.89 0.12 0.80 0.10 1.00 0.13 
Airomir 1.31 0.04 1.10 0.03 1.50 0.09 
Salamol 1.12 0.12 0.99 0.09 1.25 0.13 
 * Ventolin Evohaler 
 
In summary, the three MDIs showed in-vitro equivalent TED, MMAD and GSD. FPD 
and %FPF (%TED) of Ventolin Evohaler significantly differed from both Airomir and 
Salamol and was not in-vitro equivalent. On the other hand, Airomir and Salamol were 
in-vitro equivalent with respect to TED, FPD, FPF (%TED), FPM, S0toF, FPF (% 
S0toF), FPM (% S0toF), S0toF (%TED), MMAD and GSD.  
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Table 5.2.7. In-Vitro Equivalence of TED, FPD and S0toF of salbutamol HFA MDIs. 
Parameter 
Multiple 
Comparisons 
Mean 
Ratio 
90% CI 
p value 
In-Vitro 
Equivalence 
(0.85-1.18) 
Mean 
Difference 
95% CI 
p value 
Statistical 
Similarity LL UL LL UL 
TED (µg) 
Ventolin 
Evohaler 
Airomir 1.01 0.96 1.07 1.000 Yes 1.15 -4.37 6.68 1.000 Yes 
Salamol 0.98 0.93 1.04 1.000 Yes -1.70 -7.22 3.83 1.000 Yes 
Airomir Salamol 0.97 0.92 1.02 0.880 Yes -2.85 -8.37 2.68 0.843 Yes 
FPD (µg) 
Ventolin 
Evohaler 
Airomir 0.86 0.77 0.95 0.006 No -6.48 -11.22 -1.74 0.005 No 
Salamol 0.88 0.79 0.97 0.023 No -5.49 -10.23 -0.75 0.018 No 
Airomir Salamol 1.02 0.92 1.14 1.000 Yes 0.99 -3.76 5.73 1.000 Yes 
FPF 
(%TED) 
Ventolin 
Evohaler 
Airomir 0.85 0.78 0.92 <0.0001 No -.080 -0.12 -0.04 0.0002 No 
Salamol 0.89 0.82 0.97 0.014 No -.052 -0.09 -0.01 0.011 No 
Airomir Salamol 1.06 0.97 1.15 0.545 Yes 0.03 -0.01 0.07 0.367 Yes 
S0toF (µg) 
Ventolin 
Evohaler 
Airomir 0.84 0.76 0.93 0.001 No -8.40 -13.61 -3.18 0.001 No 
Salamol 0.88 0.79 0.97 0.020 No -6.05 -11.27 -0.84 0.018 No 
Airomir Salamol 1.05 0.95 1.16 1.000 Yes 2.34 -2.87 7.56 1.000 Yes 
%S0toF 
(%TED) 
Ventolin 
Evohaler 
Airomir 0.83 0.77 0.89 <0.0001 No -10.27 -14.72 -5.82 <0.0001 No 
Salamol 0.90 0.83 0.97 0.009 No -5.73 -10.18 -1.27 0.008 No 
Airomir Salamol 1.08 1.00 1.17 0.087 Yes 4.55 0.09 9.00 0.044 No 
FPF 
(%S0toF) 
Ventolin 
Evohaler 
Airomir 1.02 0.99 1.05 0.547 Yes 1.86 -1.31 5.04 0.577 Yes 
Salamol 1.00 0.97 1.03 1.000 Yes -0.19 -3.36 2.98 1.000 Yes 
Airomir Salamol 0.98 0.95 1.01 0.400 Yes -2.06 -5.23 1.12 0.414 Yes 
CI = Confidence Interval; LL = Lower limit; UL = Upper Limit 
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Table 5.2.8. In-Vitro Equivalence of MMAD and GSD of salbutamol HFA MDIs. 
Parameter 
Multiple 
Comparisons 
Mean 
Ratio 
90% CI 
p value 
In-Vitro 
Equivalence 
(0.85-1.18) 
Mean 
Difference 
95% CI 
p value 
Statistical 
Similarity LL UL LL UL 
MMAD (µm) 
Ventolin 
Evohaler 
Airomir 0.97 0.91 1.03 1.000 Yes -0.09 -0.27 0.09 0.951 Yes 
Salamol 1.05 0.99 1.12 0.308 Yes 0.13 -0.05 0.30 0.292 Yes 
Airomir Salamol 1.08 1.02 1.15 0.019 Yes 0.21 0.04 0.39 0.014 No 
GSD 
Ventolin 
Evohaler 
Airomir 0.98 0.93 1.04 1.000 Yes -0.03 -0.13 0.07 1.000 Yes 
Salamol 0.97 0.91 1.02 0.635 Yes -0.06 -0.16 0.05 0.680 Yes 
Airomir Salamol 0.98 0.93 1.04 1.000 Yes -0.03 -0.13 0.08 1.000 Yes 
CI = Confidence Interval; LL = Lower limit; UL = Upper Limit 
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Table 5.2.9. In-Vitro Equivalence of IP and stage group depositions of salbutamol HFA MDIs. 
Stage 
Grouping 
Multiple 
Comparisons 
Mean 
Ratio 
90% CI 
p value 
In-Vitro 
Equivalence 
(0.85-1.18) 
Mean 
Difference 
(µg) 
95% CI 
p value 
Statistical 
Similarity LL UL LL UL 
IP (Throat) 
Ventolin 
Evohaler 
Airomir 1.27 1.16 1.40 <0.0001 No 9.55 5.13 13.97 <0.0001 No 
Salamol 1.11 1.01 1.21 0.063 No 4.35 -0.07 8.78 0.055 Yes 
Airomir Salamol 0.87 0.79 0.96 0.006 No -5.20 -9.62 -0.77 0.017 No 
Group 1 
(CPM) 
(S0+S1+S2) 
Ventolin 
Evohaler 
Airomir 0.73 0.55 0.95 0.038 No -1.92 -3.67 -0.17 0.027 No 
Salamol 0.90 0.69 1.18 1.000 No -0.56 -2.31 1.19 1.000 Yes 
Airomir Salamol 1.24 0.94 1.63 0.302 No 1.36 -0.39 3.11 0.197 Yes 
Group 2 
(FPM) 
(S3+S4+S5) 
Ventolin 
Evohaler 
Airomir 0.89 0.79 1.01 0.156 No -4.19 -9.13 0.76 0.129 Yes 
Salamol 0.93 0.83 1.05 0.900 No -2.61 -7.55 2.33 0.791 Yes 
Airomir Salamol 1.04 0.92 1.18 1.000 Yes 1.58 -3.37 6.52 1.000 Yes 
Group 3 
(EPM) 
(S6+S7+F) 
Ventolin 
Evohaler 
Airomir 0.52 0.42 0.64 <0.0001 No -2.29 -3.40 -1.18 <0.0001 No 
Salamol 0.46 0.38 0.57 <0.0001 No -2.88 -3.99 -1.77 <0.0001 No 
Airomir Salamol 0.90 0.73 1.11 1.000 No -0.59 -1.70 0.52 0.773 Yes 
CI = Confidence Interval; LL = Lower limit; UL = Upper Limit 
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5.2.4 Discussion: In-Vitro Equivalence of Salbutamol HFA MDIs 
Discussion is organised into separate sections and follows underneath. 
5.2.4.1 Total Emitted Dose (TED) 
TED demonstrates in-vitro equivalence of Ventolin Evohaler, Airomir and Salamol. 
TED for Ventolin Evohaler is comparable to but higher than that reported by McCabe et 
al. (2012), Nagel et al. (2011) and Cripps et al. (2000) with corresponding ratios of 
~0.97, ~0.87 and ~0.93 (Table 2.5.1). TED reported by Johnson et al. (2016) shows a 
ratio of ~0.82 (normalised for metered dose) and indicates larger difference.  
TED of Airomir is similar to that reported by Dubus et al. (2001) and Mitchell et al. 
(1999) but higher than that of Johnson et al. (2016); their respective ratios are ~0.98, 
~0.93 and ~0.72 (normalised for metered dose of Proventil HFA) (Table 2.5.2). 
TED of ProAir HFA reported by Johnson et al. (2016), McCabe et al. (2012) and von 
Hollen et al. (2011a & b & 2012) is similar to TED reported here for Salamol, with 
respective ratios of ~0.98 (normalised for metered dose), ~1.03 and ~1.01 (Table 2.5.3). 
5.2.4.2 Induction Port (Throat) Deposition 
IP deposition was in decreasing rank order of Ventolin Evohaler > Salamol > Airomir. 
Johnson et al. (2016) also reported similar trend for Ventolin HFA, ProAir HFA and 
Proventil HFA. 
Ventolin Evohaler had significantly higher IP deposition than Airomir and Salamol. 
This is more likely associated with its inherent product characteristics, vis-à-vis: 
emission of forceful high velocity spray with resultant longer travelling, shorter life 
plume (Ross and Gabrio, 1999; Stein, 2008; Brambilla et al., 2011; McCabe et al., 
2012). Ventolin Evohaler, which contains HFA propellant only and no excipient (Table 
2.2.1), was developed to simulate product performance characteristics of Ventolin CFC 
it replaced; hence spray patterns and plume characteristics were reproduced to give 
patient the same feel of throat impaction (Cripps et al., 2000). On the other hand, in 
addition to HFA propellant, Airomir and Salamol contain ethanol as co-solvent while 
Airomir also contains surfactant oleic acid. Addition of ethanol in MDI formulation 
reduces spray velocity, impact force, plume geometry and prolongs plume life (Gabrio 
et al., 1999; Ross and Gabrio, 1999; Smyth, 2003; Leach, 2005; Stein and Myrdal,  
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2006; Hess, 2008; Stein, 2008; McCabe et al., 2012; Ivey et al., 2015). Hence, these 
formulation constituents in Airomir and Salamol may have contributed to relatively 
lower IP deposition and more proportion of their TED entered ACI assembly (S0toF) 
than Ventolin Evohaler. Besides, the three MDIs have differences in device design such 
as orifice diameter, fill volume, valve structure and components (Ross and Gabrio, 
1999; Gabrio et al., 1999; Stein, 2008; Brambilla et al., 2011; McCabe et al., 2012). 
Therefore, these differences in their formulation and device design may have resulted in 
significantly different IP deposition. 
IP deposition reported in this thesis for Ventolin Evohaler lies between that reported by 
Cripps et al. (2000) and Johnson et al. (2016). Their respective IP deposition ratios are 
~0.88 and ~1.15 (normalised for metered dose) and suggest similarity with results 
reported here although their results differed significantly from each other (ratio ~0.76). 
For Airomir, respective ratios of IP depositions reported by Johnson et al. (2016) and 
Ross and Gabrio (1999) to those reported here are ~0.82 (normalised for metered dose) 
and ~1.26 and depict significant differences. IP deposition reported in this thesis lies 
within the range of their results. Again, results of these investigators significantly differ 
from each other (ratio ~0.65). Also, Mitchell et al. (1999) reported that ~53% of 
labelled unit dose (90 µg) was retained in IP, which is higher than that reported in this 
thesis (~40% of 90 µg).  
IP deposition reported by Johnson et al. (2016) for ProAir HFA is smaller than that 
reported in this thesis for Salamol (ratio ~0.81) (normalised for metered dose). 
In addition to formulation factors, the differences in IP deposition could be due to 
continuous evaporation of propellant (and ethanol) in ACI at varying rates while 
emitted dose is traversing through it (Stein and Myrdal, 2004; Myrdal et al., 2004; 
Stein, 2008). This evaporation rate is also affected by the environment, i.e., temperature 
and humidity (Labiris and Dolovich, 2003). This is evident from the variability in IP 
deposition observed within the five runs reported in this thesis (Table 5.2.1). 
The differences in IP deposition highlight inconsistency of reported results by 
investigators and complicate safety assessment of swallowed dose for a given MDI. 
This unpredictability may be confounded by patient factors. 
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5.2.4.3 Impactor Mass (S0toF) 
Impactor deposition mimics the dose that would be inhaled and available for clinical 
effects in HRT beyond throat. S0toF results showed significant differences of Ventolin 
Evohaler with both Airomir and Salamol resulting in their in-vitro inequivalence to the 
former. These differences are due to variability of IP deposition with consequent 
differences in amounts reaching into impactor (S0toF) (Borgström et al., 2006; Cheng et 
al., 2015). Similar trend was observed when S0toF was assessed as %TED. Also, S0toF 
to IP deposition ratios were in decreasing rank order of Airomir > Salamol > Ventolin 
Evohaler. The highest S0toF Vs IP ratio of Airomir indicates its TED had more 
proportion of impactor mass which in turn resulted in higher FPD. These findings 
suggest that differing amounts of TED from these MDIs will reach into HRT beyond 
throat, which may have clinical implications. 
On the other hand, impactor mass was both statistically similar and in-vitro equivalent 
between Airomir and Salamol, albeit significantly lower IP deposition of Airomir. This 
in-vitro similarity between them is more likely due to relatively higher TED of Salamol, 
and consequently more dose entered the impactor thereby off-setting the effects of 
higher IP deposition. This was evident from their S0toF (%TED) in-vitro equivalence. 
5.2.4.4 Fine Particle Dose (FPD) 
FPD (and FPM) of Ventolin Evohaler did not meet in-vitro equivalence criteria when 
compared with Airomir and Salamol. Results suggest that the latter two MDIs were 
more efficient than the former MDI in producing FPD which was in decreasing rank 
order of Airomir > Salamol > Ventolin Evohaler. Johnson et al. (2016) reported 
significantly different FPD amongst Ventolin HFA, Proventil HFA and ProAir HFA 
which was in the decreasing rank order of ProAir HFA > Proventil HFA > Ventolin 
HFA. However, these investigators found larger differences; the ratios of Ventolin HFA 
Vs Proventil HFA and Vs ProAir HFA were 1.92 and 3.08, respectively. This is at 
variance to FPD results reported here where the ratios for Ventolin Evohaler Vs Airomir 
and Vs Salamol are 0.86 and 0.88. Besides, their reported FPD ratio between ProAir 
HFA and Proventil HFA is 1.61 which is again significantly different than reported here 
for Airomir Vs Salamol. The latter two MDIs were indeed found in-vitro equivalent in 
this study with a FPD ratio of 1.02. Hence, differences in FPD between these two 
studies may have origins in varying and smaller TED and IP deposition (Sections 
5.4.2.1 & 5.2.4.2). McCabe et al. (2012) compared ProAir HFA with Ventolin HFA.   
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The ratio of 2.04 obtained for their reported FPD indicates significant difference. This is 
in conflict with the ratio of 0.88 reported for Salamol to Ventolin Evohaler in this thesis.  
Ratios of FPD reported by Johnson et al. (2016), McCabe et al. (2012), Nagel et al. 
(2011) and Cripps et al. (2000) to the FPD of this study for Ventolin Evohaler are 
respectively ~0.44 (normalised for metered dose), ~0.67, ~ 0.89 and ~0.95. FPD 
reported by Johnson et al. (2016) and McCabe et al. (2012) are significantly lower while 
those reported by Nagel et al. (2011) and Cripps et al. (2000) are comparable to that 
reported here. In contrast, Sanders and Bruin (2015) have reported a significantly higher 
FPD (ratio ~ 1.41). Coppolo et al. (2005) reported FPD for generic Ratio-Salbutamol 
HFA MDI which is significantly lower than that reported in this thesis (ratio ~ 0.71) 
despite having been manufactured under GSK agreement with Ratio-Pharma (Patented 
Medicine Prices Review Board, 2011). 
For Airomir, FPD reported by Ross and Gabrio (1999), Mitchell et al. (1999) and Dubus 
et al. (2001) is more or less similar to that reported in this thesis having respective ratios 
of ~0.85, ~1.09 and ~1.11 (< 5.8 um). However, FPD reported by Johnson et al. (2016) 
for Proventil HFA is lower than that reported here having a ratio of ~0.73 (normalised 
for metered dose).  
Higher FPD has been reported for ProAir HFA by Johnson et al. (2016), McCabe et al. 
(2012) and von Hollen et al. (2011a & b & 2012). Their respective results have ratios of 
~1.20 (normalised for metered dose), ~1.18 and ~1.29 as compared to Salamol. This 
comparison indicates that FPD obtained by these investigators is similar between them 
but higher than that reported in this thesis. 
These comparisons with other investigators reveal that it is not uncommon to have 
differing FPD amongst HFA MDIs. The varying FPD results reported in this thesis for 
Ventolin Evohaler, Airomir and Salamol reflect on this tendency. However, the 
differences amongst these FPD results reported in this thesis are of lesser magnitude 
than those reported by Johnson et al. (2016) and McCabe et al. (2012). Nevertheless, it 
is highly likely that these differing results amongst HFA MDIs are due to differences in 
their formulations and device design. Such varied and conflicting results will have 
implications for prescribers and are likely to confuse clinicians in decision making. 
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5.2.4.5 FPD to IP Ratio 
Pritchard (2001) highlighted that the amount of inhaled drug delivery to lung in relation 
to throat deposition should be optimal to keep a balance between therapeutic effects and 
systemic side effects. He suggested that an ideal ratio of lung to total systemic exposure 
should be one. Depositions on IP and on stages 3 to 7 and filter (FPD) respectively 
represent depositions in throat and lungs in humans (Table 3.3.2). Ratios of FPD to IP 
deposition were in decreasing rank order of Airomir > Salamol > Ventolin Evohaler. 
Further, similar trend was observed with ratios of FPD (respirable dose) to IP+CPM 
(non-respirable dose) depositions. These ratios suggest that Airomir may deliver higher 
proportion of respirable dose. However, with Salamol these ratios are closer to unity 
and therefore it may be ideally placed HFA MDI with respect to a better benefit to risk 
ratio.  
5.2.4.6 Fine Particle Fraction Percentage (%FPF) 
FPF as %TED was in decreasing rank order of Airomir > Salamol > Ventolin Evohaler. 
Johnson et al. (2016) found this order to be as ProAir HFA > Proventil HFA > Ventolin 
HFA. McCabe et al. (2012) also reported higher %FPF for ProAir HFA than Ventolin 
HFA. Thus, both Airomir and Salamol had higher %FPF. This trend is more likely due 
to higher IP deposition of Ventolin Evohaler as compared to the other two MDIs. As a 
consequence, relatively lower TED entered ACI assembly (S0toF) and resulted in lower 
FPD. The role of formulation in IP deposition has been discussed earlier (Section 
5.2.4.2). 
Ratios of %FPF reported by Johnson et al. (2016), McCabe et al. (2012), Nagel et al. 
(2011) and Cripps et al. (2000) to that reported in this thesis are ~0.54, ~0.74, ~ 1.02 
and ~0.89, respectively. %FPF of former two studies is significantly different while for 
the latter two studies, it is similar to that reported here. 
For Airomir, ratios of %FPF reported by Johnson et al. (2016) (Proventil HFA), Dubus 
et al. (2001), Ross and Gabrio (1999) and Mitchell et al. (1999) to that reported in this 
thesis are ~1.02, ~1.21, ~0.91 and ~0.96, respectively. These ratios suggest similarity of 
their results with the current study, except for Dubus et al. (2001). However, Dubus et 
al. (2001) calculated %FPF with TED obtained from Emitted Dose Uniformity (EDU) 
tests rather than TED obtained from ACI testing. 
For ProAir HFA, ratios of %FPF reported by Johnson et al. (2016), McCabe et al. 
(2012) and von Hollen et al. (2011a & 2012) to the results reported here for Salamol are   
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respectively ~1.23, ~1.14 and ~1.28. These ratios show higher %FPF was found by 
others. 
It is evident that %FPF reported here for Airomir compares favourably with those 
reported by others. However, conflicting results were found with some studies for 
Ventolin Evohaler and Salamol. The magnitude of these differences in %FPF indicate 
the scale of variations noted amongst different studies for a given MDI as pointed out in 
Sections 5.2.4.2 and 5.2.4.4. 
5.2.4.7 Fine Particle Fraction as percent of Impactor Mass (FPF as %S0toF) 
This parameter reflects on the proportion of respirable dose that would reach to HRT 
beyond throat. Even though differing amounts of TED reached impactor, yet the 
proportion of FPD as %S0toF (87% to 89%) was statistically similar and in-vitro 
equivalent amongst the three MDIs. This finding is the outcome of off-set effect of the 
relative, inconsistent and disproportionate variability of S0toF and FPD. This may mask 
the actual differences in FPD delivery efficiency of these MDIs. The variability of these 
two metrics has been discussed earlier (Sections 5.2.4.3 and 5.2.4.4). 
5.2.4.8 MMAD and GSD 
Irrespective of their formulation differences, the three MDIs produced aerosol particles 
which met in-vitro equivalence criteria with respect to their MMAD and GSD; with 
only statistically significant difference observed between Airomir Vs Salamol for 
MMAD. Their MMAD range of > 2.5 µm to < 2.8 µm represents the desired particle 
size range (FPM), and therefore each of the three MDIs is expected to deliver inhaled 
dose to bronchi and bronchioles to elicit bronchodilation (Pritchard, 2001; Howarth, 
2001; Clark, 2012). Their GSD range of 1.56 to 1.62 approximates monodispersity. This 
suggests that their aerosolised drug particles had a similar and narrower particle size 
distribution around their respective MMADs (Figure 5.2.2). Since FPD and FPM were 
in order of decreasing amounts of Airomir > Salamol > Ventolin Evohaler, this may 
affect dose delivery to desired regions of HRT. Airomir may be expected to deliver 
relatively more dose to bronchi and bronchioles than both Salamol and Ventolin 
Evohaler because of having more proportion of particles within the respirable range. 
This may have clinical implications. 
Pritchard (2001) pinpointed that aerosolised particles with MMAD <2.5 µm are more 
likely to be exhaled if patients do not hold their breath. MMADs reported by other   
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investigators for Ventolin HFA, Proventil HFA and ProAir HFA are <2.5 µm (Ross and 
Gabrio, 1999; Cripps et al., 2000; von Hollen et al., 2011a & b & 2012; McCabe et al., 
2012; Hatley et al., 2014; Johnson et al., 2016;), and therefore more likely to be found 
in the region at the borderline between FPM and EPM. These results are in contrast to 
those reported here where MMAD size of > 2.5 µm suggests a larger proportion of 
particles in FPM range. Since the amount of salbutamol that reaches to lungs has been 
linked to its effects (Melchor et al., 1993; Zanen et al., 1994 & 1996; Weda et al., 2004; 
Usmani et al., 2005), therefore, results reported in this thesis may be more reflective of 
clinical effects than those reported by these investigators. 
GSDs reported by other investigators as compared to those found in this study are 
higher for Ventolin Evohaler (≥ 1.8) (McCabe et al., 2012; Johnson et al., 2016), similar 
for Airomir (~ 1.6) (Johnson et al., 2016) and lower for ProAir HFA (Vs Salamol) (≤ 
1.6) (McCabe et al., 2012; Johnson et al., 2016). These variations and similarities may 
be reflected in clinical effects when viewed in conjunction with APSD, FPM and 
MMAD. 
5.2.4.9 Role of Actuator Design 
Airomir and Salamol were in-vitro equivalent with respect to the CQAs vis-à-vis: TED, 
FPD, FPM, %FPF, S0toF, MMAD and GSD. Also, their CPM and EPM were 
statistically similar. This is perhaps understandable since both MDIs contain ethanol as 
co-solvent (Table 2.2.1). However, it is perhaps surprising given that their actuator 
mouthpiece design is different, i.e., round Vs rectangular (oval). For Airomir, it has 
been postulated that its round shaped actuator mouthpiece creates wider space in mouth 
(oral cavity) thereby providing the dispensed dose more room for evaporation into finer 
particles which are then inhaled (Ross and Gabrio, 1999). The round actuator 
mouthpiece of Airomir and its slow and soft puff of emitted dose are hypothesized to 
act in synergy thereby reducing throat deposition and enhancing lung delivery. This 
hypothesis holds good for Airomir with respect to IP deposition reported in present 
study which is significantly lower than that found for Salamol. Johnson et al. (2016) 
have also reported slightly lower IP deposition for Proventil HFA than ProAir HFA. 
However, given that Salamol performed similarly in-vitro with respect to the above 
mentioned CQAs of an MDI performance, the significance of this hypothesis is 
debatable. The data of current project could not support the possible link of actuator 
mouthpiece shape of Airomir to other MDI performance metrics mentioned above.   
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Interestingly, Johnson et al. (2016) reported lower TED and FPD for Proventil HFA 
than ProAir HFA. Also, Asmavent MDI (Neolab / Fannin (UK) Limited) was granted 
generic approval by Medicines and Healthcare Products Regulatory Agency (MHRA) 
and considered equivalent to Airomir (PL 08137/0130; 3rd July 2009). Asmavent has 
similar formulation ingredients to that of Airomir but has a rectangular mouthpiece 
design (Fannin PIL, 2014; Fannin SmPCs, 2017). Hence, based on present in-vitro 
results and other published work, it can be argued that the shape of the actuator did not 
have effect on CQAs of Airomir and Salamol. 
5.2.4.10 Stage Groups 
ACI stage pooling into groups in this study is consistent with earlier reports (Guo et al., 
2008 & 2013; de Boer et al., 2015). Collective deposition on these stage groups 
highlights their relevance to various regions of HRT (Pritchard, 2001, Weda et al., 
2004; Usmani et al., 2005). 
Stage group comparison of the three MDIs revealed in-vitro inequivalence. The only 
exception was in-vitro equivalence between Airomir and Salamol for stage group 2 
(FPM). These dissimilarities are likely due to differences in their formulations and 
device design with consequences in dose delivery characteristics (Sections 5.2.4.2 and 
5.2.4.4). These findings concur with those of de Boer et al. (2015) for four ICS/LABA 
DPI formulations in different devices. They reported marked differences in APSDs and 
amounts of submicron (diameter < 1 µm) and micron (1–3 µm) particle mass fractions. 
However, they also found most mass fractions of particles in the range of 3–5 µm were 
similar which supports findings for FPM in this thesis. Hence, different formulations 
with different inhaler device design may not produce similar APSD profiles and may 
have consequences for clinical effects. 
Thus, findings in this study for stage group comparison suggest that the three HFA 
MDIs may not be interchangeable. This is reflected in the directive of MHRA to 
prescribers to specify brand of MDI (Chrystyn and Price, 2009). Further, US Food and 
Drug Administration (FDA) categorised Ventolin HFA, Proventil HFA and ProAir HFA 
as therapeutically inequivalent (code BX) (FDA Orange Book online). Also, MHRA did 
not allow using generic name ‘Salbutamol Inhaler’ for Asmavent CFC-free MDI 
(generic of Airomir), arguing that the product must be identifiable by a brand name (PL 
08137/0130; 3
rd
 July 2009). The findings of current study complement these regulatory 
injunctions.  
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5.2.4.11 Which Criteria for in-vitro equivalence? 
Inhaled bronchodilator therapy is meant to relieve bronchospasm such as caused by 
acute asthma (GINA, 2017). The delivery of inhaled dose to lungs is dependent on 
particle size composition of dispensed dose from an MDI. Particles that have 
aerodynamic size less than 5 µm have the greatest chance to deposit in lungs (Chrystyn, 
1997) and bring about bronchodilatation.  
Clinical studies in chronic stable asthma have revealed a correlation between total dose 
of salbutamol deposited in the lung and improvement in FEV1 (Zainudin et al., 1990). 
Melchor et al. (1993) found a significant relationship between the amount of salbutamol 
deposited in lungs and its bronchodilatory effects in healthy subjects and patients. 
APSD profile (S0toF) of salbutamol MDI reported in their manuscript reflected on 
clinical effects. In studies comparing the effects of particle size of inhaled salbutamol in 
asthma (Zanen et al., 1994) and COPD (Zanen et al., 1996) patients, the bronchodilator 
response was greater when salbutamol particles of 2.8 µm size were inhaled than when 
the same patients inhaled particles sized 1.5 µm and 5 µm. These investigators also 
showed that bronchodilatory response in asthma patients was dependent on the amount 
of drug reaching lungs. Total lung deposition was also found to be linked with fine 
particle dose (Olsson et al., 1996). Lung deposition is optimal when aerosol cloud 
contains majority of particles within size range of 2-5 µm (Chrystyn, 1997). Weda et al. 
(2004) demonstrated that safety of three salbutamol formulations inhaled from 
Novolizer DPI was correlated to particles deposited on impactor stages in FPD range. 
However, it has also been shown that monodisperse salbutamol particles of 6 µm 
deposit in the airways and produce similar bronchodilatory response when compared to 
particles of 3 µm (Usmani et al., 2003 & 2005; Usmani, 2008). Hence, findings of these 
studies indicate that particles of more than one size bring about bronchodilatation. Most 
MDIs are polydisperse (Nagao et al., 2005) and produce particles over a wide range of 
size and therefore it is highly likely that a range of particles sizes are involved in 
therapeutic effects (Pritchard, 2001). Recently, it has been shown in a PK study using 
charcoal block approach that systemic availability of salbutamol was related to lung 
deposition and that adverse events were correlated to systemic levels (Moore et al., 
2017). These researchers also suggested that FPM was related to PK profile for the 
same inhaler device. These studies clearly suggest that FPD is the key CQA of 
salbutamol MDI which can provide comparative information on both in-vitro and in-
vivo performance.   
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Individual stage-wise comparisons could have value for quality assurance, product 
monitoring and in research and development of new inhaler products. However, 
differently formulated MDI products with a different device design will have a differing 
APSD profile which would result in high variability between individual stage 
depositions. This is evident from the results of current study. Also, at present no link 
between individual stage deposition and expected deposition sites in lungs has been 
established (García-Arieta, 2014). Hence stage-wise comparison would be less 
predictive of in-vivo behaviour of inhaled drug besides being impractical for 
application. However, comparisons based on stage groups are considered anticipative of 
in-vivo bioequivalence (García-Arieta, 2014). Even then it is highly unlikely to clearly 
link a stage group with efficacy and safety (Usmani et al., 2003 & 2005; Usmani, 2008).  
Salbutamol MDI is prescribed for rapid relief of airways obstruction which is achieved 
by its local lung deposition. Hence, efficacy to provide quick relief of asthma symptoms 
is the key desired objective while the incidence of side effects is of low importance. 
Efficacy of salbutamol MDI is related to its FPD that is deposited in lungs. Therefore, 
comparisons of individual stages or group of stages which reflect on side effects of a 
salbutamol MDI become less important. Besides, salbutamol related side effects from 
MDIs are rare at the recommended dose (PILs of Ventolin Evohaler, Airomir and 
Salamol). In addition, a significant portion of TED that would deposit in IP and on 
stages 0 to 2 (CPM) is removed when a spacer is used with an MDI (Barry and 
O’Callaghan, 1997; Mitchell et al., 1999; Coppolo et al., 2006; Mazhar and Chrystyn, 
2008; Hall et al., 2011; Hatley et al., 2014; Oliveira et al., 2015 & 2016; Johnson et al., 
2016) (also see Chapters 6, 7 & 8). Consequently, delivered dose from an MDI attached 
to a spacer mainly contains particles that constitute FPD. Since a comparison of an MDI 
used alone and with attached spacer is a regulatory pre-requisite where a specific spacer 
is to be used with a specific MDI, this comparison is achieved by comparing their FPDs 
(EMA, 2006 & 2009). Thus, the comparison of MDIs with respect to their FPDs would 
be a meaningful, practical and effective criterion to establish in-vitro equivalence. 
Hence, in-vitro equivalence has been concluded based on comparable FPD. 
The range of stages to represent FPD would depend on the type of inhaler product and 
objective of treatment. This choice of stages has varied amongst researchers. Cripps et 
al. (1999) defined FPD for salbutamol to consist of stages 2-6 while Peyron et al. (2005)   
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compared fine particle mass (FPM) of salmeterol on stages 3 to 5 (particles between 1.1 
µm to 4.7 um). Usmani (2008) and co-workers (2003 & 2005) have shown that 
salbutamol particle size of 6 µm also possesses bronchodilatory effects. However, in 
this thesis FPD has been defined as per recommendations of EMA guideline (2006 & 
2009), i.e., particles size < 5 µm which effectively means deposition on ACI stages 3 to 
7 and back-up filter when operated at 28.3 L/min. This FPD specification has been 
widely reported (Ross and Gabrio, 1999; Mitchell et al., 1999; Rau et al., 2006; 
Coppolo et al., 2006; Guo et al., 2008; Laube et al., 2011; Hall et al., 2011; von Hollen 
et al., 2011 and 2012; Hatley et al., 2014; Sanders and Bruin, 2015; Sandell and 
Mitchell, 2015; Johnson et al., 2016; Hillyer et al., 2018). 
5.2.4.12 Summary of Discussion 
In this in-vitro study, APSD profiles obtained from ACI analysis of Ventolin Evohaler, 
Airomir and Salamol were compared in accordance with EMA guidelines (2006 & 
2009).  
The recommendations of EMA guideline have been assessed with respect to their 
practicality for determining in-vitro equivalence using ACI. Comparisons based on 
individual stages were not performed due to high variability between individual stages 
of the three MDIs. Instead, comparisons based on grouped stages were carried out along 
with the traditional (and regulatory) approach of comparing FPD as the principal 
criterion. Stages were grouped as CPM, FPM and EPM. These comparisons showed 
significant differences amongst pooled stages. IP deposition also differed significantly. 
Therefore, the three MDIs were deemed not in-vitro equivalent. In-vitro equivalence 
was observed only between Airomir and Salamol for FPM. Similar pattern of in-vitro 
equivalence was observed when FPD was used as the main comparative criterion. Since 
similar results were obtained with the two comparative approaches, it is therefore 
deemed that comparison based on FPD represented a more practical approach to assess 
differing formulations of MDIs containing salbutamol. Besides, this approach is more 
predictive of in-vivo effects (Section 5.2.4.11). 
TED, MMAD and GSD were in-vitro equivalent amongst the three MDIs. However, 
S0toF, FPD and %FPF were only in-vitro equivalent between Airomir and Salamol. 
This similarity between these two MDIs is more likely due to the presence of ethanol in 
their formulations. Therefore, based on similar FPD, these two MDIs can be considered 
in-vitro equivalent.   
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5.2.5 Conclusions: Salbutamol HFA MDI In-Vitro Study 
Based on in-vitro significant differences in FPD, Ventolin Evohaler should not be 
considered an equivalent treatment to either Airomir or Salamol and therefore should 
not be substituted with either of them. On the other hand, Airomir and Salamol had in-
vitro similar FPD. However, on the basis of EMA (2006 & 2009) criteria, none of these 
MDI was found in-vitro equivalent and caution must be exercised for substituting one 
for the other. 
APSD profiles of the three MDIs assessed as stage groups were not in-vitro equivalent. 
This is likely due to differences in their formulation and device design with consequent 
differences in drug delivery characteristics.  
Since in-vitro equivalence studies on the three salbutamol MDIs could not be entirely 
demonstrated based on stage groups, this necessitates conducting a comparative in-vivo 
(PK) study as the next step forward. 
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5.3 In-Vivo Equivalence of Salbutamol HFA MDIs-Urinary 
Pharmacokinetic Studies 
The objectives of these PK studies are to demonstrate in-vivo equivalence of Ventolin 
Evohaler, Airomir and Salamol by comparing their relative lung and total systemic 
bioavailability in healthy subjects. This study also estimates lung deposition of inhaled 
salbutamol by preventing its gastrointestinal (GI) absorption of the swallowed fraction 
of drug using activated charcoal. 
5.3.1 Study Design 
Details of the study design have been provided in Section 3.4.5 (Chapter 3 
Methodology). In brief, thirteen trained healthy volunteers (7 females) took part in this 
six way crossed-over two part open study. In Part 1 Study, on separate study days (one 
week apart), each volunteer inhaled 2 puffs in two separate manoeuvres separated by 30 
seconds from randomly selected salbutamol MDI. The volunteers exhaled to residual 
volume prior to actuation, then took a slow deep inhalation over 5–10 seconds, followed 
by a 10 second breath hold (Section 3.4.4). This procedure was repeated for second 
actuation. In Part 2 Study, each volunteer repeated this study with the concurrent 
administration of activated charcoal by swallowing 100 mL of charcoal slurry 
immediately before and after two inhalations (Mazhar and Chrystyn, 2008). Volunteers 
swished charcoal slurry in the mouth before swallowing all of it. 
Urine samples were collected 0.5 hour before and after inhalation and thereon total 
urine was pooled for 24 hours. Volume and pH of all urine samples were recorded. All 
urine samples were stored at –20°C till extracted and assayed. 
5.3.2 Sample Analysis 
Urine and aqueous samples were processed and analysed using validated HPLC 
methods described in Chapter 4. 
5.3.3 Statistical Analysis 
Statistical analysis performed as per Section 3.4.7 (Chapter 3). 
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5.3.4 Results: In-Vivo Equivalence of Salbutamol HFA MDIs 
The mean (SD) age, height, weight and BMI of volunteers was 31.2 (7.6) years, 1.68 
(0.07) meters, 64.9 (10.8) Kg and 22.9 (2.4) Kg/m
2
, respectively; 54% were females and 
46% were Caucasians (Table 5.3.1 and Appendix 5.3.4.1). The pH of all urine samples 
was between 4.5 and 6.5. Hence, pH-dependent renal clearance of salbutamol was 
unlikely (Hindle and Chrystyn, 1992). All volunteers inhaled the dose correctly. 
 
Table 5.3.1. Demographic Characteristics of Volunteers. 
Characteristics Overall (n = 13) Male (n=6) Female (n=7) 
Age, mean (SD) 
(range), years 
31.2 (7.6)  
(23-48) 
36.8 (7.6)  
(25-48) 
26.3 (2.5)  
(23-31) 
Sex, n (%) 13 6 (46%) 7 (54%) 
Height, mean (SD) 
(range), m 
1.68 (0.07)  
(1.57-1.82) 
1.73 (0.07)  
(1.64-1.82) 
1.64 (0.05)  
(1.57-1.70) 
Weight, mean (SD) 
(range), Kg 
64.9 (10.9)  
(48-82) 
70.7 (10.3)  
(54-82) 
59.9 (9.2)  
(48-72) 
BMI, mean (SD)
 
(range), Kg/m
2
 
22.9 (2.4)  
(18.3-27.1) 
23.6 (2.4)  
(20.1-27.1) 
22.3 (2.4)  
(18.3-25.0) 
Race, n (%) 
 
  
Caucasian 6 (46%) 1 (16.7%) 5 (71.4%) 
Asian 7 (54%) 5 (83.3%) 2 (28.6%) 
BMI = Body Mass Index 
 
Summaries of the mean amounts of salbutamol recovered at 0.5h (USAL0.5) and 24h 
(USAL24) post-dose (without and with charcoal block) are provided in Table 5.3.2 and 
shown in Figure 5.3.1 to Figure 5.3.5 (see Appendices 5.3.4.2 to 5.3.4.7 for individual 
data). The table and figures also depict salbutamol as free (USAL24Pre), free and 
sulphate conjugated salbutamol (USAL24Post) and metabolised (USALMET) moieties 
excreted during 0.5h to 24h period. Figure 5.3.6 shows comparative salbutamol urinary 
recovery profiles obtained post-inhalation without and with charcoal ingestion. These 
recoveries of salbutamol as % nominal, % delivered and % recovered dose are given in 
Table 5.3.3 to Table 5.3.5. Table 5.3.6 and Table 5.3.7 provide data on in-vivo 
equivalence and statistical significance of the three salbutamol MDIs in Parts 1 and 2 
studies, respectively. 
The mean ratios of the three MDIs did not meet in-vivo equivalence criteria for any of 
the parameters studied in the two parts. In Part 1 Study (without charcoal ingestion),   
  109 
most of these parameters were statistically similar amongst the three MDIs (Table 
5.3.6). However, the amount of free salbutamol excreted in 0.5h-24h (USAL24Pre) was 
statistically significantly different amongst them. Nevertheless, total free and 
conjugated salbutamol excreted during this period (USAL24Post) was only significantly 
different between Ventolin Evohaler and Airomir. 
In Part 2 Study (with charcoal ingestion), only USAL0.5 and USALMET were 
statistically similar amongst the three MDIs (Table 5.3.7). USAL24Pre was statistically 
similar between Ventolin Evohaler Vs Airomir and Airomir Vs Salamol; the latter pair 
was also statistically similar for USAL24Post. 
 
Table 5.3.2. Mean salbutamol excreted in urine post-inhalation from MDIs. 
Treatment 
Method 
(n = 13) 
USAL0.5 USAL24† USAL24Pre USAL24Post USALMET 
µg SD µg SD µg SD µg SD µg SD 
Part 1 Study (without charcoal blockade) 
Ventolin* 5.7 1.9 100.7 15.7 58.4 18.3 95.0 16.6 36.6 15.6 
Airomir 7.1 3.3 84.2 28.1 42.1 14.0 77.1 27.0 35.0 18.2 
Salamol 6.7 3.2 94.4 19.4 42.9 11.2 87.7 18.41 44.8 12.9 
Part 2 Study (with charcoal blockade) 
Ventolin* 5.3 2.5 29.8 5.3 14.3 5.3 24.5 4.8 10.2 5.1 
Airomir 6.7 3.9 40.1 12.7 20.9 7.8 33.4 11.7 12.5 7.3 
Salamol 7.2 3.4 50.2 13.1 27.2 11.6 43.0 13.5 15.7 8.9 
* Ventolin Evohaler; † TRD = USAL24; SD = Standard Deviation 
 
 
Table 5.3.3. Mean salbutamol excretion in urine post-inhalation from MDIs, expressed 
as % of Nominal Dose. 
Treatment 
Method 
(n = 13) 
USAL0.5 USAL24† USAL24Pre USAL24Post USALMET 
% SD % SD % SD % SD % SD 
Part 1 Study (without charcoal blockade) 
Ventolin* 2.9 0.9 50.3 7.9 29.2 9.1 47.5 8.3 18.3 7.8 
Airomir 3.6 1.6 42.1 14.1 21.1 7.0 38.6 13.5 17.5 9.1 
Salamol 3.4 1.6 47.2 9.7 21.4 5.6 43.8 9.2 22.4 6.5 
Part 2 Study (with charcoal blockade) 
Ventolin* 2.6 1.2 14.9 2.7 7.2 2.7 12.3 2.4 5.1 2.5 
Airomir 3.3 1.9 20.0 6.4 10.4 3.9 16.7 5.8 6.2 3.7 
Salamol 3.6 1.7 25.1 6.5 13.6 5.8 21.5 6.8 7.9 4.5 
 * Ventolin Evohaler; † TRD = USAL24; SD = Standard Deviation 
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Table 5.3.4. Mean salbutamol excretion in urine post-inhalation from MDIs, expressed 
as % of estimated Delivered Dose. 
Treatment 
Method 
(n = 13) 
USAL0.5 USAL24† USAL24Pre USAL24Post USALMET 
% SD % SD % SD % SD % SD 
Part 1 Study (without charcoal blockade) 
Ventolin* 3.6 1.2 62.7 9.4 36.3 11.0 59.1 10.0 22.8 9.7 
Airomir 4.5 2.1 54.1 18.3 27.0 8.9 49.5 17.6 22.5 11.9 
Salamol 4.4 2.2 60.9 13.0 27.6 7.1 56.5 12.1 28.9 8.6 
Part 2 Study (with charcoal blockade) 
Ventolin* 3.3 1.5 18.7 3.4 9.0 3.4 15.4 3.1 6.4 3.2 
Airomir 4.2 2.4 25.4 8.3 13.2 5.0 21.2 7.7 8.0 4.8 
Salamol 4.6 2.1 31.8 8.4 17.3 7.6 27.2 8.6 9.9 5.6 
 * Ventolin Evohaler; † TRD = USAL24; SD = Standard Deviation 
 
Table 5.3.5. Mean salbutamol excreted in urine post-inhalation from MDIs, expressed as % 
of Recovered Dose. 
Treatment 
Method 
(n = 13) 
USAL0.5 USAL24† USAL24Pre USAL24Post USALMET 
% SD % SD % SD % SD % SD 
Part 1 Study (without charcoal blockade) 
Ventolin* 5.9 2.4 - - 57.7 14.6 94.1 2.4 36.3 14.4 
Airomir 9.4 5.5 - - 51.6 11.2 90.6 5.5 39.0 13.8 
Salamol 7.1 3.1 - - 45.4 9.4 92.9 3.1 47.5 8.7 
Part 2 Study (with charcoal blockade) 
Ventolin* 17.7 7.1 - - 48.7 16.0 82.3 7.1 33.7 14.6 
Airomir 17.3 8.7 - - 52.4 10.2 82.7 8.7 30.3 11.4 
Salamol 15.8 11.3 - - 53.2 16.0 84.2 11.3 31.0 14.3 
* Ventolin Evohaler; † TRD = USAL24; SD = Standard Deviation 
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Figure 5.3.1. Comparative salbutamol urinary excretion at 0.5h post-inhalation without and with 
charcoal ingestion. 
Numerals represent individual volunteers. nc = no charcoal ingestion; +c = with charcoal ingestion. 
 
 
 
Figure 5.3.2. Comparative total salbutamol urinary excretion during 24h post-inhalation without and 
with charcoal ingestion. 
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Figure 5.3.3. Comparative unchanged salbutamol urinary excretion during 0.5-24h post-inhalation 
without and with charcoal ingestion. 
 
 
 
Figure 5.3.4. Comparative total salbutamol urinary excretion during 0.5-24h post-inhalation without 
and with charcoal ingestion. 
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Figure 5.3.5. Comparative salbutamol metabolites urinary excretion during 0.5-24h post-inhalation 
without and with charcoal ingestion. 
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Figure 5.3.6. Comparative salbutamol urinary recovery profiles obtained post-inhalation without and with charcoal ingestion. 
Numerals represent individual volunteers. nc = no charcoal ingestion; +c = with charcoal ingestion. 
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Table 5.3.6. In-Vivo Equivalence and Statistical Significance of salbutamol urinary excretion post-inhalation without charcoal ingestion. 
Parameter 
Multiple 
Comparisons 
Mean 
Ratio 
90% CI 
p value 
In-Vivo Equivalence Mean 
Difference 
(µg) 
90% CI 
p value 
Statistical 
Similarity LL UL 0.80-1.25
a
 0.67-1.50
b
 LL UL 
USAL0.5 
NC 
Ventolin 
Evohaler 
Airomir 0.84 0.59 1.19 0.783 No No -1.39 -3.47 0.70 0.438 Yes 
Salamol 0.92 0.65 1.30 1.000 No No -0.99 -3.07 1.09 0.884 Yes 
Airomir Salamol 1.09 0.77 1.55 1.000 No No 0.40 -1.68 2.48 1.000 Yes 
USAL24 
NC 
Ventolin 
Evohaler 
Airomir 1.27 1.00 1.60 0.091 No No 16.48 -1.46 34.42 0.147 Yes 
Salamol 1.08 0.85 1.36 1.000 No Yes 6.35 -11.60 24.29 1.000 Yes 
Airomir Salamol 0.85 0.67 1.07 0.373 No Yes -10.13 -28.07 7.81 0.643 Yes 
USAL24Pre 
NC 
Ventolin 
Evohaler 
Airomir 1.41 1.05 1.88 0.044 No No 16.23 3.22 29.29 0.029 No 
Salamol 1.36 1.01 1.82 0.080 No No 15.49 2.46 28.53 0.039 No 
Airomir Salamol 0.97 0.72 1.29 1.000 No Yes -0.77 -13.80 12.27 1.000 Yes 
USAL24Post 
NC 
Ventolin 
Evohaler 
Airomir 1.32 1.02 1.70 0.064 No No 17.86 0.31 35.41 0.092 No 
Salamol 1.09 0.85 1.40 1.000 No Yes 7.33 -10.22 24.88 1.000 Yes 
Airomir Salamol 0.83 0.64 1.07 0.312 No No -10.53 -28.08 7.02 0.564 Yes 
USALMET 
 nc 
Ventolin 
Evohaler 
Airomir 1.17 0.74 1.87 1.000 No No 1.61 -11.86 15.07 1.000 Yes 
Salamol 0.77 0.48 1.22 0.636 No No -8.16 -21.6 5.30 0.551 Yes 
Airomir Salamol 0.65 0.41 1.04 0.154 No No -9.77 -23.23 3.70 0.344 Yes 
a
 EMA, 2009; 
b
 Parameswaran, 1999; CI = Confidence Interval; LL = Lower limit; UL = Upper Limit; NC or nc = No Charcoal  
  
  
1
1
6
 
 
 
Table 5.3.7. In-Vivo Equivalence and Statistical Significance of salbutamol urinary excretion post-inhalation with charcoal ingestion. 
Parameter 
Multiple 
Comparisons 
Mean 
Ratio 
90% CI 
p value 
In-Vivo Equivalence Mean 
Difference 
(µg) 
90% CI 
p value 
Statistical 
Similarity LL UL 0.80-1.25
a
 0.67-1.50
b
 LL UL 
USAL0.5 
C 
Ventolin 
Evohaler 
Airomir 0.81 0.58 1.12 0.467 No No -1.39 -3.73 0.96 0.582 Yes 
Salamol 0.72 0.52 1.00 0.103 No No -1.92 -4.26 0.43 0.231 Yes 
Airomir Salamol 0.89 0.64 1.24 1.000 No No -0.53 -2.87 1.81 1.000 Yes 
USAL24 
C 
Ventolin 
Evohaler 
Airomir 0.77 0.60 0.98 0.062 No No -10.27 -19.62 -0.91 0.062 No 
Salamol 0.61 0.48 0.77 0.0003 No No -20.38 -29.73 -11.03 0.0002 No 
Airomir Salamol 0.79 0.62 1.00 0.107 No No -10.11 -19.47 -0.76 0.067 No 
USAL24Pre 
C 
Ventolin 
Evohaler 
Airomir 0.68 0.47 0.99 0.083 No No -6.55 -14.29 1.19 0.205 Yes 
Salamol 0.54 0.37 0.78 0.003 No No -12.90 -20.64 -5.15 0.003 No 
Airomir Salamol 0.79 0.55 1.15 0.511 No No -6.35 -14.09 1.40 0.230 Yes 
USAL24Post 
C 
Ventolin 
Evohaler 
Airomir 0.77 0.58 1.01 0.120 No No -8.88 -17.73 -0.03 0.098 No 
Salamol 0.60 0.45 0.79 0.001 No Yes -18.46 -27.31 -9.61 0.0003 No 
Airomir Salamol 0.78 0.59 1.03 0.160 No No -9.58 -18.43 -0.731 0.067 Yes 
USALMET 
c 
Ventolin 
Evohaler 
Airomir 0.83 0.52 1.33 1.000 No No -2.33 -8.41 3.75 1.000 Yes 
Salamol 0.68 0.43 1.09 0.227 No No -5.57 -11.65 .51 0.149 Yes 
Airomir Salamol 0.82 0.51 1.30 1.000 No No -3.24 -9.32 2.84 0.723 Yes 
a
 EMA, 2009; 
b
 Parameswaran, 1999; CI = Confidence Interval; LL = Lower limit; UL = Upper Limit; C or c = Charcoal 
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The comparison of the two studies of the three MDIs without and with charcoal block is 
given in Table 5.3.8 (Figure 5.3.7) while Table 5.3.9 (Figure 5.3.8) shows their overall 
summary. The mean paired differences between the amounts of salbutamol excreted in 
0.5h were statistically similar between the two parts of the same MDI study (n=13) 
while all other studied parameters showed significant differences (Table 5.3.8). Similar 
trend was observed when the three MDIs were considered together (n=39) (Table 5.3.9).  
Table 5.3.8. Statistical comparison of salbutamol urinary excretion from the MDIs 
between Parts 1 and 2 studies. 
Parameter 
[nc Vs (+c)] 
MDI 
Mean 
paired 
Difference 
95% CI 
t value p value 
Statistical 
Similarity LL UL 
USAL0.5 
Ventolin* 0.43 -0.99 1.85 0.661 0.5212 Yes 
Airomir 0.43 -1.80 2.66 0.416 0.6845 Yes 
Salamol -0.50 -2.21 1.21 -0.639 0.5347 Yes 
USAL24 
Ventolin* 76.19 66.01 86.37 16.309 <0.0001 No 
Airomir 50.83 34.55 67.11 6.803 <0.0001 No 
Salamol 51.38 35.36 67.41 6.987 <0.0001 No 
USAL24Pre 
Ventolin* 44.05 32.70 55.40 8.458 <0.0001 No 
Airomir 21.24 12.23 30.26 5.134 0.0002 No 
Salamol 15.66 5.91 25.42 3.499 0.0044 No 
USAL24Post 
Ventolin* 70.47 59.71 81.24 14.261 <0.0001 No 
Airomir 43.73 28.16 59.31 6.119 0.0001 No 
Salamol 44.68 29.27 60.09 6.319 <0.0001 No 
USALMET 
Ventolin* 26.42 17.17 35.68 6.222 <0.0001 No 
Airomir 22.49 10.62 34.36 4.128 0.0014 No 
Salamol 29.02 18.57 39.47 6.052 0.0001 No 
 * Ventolin Evohaler 
 
Table 5.3.9. Statistical comparison of salbutamol urinary excretion from the 
MDIs between Parts 1 and 2 studies. 
Parameter 
[nc Vs (+c) 
Mean 
paired 
Difference 
95% CI 
t value p value 
Statistical 
Similarity LL UL 
USAL0.5 0.12 -0.84 1.08 0.249 0.8047 Yes 
USAL24 53.08 44.53 61.63 12.572 <0.0001 No 
USAL24Pre 26.99 20.35 33.62 8.236 <0.0001 No 
USAL24Post 52.96 44.56 61.37 12.752 <0.0001 No 
USALMET 25.98 20.38 31.57 9.403 <0.0001 No 
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Figure 5.3.7. Comparison of salbutamol urinary excretion from the MDIs between Parts 1 and 2 
studies. 
 
 
 
Figure 5.3.8. Comparison of salbutamol urinary excretion from the MDIs between Parts 1 and 2 
studies. 
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Table 5.3.10 shows trends of in-vitro and in-vivo correlation between MDI performance 
metrics and salbutamol urinary excretion post-inhalation. 
Table 5.3.10. In-vitro and in-vivo correlation trends between MDI performance metrics 
and salbutamol urinary excretion. 
Parameter 
Ventolin* 
µg 
Airomir 
µg 
Salamol 
µg 
Trend 
(in decreasing order) 
FPD 78.4 91.4 89.4 Airo ≥ Sala > Evo 
%FPF (%TED) 44.4 52.4 49.6 Airo ≥ Sala > Evo 
S0toF 87.9 104.7 100.0 Airo ≥ Sala > Evo 
USAL0.5 nc 5.7 7.1 6.7 Airo ≥ Sala > Evo 
USAL0.5 c 5.3 6.7 7.2 Sala ≥ Airo > Evo 
IP+CPM 98.2 82.9 90.6 Evo > Sala > Airo 
IP 88.8 69.7 80.1 Evo > Sala > Airo 
USAL24Pre nc 58.4 42.1 42.9 Evo > Sala > Airo 
USAL24Pre c 14.3 20.9 27.2 Sala > Airo > Evo 
USAL24Post nc 95.0 77.1 87.6 Evo > Sala > Airo 
USAL24Post c 24.5 33.4 43.0 Sala > Airo > Evo 
TED (ACI) 176.6 174.3 180.0 Sala > Evo > Airo 
Amount left in device (ACI) 41.2 40.6 48.9 Sala > Evo > Airo 
Amount left in device (nc) 39.4 43.8 44.7 Sala > Airo > Evo 
Amount left in device (c) 40.8 42.1 41.2 Airo > Sala > Evo 
Mean amount left in device 40.5 42.2 44.9 Sala > Airo > Evo 
USAL24 nc 100.7 84.2 94.4 Evo > Sala > Airo 
USAL24 c 24.5 33.4 43.0 Sala > Airo > Evo 
 * Ventolin Evohaler 
5.3.5 Discussion: In-Vivo Equivalence of Salbutamol HFA MDIs 
The results of Part 1 Study (Table 5.3.2 & Table 5.3.6) suggest that the amount of 
salbutamol excreted in urine in 0.5h post-inhalation (USAL0.5NC) with Ventolin 
Evohaler, Airomir and Salamol do not meet EMA (2009) in-vivo equivalence criteria 
despite being statistically similar. Since urinary excretion in the first 0.5h post-
inhalation is believed to be derived from the inhaled dose deposited in the lungs (Hindle 
and Chrystyn, 1992), these findings suggest that the three MDIs differ in their relative 
lung bioavailability. This may have clinical consequences in differing efficacies as lung 
deposition is related to improved spirometry (Chrystyn et al., 1998; Tomlinson et al., 
1999; Mazhar et al., 2008; Fahimi et al., 2011). 
Total systemic bioavailability measured as salbutamol urinary excretion over 24h post-
inhalation (USAL24) again suggests that the three MDIs were not in-vivo equivalent   
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although this was statistically similar amongst them (Table 5.3.2 & Table 5.3.6). This 
finding suggests that these MDIs may have different safety profiles.  
These findings support MHRA directive to prescribe MDIs with their brand names 
(Chrystyn and Price, 2009) and are in line with FDA’s view of therapeutic 
inequivalence of salbutamol MDIs (Ventolin HFA, Proventil HFA and ProAir HFA) 
(FDA Orange Book online). 
The excretion of free salbutamol over 0.5-24h post-inhalation was statistically similar 
only between Airo Vs Sala (Table 5.3.2 & Table 5.3.6 ). However, sulphate conjugated 
salbutamol (USALMETnc) excreted during this period was statistically similar amongst 
the three MDIs, which thereby resulted in their similar (p>0.05) total salbutamol 
(USAL24PostNC). However, none of them was in-vivo equivalent amongst them with 
respect to these parameters.  
The USAL0.5 results expressed as % of the nominal dose of this study for Ventolin 
Evohaler (HFA) (Table 5.3.3) are comparable to those reported by others for Ventolin 
CFC MDI (Hindle and Chrystyn, 1992 & 1994; Hindle et al., 1995 & 1997; Chege et 
al., 1998; Silkstone et al., 2002a; Tomlinson et al., 2003). The USAL0.5 values 
(normalised for single puff) obtained in this study for Airomir are similar to those 
reported by Clark and Lipworth (1996b). However, these investigators used 12 puffs of 
Airomir and did not determine total systemic bioavailability (USAL24). USAL24 mean 
values reported in this thesis for Ventolin Evohaler are lower than those reported by 
Hindle and Chrystyn (1992, 1994), Hindle et al. (1997) and Silkstone et al. (2002a) but 
slightly higher than those of Chege et al. (1998). The apparent differences could be due 
to subject cohort and the sample size. The similarities of USAL0.5 amongst these 
studies indicate that urinary excretion of salbutamol in the first 0.5h post-inhalation may 
be independent of formulation and adult subject variables. Also, studies with other 
inhaled drugs further indicate that 0.5h urinary excretion post-inhalation is not 
influenced by the type of inhaled drug. This has been shown with urinary PK studies on 
inhaled sodium cromoglycate (Aswania et al., 1999; Aswania and Chrystyn, 2001 & 
2002), nedocromil (Aswania et al., 1998), gentamicin (Nasr and Chrystyn, 1997; Al-
Amoud et al., 2005), formeterol (Nadarassan et al., 2007), terbutaline (Abdelrahim et 
al., 2011) and beclometasone (Said et al., 2012). Hence, this index of relative 
bioavailability to the lungs is found to be robust and can discriminate between various 
formulations of the same inhaled drugs and/or different drugs.   
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Regulatory agencies recommend using charcoal blockade to exclude GI absorption of 
the swallowed portion of inhaled drugs to assess their pulmonary deposition to 
determine bioequivalence of inhalers (EMA, 2009). Hence, to explore lung deposition, 
oral absorption was prevented by coadministration of oral activated charcoal. 
Researchers have shown that charcoal could prevent 92–98% of oral absorption of 
salbutamol (Ward et al., 2000) which is similar to that reported for terbutaline 
(Borgstrom and Nilsson, 1990). The effectiveness of charcoal blockade of GI absorption 
has been confirmed by other investigators for salbutamol (Silkstone et al., 2000 & 
2002b, Moore et al., 2017). Further, this technique has also been applied to inhaled 
nedocromil (Aswania et al., 1998), sodium cromoglycate (Aswania et al., 1999; 
Aswania and Chrystyn, 2001 & 2002), terbutaline (Abdelrahim et al., 2011) and 
beclometasone dipropionate (Said et al., 2012). Therefore, salbutamol excreted in urine 
post-inhalation with activated charcoal would have entered systemic circulation after 
absorption from the lungs. 
In Part 2 Study with charcoal block, USAL0.5c was again statistically similar amongst 
the three MDIs but not in-vivo equivalent (Table 5.3.2 & Table 5.3.7). These results are 
also statistically similar to those of Part 1 Study where no charcoal blockage was used 
(t-test, Table 5.3.8 & Table 5.3.9). The statistical similarity and the mean differences 
found between two legs of the current study for USAL0.5 amounts also highlight the 
reproducibility of urinary PK method. Statistically similar 0.5h amounts were also 
reported for Ventolin CFC (Tomlinson, 2000; Silkstone et al., 2000 & 2002a; 
Tomlinson et al., 2003). Moore et al. (2017) have also reported similar AUC0–0.5h 
plasma profiles for Evo MDI, Diskus DPI and a Unit Dose development DPI when 
administered without and with charcoal. These findings reaffirm that both plasma levels 
and urinary excretion of inhaled salbutamol in the first 0.5h are indicative of pulmonary 
absorption only. Hence, it is highly likely that systemic exposure due to oral absorption 
of the swallowed portion of inhaled salbutamol occurs after the first half hour. This is 
consistent with previous observations that GI absorption of inhaled short-acting β2-
agonists is negligible as compared to the overall systemic absorption from the inhaled 
dose in the first 0.5h post-inhalation (Girodet and Molimard, 2005). 
Further, significant statistical differences in urinary excretion of salbutamol were 
observed for USAL24, USAL24Pre, USAL24Post and USALMET between Parts 1 and 
2 of the studies, both within the same MDI (n=13; Table 5.3.8) and when the three 
MDIs were taken together (n=39; Table 5.3.9). These findings concur with other studies   
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(Silkstone et al., 2000 & 2002b; Ward et al., 2000, Abdelrahim et al., 2011; Said et al., 
2012; Moore et al., 2017). 
The results (Table 5.3.5) indicate that lung exposure achieved from the first 0.5h after 
inhalation of salbutamol without charcoal (USAL0.5NC) from Ventolin Evohaler, 
Airomir and Salamol represented 6%, 9% and 7%, respectively, of the total exposure 
(USAL24NC). The corresponding lung exposure achieved with charcoal blockage 
(USAL0.5C) for these MDIs respectively represented 18%, 17% and 16% of the total 
exposure (USAL24C). It should be noted that the absorption, distribution and 
elimination of salbutamol through the lungs is ongoing and not complete within the first 
0.5h post-inhalation. This is evident from continued salbutamol urinary recoveries over 
24h in the presence of Charcoal blockade. This is further reflected in the trend where 
increases in USAL0.5C amounts were indicative of corresponding increases in 
USAL24C amounts of these MDIs confirming that with the charcoal blockade, systemic 
exposure was mainly contributed by the dose delivered to the lungs (Table 5.3.2). 
Hence, the net systemic exposure [(USAL0.5C / USAL24C) – (USAL0.5NC / 
USAL24NC)] that may have been derived from the lung deposition is respectively 12%, 
8% and 9% for these MDIs. This is reflected in the trend seen with USAL24NC 
amounts (Evo > Sala > Airo) (Table 5.3.10).  
A trend is observed between USAL0.5C amounts and USAL24C, USAL24PreC, 
USAL24PostC and USALMETc of the three MDIs where the differences noted in the 
former parameter was translated into similar rank order of latter parameters (Table 
5.3.2). This trend is also consistent when assessed as % of USAL24C where these 
parameters respectively constituted ~17%, ~50%, ~83% and ~31% of the total systemic 
exposure (Table 5.3.5). These findings suggest that charcoal block of the swallowed 
salbutamol was effective and that systemic salbutamol mainly originated from lung 
deposition. These findings further highlight that urinary excretion of salbutamol in the 
first 0.5h can reliably predict the overall systemic exposure.  
The mean (SD; µg) total systemic exposure (USAL24) was reduced by 70.90 (17.0), 
44.16 (27.3) and 44.18 (25.5) (representing 30%, 48% and 53%) for Evo, Airo and Sala, 
respectively with charcoal block. These differences in systemic exposure are more 
likely due to differences in the swallowed portion of the inhaled salbutamol (Section 
5.2.4.2). These MDIs have different formulation excipients and plume characteristics. 
The in-vitro deposition (µg) in IP of ACI (resembling throat) was 88.8, 69.9 and 80.1,   
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respectively, for these MDIs (representing 50%, 40% and 45% of TED), and highlights 
the likelihood and contribution of varying oropharyngeal deposition in human subjects. 
Hence, differences in the magnitude of charcoal block reflect on the relative variation in 
the swallowed proportion of the dose from these MDIs. Interestingly, this magnitude of 
charcoal block is of the same order of decreasing in-vitro IP deposition (Evo > Sala > 
Airo). 
Further, the magnitude of charcoal block for Evo in this study is similar to that reported 
by Moore et al. (2017) measured via plasma salbutamol. 
In Part 1 Study, the ratios of USAL24PreNC / USALMETnc for Evo, Airo and Sala 
were 1.60, 1.20 and 0.96, respectively. In Part 2 Study with the co-administration of 
activated charcoal, their respective ratios of USAL24PreC / USALMETc were 1.41, 
1.67 and 1.73. These ratios reflect on their respective USAL0.5C amounts in the 
increasing rank order of Evo > Airo > Sala.  
In Part 1 Study, the ratios of the proportion of total unchanged salbutamol to its 
metabolites [(USAL0.5NC + USAL24PreNC) / USALMETnc] were 1.75, 1.41 and 
1.11, respectively, for Evo, Airo and Sala and this trend was in the decreasing rank 
order of Evo > Airo > Sala. In Part 2 Study, their corresponding ratios [(USAL0.5C + 
USAL24PreC) / USALMETc] were 1.93, 2.20 and 2.19, indicating that higher 
proportion of unchanged salbutamol than its metabolite was in the increasing rank order 
of Evo > Sala ≥ Airo. The in-vitro deposition in ACI beyond IP (throat) as impactor 
mass (S0toF) mimics the dose delivered to the respiratory tract beyond oropharynx and 
reaching to the lungs (Table 5.2.2). Interestingly, the results of in-vitro studies reveal 
similar trend in increasing impactor mass (S0toF) and FPD depositions Evo > Sala > 
Airo. This trend is reversed with IP deposition which decreased in the same rank order. 
This suggests that more dose may have been swallowed with Evo than the other two 
MDIs. This is reflected in the larger mean paired differences between Parts 1 and 2 (nc 
or NC Vs c or C) for USAL24 and USAL24Post amounts (Table 5.3.8). The results also 
indicate that GI absorption of the swallowed proportion of salbutamol was blocked by 
charcoal in the same decreasing rank order (Evo > Sala > Airo). Higher swallowed 
amounts found with Evo as compared to Airo and Sala are more likely due to the 
differences in their formulations with consequent differences in their plume 
characteristics and spray speed of the emitted dose (see Section 5.2.4.2). These findings  
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highlight the presence of link between the results of in-vitro and in-vivo studies (Table 
5.3.10). 
Higher amounts of unchanged salbutamol would suggest that more active drug is 
available for clinical effects since its sulphate ester metabolite (USALMET) is not 
pharmacologically active (Evans et al., 1973; Morgan et al., 1986; Morgan, 1990). The 
total unchanged salbutamol (USAL0.5 + USAL24Pre; µg) was 19.6, 27.6 and 34.4 
respectively for Evo, Airo and Sala. Therefore, their relative amounts would predict 
their relative efficacy (Tomlinson et al., 2003). Based on relative recoveries of 
unchanged salbutamol and assuming all other contributing variables constant, the results 
of Part 2 Study with charcoal blockage suggest that the efficacy of these MDIs would be 
in the increasing rank order of Evo > Airo > Sala. 
Ward et al. (2000) have shown that ~60% of (unchanged) salbutamol is absorbed into 
systemic circulation from the swallowed fraction of the inhaled dose from Ventolin 
CFC MDI. The results in this thesis for Evo reveal that this (USAL24Pre) was ~29% of 
the nominal dose in Part 1 (without charcoal) and ~7% in Part 2 (with charcoal) (Table 
5.3.3). However, the amount recovered as USAL24PreNC was 4 times more than that of 
USAL24PreC and therefore suggests that ~75% of USAL24PreNC may have originated 
from the swallowed portion of the inhaled dose. USAL24PreNC and USAL24PreC for 
Airo were ~21% & ~10% and for Sala were ~21% & ~14% of the nominal dose, 
respectively. The GI absorption of salbutamol (USAL24PreNC) correlates well with the 
IP depositions found with in-vitro studies with these MDIs (Table 5.2.2) which were in 
decreasing rank order of Evo > Sala > Airo. 
The total systemic exposure may have role in systemic effects (Fowler et al., 2001; 
Lipworth et al., 2005; Moore et al., 2017). The differences in systemic absorption of 
unchanged salbutamol (USAL24Pre) from these MDIs may result in differences in 
systemic exposure with consequent differences in systemic effects and safety profiles. 
The results in this thesis suggest that USAL24PreNC amounts of the three MDIs were 
not in-vivo equivalent (Table 5.3.6). Whether this continued GI absorption of swallowed 
unchanged salbutamol has any role in continued relief from bronchodilation is not clear.  
The USAL24PreNC and USALMETnc were respectively 29% and 18% of the nominal 
Evo dose, and total excretion (USAL24NC) was 50% of the dose (Table 5.3.3). The 
corresponding values for Ventolin CFC reported by Hindle and Chrystyn (1992) were   
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24%, 34% and 57%. The results reported by Silkstone et al. (2002b & 2002a) were 27-
30% and 28% of the nominal Ventolin CFC dose respectively, and total excretion was 
57-60% of the dose. Although USAL24PreNC compares well with theirs, USALMETnc 
and USAL24NC reported in this thesis are lower than those reported by them. These 
differences are highly likely due to sample cohort having variation in individual drug 
metabolism. Nevertheless, Chege et al. (1998) have reported total excretion of 47.6% of 
Ventolin CFC dose which is similar to that found in the current study.  
The USAL24PreNC and USALMETnc for Airo were 21% and 18% of the nominal 
Airo dose respectively, and USAL24NC was 42% of the dose. These values for Sala 
were 21%, 22% and 47%. These three parameters were statistically similar between 
these two MDIs (Table 5.3.6). These findings also reflect on their similar FPD, S0toF, 
%FPF and TED found in in-vitro studies (Table 5.2.7). On the other hand, their 
USAL24PreNC was significantly different from that of Evo while USALMETnc and 
USAL24NC were similar amongst them. This is reflected in their statistical differences 
Vs Evo for FPD, S0toF and %FPF, and similarity of TED amongst them. The 
differences and similarities amongst these three MDIs have their origins in their 
formulation which influenced their dose delivery characteristics (see Section 5.2.4.2). 
5.3.5.1 In-vitro in-vivo correlation trends 
In-vitro equivalence studies can potentially serve as surrogates for in-vivo 
bioequivalence studies (de Matas et al., 2008). Aerodynamic particle size distributions 
(APSD) using ACI broadly indicate likely deposition behaviour of inhaled products in 
the respiratory tract. Using APSD profile, it is possible to correlate in-vitro performance 
of an MDI to the pharmacokinetic profile of its active ingredient(s) in human subjects.  
Lung deposition of salbutamol is related to its efficacy and therapeutic benefit and total 
systemic bioavailability to safety (Hindle and Chrystyn, 1992). The amount of 
salbutamol recovered in urine in the first 0.5h (USAL0.5) post-inhalation is directly 
related to the amount of salbutamol delivered to the lungs (Silkstone et al., 2002c).  
Silkstone et al. (2002c) and Srichana et al. (2005) have reported linear relationships 
between pharmacokinetic indices of lung bioavailability of salbutamol and the 
respirable doses (FPD) delivered by nebulizer and dry powder inhaler (DPI), 
respectively. Further, de Matas et al. (2008) reported a clear link between FPD and 
relative lung bioavailability and efficacy of salbutamol sulphate dry powder inhalers.   
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The results in this thesis for salbutamol HFA MDIs also show a link between FPD and 
relative bioavailability to the lungs (USAL0.5) (Table 5.3.10). Larger FPD was related 
to larger USAL0.5 as evident from similar trend of in-vitro and in-vivo performance 
parameters of the three MDIs (Airo ≥ Sala > Evo).  
Total delivered dose (TDD) to human subjects could not be determined. Since the 
amount of salbutamol left in MDI devices is similar to those found with devices used 
for APSD studies using ACI, it is assumed that TDD would be similar to TED 
determined during particle size analyses (Table 5.3.10). Hence, TED would mimic the 
total systemic availability (USAL24) of inhaled salbutamol from these MDIs and would 
include systemic availability from both major pathways of systemic absorption, i.e., via 
respiratory and gastrointestinal tracts. The TED reflects similar trend (Sala > Evo > 
Airo) to that of USAL24NC (Evo ≥ Sala > Airo) given that the mean differences 
between Sala and Evo are very small and that these two parameters are statistically 
similar amongst the three MDIs (Table 5.3.2 & Table 5.3.6).  
In-vitro APSD studies have shown that IP (throat) deposition for these three MDIs 
ranged from 50% to 40% of TED (Evo > Sala > Airo). This would suggest that the 
oropharyngeal deposition of the dispensed dose of salbutamol would have marked 
contribution in its total systemic availability (USAL24). Hence, greater USAL24NC 
was observed with Evo as compared to the other two MDIs (Evo > Sala > Airo). This 
trend was reversed for Evo with charcoal block study (Sala > Airo > Evo) indicating 
that its larger swallowed proportion was prevented from GIT absorption. This similar 
reversing trend has also been observed between USAL24PreNC Vs USAL24PreC and 
USAL24PostNC Vs USAL24PostC for the three MDIs highlighting the significant 
oropharyngeal deposition.  
Borgström et al. (2006) have shown that variability of in-vivo lung deposition of inhaled 
drug is related to the variability in its throat deposition. Hence, a higher deposition in 
the throat would result in a lower lung deposition and vice versa. The results of current 
study support their findings. The in-vitro ratios of FPD/IP, FPM/IP and S0toF/IP (Table 
5.2.6) were all in the same order of in-vivo USAL0.5, a surrogate for lung deposition 
(Airo ≥ Sala > Evo) (Table 5.3.10). 
The limitation of relating in-vitro APSD to in-vivo lung deposition patterns are well 
known (Mitchell and Nagel, 2003; Dunbar and Mitchell, 2005; Mitchell et al., 2007b;   
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Newman and Chan, 2008). The induction port does not mimic the oropharyngeal region 
of the respiratory tract while the use of a constant airflow rate at a fixed period of time 
is not representative of a human subject’s inhalation flow profile. The temperature and 
humidity inside ACI are unlike those inside the lungs (Labiris and Dolovich, 2003). 
Prediction of in-vivo outcomes in individual subjects from in-vitro measurements is 
further complicated by demographic and physiological factors, such as inter-individual 
differences in breathing pattern, airways calibre, inter-subject variability in 
oropharyngeal deposition due to different airway geometries and mouth openings, high 
humidity conditions in the lungs, airways clearance mechanisms or inhalation technique 
amongst other variables (Labiris and Dolovich, 2003; de Matas et al., 2008; Daley-
Yates et al., 2014; Cheng et al., 2015). The mechanisms of particle deposition in the 
respiratory tract, therefore, are difficult to comprehensively simulate. Despite all these 
limitations, the current work has broadly identified links between in-vitro and in-vivo 
studies. 
5.3.6 Conclusions: Salbutamol HFA MDIs In-Vivo Study 
The results of current work suggest that Ventolin Evohaler, Airomir and Salamol were 
not in-vivo equivalent to each other based on their differences in relative lung and 
systemic bioavailability assessed using urinary PK in healthy subjects. Hence, caution 
should be exercised if a change of salbutamol HFA MDI brand is desired.  
The charcoal blockade suggested that urinary excretion of inhaled salbutamol in the first 
0.5h was related to the lung deposition and was independent of MDI brand. These 
findings confirm that systemic exposure due to oral absorption of the swallowed portion 
of inhaled salbutamol occurs after the first half hour. 
In-vitro studies showed a broad correlation to in-vivo studies. Trends in FPD and TED 
were reflected in similar trends in relative lung and systemic bioavailability. 
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6 Chapter 6: In-Vitro and In-Vivo Equivalence of Ventolin 
Evohaler Without and With Spacers 
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6.1 Overview 
Inhaling a dose from an MDI requires coordination between actuation and inhalation. 
However, many patients face difficulty in correctly inhaling the dose from MDIs 
(Chrystyn and Price, 2009; Laube et al. 2011; Lavorini, 2013 & 2014; Lavorini et al., 
2014). To overcome this problem, MDIs are used with spacers (Newman, 2004; 
Lavorini and Fontana, 2009; Nikander et al., 2014). Nevertheless, different spacers can 
induce change in the aerosol plume characteristics of a drug, which are spacer and drug 
specific, and vary between spacers, and with different formulations of the same drug for 
the same spacer (Ahrens et al., 1995; Barry and O’Callaghan, 1996, 1997; Lipworth and 
Clark, 1998, Dubus et al., 2001, McCabe et al., 2012; Johnson et al., 2016). 
Accordingly, APSD studies on spacers attached to Ventolin Evohaler were carried out 
to assess their comparative in-vitro performance when used alone and with spacers. This 
in-vitro work was followed-up by in-vivo studies using urinary pharmacokinetic method 
(Hindle and Chrystyn, 1992). 
This chapter is organised into separate sections comprising of in-vitro and in-vivo 
equivalence studies on Ventolin Evohaler without and with spacers. 
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6.2 In-Vitro Equivalence of Ventolin Evohaler Without and With 
Spacers-Aerodynamic Particle size Characterisation 
The objectives of this study are to: 
a) determine APSD of Ventolin Evohaler without and with spacers using ACI,  
b) investigate in-vitro equivalence between MDI alone and with spacer, and  
c) identify in-vitro equivalence between different spacers attached to Ventolin 
Evohaler. 
The in-vitro drug delivery characteristics of MDI without and with spacer were assessed 
with respect to their Critical Quality Attributes (CQAs) (ICH Q8, 2009). FPD is a key 
performance indicator and provides a common ground to compare inhaler treatment 
methods (Section 3.3.4). However, APSD profiles were also assessed as stage groups 
(EMA, 2006 & 2009). 
6.2.1 Materials and Methods 
6.2.1.1 Materials and Equipments 
See Chapter 3 (Section 3.3.1.1).  
6.2.1.2 Test MDI 
Ventolin Evohaler™ (Evo).  
6.2.1.3 Test Spacers  
Volumatic™ (VOL), AeroChamber Plus™ (AERO) and Able™ (ABLE) spacer (Figure 
3.3.1). 
6.2.2 Study Design 
APSD studies using ACI were performed as per Protocols 3.3.1 and 3.3.2 (Sections 
3.3.2.3 & 3.3.2.4) in compliance to pharmacopoeial requirements (BP, 2005; USP28-
NF23, 2005; Ph. Eur., 2011) (see Chapter 3 Methodology). Briefly, one puff of primed 
Ventolin Evohaler was discharged into ACI operated at a flow rate of 28.3 L/min for 8.5 
seconds to allow 4L of air to pass through it. The second puff was similarly discharged 
after 30 seconds. This procedure was repeated with a randomly selected spacer. All 
spacers were pre-treated with lukewarm soapy water to disseminate electrostatic charge 
and drip dried after a water rinse (Section 2.4). The amounts of  
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salbutamol deposited in the MDI device, spacer and ACI components and stages were 
recovered and quantified using a validated HPLC method (see Chapter 4). 
6.2.3 Deposition Profiles, CQAs and Data Analysis  
The data for critical performance metrics, APSD profiles and spacer deposition were 
analysed as per pharmacopoeial requirements and regulatory guidelines, and described 
in Chapter 3 (Section 3.3.3). 
6.2.4 APSD and ACI Stage Grouping 
See Chapter 3 (Section 3.3.4). 
6.2.5 Statistical Analysis 
See Chapter 3 (Section 3.3.5). 
6.2.6 Results: In-Vitro Equivalence of Ventolin Evohaler Without and With 
Spacers 
The mean amount (n=5) of two actuations of salbutamol deposited on various 
components and stages of ACI recovered from Ventolin Evohaler alone and with VOL, 
AERO and ABLE spacers are shown in Table 6.2.1. Data on their respective individual 
runs is given in Appendices 5.2.3.1 and 6.2.6.1 to 6.2.6.3. Figure 6.2.1 and Figure 6.2.2 
respectively show their complete mean APSD and cumulative particle size deposition 
profiles. Their comparative CQAs and stage group depositions are shown in Figure 
6.2.3 and Figure 6.2.4 and summaries provided in Table 6.2.2 to Table 6.2.6. Dose 
delivery efficiency of these treatment methods is compared in Table 6.2.7. Table 6.2.8 
to Table 6.2.12 present their in-vitro equivalence and statistical comparisons. The 
characteristics of these spacers are given in Table 6.2.13 and Figure 6.2.5 displays 
dimensional measurements. 
Mass balance and TED of Ventolin Evohaler, Evo+VOL, Evo+AERO and Evo+ABLE 
were respectively within 5% and 25% of labelled claim of 100 µg metered dose (Table 
6.2.1). This confirms system suitability of the ACI equipment used. Hence, the results 
generated are valid and accurate (Christopher et al., 2003).  
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Table 6.2.1. APSD of Ventolin Evohaler alone and with spacers. 
Identity 
Ventolin Evohaler Evo+VOL Evo+AERO Evo+ABLE Notations 
µg SD RSD µg SD RSD µg SD RSD µg SD RSD a = % Recovery calculated with 
respect to Nominal Dose (ND), 
i.e., two actuations of 100 µg per 
puff 
 
b = Mass Balance = Ex-Canister 
Valve recovery. Recovery 
calculated with respect to 
Nominal Dose (ND) excluding 
deposition on Canister Valve but 
including deposition on Actuator 
(mouth piece). 
 
c = TED (Total Emitted Dose Ex-
Actuator); Recovery calculated 
with respect to Nominal Dose 
(ND) excluding deposition on 
Canister Valve and Actuator 
(mouth piece). 
 
d = TDD (Total Delivered Dose 
Ex-Spacer); Recovery calculated 
with respect to Nominal Dose 
(ND) and excludes deposition on 
Canister Valve, Actuator (mouth 
piece) and spacer. 
MDI Canister Valve 5.0 0.5 9.9 6.2 0.9 14.4 5.8 1.2 21.5 6.7 2.0 29.6 
MDI Actuator 36.2 2.9 8.1 23.1 1.3 5.8 24.1 1.9 7.8 20.0 2.7 13.5 
Spacer - - - 74.9 6.1 8.2 90.6 6.7 7.4 87.6 4.4 5.0 
ACI IP (Throat) 88.8 7.4 8.3 5.5 1.9 34.4 5.0 1.1 22.5 5.1 0.9 18.1 
ACI S-0 2.1 0.2 8.8 1.9 0.5 24.4 2.3 0.7 30.2 2.3 0.4 17.0 
ACI S-1 2.8 0.3 12.5 3.8 0.7 18.0 4.4 0.8 17.4 4.5 0.5 11.8 
ACI S-2 4.6 0.6 12.1 5.5 1.3 23.4 6.1 0.9 14.5 6.3 0.9 14.1 
ACI S-3 18.4 2.2 12.1 20.1 3.5 17.2 18.9 2.4 12.9 19.9 3.4 17.0 
ACI S-4 35.2 2.6 7.3 33.2 1.9 5.7 28.7 2.3 8.2 27.9 4.5 16.3 
ACI S-5 19.9 1.9 9.7 19.0 1.6 8.7 15.4 1.4 8.8 17.3 2.1 12.4 
ACI S-6 3.4 0.3 8.3 4.0 0.9 23.0 2.7 0.7 25.4 5.0 1.1 21.3 
ACI S-7 0.6 0.1 13.2 0.9 0.1 14.4 0.9 0.3 33.0 1.9 0.3 16.2 
ACI Filter 0.9 0.2 19.9 0.9 0.2 21.0 1.0 0.2 17.6 2.0 0.3 13.5 
Total Recovery (µg) 217.8 8.9 4.1 199.1 5.0 2.5 205.8 6.0 2.9 206.6 2.1 1.0 
% Recovery
a
 108.9 4.4 4.1 99.5 2.5 2.5 102.9 3.0 2.9 103.3 1.0 1.0 
Mass Balance
b
 (µg) 212.8 8.6 4.0 192.9 4.4 2.3 200.1 6.3 3.1 199.9 2.1 1.1 
% Recovery  106.4 4.3 4.0 96.5 2.2 2.3 100.0 3.1 3.1 99.9 1.1 1.1 
TED
c
 (µg) 176.6 7.6 4.3 169.8 4.5 2.7 176.0 4.5 2.5 179.8 1.1 0.6 
% TED 88.3 3.8 4.3 84.9 2.3 2.7 88.0 2.2 2.5 89.9 0.6 0.6 
TDD
d
 (µg) - - - 94.9 3.5 3.7 85.3 4.7 5.6 92.2 3.7 4.0 
% TDD - - - 47.4 1.8 3.7 42.7 2.4 5.6 46.1 1.9 4.0 
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Figure 6.2.1. Mean APSD profiles of Ventolin Evohaler alone and with spacers. 
Can = MDI Canister; Actu = MDI Actuator 
 
 
 
Figure 6.2.2. Mean percent cumulative particle size deposition profiles of 
Ventolin Evohaler alone and with spacers. 
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Figure 6.2.3. Dose delivery characteristics of Ventolin Evohaler alone and with spacers. 
 
 
 
Figure 6.2.4. Stage group deposition of Ventolin Evohaler alone and with spacers. 
 
 
TED (ex-actuator) of Evo alone compared to three spacers (Evo+SP) was in-vitro 
equivalent and statistically similar (Table 6.2.2 & Table 6.2.8). However, TDD (ex-
spacer) was not in-vitro equivalent between them and also showed significant statistical 
differences. TDD of Evo (=TED) was about twice the TDD of Evo+SP. 
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TED (ex-actuator) of Evo+SP was in-vitro equivalent between them. However, 
statistically similarity was not observed between Evo+VOL Vs Evo+ABLE (Table 6.2.2 
& Table 6.2.9). On the other hand, in-vitro equivalent TDD between spacer treatment 
methods was observed only for Evo+VOL Vs Evo+ABLE and Evo+AERO Vs 
Evo+ABLE while TDD of the three Evo+SP was statistically similar. 
IP deposition of Evo alone Vs Evo+SP showed in-vitro inequivalence and significant 
statistical difference (Table 6.2.2 & Table 6.2.11; Figure 6.2.3). This is because about 
50% of TED of Evo deposited in IP. Interestingly, while being in-vitro inequivalent, IP 
deposition of Evo alone was statistically similar to the combined deposition of SP+IP 
with spacer treatment methods.  
In contrast, statistical difference of SP+IP deposition between Evo+VOL Vs 
Evo+AERO was significant and Vs Evo+ABLE was marginally significant with the 
least salbutamol SP+IP deposition in Evo+VOL; nonetheless, both were in-vitro 
inequivalent (Table 6.2.2 & Table 6.2.12). Similar trend was observed with dose 
retained in these two spacers, however, the statistical differences were significant. 
Nevertheless, SP+IP and SP depositions of Evo+AERO Vs Evo+ABLE were both 
statistically similar and in-vitro equivalent. IP depositions of the three Evo+SP were 
statistically similar between them while being in-vitro inequivalent. 
Deposition of IP+CPM (non-respirable fraction) from Evo alone was 5 to 6 times more 
than that of Evo+SP (Table 6.2.2; Figure 6.2.3). However, only Evo+VOL showed 
lower ratio of SP+IP+CPM deposition (non-respirable fraction) than IP+CPM 
deposition of Evo alone while the other two spacers attached to Evo had higher non-
respirable fraction. This trend was also observed when IP+CPM and SP+IP+CPM were 
assessed as %TED. IP+CPM depositions assessed as % TDD were ~3 times more with 
Evo alone than those from Evo+SP; Evo+VOL showed the lowest deposition while the 
other two spacers followed the above noted trend. 
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Table 6.2.2. Dose delivery and deposition in ACI of Ventolin Evohaler alone and with spacers. 
Treatment 
Method 
TED TDD SP IP SP+IP IP+CPM SP+IP+CPM S0toF 
µg SD µg SD µg SD µg SD µg SD µg SD µg SD µg SD 
Ventolin* 176.63 7.55 176.63 7.55 - - 88.78 7.36 - - 98.21 7.40 - - 87.85 6.77 
Evo+VOL 169.78 4.55 94.89 3.50 74.89 6.13 5.51 1.90 80.40 6.75 16.81 2.31 91.70 6.29 89.38 4.63 
Evo+AERO 175.96 4.47 85.33 4.75 90.62 6.73 5.02 1.13 95.64 6.67 17.86 2.46 108.48 4.84 80.32 4.01 
Evo+ABLE 179.84 1.10 92.25 3.73 87.59 4.40 5.13 0.93 92.72 4.44 18.23 1.48 105.82 3.52 87.12 3.66 
* Ventolin Evohaler; SD = Standard Deviation 
Table 6.2.3. Dose delivery and deposition in ACI as %TED and %TDD of Ventolin Evohaler alone and with spacers. 
Treatment 
Method 
TDD_ED SP_ED IP_ED SP+IP_ED IP+CPM_ED SP+IP+CPM_ED S0toF_ED IP_DD IP+CPM_DD S0toF_DD 
%ED SD %ED SD %ED SD %ED SD %ED SD %ED SD %ED SD %DD SD %DD SD %DD SD 
Ventolin* 100.00 - - - 50.25 3.48 - - 55.59 3.31 - - 49.75 3.48 50.25 3.48 55.59 3.31 49.75 3.48 
Evo+VOL 55.93 2.73 44.07 2.73 3.25 1.12 47.32 3.16 9.92 1.51 53.99 2.94 52.68 3.16 5.83 2.09 17.76 2.74 94.17 2.09 
Evo+AERO 48.53 3.02 51.47 3.02 2.85 0.60 54.32 2.78 10.16 1.46 61.63 1.58 45.68 2.78 5.85 1.10 20.85 1.77 94.15 1.10 
Evo+ABLE 51.30 2.25 59.84 2.03 2.85 0.51 51.55 2.23 10.14 0.83 58.84 1.69 48.45 2.23 5.56 1.01 19.75 1.12 94.44 1.01 
ED = TED; DD = TDD 
Table 6.2.4. FPD, Stage groups, MMAD and GSD of Ventolin Evohaler alone and with spacers. 
Treatment 
Method 
FPD FPM EPM CPM MMAD GSD 
µg SD µg SD µg SD µg SD um SD 
 
SD 
Ventolin* 78.42 6.28 73.49 6.46 4.93 0.51 9.43 0.68 2.68 0.03 1.56 0.02 
Evo+VOL 78.08 4.80 72.28 5.50 5.80 1.00 11.30 1.60 2.77 0.07 1.67 0.06 
Evo+AERO 67.48 2.39 62.91 2.49 4.56 1.12 12.84 2.03 2.91 0.10 1.68 0.05 
Evo+ABLE 74.02 2.73 65.11 3.29 8.90 1.21 13.10 1.35 2.79 0.10 1.67 0.03 
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Impactor mass (S0toF) deposition was both statistically similar and in-vitro equivalent 
between Evo alone Vs Evo+VOL and Vs Evo+ABLE. With Evo+AERO, slightly less 
S0toF deposition was noted, and comparison to Evo alone was in-vitro inequivalent 
albeit being statistically similar (Table 6.2.8). Also, S0toF of Evo+VOL Vs Evo+AERO 
and Evo+AERO Vs Evo+ABLE were in-vitro inequivalent despite these being 
statistically similar (Table 6.2.9).  
In-vitro equivalent and statistically similar FPD was observed for Evo Vs Evo+VOL 
and Vs Evo+ABLE (Table 6.2.4 & Table 6.2.8). However, FPD was not in-vitro 
equivalent and had statistically significant difference between Evo Vs Evo+AERO. 
Amongst Evo+SP comparisons (Table 6.2.9), FPD of Evo+VOL Vs Evo+ABLE was 
both in-vitro equivalent and statistically similar. Nevertheless, FPD of Evo+VOL Vs 
Evo+AERO and Evo+AERO Vs Evo+ABLE were in-vitro inequivalent, though it was 
statistically similar for the latter pair.  
FPD as %TED (%FPF ex-actuator) was statistically similar and in-vitro equivalent 
between Evo Vs Evo+VOL only (Table 6.2.5 & Table 6.2.8). This parameter was also 
statistically similar between Evo and Evo+ABLE. Amongst Evo+SP, %FPF (ex-
actuator) was statistically similar only between Evo+AERO Vs Evo+ABLE and none of 
them were in-vitro equivalent (Table 6.2.5 & Table 6.2.9). 
FPF as %TED (ex-actuator) of Evo alone Vs FPF as %TDD (ex-spacer) of Evo+SP was 
significantly different and in-vitro inequivalent (Table 6.2.5 & Table 6.2.8). However, 
FPD as %TDD (ex-spacer) was in-vitro equivalent and statistically similar amongst the 
three spacers (Table 6.2.6 & Table 6.2.9). 
MMADs and GSDs of Evo alone and Evo+SP were all in-vitro equivalent (Table 6.2.4 
& Table 6.2.10). However, there were statistically significant differences between Evo 
Vs Evo+AERO for MMAD, and Evo Vs the three Evo+SP for GSD.  
FPM deposition was both statistically similar and in-vitro equivalent between Evo Vs 
Evo+VOL while Evo Vs Evo+ABLE it was statistically similar only (Table 6.2.4 & 
Table 6.2.11). Also, between Evo+SP comparisons, Evo+AERO Vs Evo+ABLE had 
both statistically similar and in-vitro equivalent FPM which was however only 
statistically similar between Evo+VOL Vs Evo+ABLE (Table 6.2.4 & Table 6.2.12).  
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CPM deposition was not in-vitro equivalent either between Evo Vs Evo+SP or amongst 
the spacer treatment methods (Table 6.2.4, Table 6.2.11 & Table 6.2.12). Nevertheless, 
CPM of Evo Vs Evo+VOL and Evo Vs Evo+AERO, and the three Evo+SP treatment 
methods was statistically similar.  
EPM deposition was in-vitro inequivalent between Evo Vs Evo+SP and amongst the 
three Evo+SP treatments (Table 6.2.4, Table 6.2.11 & Table 6.2.12). However, EPM 
was statistically similar between Evo Vs Evo+VOL and Evo Vs Evo+AERO, and 
Evo+VOL Vs Evo+AERO. 
Summary of Results 
TED (ex-actuator), FPD (%S0toF), MMAD and GSD were in-vitro equivalent with all 
treatment methods, i.e., Evo alone Vs Evo+SP.  
Comparisons between Ventolin Evohaler alone and with attached VOL were in-vitro 
equivalent with respect to TED (ex-actuator), FPD, FPF (%TED), MMAD, GSD, S0toF 
and FPM deposition. 
Comparisons between Evo alone and when attached to AERO were in-vitro equivalent 
with respect to TED (ex-actuator), MMAD and GSD. 
Comparisons between Evo alone and with attached ABLE were in-vitro equivalent with 
respect to TED (ex-actuator), FPD, MMAD, GSD and S0toF. 
Moreover, TED (ex-actuator), FPF (%TDD), MMAD and GSD were in-vitro equivalent 
amongst Evo+SP treatment methods. Also, TDD (ex-spacer) of Evo+VOL Vs 
Evo+ABLE and Evo+AERO Vs Evo+ABLE were in-vitro equivalent. 
TED, TDD, FPD, S0toF, MMAD and GSD were in-vitro equivalent for Evo+VOL Vs 
Evo+ABLE. 
TED, MMAD and GSD were in-vitro equivalent for Evo+VOL Vs Evo+AERO. TDD, 
S0toF and FPD were each ~5 µg lower with Evo+AERO. 
TED, TDD, MMAD and GSD were in-vitro equivalent between Evo+AERO and 
Evo+ABLE. S0toF and FPD were statistically similar between them but were not in-
vitro equivalent. S0toF and FPD were both ~3 µg lower for Evo+AERO. 
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Table 6.2.5. FPD and stage groups as %TED of Ventolin Evohaler alone and with spacers. 
Treatment 
Method 
FPF (%) FPM_ED EPM_ED CPM_ED 
%TED SD %TED SD %TED SD %TED SD 
Ventolin* 44.41 3.31 41.62 3.49 2.79 0.26 5.34 0.28 
Evo+VOL 46.01 2.94 42.60 3.36 3.41 0.56 6.67 1.06 
Evo+AERO 38.37 1.58 35.76 1.40 2.60 0.67 7.32 1.27 
Evo+ABLE 41.16 1.69 36.21 1.95 4.95 0.67 7.29 0.77 
* Ventolin Evohaler; SD = Standard Deviation; ED = TED; DD = TDD 
 
Table 6.2.6. FPD and stage groups as %TDD of Ventolin Evohaler alone and with spacers. 
Treatment 
Method 
FPF (%) FPM_DD EPM_DD CPM_DD 
%TDD SD %TDD SD %TDD SD %TDD SD 
Ventolin* 44.41 3.31 41.62 3.49 2.79 0.26 5.34 0.28 
Evo+VOL 82.24 2.74 76.12 3.72 6.13 1.18 11.92 1.76 
Evo+AERO 79.15 1.77 73.80 2.39 5.35 1.24 15.00 1.83 
Evo+ABLE 80.25 1.12 70.58 1.67 9.68 1.47 14.19 1.13 
 
Table 6.2.7. FPD and S0toF delivery efficiency of Ventolin Evohaler alone and with spacers. 
Treatment 
Method 
FPD / SP FPD / IP FPD / SP+IP FPD / IP+CPM FPD / SP+IP+CPM S0toF / IP S0toF / SP+IP 
Ratio SD Ratio SD Ratio SD Ratio SD Ratio SD Ratio SD Ratio SD 
Ventolin* - - 0.89 0.12 - - 0.80 0.10 - - 1.00 0.13 - - 
Evo+VOL 1.05 0.12 17.17 11.02 0.98 0.12 4.75 0.94 0.86 0.10 19.61 12.42 1.12 0.14 
Evo+AERO 0.75 0.07 13.91 2.59 0.71 0.06 3.82 0.42 0.62 0.04 16.56 3.15 0.84 0.09 
Evo+ABLE 0.85 0.07 14.80 2.51 0.80 0.07 4.08 0.29 0.70 0.05 17.43 2.99 0.94 0.08 
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Table 6.2.8. In-Vitro Equivalence and Statistical Significance of CQAs of Ventolin Evohaler alone and with spacers. 
Parameter 
Multiple Comparisons 
Mean 
Ratio 
90% CI 
p value 
In-Vitro 
Equivalence 
(0.85-1.18) 
Mean 
Difference 
(µg) 
95% CI 
p value 
Statistical 
Similarity Ventolin Evohaler 
Vs 
LL UL LL UL 
TED  
(Ex-Actuator) 
Evo + VOL 1.04 0.99 1.09 0.285 Yes 3.43 -1.30 8.15 0.267 Yes 
Evo + AERO 1.00 0.96 1.05 1.000 Yes 0.34 -4.39 5.07 1.000 Yes 
Evo + ABLE 0.98 0.93 1.03 1.000 Yes -1.60 -6.33 3.12 1.000 Yes 
TDD  
(into ACI 
Throat) 
Evo + VOL 1.86 1.73 2.01 <0.0001 No 40.87 35.98 45.76 <0.0001 No 
Evo + AERO 2.07 1.92 2.23 <0.0001 No 45.65 40.76 50.54 <0.0001 No 
Evo + ABLE 1.91 1.78 2.06 <0.0001 No 42.19 37.30 47.08 <0.0001 No 
FPD 
Evo + VOL 1.00 0.91 1.11 1.000 Yes 0.17 -3.97 4.31 1.000 Yes 
Evo + AERO 1.16 1.05 1.28 0.006 No 5.47 1.33 9.61 0.006 No 
Evo + ABLE 1.06 0.96 1.17 0.900 Yes 2.20 -1.94 6.34 0.773 Yes 
%FPF 
(%TED) 
Evo + VOL 0.96 0.87 1.06 1.000 Yes -1.60 -6.34 3.15 1.000 Yes 
Evo + AERO 1.16 1.05 1.28 0.007 No 6.05 1.30 10.80 0.009 No 
Evo + ABLE 1.08 0.98 1.19 0.367 No 3.25 -1.50 8.00 0.337 Yes 
%FPF 
(%TDD) 
Evo + VOL 0.54 0.50 0.58 <0.0001 No -37.83 -42.38 -33.28 <0.0001 No 
Evo + AERO 0.56 0.52 0.60 <0.0001 No -34.73 -39.28 -30.18 <0.0001 No 
Evo + ABLE 0.55 0.51 0.59 <0.0001 No -35.84 -40.39 -31.29 <0.0001 No 
S0toF 
(S0 to S7 & 
Filter) 
Evo + VOL 0.98 0.89 1.08 1.000 Yes -0.76 -5.44 3.92 1.000 Yes 
Evo + AERO 1.09 0.99 1.20 0.174 No 3.77 -0.91 8.45 0.166 Yes 
Evo + ABLE 1.01 0.91 1.11 1.000 Yes 0.37 -4.31 5.05 1.000 Yes 
CQA = Critical Quality Attribute; CI = Confidence Interval; LL = Lower limit; UL = Upper Limit 
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Table 6.2.9. In-Vitro Equivalence and Statistical Significance of CQAs of Ventolin Evohaler with spacers. 
Parameter Multiple Comparisons 
Mean 
Ratio 
90% CI 
p value 
In-Vitro 
Equivalence 
(0.85-1.18) 
Mean 
Difference 
(µg) 
95% CI 
p value 
Statistical 
Similarity LL UL LL UL 
TED  
(Ex-
Actuator) 
Evo+VOL 
Evo+AERO 0.96 0.92 1.01 0.404 Yes -3.09 -7.82 1.64 0.402 Yes 
Evo+ABLE 0.94 0.90 0.99 0.035 Yes -5.03 -9.76 -0.30 0.033 No 
Evo+AERO Evo+ABLE 0.98 0.93 1.03 1.000 Yes -1.94 -6.67 2.79 1.000 Yes 
TDD (into 
ACI 
Throat) 
Evo+VOL 
Evo+AERO 1.11 1.03 1.20 0.010 No 4.78 -0.12 9.67 0.058 Yes 
Evo+ABLE 1.03 0.95 1.11 1.000 Yes 1.32 -3.57 6.21 1.000 Yes 
Evo+AERO Evo+ABLE 0.92 0.86 1.00 0.080 Yes -3.46 -8.35 1.44 0.297 Yes 
FPD 
Evo+VOL 
Evo+AERO 1.16 1.05 1.28 0.007 No 5.30 1.16 9.44 0.008 No 
Evo+ABLE 1.05 0.96 1.16 1.000 Yes 2.03 -2.11 6.17 0.956 Yes 
Evo+AERO Evo+ABLE 0.91 0.83 1.01 0.138 No -3.27 -7.41 0.87 0.182 Yes 
%FPF 
(%TED) 
Evo+VOL 
Evo+AERO 1.20 1.09 1.32 0.001 No 7.64 2.90 12.39 0.001 No 
Evo+ABLE 1.12 1.01 1.23 0.052 No 4.85 0.10 9.60 0.044 No 
Evo+AERO Evo+ABLE 0.93 0.84 1.03 0.448 No -2.80 -7.55 1.95 0.572 Yes 
%FPF 
(%TDD) 
Evo+VOL 
Evo+AERO 1.04 0.96 1.12 1.000 Yes 3.10 -1.45 7.64 0.344 Yes 
Evo+ABLE 1.02 0.95 1.10 1.000 Yes 1.99 -2.56 6.54 1.000 Yes 
Evo+AERO Evo+ABLE 0.99 0.92 1.06 1.000 Yes -1.11 -5.65 3.44 1.000 Yes 
S0toF 
(S0 to S7 
& Filter) 
Evo+VOL 
Evo+AERO 1.11 1.01 1.23 0.062 No 4.53 -0.15 9.21 0.061 Yes 
Evo+ABLE 1.03 0.93 1.13 1.000 Yes 1.13 -3.55 5.81 1.000 Yes 
Evo+AERO Evo+ABLE 0.92 0.84 1.02 0.247 No -3.40 -8.08 1.28 0.264 Yes 
CQA = Critical Quality Attribute; CI = Confidence Interval; LL = Lower limit; UL = Upper Limit 
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Table 6.2.10. In-Vitro Equivalence and Statistical Significance of MMAD and GSD of Ventolin Evohaler alone and with spacers. 
Parameter Multiple Comparisons 
Mean 
Ratio 
90% CI 
p value 
In-Vitro 
Equivalence 
(0.85-1.18) 
Mean 
Difference 
95% CI 
p value 
Statistical 
Similarity LL UL LL UL 
MMAD 
(µm) 
Ventolin 
Evohaler 
Evo+VOL 0.97 0.92 1.02 0.652 Yes -0.08 -0.24 0.07 0.713 Yes 
Evo+AERO 0.92 0.88 0.97 0.002 Yes -0.23 -0.38 -0.07 0.002 No 
Evo+ABLE 0.96 0.92 1.01 0.330 Yes -0.10 -0.26 0.05 0.360 Yes 
Evo+VOL 
Evo+AERO 0.95 0.91 1.00 0.077 Yes -0.14 -0.30 0.01 0.074 Yes 
Evo+ABLE 0.99 0.95 1.04 1.000 Yes -0.02 -0.17 0.13 1.000 Yes 
Evo+AERO Evo+ABLE 1.04 1.00 1.10 0.164 Yes 0.12 -0.03 0.28 0.159 Yes 
GSD 
Ventolin 
Evohaler 
Evo+VOL 0.94 0.90 0.98 0.007 Yes -0.11 -0.19 -0.02 0.010 No 
Evo+AERO 0.93 0.89 0.98 0.004 Yes -0.11 -0.20 -0.03 0.005 No 
Evo+ABLE 0.94 0.90 0.98 0.007 Yes -0.11 -0.19 -0.02 0.009 No 
Evo+VOL 
Evo+AERO 1.00 0.95 1.04 1.000 Yes -0.01 -0.09 0.08 1.000 Yes 
Evo+ABLE 1.00 0.96 1.04 1.000 Yes -0.001 -0.08 0.08 1.000 Yes 
Evo+AERO Evo+ABLE 1.00 0.96 1.05 1.000 Yes 0.01 -0.08 0.09 1.000 Yes 
CI = Confidence Interval; LL = Lower limit; UL = Upper Limit 
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Table 6.2.11. In-Vitro Equivalence and Statistical Significance of Stage Group deposition of Ventolin Evohaler alone and with spacers. 
Parameter 
Multiple Comparisons 
Mean 
Ratio 
90% CI 
p value 
In-Vitro 
Equivalence 
(0.85-1.18) 
Mean 
Difference 
(µg) 
95% CI 
p value 
Statistical 
Similarity Ventolin Evohaler 
Vs 
LL UL LL UL 
SP+IP  
(Spacer + Throat 
(MDI SP+IP = IP) 
Evo + VOL 1.10 0.98 1.25 0.289 No 4.19 -1.90 10.28 0.330 Yes 
Evo + AERO 0.93 0.82 1.05 0.739 No -3.43 -9.52 2.66 0.656 Yes 
Evo + ABLE 0.96 0.84 1.08 1.000 No -1.97 -8.06 4.12 1.000 Yes 
IP (Throat) 
Evo + VOL 17.26 10.82 27.53 <0.0001 No 41.63 37.96 45.31 <0.0001 No 
Evo + AERO 17.99 11.28 28.69 <0.0001 No 41.88 38.20 45.56 <0.0001 No 
Evo + ABLE 17.49 10.97 27.90 <0.0001 No 41.82 38.15 45.50 <0.0001 No 
Group 1 
(CPM) Stages 
(S0+S1+S2) 
Evo + VOL 0.84 0.68 1.04 0.271 No 0.13 -0.87 1.14 0.784 Yes 
Evo + AERO 0.74 0.60 0.92 0.011 No -0.94 -2.36 0.49 0.395 Yes 
Evo + ABLE 0.72 0.58 0.89 0.005 No -1.71 -3.13 -0.28 0.014 No 
Group 2 
(FPM) Stages 
(S3+S4+S5) 
Evo + VOL 1.02 0.91 1.14 1.000 Yes 0.60 -3.88 5.09 1.000 Yes 
Evo + AERO 1.16 1.04 1.31 0.016 No 5.29 0.80 9.78 0.016 No 
Evo + ABLE 1.13 1.00 1.26 0.085 No 4.19 -0.30 8.68 0.076 Yes 
Group 3 
(EPM) Stages 
(S6+S7+F) 
Evo + VOL 0.86 0.64 1.15 1.000 No -0.43 -1.38 0.52 1.000 Yes 
Evo + AERO 1.10 0.82 1.47 1.000 No 0.18 -0.76 1.13 1.000 Yes 
Evo + ABLE 0.56 0.42 0.74 <0.0001 No -1.99 -2.93 -1.04 <0.0001 No 
CI = Confidence Interval; LL = Lower limit; UL = Upper Limit 
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Table 6.2.12. In-Vitro Equivalence and Statistical Significance of Spacer and Stage group deposition of Ventolin Evohaler with spacers. 
Parameter Multiple Comparisons 
Mean 
Ratio 
90% CI 
p value 
In-Vitro 
Equivalence 
(0.85-1.18) 
Mean 
Difference 
(µg) 
95% CI 
p value 
Statistical 
Similarity LL UL LL UL 
SP 
Evo+VOL 
Evo+AERO 0.83 0.73 0.94 0.002 No -7.86 -13.52 -2.21 0.002 No 
Evo+ABLE 0.85 0.75 0.97 0.013 No -6.35 -12.00 -0.69 0.017 No 
Evo+AERO Evo+ABLE 1.03 0.91 1.17 1.000 Yes 1.52 -4.14 7.17 1.000 Yes 
SP+IP 
Evo+VOL 
Evo+AERO 0.84 0.74 0.95 0.010 No -7.62 -13.71 -1.53 0.010 No 
Evo+ABLE 0.87 0.76 0.98 0.040 No -6.16 -12.25 -0.07 0.047 No* 
Evo+AERO Evo+ABLE 1.03 0.91 1.17 1.000 Yes 1.46 -4.63 7.55 1.000 Yes 
IP (Throat) 
Evo+VOL 
Evo+AERO 1.04 0.65 1.66 1.000 No 0.24 -3.44 3.92 1.000 Yes 
Evo+ABLE 1.01 0.64 1.62 1.000 No 0.19 -3.49 3.87 1.000 Yes 
Evo+AERO Evo+ABLE 0.97 0.61 1.55 1.000 No -0.05 -3.73 3.63 1.000 Yes 
Group 1 
(CPM) Stages 
(S0+S1+S2) 
Evo+VOL 
Evo+AERO 0.88 0.71 1.09 0.825 No 0.94 -0.49 2.36 0.395 Yes 
Evo+ABLE 0.86 0.69 1.06 0.458 No -0.77 -2.20 0.66 0.742 Yes 
Evo+AERO Evo+ABLE 0.97 0.79 1.21 1.000 No 0.77 -0.66 2.20 0.742 Yes 
Group 2 
(FPM) Stages 
(S3+S4+S5) 
Evo+VOL 
Evo+AERO 1.15 1.02 1.29 0.035 No 4.69 0.20 9.17 0.038 No 
Evo+ABLE 1.11 0.99 1.24 0.176 No 3.59 -0.90 8.07 0.172 Yes 
Evo+AERO Evo+ABLE 0.97 0.86 1.08 1.000 Yes -1.10 -5.59 3.39 1.000 Yes 
Group 3 
(EPM) Stages 
(S6+S7+F) 
Evo+VOL 
Evo+AERO 1.28 0.96 1.71 0.212 No 0.62 -0.33 1.56 0.409 Yes 
Evo+ABLE 0.65 0.48 0.86 0.006 No -1.55 -2.50 -0.61 0.001 No 
Evo+AERO Evo+ABLE 0.50 0.38 0.67 <0.0001 No -2.17 -3.12 -1.22 <0.0001 No 
*Marginally significant; CI = Confidence Interval; LL = Lower limit; UL = Upper Limit 
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Table 6.2.13. Characteristics of spacers. 
Parameter VOL AERO ABLE 
Valve Type (Oliveira et al., 2015) Coin 
O-ring flap; Circular 
with internal baffle 
Leaflets 
Total Length with mouthpiece 
(external) (cm) 
23.3 14.5 14.7 
Mouthpiece length (external) (cm) 3.0 3.5 2.9 
Length excluding mouthpiece 
(external)* (cm) 
20.3 11.1 11.8 
Length of MDI Port  (cm) 1.1 1.5 1.9 
 Axial distance* (cm) 19.0 9.3 9.9 
Total volume including mouthpiece 
(mL) 
830 149 150 
Volume of mouthpiece (mL) 10 14 7 
Internal Volume excluding mouthpiece 
(mL) 
820 135 143 
Construction material Polycarbonate Clear copolyester
a
 
transparent 
polypropylene
b
 
a
 Asmus et al., 2003; 
b
 Goncalves et al., 2013 
*Corrected for:  
VOL: Subtracted 0.25 cm [(wall thickness 0.15 cm) + (valve protrusion 0.1 cm)]; 18.95 rounded to 19 cm 
AERO: Subtracted 0.3 cm (Axial distance measured 10.8 cm at the surface of valve protrusion 0.3 cm) 
ABLE: Subtracted 1.9 cm [(1.4 cm Ventolin MDI Actuator mouthpiece length) + 0.5 cm inside depth of 
the spacer MDI Port)] 
 
 
 
 
 
Figure 6.2.5. Spacer dimensional measurements. 
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6.2.7 Discussion: In-Vitro Equivalence of Ventolin Evohaler Without and With 
Spacer 
EMA guideline (2009) recommends enlisting named spacer (VHC) in product 
summary. Spacers are used to assist patients who have either difficulty in coordinating 
discharge and inhaling dose from MDI such as elderly or children, or where the 
objective is to minimise localised and/or systemic side effect of inhaled medication. 
With the availability of a number of spacers, it has been necessary to determine their 
compatibility and suitability to be used with a given MDI medication and to challenge 
the claims of manufacturers. It is also prudent to investigate independently and re-affirm 
effectiveness of a recommended spacer in the Patient Information Leaflet (PIL) and 
Summary of Product Characteristics (SPC) for use with a given MDI. 
In the following sections, critical performance metrics of Ventolin Evohaler (Evo) alone 
and with three spacers [Volumatic (VOL), AeroChamber Plus (AERO) and Able 
(ABLE)] have been examined separately. 
6.2.7.1 TED and TDD 
TDD of Evo alone was significantly greater than that of the three Evo+SP treatments. 
This is because about half of TED was retained within spacer. For an MDI, TED = 
TDD, therefore, all emitted dose is delivered. This is consistent with significantly 
greater deposition in IP observed with Evo alone as compared to that of Evo+SP 
treatment methods (Figure 6.2.3). These differences may have clinical implications (see 
Section 6.2.7.2). 
However, TDD from Evo+SP treatment methods varied between them. Also, TDD from 
Evo+ABLE was slightly higher than that obtained with Evo+AERO. These differences 
in TDD are more likely due to differences in spacer design with consequent varying 
TED retained in each of them. Nevertheless, these TED (ex-actuator) and TDD (ex-
spacer) (calculated by this author) are similar to those reported by Cripps et al. (2000) 
for Evo+VOL with respective ratios of ~1.06 and ~1.12. 
6.2.7.2 Deposition in Spacer, IP and SP+IP 
VOL is a diamond shaped large volume spacer. AERO is cylindrically shaped and 
ABLE is pear-shaped, both having relatively small volumes. Their respective reported 
volumes are 750 mL, 149 mL and 150 mL. The volume (including mouthpiece) of VOL   
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measured in this lab is 830 mL (Table 6.2.13) which differs from its often quoted 
volume (Mitchell et al., 1999; Cripps et al., 2000; Barry and O’Callaghan, 1996; Hall et 
al., 2011; Brambilla et al., 2011; Huatmann et al., 2013; Oliveira et al., 2015 & 2016). 
However, volumes (including mouthpiece) of AERO and ABLE measured in this lab 
confer to reported volumes. The respective volumes of these spacers without 
mouthpiece are 820 mL, 135 mL and 143 mL. The internal effective axial lengths up to 
the valve (excluding MDI actuator port length) of these spacers are 19 cm, 9.3 cm and 
9.9 cm, respectively (Figure 6.2.5). 
The internal spacer dimensions and volume excluding mouthpiece provide the effective 
space to emitted cloud of aerosolised drug to evaporate and form smaller particles. 
Plume geometry, spray velocity and impaction force of emitted dose influence 
deposition in spacer (Barry and O’Calaghan, 1997; Gabrio et al., 1999; McCabe et al., 
2012). Ventolin Evohaler has a fast and forceful spray and therefore travels longer 
distance and may require more space for emitted droplets to evaporate (Barry and 
O’Calaghan, 1997; Gabrio et al., 1999; McCabe et al., 2012; Hautmann et al., 2013; 
Johnson et al., 2016). Therefore, with smaller volume and diameter of a cylindrical 
spacer, it is highly likely that relatively more proportion of fast moving evaporating 
droplets will impact on side walls and distal end of spacer and will be retained therein. 
This explains the likely reason of the highest spacer deposition in AERO with resultant 
lower TDD and in-vitro inequivalence between Evo+AERO and Evo+VOL.  
The distance from actuator mouthpiece of MDI placed at lips to the throat of an adult 
human is up to 10 cm (Brambilla et al., 2011; Hautmann et al., 2013). The internal axial 
length (excluding spacer mouthpiece) of VOL and ABLE account for this distance 
while AERO is 0.7 cm short of providing for this distance (Table 6.2.13). Therefore, 
with AERO attached to Evo, more proportion of TED is likely to deposit in it. This is 
reflected in relatively larger aerosol deposition in AERO than the other two spacers; this 
spacer deposition decreased in order of AERO > ABLE > VOL. This reflects on their 
relative space and internal axial distances which increase in order of AERO > ABLE > 
VOL. These findings are in agreement with the work of Cripps et al. (2000) who 
reported higher deposition in smaller volume cylindrical Babyhaler (350 mL) than VOL 
when used with Evo. Hence, spacer volume and dimensions are linked to the degree of 
aerosol dose retention in it when used with Evo. 
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The discharged puff from Evo has high velocity and travels long distance (Gabrio et al., 
1999; Ross and Gabrio, 1999; McCabe et al., 2012). Large volume VOL and its 
diamond shape therefore provide adequate space for this spray to move forward with 
relatively smaller impaction of spray cone on side walls and at distal end. This also 
provides enough time to emitted dose droplets to evaporate and form finer particles 
besides slowing down their velocity. This is reflected in relatively lower deposition in 
VOL than that was found with either AERO or ABLE; differences between them were 
statistically significant and in-vitro inequivalent (Table 6.2.12). However, the dose 
retained in Evo+AERO and Evo+ABLE was statistically similar and in-vitro equivalent. 
This finding is suggestive of their similar performance and is more likely due to their 
closely related internal volumes and axial distances. 
On the other hand, TDD similarity of Evo between VOL and ABLE is more likely 
related to the shape of the spacer. The pear-shape of ABLE spacer may have provided 
enough room to the spray cone of the emitted dose and may have facilitated its forward 
movement alongside it by virtue of increasing cone angle of its walls with increasing 
distance from the MDI port and thereby may have reduced loss of drug due to impaction 
on walls by alignment with moving plume. This also explains the highest TDD from 
VOL which has wider cone angle due to its diamond shape and takes into account spray 
cone angle of emitted dose from Evo. These findings therefore suggest a possible link 
between shape, volume and diameter of spacer to dose retention and emission from 
them (Mazhar and Chrystyn, 2008). Other investigators have also reported similar 
relationship for Ventolin CFC (Mitchell et al., 1999) and sodium chromoglycate CFC 
(Intal) (Barry and O’Callaghan, 1995a). 
IP deposition of Evo alone was about 17 times more than that of Evo+SP. Hence, IP 
deposition was effectively reduced by these spacers. This outcome was expected. 
Spacers used in this study retained a significant portion of TED (44% to 52%). This is 
in agreement with previously reported dose retention in VOL of Ventolin CFC (Hindle 
and Chrystyn, 1994, Silkstone et al., 2002a) and Evo (Cripps et al., 2000). Deposition in 
VOL found in this study (37 µg) is the same as reported by Cripps et al. (2000). 
However, their reported IP deposition is about half of that found in current study. 
The dose retention of aerosol droplets and larger particles in these spacers eventually 
resulted in only about 3% (TED) deposition in IP. These results also show similar  
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deposition in IP irrespective of the type of spacer attached to Ventolin Evohaler. 
Interestingly, deposition in SP+IP was similar to IP deposition of Evo alone. This was 
also reflected when these depositions were assessed as %TED. These findings indicate 
that the proportion of Ventolin Evohaler delivered dose containing non-respirable 
particles size (> 10 um) was not affected by spacer shape and volume. Hence, 
generation of larger non-respirable particles is more likely related to Ventolin Evohaler 
device design and is intrinsic to its formulation.  
The reduction in IP deposition with spacer is important clinically and from the 
perspective of patient compliance (Brennan et al., 2005; Lavorini, 2014). Clinically, this 
will reduce the amount of swallowed drug and thereby reduce systemic side effects of 
salbutamol. Plume temperature of Ventolin Evohaler is below zero (
°
C) (Gabrio et al., 
1999; Ross and Gabrio, 1999; McCabe et al., 2012). On actuation, the discharged puff 
produces “Cold Freon” effect on throat impaction (Fink, 2000; Bell and Newman, 
2007). This may cause reflexive cessation of inhaling manoeuvres in some patients 
(Crompton, 1982; Fink, 2000; Newman, 2004) and may result in complete or partial 
loss of dose with clinical consequence for treatment (Melani et al., 2011). Spacers used 
with Evo will therefore minimise this effect. 
Non-respirable fractions of Evo Vs Evo+VOL (IP+CPM Vs SP+IP+CPM) were more 
closely related to each other than those of the other two spacers (AERO and ABLE). 
This suggests that former two treatment methods produced similar non-respirable 
fraction of discharged dose. Non-respirable fraction of dose decreased in order of 
Evo+VOL > Evo MDI alone > Evo+ABLE > Evo+AERO. This trend was also 
observed when non-respirable fraction was assessed as %TED (IP+CPM Vs 
SP+IP+CPM) and %TDD (IP+CPM). The relative fractions of respirable and non-
respirable dose may have implication for efficacy and safety. 
6.2.7.3 Impactor Mass (S0toF) 
Due to similar deposition in IP and SP+IP, statistically similar TED (TDD) entered 
impactor assembly (S0toF) with all treatment methods (MDI & MDI+SP). This shows 
that Evo alone and Evo+SP treatments of Evo were similar in delivering dose to 
impactor assembly. This implies that similar dose will be delivered to lower respiratory 
tract (HRT) whether or not a spacers is attached to it. This is perhaps surprising. 
However, difference between two delivery systems (MDI Vs MDI+SP) is evident from  
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the greater proportion of respirable dose composition of spacer treatment method. With 
spacer attached to Evo, about 80% of TDD consisted of FPD as compared to ~44% of 
Evo alone, thereby resulting in significant statistical differences and in-vitro 
inequivalence. These results further reveal that dose that reached to impactor assembly 
as %TDD with attached spacer was almost twice of that from MDI alone. These 
findings clearly highlight benefits and efficiency of spacer use (Lavorini and Fontana, 
2009). Conversely, with S0toF as %TDD, statistical similarity and in-vitro equivalence 
were observed amongst all Evo+SP treatment methods. This would infer that any of 
these three spacers can be used with Evo. However, this inference based solely on 
derived data could be potentially incorrect (see Section 6.2.7.5) since it is known that 
differences exist between spacers (Barry and O’Callaghan, 1996, 1997; Hall et al., 
2011). Besides, a given spacer can only be recommended to be used with a given MDI 
if the desired CQAs are similar and are found in-vitro equivalent in one-to-one 
comparison (EMA, 2006 & 2009).  
6.2.7.4 Respirable Dose (FPD) 
FPD obtained from Evo alone and with attached VOL was both statistically similar and 
in-vitro equivalent. This finding supports the recommendation in PIL to use VOL as an 
add-on device (GSK, 2018). The similarity of FPD obtained from the two delivery 
systems is clinically important. For clinicians, it provides smooth switch-over from 
Evohaler alone to EVO+VOL. If their FPD is significantly different, then this may have 
implications for efficacy and safety. Besides, such differences may require PK and/or 
PD studies to establish their comparability in EU area. Cripps et al. (2000) found 
slightly higher FPD (stages 2-6) with attached VOL (43 µg) than with Evo alone (34 
µg) (ratio ~ 1.27). Nevertheless, these investigators concluded that two treatment 
methods were similar. They were of the view that this difference in FPD was unlikely to 
be of clinical significance due to inter-patient variability observed with inhaled drug 
delivery. Nonetheless, their reported FPD obtained with Evo+VOL is similar to that 
found in current study (41 µg) (ratio ~ 1.05) (stages 2-6). 
FPD of Evo alone Vs Evo+ABLE and Evo+VOL Vs Evo+ABLE were both statistically 
similar and in-vitro equivalent. Although internal volume of ABLE is small (143 mL), 
however, it is pear-shaped, which may have provided enough space and span to emitted 
droplets of moving spray cone to evaporate and form finer particles. On the other hand, 
FPD of Evo+AERO was neither statistically similar nor in-vitro equivalent to Evo alone 
and Evo+VOL. Nevertheless, statistical similarity of FPD (and FPM) was observed   
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between AERO and ABLE while FPM was also in-vitro equivalent between them. 
Therefore, it can be concluded that similarities of FPD and FPM between AERO and 
ABLE are more likely due to their comparable spacer internal volumes. Taylor et al. 
(2003) found that when spacer shape is similar, in-vitro FPD of corticosteroid inhaler 
was not affected by increasing spacer volume from 250 mL to 1500 mL. Barry and 
O’Callaghan (1995a) found that increasing spacer diameter had more effect than 
increasing spacer volume on in-vitro recovery of FPD of sodium cromoglycate CFC 
MDI (Intal). Also, Cripps et al. (2000) reported similar FPD of Evo alone and when 
attached to Babyhaler. Babyhaler is a tube shaped spacer having a volume of 350 mL 
and length of 30 cm (Blake et al., 2012). Hence, results of ABLE spacer obtained in this 
project suggest that a spacer with an internal volume of 143 mL and internal effective 
axial length of ~10 cm with pear-shape (cone) geometry would be an optimal 
configuration for a spacer to be used with Evo. This finding suggests that ABLE spacer 
can also be used as an add-on device to Evo. 
Although the FPD of Evo+AERO was neither statistically similar nor in-vitro 
equivalent to that obtained from Evo alone and Evo+VOL, yet FPD of the latter was 
about 6 µg more than the former (Evo+AERO). Hall et al. (2011) also found higher 
FPD (~8 µg) with EVO+VOL as compared to cylindrically shaped small volume 
Breath-a-tech spacer (218 mL). Moreover, FPD obtained from EVO+ABLE was only ~ 
3 µg higher than that obtained from EVO+AERO. Even though PK and or PD studies 
may be required, however, clinical significance of such smaller differences probably 
may not be known due to difficulty of bioequivalence methods presently used to detect 
such small differences (García-Arieta, 2014). This shortcoming is confounded by 
patient factors such as underling individual variations in respiratory tract anatomy and 
physiology, gender, age, disease state and inhalation technique (Lipworth and Clark 
1997; Chrystyn, 1999; Labiris and Dolovich, 2003; Rubin, 2010; Venegas et al., 2013). 
6.2.7.5 Fine Particle Fraction 
The significant differences between Fine Particle Fraction (FPF) as %TED (ex-actuator) 
and %TDD (ex-spacer) were obviously related to their differences in the dose that 
reached impactor stages (S0toF). These differences were expected. As mentioned earlier 
(see Section 6.2.7.1), all of emitted dose was delivered to ACI with Evo alone, and 
therefore TED = TDD. While with spacer attached to Evo, a large proportion of this 
emitted dose was retained by spacer and significantly smaller dose was delivered to 
ACI. This resulted in them being in-vitro inequivalent with respect to FPF as %TDD.  
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The finding that FPF as %TDD of the three spacers were all statistically similar and in-
vitro equivalent is not surprising since these add-on devices removed most proportion of 
non-respirable dose from the aerosol cloud. Although these findings do suggest their 
similar efficiency in reducing large sized particle mass that otherwise would have 
deposited in IP, yet these could be misleading for comparative purposes. This is because 
a similar ratio of FPD to TDD could be obtained with an MDI+SP combination with a 
proportionally higher FPD and TDD as compared to that which has both these metrics 
at proportionally lower values. Also, with a disproportionate relationship between FPD 
and TDD, this could even show a relatively inferior recovery of either of these metrics 
to be equivalent or superior to comparator MDI+SP. This is because FPF is a function 
of two attributes, TED (or TDD) and FPD, both of which can vary independently of 
each other and thereby affect the resultant FPF as mentioned above. For example, Hall 
et al. (2011) have reported TDD and FPD of 41 µg and 37 µg, respectively, for 
Evo+VOL. TDD and FPD reported in this thesis are respectively 7 µg (~14%) and 2 µg 
(~5%) higher than they reported. This resulted in their 8.9% (ratio ~1.11) higher FPF 
(ex-spacer) value despite having smaller FPD. Even though the individual ratios of 
TDD and FPD suggest superiority of these raw data results obtained in the current study 
to theirs, yet their reported FPF as %TDD implies relatively better performance of VOL 
than was found here. This outcome assessment is therefore inherently incorrect. 
On the other hand, Mitchell et al. (2009) obtained TDD and FPD of Evo+AERO of 54 
µg and 49 µg, respectively, which gives ~91% as FPF. Their results for TDD and FPD 
are 11 µg (~20%) and 15 µg (~31%) higher than those reported in this thesis. The two 
results are significantly different but the disproportionate differences between TDD and 
FPD obtained with these two studies resulted in %FPF value which only differed by 
~11.5% (ratio ~1.15), thereby suggesting similarity of the two results. Hence, inferences 
from %FPF regarding similarity of different treatment methods should be drawn with 
caution since these may have clinical consequences.  
In another in-vitro study on Evo with attached VOL, Cripps et al. (2000) reported TED 
(ex-actuator), TDD (ex-spacer) and fine particle mass (stages 2-6) of 90 µg, ~53 µg 
(calculated by this author) and 43 µg (stages 2-6), respectively. This gives 
corresponding FPF as %TED (ex-actuator) and % of TDD (ex-spacer) of ~48% and 
~82%. Their reported TED (ex-actuator), TDD (ex-spacer) and fine particle mass 
(stages 2-6) are ~5 µg (~5%), ~5 µg (~10%) and 2 µg (~5%) higher than those found   
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with the current study. Since percentages of these CQAs are within EMA limits (±15%), 
it can be concluded that two studies had effectively similar results. 
These examples of in-vitro comparative studies show that %FPF alone may not 
correctly reflect on in-vitro performance of an inhaler treatment method which is being 
compared with others. The bronchodilator response is related to minimum effective 
amount of FPD of salbutamol that is available at the site of action rather than the 
fraction of TED containing FPD that reaches there. Clinical studies involving 
salbutamol dose-response such as methacholine challenge and dose titration identify 
this minimum required dose (Tomlinson et al., 2003; García-Arieta, 2014). Studies 
using FEV1 as the endpoint reach plateau after achieving this minimum dose and further 
increase in the dose would not add additional relief. Hence minimum effective amount 
of salbutamol would bring about the desired relief. It is therefore prudent to use raw 
data to assess comparative performances of two or more MDIs without or with attached 
spacer while derived data can be used to assess individual performance efficiency of a 
treatment method. 
6.2.7.6 MMAD and GSD 
MMAD and GSD for Evo alone were relatively smaller than those obtained with 
attached spacer. Hence, the theory of spacer providing more time and space to generate 
finer particles (Fink, 2000) apparently seems to have not held ground here. However, 
the findings in this study for Evo are in concord with those of Cripps et al. (2000) who 
have also reported a lower MMAD with Evo alone (2.1 µm) than that found with VOL 
(2.4 µm). 
Impactor mass (S0toF) profile (Figure 6.2.1) shows that with Evo, comparatively more 
TDD deposition was centred on group 2 stages (FPM) as compared to Evo+SP and had 
relatively smaller asymmetrical influences on the distribution profile from depositions 
on stages of groups 1 (fronting) (CPM) and 3 (tailing) (EPM). The size of MMAD 
found with spacer devices increased in order of VOL > ABLE > AERO. Also CPM, 
assessed as %TDD and as %S0toF, shows similar increasing order. Moreover, FPM was 
found in the same order but of decreasing amounts. This suggests that spacer shape and 
volume may have contributed to this sizing order. Larger volume and space provided by 
VOL resulted in lower proportions of CPM in TDD and S0toF which affected MMAD 
size accordingly. Nonetheless, MMAD and GSD obtained in present study lie between 
>2.5 to < 3 µm (range 0.23 µm) and > 1.5 to < 1.7 (range 0.12), respectively, and fall   
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within the desired size range for an optimal MDI performance (Section 2.3). Besides, 
the narrow window of GSD indicates that dispersion of aerodynamic particle size 
around their respective MMADs for these spacer combinations is similar.  
6.2.7.7 Stage Groups 
Efficacy and safety of an MDI is related to its APSD profile (Sections 2.3 & 3.3.4). The 
fractionation of TED/TDD from an MDI into various components of ACI could be 
useful in predicting its effectiveness and safety (Pritchard, 2001). Hence, APSD profiles 
have also been assessed as separate groups which may be representative of various 
regions of HRT (see Sections 3.3.4 & 5.2.4.10). 
Statistical similarities of CPM, FPM and EPM (and FPD) observed between Evo alone 
and Evo+VOL suggest that the geometry and volume of this spacer correspond 
adequately with these MDI performance characteristics. CPM and EPM of Evo Vs 
Evo+AERO were statistically similar while their FPM (and FPD) was statistically 
different. Nevertheless, CPM and EPM of Evo Vs Evo+ABLE were statistically 
different even though their FPM (and FPD) was statistically similar. Also, CPM, FPM 
and EPM were not in-vitro equivalent between Evo Vs Evo+AERO and Vs Evo+ABLE. 
These findings indicate that stage grouped profile of Evo alone was not similar to either 
of them. In addition, EPM of Evo+VOL Vs Evo+AERO was statistically similar but 
significantly different Vs Evo+ABLE, the latter producing higher EPM. These findings 
however could not be reconciled with the theory of role of spacer volume since highest 
EPM was observed with Evo+ABLE rather than Evo+VOL. This would need further 
investigation given that VOL has larger diameter and axial length (Table 6.2.13), which 
theoretically allows more space to form finer particles.  
6.2.7.8 Efficiency of dose delivery to ACI stages 
The dose reaching ACI stages (S0toF) resembles that proportion of dose which enters 
respiratory system beyond oropharynx. Hence a ratio of S0toF to IP deposition could be 
used to predict the proportion of dose that would enter respiratory system post-pharynx. 
Evo alone delivered half of the dose to S0toF while this dose delivery ratio was 
increased to over 16 times with spacer; for Evo+VOL this dose delivery ratio was ~20 
times more than that of Evo alone. This further supports use of spacers with Evo. 
Relatively greater amount of dose was delivered to ACI stages (S0toF) for Evo+VOL 
than other spacers; the least dose delivered with AERO. However, the dose retained in   
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SP+IP was lower with Evo+VOL than that of IP deposition with Evo alone while it was 
higher with other two spacers, with consequent lower delivery to ACI stages. 
6.2.7.9 Efficiency of respirable dose delivery (FPD/IP Ratio) 
The ratio between lung (L) bioavailability of an inhaled drug to that of its total systemic 
(T) bioavailability would predict its efficacy and safety (Borgström, 1998). A higher 
L/T ratio would result in optimal efficacy with fewer side effects. Systemic 
bioavailability of inhaled drugs is a function of swallowing of inhaled dose impacted in 
oropharyngeal region and absorption from the upper HRT (laryngeal region). The ratio 
of FPD to IP deposition mimics L/T bioavailability and is considered an effective in-
vitro means of determining efficiency of MDI dose delivery to the lungs (Wilkes et al., 
2001). Evo when used alone was the least efficient in delivering FPD while this 
efficiency was the highest with Evo+VOL. FPD (Lung) to IP (throat) ratio decreased in 
order of Evo+VOL > Evo+ABLE > Evo+AERO > Evo (Table 6.2.7). The ratio of the 
respirable dose (FPD) to non-respirable dose (IP+CPM) followed similar trend of dose 
delivery efficiency. This trend was also reflected with spacer treatment methods 
(SP+IP+CPM). The ratios of respirable and non-respirable fractions suggest that spacers 
effectively retained large particle mass while significantly reducing IP deposition. 
However, their effect on reducing CPM deposition was not considerable. Hence the 
trend in decreasing ratio of FPD to IP+CPM Vs FPD to SP+IP+CPM, that is, the net 
respirable dose delivery decreased in order of Evo+VOL > Evo > Evo+ABLE > 
Evo+AERO. These findings suggest that Evo+VOL delivered more dose in-vitro in the 
respirable range than Evo alone and when attached to either ABLE or AERO. Further, 
FPD dose delivery of Evo alone was better than AERO and ABLE. 
6.2.7.10 The dilemma of conflicting in-vitro results! 
Differences and similarities amongst in-vitro studies conducted by different 
investigators are of a common occurrence. Even though same MDI products have been 
compared with each other in the present study, the differences in results have been 
found across regions and continents. This is because APSD measurements using ACI 
are a very sensitive technique with many potential sources of variability (Stein, 1999, 
2008; Christopher et al., 2003; Mitchell and Nagel, 2003). Even results obtained from 
the same ACI equipment differ (Stein, 1999 & 2008). These potential sources of 
variability also include varying level of lab techniques, availability of supportive 
equipments and instruments, environmental conditions, methodology and protocols   
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(Christopher et al., 2003). With add-on devices such as spacers, this could introduce 
additional sources of variability between different laboratories. Hence, APSD data 
would reflect on these differences. Besides, differing objectives in assessing raw and 
derived data will have their own implications. Nevertheless, drastic differences would 
raise questions which would need to be investigated and answered. 
Nonetheless, clinical studies have been reported where in-vitro performance of MDIs 
with and without attached spacers have not produced equivalent results yet these 
treatment methods were found to be bioequivalent (Dompeling et al., 2001; Barben et 
al., 2003; Dubus et al., 2003). Also, in-vitro studies are carried out in a controlled 
laboratory environment and the equipments used do not exactly replicate human 
respiratory system. Besides, in-vitro results are often higher than in-vivo results (Chan 
et al., 2014). Hence, in-vitro equivalence or its absence should not preclude in-vivo tests 
and clinical studies so as to allow researchers to see the wider picture. Conclusions 
based merely on in-vitro studies might be erroneous since at times these may not be 
predictive of clinical outcomes due to biological and behavioural variables.  
6.2.8 Conclusions: In-Vitro Equivalence Studies of Ventolin Evohaler Without 
and With Spacer 
The choice of an add-on device to be used with an MDI has been a popular research 
topic of interest lately. This is in part due to availability of a number of spacers and the 
intent of manufacturers to promote their products with a consequent emergence of 
studies to show their suitability to be used with a specific MDI. This independent study 
focussed on suitability of VOL, AERO and ABLE spacers as add-on device for 
Ventolin Evohaler. 
TED (ex-actuator), FPD, MMAD and GSD of Ventolin Evohaler Vs EVO+VOL were 
in-vitro equivalent. Hence, VOL can be used as an add-on device for Evo when desired. 
In-vitro equivalence with respect to TED (ex-actuator), FPD, MMAD and GSD were 
also observed between Evo and Evo+ABLE. Thus, ABLE spacer can be used as an add-
on device with Ventolin Evohaler.  
Evo alone and Evo+AERO were in-vitro equivalent with respect to TED (ex-actuator), 
MMAD and GSD only. FPD obtained with Evo+AERO was 5.5 µg lower than that of 
Evo alone and differed statistically and was not in-vitro equivalent. Based on this in-
vitro information, AERO should not be recommended as an add-on device with   
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Ventolin Evohaler. Nevertheless, in-vivo studies with healthy volunteers have shown 
that AERO could be used with Ventolin Evohaler (Mazhar and Chrystyn, 2008). 
Decisions on suitability of a given spacer should not be based on results of in-vitro 
studies only. In the event of failure to meet in-vitro equivalence, in-vivo studies should 
be conducted to support this or to ascertain its suitability. 
The three spacers (VOL, AERO & ABLE) significantly reduced IP deposition to less 
than 6% and more than 79% of their TDD constituted FPD. Thus, these spacers were 
efficient in removing a large non-respirable fraction of TED. 
Comparative performance of CQAs of MDI alone and with attached spacer should be 
assessed using raw data while derived data can be used for evaluating performance 
efficiency of a treatment method.  
Findings of this study apply only to Ventolin Evohaler with VOL, AERO and ABLE 
and cannot be extended to other MDIs and spacers. 
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6.3 In-Vivo Equivalence of Ventolin Evohaler Without and With 
Spacers-Urinary Pharmacokinetic Studies 
The objectives of this study are to determine bioavailability and in-vivo equivalence of 
Ventolin Evohaler alone and when used with spacers via urinary pharmacokinetic 
method (Hindle and Chrystyn, 1992). This will be achieved by comparing relative lung 
and total systemic bioavailability in healthy subjects. This will be complemented by 
charcoal blockade study to estimate lung deposition of inhaled salbutamol by preventing 
GI absorption of its swallowed fraction. These studies are of their first kind. Part of this 
work has been published. 
6.3.1 Study Design 
Study plan was implemented as per Section 3.4.5; subjects selected and trained as 
enumerated in Sections 3.4.3 and 3.4.4, respectively (Chapter 3). Subject cohort was the 
same as described in Section 5.3.1 (Chapter 5).  
In summary, the clinical study consisted of two parts, each part with four sub-sets 
involving four treatment methods of salbutamol inhalation from Ventolin Evohaler 
(Evo), either the MDI alone or attached to one of the three spacers (SP): Volumatic 
(VOL), AeroChamber Plus (AERO) or Able (ABLE). In Part 1 Study, on separate study 
day one week apart, trained healthy subjects inhaled two separate puffs of salbutamol 
from one of these treatment methods selected randomly. Each dose discharged from 
Evo or into a spacer was inhaled using a slow vital capacity inhalation manoeuvre. The 
subjects exhaled to residual volume prior to actuating the dose, then took a slow deep 
inhalation over 5–10 seconds, followed by a 10 second breath hold. Subjects repeated 
this procedure for second actuation (Hindle et al., 1993). Before dosing Evo was primed 
and all spacers were washed in lukewarm mild detergent (equivalent to hand washing 
dishes), rinsed with water and left to air dry (Protocols 3.3.1 & 3.3.2; Sections 3.3.2.3 & 
3.3.2.4; Chapter 3). Each single dose discharged into a spacer was inhaled within the 
first second of discharge into the spacer. All subjects voided their urine 0.5h pre-dosing. 
Thirty minutes after the start of each study dose inhalation subjects provided a urine 
sample (USAL0.5). They then pooled all their urine over the next 24h into a container 
(USAL24). In Part 2 Study, each subject repeated this study with the coadministration 
of activated charcoal by swallowing 100 mL of charcoal slurry immediately before and 
after completing two inhalations.  
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The pH and volume of each sample was recorded and samples were stored at –20◦C 
before analysis. The pH values of the urine samples were all below pH 7, hence there 
was no variability due to passive tubular reabsorption (Hindle and Chrystyn, 1992). 
After inhalation of the two study doses each spacer was rinsed with water to collect the 
residual dose. 
6.3.2 Sample Analysis 
Aqueous and urine samples were assayed for their salbutamol content using validated 
HPLC methods described in Chapter 4. 
6.3.3 Statistical Analysis 
Statistical analysis undertaken as per Section 3.4.7 (Chapter 3). 
6.3.4 Results: In-Vivo Equivalence of Ventolin Evohaler Without and With 
Spacers 
Volunteers’ demographic characteristics are provided in Table 5.3.1 and Appendix 
5.3.4.1 (Chapter 5). Summaries of USAL0.5 and USAL24 amounts post-dose (without 
and with charcoal blockade) are provided in Table 6.3.1 and Figure 6.3.1 to Figure 
6.3.5. The table and figures also show salbutamol as active (USAL24Pre), active and 
sulphate conjugated (USAL24Post) and metabolised (USALMET) moieties excreted 
during 0.5h–24h period. Figure 6.3.6 shows comparative salbutamol urinary recovery 
profiles obtained post-inhalation without and with charcoal blockade. These recoveries 
of salbutamol as % nominal, % delivered and % recovered dose are given in Table 6.3.2 
to Table 6.3.4. Urinary excretion data of individual subjects for Ventolin Evohaler is 
given in Appendices 5.3.4.2 and 5.3.4.5. Appendices 6.3.4.1 to 6.3.4.6 provide 
individual data for Evo+VOL, Evo+AERO and Evo+ABLE for both legs of the study. 
Table 6.3.5 to Table 6.3.8 provide data on in-vivo equivalence and comparative 
bioavailability of the four inhaled salbutamol treatment methods for both parts of the 
study. Table 6.3.9 compares charcoal blockade effect while in-vitro and in-vivo trends 
are shown in Table 6.3.10. 
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In Part 1 Study, relative lung bioavailability (USAL0.5NC) of Evo was not in-vivo 
equivalent to any of the three spacers attached to it (Table 6.3.1 & Table 6.3.5). 
USAL0.5NC of Evo attached to spacers (Evo+SP) was 2.5 times more than the amount 
of Evo alone and hence statistically significant. For total systemic bioavailability 
(USAL24NC), in-vivo equivalence as per EMA (2009) criteria was noted between Evo 
Vs Evo+VOL only although the three spacers had statistically similar total systemic 
bioavailability. However, these comparisons were in-vivo equivalent as per limits 
suggested by Parameswaran (1999). The excretion of active salbutamol 
(USAL24PreNC), its metabolites (USALMETnc) and total salbutamol 
(USAL24PostNC) were all in-vivo inequivalent between Evo Vs Evo+SP as per EMA 
(2009) criteria. Nevertheless, USAL24PreNC and USAL24PostNC (except Evo Vs 
Evo+AERO) were in-vivo equivalent on the basis of Parameswaran (1999) criteria. On 
the other hand, statistically similar bioavailability was only observed between Evo Vs 
Evo+SP and Evo Vs Evo+VOL for USAL24PreNC and USAL24PostNC, respectively.  
The comparison of the two parts of the study is given in Table 6.3.9 (Figure 6.3.7). The 
mean paired differences between the amounts of salbutamol excreted in 0.5h were 
statistically similar between the two parts of the same treatment method (n=13). 
 
Table 6.3.1. Mean salbutamol excreted in urine from Ventolin Evohaler without and with 
spacer. 
Treatment 
(n = 13) 
USAL0.5 USAL24† USAL24Pre USAL24Post USALMET 
µg SD µg SD µg SD µg SD µg SD 
Part 1 Study (without charcoal blockade) 
Ventolin* 5.7 1.9 100.7 15.7 58.4 18.3 95.0 16.6 36.6 15.6 
Evo + VOL 16.4 8.2 97.3 12.7 62.8 11.8 85.3 12.5 22.5 8.9 
Evo + AERO 14.8 7.4 84.6 25.8 57.1 19.6 71.9 21.5 14.8 4.5 
Evo + ABLE 14.4 5.4 89.7 21.0 61.9 15.3 75.3 16.4 13.4 4.8 
Part 2 Study (with charcoal blockade) 
Ventolin* 5.3 2.5 29.8 5.3 14.3 5.3 24.5 4.8 10.2 5.1 
Evo + VOL 14.8 4.9 68.9 15.1 39.0 10.0 54.1 11.8 15.1 6.3 
Evo + AERO 13.8 6.7 64.6 17.6 39.6 10.7 50.8 11.8 11.2 4.4 
Evo + ABLE 14.1 5.8 62.0 19.6 35.0 11.1 47.9 14.1 12.9 5.7 
* Ventolin Evohaler; † TRD = USAL24; SD = Standard Deviation 
 
 
Between spacers, USAL0.5NC and USAL24NC were not in-vivo equivalent as per 
EMA (2009) despite having statistically similar bioavailability (Table 6.3.1 & Table 
6.3.6). These parameters were, however, within the limits suggested by Parameswaran 
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(1999). Similar results were observed for USAL24PreNC and USAL24PostNC. 
Nevertheless, USALMETnc was statistically different between Evo+VOL Vs 
Evo+AERO and Vs Evo+ABLE which also failed to meet in-vivo equivalence criteria 
of Parameswaran (1999). 
 
Table 6.3.2. Mean salbutamol excretion in urine from Ventolin Evohaler without and with 
the spacer, expressed as % of Nominal Dose. 
Treatment 
Method 
(n = 13) 
USAL0.5 USAL24† USAL24Pre USAL24Post USALMET 
% SD % SD % SD % SD % SD 
Part 1 Study (without charcoal blockade) 
Ventolin* 2.9 0.9 50.3 7.9 29.2 9.1 47.5 8.3 18.3 7.8 
Evo + VOL 8.2 4.1 48.7 6.3 31.4 5.9 42.6 6.3 11.2 4.5 
Evo + AERO 7.4 3.7 42.3 12.9 28.6 9.8 36.0 10.7 7.4 2.3 
Evo + ABLE 7.2 2.7 44.9 10.5 31.0 7.6 37.6 8.2 6.7 2.4 
Part 2 Study (with charcoal blockade) 
Ventolin* 2.6 1.2 14.9 2.7 7.2 2.7 12.3 2.4 5.1 2.5 
Evo + VOL 7.4 2.5 34.5 7.5 19.5 5.0 27.1 5.9 7.5 3.2 
Evo + AERO 6.9 3.4 32.3 8.8 19.8 5.4 25.4 5.9 5.6 2.2 
Evo + ABLE 7.0 2.9 31.0 9.8 17.5 5.5 24.0 7.1 6.4 2.9 
* Ventolin Evohaler; † TRD = USAL24; SD = Standard Deviation 
 
In Part 2 Study with charcoal blockade, none of these PK parameters were either in-vivo 
equivalent or had statistically similar bioavailability between Evo Vs Evo+SP. 
Exceptions were for USALMETc; Evo Vs Evo+AERO were in-vivo equivalent as per 
Parameswaran (1999) criteria which also showed similar bioavailability along with Evo 
Vs Evo+ABLE (Table 6.3.1 & Table 6.3.7). The USAL0.5C amount of Evo+SP was 
over 2.5 times more than Evo alone and was statistically significant. On the other hand, 
charcoal prevented GI absorption of swallowed salbutamol from Evo thereby 
significantly reducing its USAL24C by more than half of Evo+SP. Similar in-vivo 
inequivalent trend in other pharmacokinetic (PK) parameters was observed between 
Evo+SP as per EMA (2009) criteria. On the contrary, these PK parameters were in-vivo 
equivalent and had statistically similar bioavailability; exception of both measurements 
being between Evo+VOL Vs Evo+AERO for USALMETc (Table 6.3.1 & Table 6.3.8). 
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Table 6.3.3. Mean salbutamol excretion in urine from Ventolin Evohaler without and with 
spacers, expressed as % of estimated Delivered Dose. 
Treatment 
Method 
(n = 13) 
USAL0.5 USAL24† USAL24Pre USAL24Post USALMET 
% SD % SD % SD % SD % SD 
Part 1 Study (without charcoal blockade) 
Ventolin* 3.6 1.2 62.7 9.4 36.3 11.0 59.1 10.0 22.8 9.7 
Evo + VOL 16.0 8.4 93.2 2.1 60.2 8.4 81.6 5.3 21.4 7.2 
Evo + AERO 17.9 11.3 93.5 6.7 62.5 10.3 79.8 7.3 17.3 5.4 
Evo + ABLE 14.6 3.7 93.0 4.0 64.3 5.6 78.3 3.0 14.1 5.5 
Part 2 Study (with charcoal blockade) 
Ventolin* 3.3 1.5 18.7 3.4 9.0 3.4 15.4 3.1 6.4 3.2 
Evo + VOL 14.3 4.7 66.1 12.8 37.4 8.8 51.8 9.7 14.4 5.8 
Evo + AERO 15.3 6.5 72.6 14.8 44.6 9.8 57.3 9.8 12.7 4.7 
Evo + ABLE 14.6 4.9 64.9 14.9 36.8 9.2 50.3 10.4 13.5 5.1 
* Ventolin Evohaler; † TRD = USAL24; SD = Standard Deviation 
 
 
Table 6.3.4. Mean salbutamol excretion in urine from Ventolin Evohaler without and with 
spacers, expressed as % of Recovered Dose. 
Treatment 
Method 
(n = 13) 
USAL0.5 USAL24† USAL24Pre USAL24Post USALMET 
% SD % SD % SD % SD % SD 
Part 1 Study (without charcoal blockade) 
Ventolin* 5.9 2.4 - - 57.7 14.6 94.1 2.4 36.3 14.4 
Evo + VOL 17.3 9.2 - - 64.6 8.7 87.5 5.7 23.0 7.9 
Evo + AERO 19.4 12.4 - - 66.7 8.8 85.5 6.4 18.8 7.0 
Evo + ABLE 15.7 3.6 - - 69.2 5.9 84.3 3.6 15.2 6.1 
Part 2 Study (with charcoal blockade) 
Ventolin* 17.7 7.1 - - 48.7 16.0 82.3 7.1 33.7 14.6 
Evo + VOL 21.3 5.1 - - 56.6 7.4 78.7 5.1 22.1 8.2 
Evo + AERO 20.4 5.5 - - 61.5 7.4 79.6 5.5 18.1 7.9 
Evo + ABLE 22.0 3.7 - - 56.8 8.9 78.0 3.7 21.2 7.6 
* Ventolin Evohaler; † TRD = USAL24; SD = Standard Deviation 
 
  
  163 
 
Figure 6.3.1. Comparative salbutamol urinary excretion at 0.5h post-inhalation without and with 
charcoal ingestion. 
Numerals represent individual volunteers. nc = no charcoal ingestion; +c = with charcoal ingestion. 
 
 
 
Figure 6.3.2. Comparative total salbutamol urinary excretion during 24h post-inhalation without and 
with charcoal ingestion. 
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Figure 6.3.3. Comparative unchanged salbutamol urinary excretion during 0.5-24h post-inhalation 
without and with charcoal ingestion. 
 
 
 
Figure 6.3.4. Comparative total salbutamol urinary excretion during 0.5-24h post-inhalation without 
and with charcoal ingestion. 
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Figure 6.3.5. Comparative salbutamol metabolites urinary excretion during 0.5-24h post-inhalation 
without and with charcoal ingestion. 
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Figure 6.3.6. Comparative salbutamol urinary recovery profiles obtained post-inhalation without and with charcoal ingestion. 
Numerals represent individual volunteers. nc = no charcoal ingestion; +c = with charcoal ingestion. 
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Table 6.3.5. In-Vivo Equivalence and Statistical Significance of Ventolin Evohaler Vs Evo+SP salbutamol urinary excretion without charcoal blockade (Part 1 Study). 
Parameter 
Multiple Comparisons 
Mean 
Ratio 
90% CI 
p value 
In-Vivo Equivalence Mean 
Difference 
(µg) 
95% CI 
p value 
Statistical 
Similarity Ventolin Evohaler MDI 
Vs 
LL UL 0.80-1.25
a
 0.67-1.50
b
 LL UL 
USAL0.5 
NC 
Evo + Volumatic 0.39 0.31 0.49 <0.0001 No No -10.64 -14.17 -7.12 <0.0001 No 
Evo + AeroChamber Plus 0.42 0.33 0.53 <0.0001 No No -9.11 -12.63 -5.58 <0.0001 No 
Evo + ABLE 0.41 0.32 0.51 <0.0001 No No -8.72 -12.24 -5.19 <0.0001 No 
USAL24 
NC 
Evo + Volumatic 1.02 0.86 1.22 0.814 Yes Yes 2.92 -13.78 19.61 0.725 Yes 
Evo + AeroChamber Plus 1.24 1.04 1.47 0.044 No Yes 15.67 -1.03 32.36 0.065 Yes 
Evo + ABLE 1.13 0.95 1.35 0.234 No Yes 10.56 -6.13 27.25 0.208 Yes 
USAL24Pre 
NC 
Evo + Volumatic 0.90 0.72 1.13 0.448 No Yes -4.45 -24.31 15.41 1.000 Yes 
Evo + AeroChamber Plus 1.05 0.84 1.33 0.706 No Yes 1.68 -18.18 21.54 1.000 Yes 
Evo + ABLE 0.92 0.73 1.16 0.565 No Yes -3.53 -23.39 16.33 1.000 Yes 
USAL24Post 
NC 
Evo + Volumatic 1.11 0.94 1.31 0.301 No Yes 9.69 -4.61 23.98 0.178 Yes 
Evo + AeroChamber Plus 1.37 1.16 1.62 0.003 No No 23.08 8.78 37.37 0.002 No 
Evo + ABLE 1.27 1.08 1.50 0.021 No Yes 19.70 5.41 34.00 0.008 No 
USALMET 
nc 
Evo + Volumatic 1.58 1.22 2.05 0.005 No No 14.14 7.47 20.82 <0.0001 No 
Evo + AeroChamber Plus 2.37 1.83 3.07 <0.0001 No No 21.79 15.12 28.47 <0.0001 No 
Evo + ABLE 2.74 2.12 3.56 <0.0001 No No 23.23 16.56 29.91 <0.0001 No 
a
 EMA, 2009; 
b
 Parameswaran, 1999; CI = Confidence Interval; LL = Lower limit; UL = Upper Limit; NC or nc = No Charcoal 
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Table 6.3.6. In-Vivo Equivalence and Statistical Significance of salbutamol urinary excretion post-inhalation from Ventolin Evohaler with spacer without charcoal blockade 
(Part 1 Study). 
Parameter Multiple Comparisons 
Mean 
Ratio 
90% CI 
p value 
In-Vivo Equivalence Mean 
Difference 
(µg) 
95% CI 
p value 
Statistical 
Similarity LL UL 0.80-1.25
a
 0.67-1.50
b
 LL UL 
USAL0.5 
NC 
Evo+VOL 
Evo+AERO 1.08 0.86 1.36 0.562 No Yes 1.54 -1.99 5.06 0.382 Yes 
Evo+ABLE 1.05 0.83 1.32 0.737 No Yes 1.93 -1.60 5.45 0.275 Yes 
Evo+AERO Evo+ABLE 0.97 0.77 1.22 0.806 No Yes 0.39 -3.13 3.91 0.824 Yes 
USAL24 
NC 
Evo+VOL 
Evo+AERO 1.21 1.02 1.44 0.073 No Yes 12.75 -3.94 29.45 0.130 Yes 
Evo+ABLE 1.10 0.93 1.31 0.336 No Yes 7.64 -9.05 24.34 0.359 Yes 
Evo+AERO Evo+ABLE 0.91 0.77 1.09 0.390 No Yes -5.11 -21.80 11.59 0.539 Yes 
USAL24Pre 
NC 
Evo+VOL 
Evo+AERO 1.17 0.93 1.47 0.258 No Yes 5.74 -8.55 20.02 0.421 Yes 
Evo+ABLE 1.03 0.82 1.29 0.853 No Yes 0.92 -13.36 15.21 0.896 Yes 
Evo+AERO Evo+ABLE 0.88 0.70 1.10 0.342 No Yes -4.81 -19.10 9.47 0.499 Yes 
USAL24Post 
NC 
Evo+VOL 
Evo+AERO 1.24 1.05 1.46 0.038 No Yes 13.39 -0.91 27.69 0.066 Yes 
Evo+ABLE 1.15 0.97 1.35 0.178 No Yes 10.02 -4.28 24.31 0.164 Yes 
Evo+AERO Evo+ABLE 0.93 0.78 1.09 0.441 No Yes -3.37 -17.67 10.93 0.635 Yes 
USALMET 
nc 
Evo+VOL 
Evo+AERO 1.50 1.16 1.95 0.012 No No 7.65 0.98 14.33 0.026 No 
Evo+ABLE 1.74 1.34 2.26 0.001 No No 9.09 2.42 15.77 0.009 No 
Evo+AERO Evo+ABLE 1.16 0.89 1.50 0.346 No Yes 1.44 -5.23 8.11 0.664 Yes 
 a
 EMA, 2009; 
b
 Parameswaran, 1999; CI = Confidence Interval; LL = Lower limit; UL = Upper Limit; NC or nc = No Charcoal 
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Table 6.3.7. In-Vivo Equivalence and Statistical Significance of Evohaler Vs Evo+SP salbutamol urinary excretion post-inhalation with charcoal blockade (Part 2 Study). 
Parameter 
Multiple Comparisons 
Mean 
Ratio 
90% CI 
p value 
In-Vivo Equivalence Mean 
Difference 
(µg) 
95% CI 
p value 
Statistical 
Similarity Ventolin Evohaler MDI 
Vs 
LL UL 0.80-1.25
a
 0.67-1.50
b
 LL UL 
USAL0.5 
C 
Evo + Volumatic 0.34 0.26 0.44 <0.0001 No No -9.54 -13.16 -5.92 <0.0001 No 
Evo + AeroChamber Plus 0.39 0.30 0.50 <0.0001 No No -8.53 -12.15 -4.91 <0.0001 No 
Evo + ABLE 0.37 0.29 0.48 <0.0001 No No -8.77 -12.39 -5.15 <0.0001 No 
USAL24 
C 
Evo + Volumatic 0.43 0.37 0.51 <0.0001 No No -39.14 -50.05 -28.23 <0.0001 No 
Evo + AeroChamber Plus 0.47 0.40 0.55 <0.0001 No No -34.86 -45.77 -23.94 <0.0001 No 
Evo + ABLE 0.50 0.42 0.58 <0.0001 No No -32.18 -43.09 -21.27 <0.0001 No 
USAL24Pre 
C 
Evo + Volumatic 0.35 0.28 0.44 <0.0001 No No -24.68 -32.18 -17.18 <0.0001 No 
Evo + AeroChamber Plus 0.35 0.28 0.44 <0.0001 No No -25.32 -32.82 -17.82 <0.0001 No 
Evo + ABLE 0.40 0.32 0.51 <0.0001 No No -20.68 -28.18 -13.18 <0.0001 No 
USAL24Post 
C 
Evo + Volumatic 0.45 0.39 0.53 <0.0001 No No -29.60 -37.75 -21.45 <0.0001 No 
Evo + AeroChamber Plus 0.49 0.42 0.57 <0.0001 No No -26.33 -34.48 -18.18 <0.0001 No 
Evo + ABLE 0.52 0.45 0.61 <0.0001 No No -23.41 -31.56 -15.25 <0.0001 No 
USALMET 
c 
Evo + Volumatic 0.65 0.51 0.83 0.004 No No -4.92 -8.21 -1.63 0.004 No 
Evo + AeroChamber Plus 0.87 0.68 1.10 0.326 No Yes -1.01 -4.30 2.28 0.536 Yes 
Evo + ABLE 0.77 0.60 0.97 0.069 No No -2.72 -6.01 0.57 0.102 Yes 
a
 EMA, 2009; 
b
 Parameswaran, 1999; CI = Confidence Interval; LL = Lower limit; UL = Upper Limit; C or c = Charcoal 
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Table 6.3.8. In-Vivo Equivalence and Statistical Significance of salbutamol urinary excretion post-inhalation from Ventolin Evohaler with spacer with charcoal ingestion (Part 2 
Study). 
Parameter Multiple Comparisons 
Mean 
Ratio 
90% CI 
p value 
In-Vivo Equivalence Mean 
Difference 
(µg)  
95% CI 
p value 
Statistical 
Similarity LL UL 0.80-1.25
a
 0.67-1.50
b
 LL UL 
USAL0.5 
C 
Evo+VOL 
Evo+AERO 1.14 0.88 1.47 0.406 No Yes 1.01 -2.61 4.63 0.574 Yes 
Evo+ABLE 1.09 0.84 1.41 0.574 No Yes 0.77 -2.85 4.39 0.670 Yes 
Evo+AERO Evo+ABLE 0.96 0.74 1.24 0.786 No Yes -0.25 -3.87 3.37 0.891 Yes 
USAL24 
C 
Evo+VOL 
Evo+AERO 1.08 0.92 1.27 0.408 No Yes 4.28 -6.63 15.20 0.431 Yes 
Evo+ABLE 1.14 0.98 1.34 0.161 No Yes 6.96 -3.95 17.87 0.204 Yes 
Evo+AERO Evo+ABLE 1.06 0.90 1.24 0.557 Yes Yes 2.68 -8.23 13.59 0.622 Yes 
USAL24Pre 
C 
Evo+VOL 
Evo+AERO 0.99 0.79 1.25 0.970 No Yes -0.64 -8.14 6.86 0.864 Yes 
Evo+ABLE 1.15 0.91 1.44 0.321 No Yes 4.00 -3.51 11.50 0.287 Yes 
Evo+AERO Evo+ABLE 1.15 0.92 1.45 0.303 No Yes 4.63 -2.87 12.14 0.218 Yes 
USAL24Post 
C 
Evo+VOL 
Evo+AERO 1.07 0.92 1.25 0.460 Yes Yes 3.27 -4.88 11.42 0.422 Yes 
Evo+ABLE 1.15 0.99 1.35 0.126 No Yes 6.19 -1.96 14.35 0.132 Yes 
Evo+AERO Evo+ABLE 1.08 0.92 1.26 0.418 No Yes 2.93 -5.23 11.08 0.471 Yes 
USALMET 
c 
Evo+VOL 
Evo+AERO 1.34 1.05 1.70 0.048 No No 3.91 0.62 7.20 0.021 No 
Evo+ABLE 1.18 0.93 1.50 0.252 No Yes 2.20 -1.09 5.49 0.184 Yes 
Evo+AERO Evo+ABLE 0.88 0.69 1.12 0.386 No Yes -1.71 -5.00 1.58 0.299 Yes 
a
 EMA, 2009; 
b
 Parameswaran, 1999; CI = Confidence Interval; LL = Lower limit; UL = Upper Limit; C or c = Charcoal 
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Table 6.3.9. Statistical comparison of salbutamol urinary excretion between Parts 1 and 2 
studies. 
Parameter 
[nc Vs (+c)] 
Treatment 
Method 
Mean 
paired 
Difference 
95% CI 
t value p value 
Statistical 
Similarity LL UL 
USAL0.5 
Ventolin* 0.43 -0.99 1.85 .661 0.521 Yes 
Evo+VOL 1.53 -2.70 5.76 .789 0.445 Yes 
Evo+AERO 1.01 -4.32 6.34 .412 0.687 Yes 
Evo+ABLE 0.37 -4.13 4.88 .180 0.860 Yes 
USAL24 
Ventolin* 76.19 66.01 86.37 16.309 <0.0001 No 
Evo+VOL 28.42 15.26 41.58 4.705 0.001 No 
Evo+AERO 19.95 1.79 38.11 2.394 0.034 No 
Evo+ABLE 27.74 12.88 42.59 4.068 0.002 No 
USAL24Pre 
Ventolin* 44.05 32.70 55.40 8.458 <0.0001 No 
Evo+VOL 23.83 14.16 33.49 5.373 <0.0001 No 
Evo+AERO 17.45 2.89 32.01 2.612 0.023 No 
Evo+ABLE 26.90 16.93 36.87 5.877 <0.0001 No 
USAL24Post 
Ventolin* 70.47 59.71 81.24 59.71 <0.0001 No 
Evo+VOL 31.19 20.43 41.95 20.43 <0.0001 No 
Evo+AERO 21.07 6.19 35.95 6.19 0.009 No 
Evo+ABLE 27.37 16.39 38.35 16.39 <0.0001 No 
USALMET 
Ventolin* 26.42 17.17 35.68 6.222 <0.0001 No 
Evo+VOL 7.36 0.58 14.14 2.366 0.036 No 
Evo+AERO 3.62 0.46 6.78 2.493 0.028 No 
Evo+ABLE 0.47 -3.71 4.65 .244 0.812 Yes 
* Ventolin Evohaler 
 
 
Figure 6.3.7. Comparison of salbutamol urinary excretion from Ventolin Evohaler treatment 
methods between Parts 1 and 2 studies. 
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Table 6.3.10. In-vitro and in-vivo correlation trends between Evo and Evo+SP performance metrics and salbutamol urinary excretion 
post-inhalation. 
Parameter 
Ventolin* Evo+VOL Evo+AERO Evo+ABLE Trend 
(in decreasing order) µg µg µg µg 
FPD 78.4 78.1 67.5 74.0 Evo > Evo+VOL > Evo+ABLE > Evo+AERO 
%FPF (%TDD) 44.4 82.2 79.2 80.3 Evo+VOL > Evo+ABLE > Evo+AERO > Evo 
S0toF 87.9 89.4 80.3 87.1 Evo+VOL > Evo > Evo+ABLE > Evo+AERO 
USAL0.5NC 5.7 16.4 14.8 14.4 Evo+VOL > Evo+AERO > Evo+ABLE > Evo 
USAL0.5C 5.3 14.8 13.8 14.1 Evo+VOL > Evo+ABLE > Evo+AERO > Evo 
IP+CPM 98.2 16.8 17.9 18.2 Evo > Evo+ABLE > Evo+AERO > Evo+VOL 
IP 88.8 5.5 5.0 5.1 Evo > Evo+VOL > Evo+ABLE > Evo+AERO 
USAL24PreNC 58.4 62.8 57.1 61.9 Evo+VOL > Evo+ABLE > Evo > Evo+AERO 
USAL24PreC 14.3 39.0 39.6 35.0 Evo+AERO > Evo+VOL > Evo+ABLE > Evo 
USAL24PostNC 95.0 85.3 71.9 75.3 Evo > Evo+VOL > Evo+ABLE > Evo+AERO 
USAL24PostC 24.5 54.1 50.8 47.9 Evo+VOL > Evo+AERO > Evo+ABLE > Evo 
TDD (ACI) 176.6 94.9 85.3 92.3 Evo > Evo+VOL > Evo+ABLE > Evo+AERO 
TDD (NC) 160.6 104.3 89.3 95.9 Evo > Evo+VOL > Evo+ABLE > Evo+AERO 
TDD (C) 159.2 104.0 87.8 93.7 Evo > Evo+VOL > Evo+ABLE > Evo+AERO 
USAL24NC 100.7 97.3 84.6 89.7 Evo > Evo+VOL > Evo+ABLE > Evo+AERO 
USAL24C 29.8 68.9 64.6 62.0 Evo+VOL > Evo+AERO > Evo+ABLE > Evo 
* Ventolin Evohaler 
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6.3.5 Discussion 
Bronchodilator MDIs are widely prescribed for respiratory ailments even though many 
patients find it difficult to use them correctly (Levy et al., 2013 & 2016; Sanchis et al. 
2016), and in particular during acute asthma attack. The problem of MDI technique may 
be of greater concern for paediatric and elderly patients. A common issue is poor 
coordination between actuation of the MDI and inhalation of the medication (Crompton, 
1982; Rau, 2006; Al-Showair et al., 2007; Melani et al., 2011; Roche et al., 2013), 
which persists even after training (Crompton et al., 2006). The use of spacers with 
MDIs has been found to ease this coordination difficulty by allowing few seconds after 
inhaler is actuated and the patient starts inhaling (Mitchell and Nagel, 2007; Nikander et 
al., 2014). Compatible spacers, therefore, may potentially improve drug delivery from 
MDIs (Newman, 1991; Chrystyn and Price, 2009; Levy et al., 2013).  
The results of this work indicate that the three spacers used with Evo significantly 
increased lung deposition (USAL0.5NC) as compared to Evo alone; this increase being 
over 2.5-fold (Table 6.3.1). Hence, relative lung bioavailability of Evo was higher with 
the three spacers than Evo alone. This increase in dose delivery with Evo+SP was 
consistent in both legs of the study, i.e., without and with charcoal blockade, 
reaffirming that the urinary excretion of inhaled salbutamol in the first 0.5h originated 
from the proportion of the dose deposited in the lungs.  
The statistical similarity of relative lung bioavailability (USAL0.5NC) between Evo+SP 
treatment methods in Part 1 Study suggests that lung deposition was not affected by 
either the spacer dimension or volume (Table 6.3.1 & Table 6.3.6). This is further 
supported by the results of Part 2 Study for USAL0.5C (Table 6.3.1 & Table 6.3.8). 
In Part 1 Study, total systemic bioavailability (USAL24NC) was statistically similar, 
indicating that the total systemic delivery from either Evo alone or with spacer was not 
affected by the treatment method. This suggests that both methods of treatment may 
have similar pattern of systemic effects.  
In Part 2 Study with charcoal blockade, the significant differences between the 
treatment methods for total systemic bioavailability (USAL24C) indicate a correlation 
existed between USAL0.5C and USAL24C within them; USAL24C amount of Evo 
alone was 5.6 times of USAL0.5C while within Evo+SP, this was 4.4 to 4.7 times.  
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USAL0.5C constituted 18% for Evo alone and 20-22% for Evo+SP of the total systemic 
bioavailability (Table 6.3.4). Interestingly, USAL0.5NC represented 16-19% of 
USAL24NC in Part 1 Study. These findings for Evo+SP in both legs of study suggest 
that major contribution to total systemic bioavailability was derived from the lung 
deposition. The 3-fold difference in USAL0.5 between the two parts of the study 
highlights the smaller contribution of USAL0.5NC to USAL24NC due to GI absorption 
of swallowed proportion of salbutamol. 
In Part 1 Study, USAL24NC of spacer treatment methods was 1.3 to 1.5 folds more 
than that of USAL24C of Part 2 Study and these were significantly different between 
the two parts. USAL24NC represented 42 to 49 % and USAL24C 31 to 35 % of the 
nominal dose (Table 6.3.2 and Table 6.3.4). When normalised for TDD, these values 
were 93 to 94 % and 65 to 73 %, respectively (Table 6.3.9). These results suggest that 
total systemic bioavailability (USAL24) with spacer treatment method had more than 
65% contribution from the lung deposition. This further highlights the dose delivery 
efficiency of the three spacer treatment methods. 
Total systemic bioavailability (USAL24) of spacer treatment methods was statistically 
similar in both legs of the study (Table 6.3.6 and Table 6.3.8). This indicates 
consistency in dose delivery from spacers. This also highlights that the subjects may 
have greater control over inhaling the dispensed dose from Evo when used with any one 
of the three spacers. 
In Part 1 Study, recovery of statistically similar unchanged salbutamol (USAL24PreNC) 
suggests that equivalent pharmacologically active salbutamol was bioavailable for 
continued bronchodilation from Evo alone and with the three spacers (Table 6.3.5). 
However, in Part 2 Study, this was not the case and goes against this hypothesis (Table 
6.3.7). With Evo+SP treatment methods, USAL24PreNC was 1.4 to 1.8 folds more than 
that of USAL24PreC. Further, the former constituted 57 to 69% and the latter 57 to 62% 
of the active salbutamol (Table 6.3.4). On the other hand, USAL24PreC was 1/4
th
 of 
USAL24PreNC for Evo alone and indicates that only 25% of the USAL24PreNC was 
bioavailable for continued relief from the dose deposited in the lungs. Interestingly, 
these amounts of USAL24PreNC and USAL24PreC represented respectively 58% and 
49% of total systemic bioavailability. These findings suggest that with Evo alone, a 
fraction of active salbutamol (USAL24PreNC) may have bypassed enterohepatic 
metabolism and that this may have also entered into systemic circulation from the lungs   
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over 24h post-inhalation (Ward et al., 2000; Chrystyn, 2001). This is evident from 4-
fold higher recovery of USAL24PreNC than USAL24PreC and reflected on recoveries 
of respective metabolites (USALMET) in the two legs of the study. Hence, the apparent 
statistical similarity of the USAL24PreNC of Evo MDI Vs Evo+SP may be misleading 
in terms of their continued equal relief and effectiveness. The inspection of results 
rather suggest that Evo+SP may be more effective in providing relief with inhaled 
salbutamol spread over the dosing interval. However, this should be understood with 
caution since the efficacy indicators such as FEV1 do not show further improvement 
after achieving endpoint and increasing salbutamol dose may not change the plateau, 
i.e., after achieving minimum effective dose, further improvement in spirometry may 
not be observed. Nevertheless, USAL24Pre has been measured over 0.5 to 24 hour post-
inhalation, hence it can be safely assumed that there may have been a prolonged 
presence of active salbutamol in the lungs for continued relief. 
Chege and Chrystyn (1994) reported the use of VOL with Ventolin CFC and generic 
salbutamol MDI (Baker Norton, UK) employing 4 puffs of 100 µg each. They found 
that these two treatment methods delivered similar amounts of drug to the lungs and the 
total systemic absorption was the same. The results of current work for Evo+SP in both 
legs of study are consistent with their findings. Their reported amounts of USAL0.5 and 
USAL24 for Ventolin CFC attached to VOL were 5.3% and 28.7% of the nominal dose. 
The respective amounts reported in this thesis for Evo+VOL are however higher by 
factors of 1.5 and 1.7 to theirs.  
Silkstone et al. (2002a) reported the amounts for USAL0.5 of 12.6 µg and 27.1 µg for 
Ventolin CFC alone and attached to VOL for 5 puffs which are equivalent of 2.5% and 
5.4% of the nominal dose. Their respective USAL24 amounts were 287.0 µg and 198.1 
µg which are equivalent of 57.4% and 39.6% of the nominal dose. The USAL0.5 
amounts when normalised for the dose available for inhalation were equivalent to 2.9% 
and 9.2%, respectively, for the two treatment methods. The normalised values of 
USAL24 for these treatments were 64.9% and 67.7%, respectively. The corresponding 
USAL0.5 normalised values for Evo alone and Evo+VOL reported in this thesis are 
3.6% and 16% and show respective ratios of 1.24 and 1.74 to their results. These results 
suggest that relative lung delivery of Ventolin Evohaler was better than that of Ventolin 
CFC with both treatment methods. Also, normalised values for USAL24 reported in the 
present work are 62.7% and 93% for the two treatment methods which have ratios of 
0.97 and 1.38 to theirs. Total systemic absorption of Evo and Ventolin CFC is similar   
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while it is higher for Evo+VOL. Silkstone and colleagues showed that Ventolin CFC 
attached to VOL improved lung deposition by a factor of 2.3 compared with the MDI 
alone. The results in this thesis show this increase in lung deposition with Evo+VOL to 
be by a factor of 2.9 compared to Evo alone. This increase is much larger than a factor 
of 1.2 reported by Hindle and Chrystyn (1994) for Ventolin CFC attached to VOL. 
These researchers reported USAL0.5 for Ventolin CFC alone and with VOL of 2.8% 
and 3.4% of the nominal dose. The USAL0.5 values as % nominal dose reported in this 
thesis for Evo alone are similar while Evo+VOL value is greater than Ventolin CFC 
attached to VOL by a factor of 2.4.  
The three spacers significantly reduced the systemic availability of the dose; VOL, 
AERO and ABLE spacers retained 37.3%, 44.8% and 42.9% of the dispensed dose. 
This dose retention in spacers is reflective of their volumes and similar to those reported 
in this thesis for in-vitro studies (Table 6.2.2 & Table 6.2.13; Section 6.2.7.2). The dose 
remained in VOL found in the present study is lower than 54.7% and 40.6% reported 
respectively by Hindle and Chrystyn (1994) and Silkstone et al. (2002a) for Ventolin 
CFC attached to VOL. 
6.3.5.1 In-vitro in-vivo correlation trends 
FPD was similar between Evo alone and when attached with VOL and ABLE while 
with AERO it was significantly higher. This trend was however not translated into 
similar pattern of relative lung deposition (USAL0.5) in both legs of study (Table 
6.3.10). The USAL0.5 of Evo alone was ~40% of Evo+SP. On the other hand, a broadly 
similar trend in USAL0.5 was observed with Evo+SP and mimicked their respective 
FPD.  
Total systemic availability (USAL24NC) showed a similar trend that reflected on both 
in-vitro TDD into ACI and in-vivo total dose available for inhalation. Interestingly, in 
Part 2 Study with charcoal blockade, USAL24C amounts of Evo alone and Evo+SP 
approximated respectively to IP and SP+IP depositions thereby providing an estimate of 
salbutamol amounts which may have been swallowed and prevented from GI 
absorption. The ratios of FPD to USAL24C were 2.63, 1.13, 1.04 and 1.19 for Evo, 
Evo+VOL, Evo+AERO and Evo+ABLE, respectively. This reinforces that with 
charcoal blockade of GI absorption, total systemic bioavailability of salbutamol from 
these treatment methods was from the dose deposited in the lungs. This is reflected in  
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corresponding similar ratios of USAL0.5C to USAL24C of 0.18, 0.21, 0.21 and 0.23 for 
these treatment methods. 
In-vitro and in-vivo relationship was more convincing within spacer treatment methods 
(Table 6.3.10). The trend in amounts of FPD (Evo+VOL > Evo+ABLE > Evo+AERO) 
and relative lung deposition (USAL0.5NC) was broadly similar (Evo+VOL > 
Evo+AERO ≥ Evo+ABLE) in the 1st leg of study given that mean USAL0.5NC from 
the latter two spacers differed by 0.4 µg only. However, USAL0.5C in the 2
nd
 leg (with 
charcoal blockade) showed the same trend as that of FPD. Total delivered dose into 
cascade impactor (TDD (ACI)) and dose available for inhalation (TDD (NC)) in the 1
st
 
leg of study translated into the total systemic bioavailability (USAL24NC) and this 
trend was same as that of FPD. Deposition in IP (throat) and impactor plates (S0toF) 
also reflected on USAL24PreNC, USAL24PostNC and USAL24NC with the same FPD 
trend. It is interesting to note that FPM (stages 3, 4 & 5 deposition) followed the same 
trend of FPD while the trend with EPM (stages 6, 7 & filter deposition) and CPM 
(stages 0, 1 & 2 deposition) was different (Table 6.2.4). Given that S0toF mimicked 
FPD trend, it can be concluded that individual stage group may not reflect on in-vivo 
bioavailability. This is because CPM and EPM form smaller proportions of S0toF and 
their comparative effects on predicting in-vivo bioavailability may not be significant. 
These findings therefore reveal that in-vitro FPD may be a determining factor in 
predicting the in-vivo trends between spacers that are attached to Ventolin Evohaler.  
Regulatory limits for the bioequivalence of formulations are that the 90% confidence 
limits should be between 0.80–1.25 for Cmax and AUC (EMA, 2009). Applying these 
limits to the results of current study show that relative lung delivery of Ventolin 
Evohaler (Evo) alone was not in-vivo equivalent to any of the three spacers attached to 
it. However, total systemic delivery was in-vivo equivalent between Evo Vs Evo+VOL 
only. Nevertheless, it has been suggested that when comparing relative potencies of 
inhaled products these limits should be between 0.67 and 1.50 (Parameswaran, 1999). 
Application of these limits to the urinary salbutamol excretions in the first 30-min post-
dose (USAL0.5) suggested that there was a trend for the relative lung deposition and 
systemic delivery of salbutamol from a Ventolin Evohaler to be similar when it was 
attached to Volumatic, AeroChamber Plus and Able spacer. This cautious conclusion is 
made due to the small number of volunteers studied (n=13); much larger numbers of 
subjects may need to be studied to make firmer conclusions. This comment would apply 
for all studies that have been shown to suggest comparability between inhaled products.   
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Most of the studies that were included in a meta-analysis comparing different inhalation 
methods also used a low number of subjects (Brocklebank et al., 2001), and were 
designed to show equivalence. Nevertheless, EMA (2010) recommends a minimum 
number of 12 evaluable subjects for any bioequivalence study. The urinary salbutamol 
pharmacokinetic method has been shown to be more sensitive to detect a difference in 
relative lung deposition than the methacholine challenge method recommended by 
Regulatory Authorities (Tomlinson et al., 2003). Furthermore, healthy volunteers 
participated in the current study and it may be that those with asthma may have different 
airway deposition. However, it has been shown that the only difference between 
volunteers and those with asthma is that lung deposition is related to airway calibre 
(Lipworth and Clark, 1997). 
The larger relative bioavailability to the body (described by the USAL24 amounts) for 
the MDI method compared with that of the spacers was due to the larger emitted dose. 
Also, a larger proportion of the emitted dose will have been swallowed compared with 
when the MDI was attached to a spacer. The similar values for the 24h urinary excretion 
for the three spacers suggested that the amounts swallowed following inhalation of 
these methods was similar. 
When a dose is discharged into a spacer, impaction of the particles onto its walls will 
increase as the size of the spacer decreases. This is because the velocity effects of the 
emitted plume will be greater. This is confirmed by the smaller emitted dose from the 
AeroChamber Plus (135 mL internal capacity) and the Able spacer (143 mL) compared 
with the Volumatic (820 mL). Also, despite the minimal delay between dose discharge 
into the spacer and inhalation, the larger volume of the Volumatic would result in more 
evaporation of the aerosolized dose. This contributed to a smaller particle size. These all 
combined to provide a dose that was emitted from the Volumatic that had a higher fine 
particle dose and smaller MMAD compared with the AeroChamber Plus and the Able 
spacer. These in-vitro parameters translated to the observed small (but insignificant) 
differences in the relative lung and systemic bioavailability of the three spacers. This 
observation provided further evidence of in-vitro and in-vivo correlations in line with 
previous suggestions (Silkstone et al., 2002c; Barry and O’Callaghan, 2003; de Matas et 
al., 2008). However, when this comparison was extended to the MDI alone with the 
spacers the link was not so clear. For example, the fine particle dose and MMAD of the 
MDI alone and the Volumatic were very similar yet the relative lung deposition was 
not. This highlights the value of inhaling from a static cloud, which occurs when using a   
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spacer, and suggests that comparisons that attempt to find a link between in-vitro and 
in-vivo data should consider the inhalation method and technique used. The higher 
emitted dose for the MDI compared with that of the spacers did translate into more drug 
being delivered to the systemic circulation (via the pulmonary and the gastrointestinal 
routes, with the latter predominating for the MDI). 
The greater relative lung bioavailability of salbutamol for the MDI attached to a spacer 
compared with the MDI alone was consistent with previous reports of the corresponding 
CFC formulation attached to a spacer (Newman et al., 1991; Silkstone et al., 2002a). In 
contrast, Lipworth and Clark (1998) have shown that when using Airomir MDI, the 
relative lung deposition was greater when attached to a Volumatic compared with the 
AeroChamber, and that the latter was similar to the MDI used alone. This Airomir study 
did not present any in-vitro data to help understand the results and 12 doses were 
inhaled for each study dose. The effect of multiple dosing, each separated by 30 
seconds, on the aerodynamics of the emitted dose was not addressed. The formulation 
of Airomir is different from Ventolin Evohaler, the main difference being that Airomir 
contains ethanol and so the emitted dose is slower and the aerosol is warmer than that of 
Ventolin Evohaler (Gabrio et al., 1999; Hautmann et al., 2013; Kunda et al., 2017). The 
difference in relative lung deposition of Airomir with large and small spacers (Lipworth 
and Clark, 1998) compared with contrasting results of the current study with Ventolin 
Evohaler pinpoint that each MDI product needs to be evaluated with different spacers 
before claims of interchangeability are made. 
6.3.6 Conclusion 
The results of this study highlight that a Ventolin Evohaler could be used with a 
Volumatic large volume spacer, an AeroChamber Plus or Able spacer without any 
difference in the relative lung and systemic delivery. This suggests that during routine 
use there should be no difference in the relative efficacy and safety if one of these 
spacers is substituted for the other when used with the Ventolin Evohaler. These results 
cannot be extrapolated to other inhalers and thus each formulation needs to be evaluated 
before a general claim of interchangeability can be made. 
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7 Chapter 7: In-Vitro and In-Vivo Equivalence of Airomir 
Without and With AeroChamber Plus 
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7.1 Overview 
Salbutamol MDI is widely prescribed. Many patients use their MDIs correctly, and 
many do not, or cannot. Patients who cannot master inhaler technique will benefit from 
using a spacer with the MDI which makes inhaler easier to use. 
Spacer use with an MDI can reduce problems relating to mismatch of actuation–
inhalation coordination. A spacer slows the delivery of medication and can hold the 
discharged aerosol for 2-3 seconds, thereby easing coordination problems and allowing 
time for the patient to inhale slowly. In-vitro studies suggests that a spacer can reduce 
the impact of poorly coordinated inhalation manoeuvres (Barry and O’Callaghan, 1997; 
Lavorini and Fontana, 2009; Nikander et al., 2014) and even if this is completely 
mistimed (Foss and Keppel, 1999). Its use may also potentially improve the lung 
deposition of aerosolised medication as compared to MDI alone. Using gamma 
scintigraphy, Roller et al. (2007) have shown that use of a spacer with an MDI can 
result in favourable lung deposition, regardless of whether the patient performs a 
recommended breathing manoeuvre (slow inhalation followed by breath hold) or 
inhales in tidal breaths.  
There is a lack of studies that use clinically relevant doses of Airomir alone and when 
used with a spacer. AeroChamber Plus is the recommended spacer for use with Airomir 
(Teva, 2016; PIL). Hence, the in-vitro and in-vivo performance of the two treatment 
methods was assessed and reported in this chapter in separate sections. 
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7.2 In-Vitro Equivalence of Airomir Without and With AeroChamber 
Plus-Aerodynamic Particle size Characterisation 
The objectives of this study are to: 
d) determine APSD of Airomir without and with AeroChamber Plus using ACI  
e) investigate in-vitro equivalence between Airomir alone and with AeroChamber 
Plus.  
7.2.1 Materials and Methods 
7.2.1.1 Materials and Equipments 
See Chapter 3 (Section 3.3.1.1). 
7.2.1.2 Test MDI 
Airomir™ (Airo). 
7.2.1.3 Test Spacer 
Aerochmaber Plus™ (AERO) (Figure 3.3.1). 
7.2.2 Study Design 
Protocols 3.3.1 and 3.3.2 (Sections 3.3.2.3 & 3.3.2.4) describe pharmacopoeia 
compliant study design of APSD investigations (BP, 2005; USP28-NF23, 2005; Ph. 
Eur., 2011) (see Chapter 3). In short, one puff of primed Airomir was discharged into 
ACI operated at a flow rate of 28.3 L/min for 8.5 seconds to allow 4 L of air to pass 
through it. The second puff was similarly discharged after 30 seconds. This procedure 
was repeated with AeroChamber Plus. The two treatment methods were chosen at 
random. AERO was pre-treated with lukewarm soapy water and drip dried after a water 
rinse (Section 2.4). Salbutamol was recovered from the MDI device, spacer and ACI 
components and stages, and quantified using a validated HPLC method (Chapter 4). 
7.2.3 Deposition Profiles, CQAs and Data Analysis  
The data for critical performance metrics, APSD profiles and spacer deposition were 
analysed as per pharmacopoeial requirements and regulatory guidelines, and described 
in Chapter 3 Methodology (Section 3.3.3). 
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7.2.4 APSD and ACI Stage Grouping  
See Chapter 3 (Section 3.3.4). 
7.2.5 Statistical Analysis 
 See Chapter 3 (Section 3.3.5). 
7.2.6 Results: In-Vitro Equivalence of Airomir Without and With AeroChamber 
Plus 
The mean amount (n=5) of salbutamol deposited on Airomir device, AERO and ACI 
are shown in Table 7.2.1. Their individual run data is provided in Appendices 5.2.3.2 
and 7.2.6.1. The mass balance and TED of both treatment methods was, respectively, 
within 3% (RSD ≤1.8) and 25% (RSD ≤2.5) of labelled metered dose. TDD (ex-spacer) 
was also consistent and precise (RSD ≤3.2). Hence, APSD results of Airomir alone and 
with AERO are valid, accurate and precise (Christopher et al., 2003). 
Figure 7.2.1 and Figure 7.2.2 respectively show deposition profiles of complete APSD 
and cumulative particle size for Airomir alone and with AERO. Figure 7.2.3 and Figure 
7.2.4 show comparative deposition of their CQAs and stage groups, respectively. 
Summaries of dose delivery metrics and their percentages are given in Table 7.2.2 and 
Table 7.2.3. FPD, stage group and aerodynamic characteristics and their percentages are 
summarised in Table 7.2.4 to Table 7.2.7. Data on dose delivery efficiencies of the two 
treatment methods is shown in Table 7.2.8. In-vitro equivalence assessment and 
statistical comparisons of CQAs are provided in Table 7.2.9 to Table 7.2.11. 
TED (ex-actuator) of Airo Vs Airo+AERO was in-vitro equivalent albeit with a 
statistically significant difference (Table 7.2.2 & Table 7.2.9; Figure 7.2.3). TDD was 
neither statistically similar nor in-vitro equivalent as TDD (=TED) of Airomir was 
significantly more than that of Airo+AERO.  
IP deposition of Airomir alone and with AERO was significantly different and in-vitro 
inequivalent (Table 7.2.2 & Table 7.2.11; Figure 7.2.3). These respectively constituted 
~40% and ≤ 3% of their TED (Table 7.2.3). Also, the combined AERO+IP deposition 
was slightly more than that of IP deposition of Airomir alone. These depositions were 
42% and 40% of TED, respectively, and were in-vitro equivalent despite being   
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statistically significantly different. IP+CPM deposition (non-respirable fraction) with 
Airomir alone was 5.5 times more than that of Airo+AERO (Table 7.2.2) and 
represented 3.5-fold higher proportion of TDD (Table 7.2.3). However, SP+IP+CPM 
deposition (non-respirable fraction) of Airo+AERO was ~3 µg more than IP+CPM 
deposition of Airomir alone (ratio 1.04).  
S0toF deposition was similar and in-vitro equivalent between the two treatment 
methods (Table 7.2.2 & Table 7.2.9; Figure 7.2.3). Also, S0toF as %TED was in-vitro 
equivalent albeit having a marginal statistical difference (Table 7.2.3). Nevertheless, 
S0toF as %TDD was both statistically significantly different and in-vitro inequivalent.  
 
Table 7.2.1. APSD of Airomir alone and with AeroChamber Plus. 
Identity 
Airomir Airo+AERO 
µg SD RSD µg SD RSD 
MDI Canister Valve 19.6 2.7 13.8 14.3 1.4 9.5 
MDI Actuator 21.0 1.9 9.1 19.7 1.1 5.6 
Spacer - - - 70.8 2.6 3.7 
ACI Throat 69.7 2.1 3.0 4.9 0.5 10.9 
ACI S-0 3.5 0.8 24.3 2.1 0.2 9.7 
ACI S-1 4.0 1.1 27.5 1.6 0.3 18.1 
ACI S-2 5.8 1.4 23.7 6.5 0.8 12.7 
ACI S-3 25.1 3.4 13.5 19.7 2.3 11.9 
ACI S-4 35.7 1.8 4.9 40.0 3.1 7.8 
ACI S-5 21.0 1.4 6.8 23.4 3.2 13.8 
ACI S-6 5.2 0.5 8.7 7.5 1.4 18.7 
ACI S-7 2.0 0.0 1.5 2.2 0.3 13.3 
ACI Filter 2.3 0.4 17.8 2.0 0.3 15.4 
Total Recovery (µg) 214.9 3.4 1.6 214.7 4.1 1.9 
% Recovery
a
 107.5 1.7 1.6 107.3 2.1 1.9 
Mass Balance
b
 (µg) 195.3 3.5 1.8 200.3 3.4 1.7 
% Recovery  97.7 1.8 1.8 100.2 1.7 1.7 
TED
c
 (µg) 174.3 1.7 1.0 180.6 4.4 2.4 
% TED 87.2 0.8 1.0 90.3 2.2 2.4 
TDD
d
 (µg) 
   
109.8 3.4 3.1 
% TDD 
   
54.9 1.7 3.1 
a = % Recovery calculated with respect to Nominal Dose (ND), i.e., two actuations of 100 µg per puff 
b = Mass Balance = Ex-Canister Valve recovery. Recovery calculated with respect to Nominal Dose 
(ND) excluding deposition on Canister Valve but including deposition on Actuator (mouth piece). 
c = TED (Total Emitted Dose Ex-Actuator); Recovery calculated with respect to Nominal Dose (ND) 
excluding deposition on Canister Valve and Actuator (mouth piece). 
d = TDD (Total Delivered Dose Ex-Spacer); Recovery calculated with respect to Nominal Dose (ND) 
and excludes deposition on Canister Valve, Actuator (mouth piece) and spacer. 
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Figure 7.2.1. Complete mean APSD profiles of Airomir alone and with 
AeroChamber Plus. 
Actu = Actuator; AERO = AeroChamber Plus; S = Stage of ACI 
 
 
 
Figure 7.2.2. Mean percent cumulative particle size deposition profiles of Airomir 
alone and with AeroChamber Plus. 
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Figure 7.2.3. Dose delivery characteristics of Airomir alone and with AeroChamber Plus. 
 
 
Figure 7.2.4. Stage group deposition of Airomir alone and with 
AeroChamber Plus. 
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FPD and FPM were slightly more for Airo+ AERO than those of Airomir alone and 
were statistically similar and in-vitro equivalent (Table 7.2.4, Table 7.2.9 & Table 
7.2.11; Figure 7.2.3 and Figure 7.2.4 ). However, these CQAs constituted 86% and 76% 
of TDD of Airo+AERO, respectively, as compared to 52% and 47% of the MDI alone; 
these differences being >1.6-fold between the two treatment methods (Table 7.2.6). The 
fraction of FPD in TDD was therefore statistically different and in-vitro inequivalent 
(Table 7.2.9). Nevertheless, FPD as %TED (ex-actuator) was statistically similar and in-
vitro equivalent and highlights the consistency in MDI performance.  
CPM was in-vitro inequivalent despite being statistically similar between Airomir and 
Airo+AERO (Table 7.2.4 to Table 7.2.7 & Table 7.2.11; Figure 7.2.4). On the other 
hand, EPM was neither in-vitro equivalent nor statistically similar between them.  
More proportion of dose was delivered to ACI as FPD (lung deposition) when Airomir 
was attached to AERO than without it (Table 7.2.8). FPD/IP ratio of Airo+AERO was 
higher than Airomir alone. However, FPD/AERO+IP ratio of Airo+AERO was lower as 
compared to FPD/IP ratio of Airomir alone. Similar trend was observed when FPD was 
compared with IP+CPM (representing oropharyngeal deposition). 
MMAD of Airomir was significantly larger than that of Airo+AERO and was not in-
vitro equivalent (Table 7.2.4 & Table 7.2.10). GSD was however statistically similar 
and in-vitro equivalent between them. 
Summary of Results 
TED (ex-actuator), FPD, FPF (%TED), FPM and GSD were in-vitro equivalent 
between Airomir and Airo+AERO. Moreover, FPD, FPM and GSD were also 
statistically similar. MMAD and GSD were smaller with Airo+AERO as compared to 
Airomir alone. About 39% TED (ex-actuator) was retained in AERO. 
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Table 7.2.2. Dose delivery and deposition in ACI of Airomir alone and with AeroChamber Plus. 
Treatment 
Method 
TED TDD SP IP SP+IP IP+CPM SP+IP+CPM S0toF 
(µg) SD (µg) SD (µg) SD (µg) SD (µg) SD (µg) SD (µg) SD (µg) SD 
Airomir 174.33 1.69 174.33 1.69 - - 69.68 2.10 - - 82.94 1.66 - - 104.65 3.24 
Airo+AERO 180.61 4.38 109.78 3.43 70.82 2.63 4.85 0.53 75.67 2.62 15.07 0.97 85.89 2.77 104.94 3.58 
 
Table 7.2.3. Dose delivery and deposition in ACI as %TED and %TDD of Airomir alone and with AeroChamber Plus. 
Treatment 
Method 
TDD_ED SP_ED IP_ED SP+IP_ED IP+CPM_ED SP+IP+CPM_ED S0toF_ED IP_DD IP+CPM_DD S0toF_DD 
%TED SD %TED SD %TED SD %TED SD %TED SD %TED SD %TED SD %TDD SD %TDD SD %TDD SD 
Airomir 100.0 - - - 39.98 1.4 - - 47.6 0.57 - - 60.0 1.4 39.98 1.4 47.6 0.6 60.0 1.4 
Airo+AERO 60.8 4.5 39.2 1.1 2.7 0.3 41.9 1.29 8.4 0.54 47.6 1.2 58.1 1.2 4.42 0.5 13.7 0.9 95.6 0.5 
ED = TED; DD = TDD 
 
Table 7.2.4. FPD, Stage groups, MMAD and GSD of Airomir alone and with AeroChamber Plus. 
Treatment 
Method 
FPD FPM EPM CPM MMAD GSD 
(µg) SD (µg) SD (µg) SD (µg) SD µm SD 
 
SD 
Airomir 91.38 0.75 81.87 0.89 9.51 0.72 13.27 3.08 2.77 0.13 1.60 0.06 
Airo+AERO 94.72 3.36 83.07 3.18 11.65 1.28 10.22 1.11 2.56 0.06 1.59 0.05 
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Table 7.2.5. FPD and stage groups as %TED of Airomir alone and with AeroChamber Plus. 
Treatment 
Method 
FPF (%) FPM_TED EPM_ED CPM_ED 
%TED SD %TED SD %TED SD %TED SD 
Airomir 52.42 0.57 46.96 0.51 5.46 0.43 7.60 1.71 
Airo+AERO 52.44 1.20 45.99 1.27 6.45 0.67 5.66 0.60 
ED = TED 
 
Table 7.2.6. FPD and stage groups as %TDD of Airomir alone and with AeroChamber Plus. 
Treatment 
Method 
FPF (%) FPM_DD EPM_DD CPM_DD 
%TDD SD %TDD SD %TDD SD %TDD SD 
Airomir 52.42 0.57 46.96 0.51 5.46 0.43 7.60 1.71 
Airo+AERO 86.27 0.90 75.65 0.72 10.62 1.16 9.31 0.99 
DD = TDD 
 
Table 7.2.7. FPD and stage groups as %S0toF of Airomir alone and with AeroChamber Plus. 
Treatment 
Method 
FPD_S0toF FPM_S0toF EPM_S0toF CPM_S0toF 
% S0toF SD % S0toF SD % S0toF SD % S0toF SD 
Airomir 87.38 2.59 78.28 2.22 9.10 0.80 12.62 2.59 
Airo+AERO 90.26 1.01 79.16 0.91 11.11 1.21 9.74 1.01 
S0toF = Impactor mass (Deposition on stages S0-S7+F) 
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Table 7.2.8. FPD and S0toF delivery efficiency of Airomir alone and with AeroChamber Plus. 
Treatment 
Method 
FPD / SP FPD / IP FPD / SP+IP FPD / IP+CPM FPD / SP+IP+CPM S0toF / IP S0toF / SP+IP 
Ratio SD Ratio SD Ratio SD Ratio SD Ratio SD Ratio SD Ratio SD 
Airomir - - 1.31 0.04 - - 1.10 0.03 - - 1.50 0.09 - - 
Airo+AERO 1.34 0.07 19.74 2.55 1.25 0.06 6.31 0.48 1.10 0.05 21.88 2.88 1.39 0.07 
 
 
Table 7.2.9. In-Vitro Equivalence and Statistical Significance of CQAs of Airomir alone and with AeroChamber Plus. 
Airomir Vs 
Airo+AERO 
Parameter 
Mean 
Ratio 
90% CI 
p value 
In-Vitro 
Equivalence 
(0.85-1.18) 
Mean 
Difference 
(µg) 
95% CI 
p value 
Statistical 
Similarity LL UL LL UL 
TED 1.04 1.01 1.06 0.017 Yes 3.14 0.72 5.56 0.017 No 
TDD 0.63 0.61 0.65 <0.0001 No -32.27 -34.24 -30.30 <0.0001 No 
FPD 1.04 1.01 1.07 0.062 Yes 1.67 -0.11 3.44 0.062 Yes 
FPF (%TED) 1.00 0.98 1.02 0.989 Yes 0.02 -1.35 1.39 0.977 Yes 
FPF (%TDD) 1.65 1.63 1.67 <0.0001 No 33.85 32.75 34.95 <0.0001 No 
S0toF 1.00 0.97 1.04 0.901 Yes 0.14 -2.34 2.63 0.897 Yes 
S0toF (%TED) 0.97 0.94 0.99 0.050 Yes -1.93 -3.84 -0.01 0.049 No* 
S0toF (%TDD) 1.59 1.56 1.63 <0.0001 No 35.55 33.99 37.12 <0.0001 No 
*Marginally significant; CQA = Critical Quality Attribute; CI = Confidence Interval; LL = Lower limit; UL = Upper Limit 
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Table 7.2.10. In-Vitro Equivalence and Statistical Significance of MMAD and GSD of Airomir alone and with AeroChamber Plus. 
Airomir Vs 
Airo+AERO 
Parameter 
Mean 
Ratio 
90% CI 
p value 
In-Vitro 
Equivalence 
(0.85-1.18) 
Mean 
Difference 
95% CI 
p value 
Statistical 
Similarity LL UL LL UL 
MMAD (µm) 0.87 0.82 0.92 0.001 No -0.21 -0.35 -0.07 0.009 No 
GSD 0.92 0.88 0.95 0.003 Yes -0.01 -0.09 0.07 0.839 Yes 
 
 
Table 7.2.11. In-Vitro Equivalence and Statistical Significance of IP and Stage Groups of Airomir alone and with AeroChamber Plus. 
Airomir Vs 
Airo+AERO 
Parameter 
Mean 
Ratio 
90% CI 
p value 
In-Vitro 
Equivalence 
(0.85-1.18) 
Mean 
Difference 
(µg) 
95% CI 
p value 
Statistical 
Similarity LL UL LL UL 
SP+IP* 1.09 1.05 1.13 0.004 Yes 3.00 1.26 4.73 0.004 No 
IP (Throat) 0.07 0.06 0.08 <0.0001 No -32.41 -33.53 -31.30 <0.0001 No 
Group 1 (CPM) 0.79 0.63 0.98 0.080 No -1.52 -3.21 0.16 0.071 Yes 
Group 2 (FPM) 1.01 0.98 1.05 0.451 Yes 0.60 -1.10 2.30 0.439 Yes 
Group 3 (EPM) 1.22 1.09 1.37 0.011 No 1.07 0.31 1.83 0.012 No 
*(Spacer + Throat) (MDI SP+IP = IP) 
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7.2.7 Discussion: In-Vitro Equivalence Studies of Airomir Without and With 
AeroChamber Plus 
AeroChamber Plus (AERO) is named spacer for use with Airomir as and when required 
(Teva, 2014). TED of Airo+AERO was 3.6% (3 µg per puff) more than that of Airomir 
alone. Although this difference between the two treatment methods was statistically 
significant, yet both were in-vitro equivalent. However, with Airo+AERO, 61% of TED 
was delivered into ACI while 39% of TED was retained within AERO. Hence, there 
was a significant difference in TDD between them which was also manifest in their in-
vitro inequivalence. 
Mitchell et al. (1999) and Ross and Gabrio (1999) have reported TDD of 64.2 µg and 
74.4 µg (calculated from FPF) when Airomir was used with AeroChamber (a 
predecessor of AERO). These TDDs are higher than that of current study by 9.3 µg 
(ratio 1.17) and 19.5 µg (ratio 1.36), respectively. Further, the TDD of Ross and Gabrio 
was 10.2 µg greater than that of Mitchell et al. (ratio 1.16). These investigators however 
used 20 and 5 puffs of Airomir, respectively.  
The likelihood of electrostatic forces in retaining Airomir dose in AERO is not being 
ruled out. However, since AERO was pre-treated with mild detergent to dissipate such 
forces (Table 2.4.2), it is assumed that the presence of these electrostatic forces was 
minimal (Dewsbury et al., 1996; Kwok et al., 2006) and may have existed at a similar 
level irrespective of the material used in their manufacture (Chuffart et al., 2001; 
Coppolo et al., 2006). Further, detergent treatment does not eliminate all charge on the 
spacer and a minimum ground charge is inherently present (Dewsbury et al, 1996; 
Kwok et al., 2006; Prabhakaran et al., 2012). 
It is reported that the emitted salbutamol sulphate particles acquire charge due to 
frictions with the device components and actuator surfaces (Noakes, 2004; Kwoke et al., 
2006; Mitchell and Nagel, 2007). In the presence of a minimum residual charge on the 
spacer internal surfaces, it is likely that some electrostatic interaction would take place 
and removes and/or deflects aerosol particles from the mainstream. It has been shown 
that the aerosol cloud of salbutamol suspension MDI contains large particles, droplets 
and multiplets (droplets containing multiple drug particles) immediately after emission 
(Sheth et al., 2015) and that the presence of ethanol slows down their   
 193 
evaporation and dispersion due to its relatively slower evaporating speed than the HFA 
propellants (Barry and O’Calaghan, 1997; Ross and Gabrio, 1999; Stein and Myrdal, 
2006). It has also been shown that the diameter of Proventil HFA (US equivalent of 
Airomir) plume was larger in the immediate vicinity of actuator (Hautmann et al., 2013; 
Johnson et al., 2016; Kunda et al., 2017). Citing Hinds (1982), Coppolo et al. (2006) 
reported that the charge acquired by field, and also partly by diffusion, increases as a 
strong function of particle size within the range of 0.4–10 µm aerodynamic diameter. 
Coppolo et al. elaborated that this phenomenon may increase electrical mobility of 
larger particles, and therefore likelihood of their electrostatic capture on the interior 
surfaces of the spacer will be greater. Hence, when large numbers of puffs are used 
sequentially and are fired separately into the spacer, the emitted particles of the initial 
puffs would interact with the residual charge on the un-primed spacer surface more than 
those released by the later puffs; the magnitude of this particle interaction would be 
particle size dependent. This would therefore influence the total amount of drug leaving 
the spacer which may alter lung deposition (Mitchell and Nagel, 2007). 
Priming the interior surfaces of a spacer with several puffs of the medication has been 
found to increase whole lung deposition (Kenyon et al., 1998; Rau et al., 2006). 
Accordingly, studies employing numerous doses further reduce the electrostatic charge 
on a spacer (Terzano, 2001). Wilkes et al. (2001) used 5 puffs of salbutamol MDI to 
prime the internal surfaces of spacers to reduce the electrostatic charge while Berg et al. 
(1998) used 15 actuations for inhaled corticosteroids (ICS). Australian Asthma 
Handbook (v1.2) suggests that in hospitals and emergency departments, a new spacer 
can be primed using multiple (at least 10) puffs of salbutamol. The GINA guidelines 
(2017) recommend using at least 20 puffs into a new unwashed chamber before delivery 
of a rescue dose. Given that Airomir contains oleic acid, which is a surfactant, the effect 
of several doses may be more pronounced. Since clinically relevant 2 puffs of Airomir 
were used in the current study, this antistatic priming effect may be lacking and explains 
the differences in TDD found with the studies by Mitchell et al. (1999) and Ross and 
Gabrio (1999). Regression analysis of the number of puffs and TDD of these two 
studies along with the current study revealed a linear relationship between these metrics 
(R
2
=0.888; y = 0.953x + 55.92), highlighting that TDD increased with increasing the 
number of Airomir puffs. Hence, it is clear that the differences in TDD between these 
studies were due to the higher number of puffs used by these investigators. On another  
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note, the TDD results of the current study are more reflective on the actual use scenario 
of AERO by the patients.  
AERO significantly reduced IP deposition by 93% (65 µg). This difference in IP 
deposition between the two treatment methods was 37% of TED (ex-actuator). 
Although 14 times more non-respirable dose was deposited in IP with Airomir alone 
than Airo+AERO, yet combined AERO+IP deposition of Airo+AERO was 6 µg (ratio 
1.09) more than IP deposition of the MDI alone (Table 7.2.2). Higher combined 
AERO+IP deposition was also noted with Ventolin Evohaler (3.4 µg; ratio 1.08) and 
Salamol (4.3 µg; ratio 1.11) when compared with their respective IP depositions of MDI 
alone (Table 6.2.2 & Table 7.2.2, respectively). These findings confirm that spacers 
remove the ballistic portion of the dispensed dose that would otherwise impact on the 
throat and oral cavity (Table 2.5.2). This may have clinical implications for systemic 
effects that may be caused by oropharyngeal deposition and consequent GI absorption 
when the MDI is used alone. 
Further, non-respirable dose of Airo+AERO (AERO+IP+CPM) was 1.04 times more 
than that of Airomir alone (IP+CPM). Similar trend was observed between the two 
treatment methods when respirable dose (FPD) was compared with non-respirable dose 
(IP+CPM and AERO+IP+CPM) (Table 7.2.8). The results show that AERO retained 
more of the non-respirable dose while produced lesser CPM than Airomir alone. 
Additionally, AERO reduced significant proportion of TED without affecting APSD 
profile of Airomir. This would reflect on the efficacy of the two treatment methods. 
Impactor mass of Airo+AERO as %TDD was 96% which was 1.6-fold more than that 
of 60% with Airomir alone (Table 7.2.3). This is also reflected in their respective ratios 
of S0toF to IP deposition of 21.9 and 1.5, indicating that salbutamol delivery to S0toF 
was 15-fold more efficient with Airo+AERO than the MDI alone (Table 7.2.8). This 
finding from derived data implies that drug delivery to the human respiratory tract 
(HRT) would be better with the spacer (Airo+AERO) treatment method. However, 
comparison of the ratios of S0toF to AERO+IP for Airo+AERO (1.39) to that of S0toF 
to IP of Airomir alone suggests otherwise and indicates that both treatment methods will 
have similar dose delivery to the HRT. This is consistent with findings that statistically 
similar and in-vitro equivalent impactor mass (S0toF) was recovered with both 
treatment methods. Also, comparison of lung to throat (FPD/IP & FPD/AERO+IP) and 
respirable to non-respirable (FPD/IP+CPM & FPD/AERO+IP+CPM) fractions of the   
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two treatment methods reveal similar respective trends between them. Again, this would 
imply a better FPD delivery with Airo+AERO which was, however, only 1.7 µg (per 
actuation) more than that of MDI alone (ratio 1.04). Interestingly, FPD of the two 
treatment methods was statistically similar and in-vitro equivalent (Table 7.2.9). In 
contrast, Mitchell et al. (1999) and Ross and Gabrio (1999) reported significantly higher 
FPD when Airomir was used with AeroChamber than the MDI alone in their studies; 
this difference was 23 µg (ratio 1.60) and 14.7 µg (ratio 1.30), respectively. These 
investigators however used 5 and 20 puffs of Airomir, respectively. Again, a linear 
correlation was found when TDD was compared with FPD of these studies with the 
current study (R
2
=0.837; y = 0.866x + 2.060). As discussed earlier, these differences are 
related to the number of puffs used which showed a ratcheting effect on spacer dose 
delivery output and consequently on FPD. Hence, the results of studies which use many 
puffs can be misleading and can have clinical ramifications. 
Mitchell et al. (1999) and Ross and Gabrio (1999) reported FPD of 62 µg and 64.5 µg, 
respectively with the spacer treatment method which are significantly higher than that 
found with the current study having respective ratios of 1.31 and 1.36. , their FPD of the 
MDI alone are 38.7 µg and 49.8 µg having ratios of 0.85 and 1.09, respectively, to the 
FPD of the current study which lies between this range. Further, FPD of Airomir 
reported by Barry and O’Calaghan (1997), Dubus et al. (2001) and Johnson et al. (2016) 
are 37.2 µg (10 Puffs), 54.1 µg (5 puffs) and 40.1 µg (6 puffs) and their respective ratios 
to the current FPD are 0.81, 1.18 (< 5.8 µm) and 0.88. The analyses of these results 
further substantiate that use of several Airomir puffs with the detergent treated 
AeroChamber proportionally increased FPD in the in-vitro studies. It is known that 
spacers improve FPD delivery (Newman and Newhouse, 1996; Newman, 2004); 
however, this improvement should be shown in the clinically relevant dose. The results 
of current study confirm FPD improvement in clinically relevant dose of Airomir when 
used with AERO.  
The results of the current study show that FPF as %TED was similar and in-vitro 
equivalent between Airomir alone and when used with AERO. AERO retained most of 
large particle mass and emitted dose leaving it contained ~86% of FPF as %TDD. 
However, even with these advantages, it is known that use of a spacer cannot entirely 
obviate the need for coordination and a delay can reduce the amount of drug available to 
inhalation (Barry and O’Callaghan, 1997; Rau, 2006; Mitchell and Nagel, 2007; Slator 
et al., 2014; Liu et al., 2017). The analyses of actual and derived data   
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indicate that delivery of salbutamol to the lungs from Airo+AERO may be more 
efficient, however, not better than that from Airomir alone. Patient preference and 
compliance studies have revealed that they do not always adhere to using spacer with 
the MDI medication (Laube et al., 2011; Levy et al., 2016). The findings of the current 
study suggest that patients would still have equal benefits from Airomir alone because 
the FPD is similar and provided that they are able to inhale correctly. Further, Airomir 
may be a better choice for patients who could master inhalation technique and can 
tolerate systemic effects. Nevertheless, this assessment applies only to AERO. 
FPM (3–5 µm) deposition represents the mass which is more likely to deposit in bronchi 
and bronchioles (Pritchard, 2001). FPM was in-vitro equivalent and statistically similar 
between Airomir alone and Airo+AERO. Although FPM of Airo+AERO was only 1.2 
µg more than that of Airomir alone, these constituted 77% and 47% of TDD, 
respectively. However, their contribution to impactor mass (S0toF) was about similar at 
79% and 78%, respectively (Table 7.2.7). Significantly greater and in-vitro inequivalent 
EPM was delivered with Airo+AERO than Airomir alone and formed 11% and 9% of 
their respective S0toF. This is consistent with the benefits of using a spacer which 
allows the emitted aerosol more space and time to form finer particles (Lavorini and 
Fontana, 2009; Laube et al., 2011). Higher EPM may also contribute to systemic 
effects. Nevertheless, EPM differs by only 2 µg between the two treatment methods and 
therefore may not be of clinical significance despite being 18% in magnitude. CPM 
(Group 1 stages, > 5 µm) was however statistically similar though not in-vitro 
equivalent between the two treatment methods. CPM of Airomir alone was 3 µg more 
than that of Airo+AERO and constituted 13% and 10% of their respective S0toF. This is 
expected, however, the small difference is perhaps surprising even though the 
magnitude of this difference is paradoxically 23%. Although salbutamol dose in particle 
size of 6 µm (S2 deposition) has shown bronchodilation (Usmani et al., 2003), whether 
this small difference in CPM amounts can have any clinical significance would be 
difficult to identify. Nonetheless, the use of derived data may lead to inherently 
incorrect conclusions and decisions (also see Section 6.2.7.5). Since derived data at 
times has a tendency to inflate the results, in particular for smaller amounts, regulatory 
authorities have always asked for the raw data (actual results).  
MMAD highlights the midpoint of APSD while GSD shows the dispersion around this 
MMAD. Significantly higher MMAD was obtained with Airomir alone as compared to 
Airo+AERO (Table 7.2.4 & Table 7.2.10). Airomir contains co-solvent ethanol and   
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surfactant oleic acid, and therefore produces slow and longer lasting puff (Barry and 
O’Calaghan, 1997; Ross and Gabrio, 1999; Hautmann et al., 2013; Johnson et al., 
2016). It can be hypothesized that when a puff of Airomir is discharged into AERO, the 
propellant and co-solvent have enough space and time to evaporate and form fine 
particles before being carried away into ACI with airflow with a higher proportion of 
finer particles. This is evident from the relatively higher EPM and lower CPM for 
Airo+AERO than Airomir alone (Table 7.2.4); their respective EPM and CPM ratios 
were 1.23 and 0.77 while FPD/CPM ratios being 9.3 and 6.9. It is therefore likely that 
higher proportion of CPM found with Airomir alone may have additionally contributed 
to larger MMAD and GSD. Nevertheless, these MDI performance metrics lie in the 
desired size range required for relieving bronchospasm. Given that FPD and FPM of the 
two treatment methods were in-vitro equivalent and statistically similar, these 
differences in MMAD and GSD are unlikely to affect clinical outcome. 
7.2.8 Conclusions: In-Vitro Equivalence of Airomir Without and With AERO 
1. The data suggests that Airomir can be used without AERO, provided that patients 
are skilful in inhalation manoeuvres. 
2. AERO has shown to be a compatible add-on device with Airomir; depicting similar 
impactor mass profiles and generating in-vitro equivalent FPD while significantly 
reducing IP deposition. This could be beneficial to those patients with press-and-
breathe coordination difficulties and those hypersensitive to known side effects of 
salbutamol. 
3. Finer MMAD and GSD were obtained with Airo+AERO than Airomir alone. 
Higher CPM found with MDI alone may have impacted MMAD size.  
4. Raw quantitative data should be used to make comparative assessment of MDI 
performance metrics. Derived data needs to be assessed within the overall context. 
5. Findings of this study apply only to Airomir and AERO and cannot be extended to 
other MDIs and spacers. 
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7.3 In-Vivo Equivalence of Airomir Without and With AeroChamber 
Plus-Urinary Pharmacokinetic Studies 
MDIs require coordination of press and breathe manoeuvres by patient to ensure 
effective drug delivery to the lungs (Crompton, 1982; Chapman et al., 1993; Crompton 
et al., 2006). Poor inhalation technique can decrease pulmonary deposition (Newman et 
al., 1991b), increase oropharyngeal deposition and reduce therapeutic effect (Lindgren 
et al., 1987; Chapman et al., 1993). The use of spacer can minimise these phenomena 
(Newman, 2004; Lavorini and Fontana, 2009). 
Accordingly, the objectives of this study are to investigate the effects of AeroChamber 
Plus on the relative lung and total systemic bioavailability of Airomir in healthy 
subjects using urinary pharmacokinetic method (Hindle and Chrystyn, 1992). A 
charcoal blockade study is also conducted to estimate salbutamol lung deposition from 
Airomir alone and when used with AeroChamber Plus. 
7.3.1 Study Design 
The Study plan is elaborated in Sections 5.3.1 (Chapter 5) and 6.3.1 (Chapter 6). 
In short, this study comprised of two parts, each part with two sub-sets involving two 
methods of salbutamol inhalation, vis-à-vis: Airomir alone (Airo) and with 
AeroChamber Plus (Airo+AERO). In Part 1 Study, on separate study day (one week 
apart) trained healthy subjects inhaled two separate 100 µg doses of salbutamol from 
one of these treatment methods selected randomly. Each dose discharged from primed 
Airo or into pre-washed AERO (see Protocols 3.3.1 & 3.3.2 (Sections 3.3.2.3 & 3.3.2.4; 
Chapter 3)) was inhaled using a slow vital capacity inhalation manoeuvre (Hindle et al., 
1993). Each single dose discharged into AERO was inhaled within the first second of 
discharge into the spacer. All subjects provided their blank urine 0.5h pre-dosing. Urine 
samples were then collected 0.5h after the start of each study dose (USAL0.5) and 
thereafter subjects pooled all their urine over the next 24h into a container (USAL24). 
In Part 2 Study, each subject repeated this study with the concurrent administration of 
activated charcoal by swallowing 100 mL of charcoal slurry immediately before and 
after two inhalations. 
The pH and volume of each sample was recorded and samples were stored at –20◦C 
before analysis. The pH values of the urine samples were all below pH 7, hence there 
was no variability due to passive tubular reabsorption (Hindle and Chrystyn, 1992).   
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After inhalation of the two study doses each spacer was rinsed with water to collect the 
residual dose. 
7.3.2 Sample Analysis 
Aqueous and urine samples were assayed for their salbutamol content using validated 
HPLC methods described in Chapter 4. 
7.3.3 Statistical Analysis 
See Section 3.4.7 (Chapter 3). 
7.3.4 Results: In-Vivo Equivalence of Airomir Without and With AeroChamber 
Plus 
Demographic characteristics of volunteers are given in Table 5.3.1 & Appendix 5.3.4.1. 
Summaries of USAL0.5 and USAL24 amounts post-dose (without and with charcoal 
blockade) are provided in Table 7.3.1 and Figure 7.3.1 to Figure 7.3.5. These table and 
figures also show salbutamol as active (USAL24Pre), active and sulphate conjugated 
(USAL24Post) and metabolised (USALMET) moieties excreted during 0.5h to 24h 
period. Comparative salbutamol urinary recovery profiles obtained post-inhalation 
without and with charcoal blockade are shown in Figure 7.3.6. Mean salbutamol urinary 
excretions as % nominal, % delivered and % recovered dose are given in Table 7.3.2 to 
Table 7.3.4. Urinary excretion data of individual subjects for Airomir is given in 
Appendices 5.3.4.3 and 5.3.4.6. Appendices 7.3.4.1 and 7.4.3.2 provide individual data 
for Airo+AERO for both legs of the study. Table 7.3.5 provides data on in-vivo 
equivalence and comparative bioavailability of the two inhaled salbutamol treatment 
methods for both parts of the study.  
In Part 1 Study, relative lung bioavailability (USAL0.5NC) of Airomir attached to 
AERO was significantly greater than the MDI alone and was not in-vivo equivalent 
(Table 7.3.1 & Table 7.3.5). The amount of USAL0.5NC of Airo+AERO was more than 
twice that of Airo alone. However, total systemic bioavailability (USAL24NC) between 
them was in-vivo equivalent as per EMA (2009) criteria and statistically similar. The 
excretion of active salbutamol (USAL24PreNC) and its metabolites (USALMETnc) 
were not in-vivo equivalent while total salbutamol (USAL24PostNC) met this criterion. 
Further, USAL24PreNC and USAL24PostNC were in-vivo equivalent as per limits   
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suggested by Parameswaran (1999). Nonetheless, bioavailability of only 
USAL24PostNC was statistically similar.  
In Part 2 Study with charcoal blockade, none of these PK parameters were in-vivo 
equivalent between Airo and Airo+AERO as per EMA (2009) criteria (Table 7.3.1 & 
Table 7.3.5). However, their total systemic bioavailability (and also USAL24PostC) 
was in-vivo equivalent as per Parameswaran (1999) criteria. Moreover, the 
bioavailability of only USAL24PostC and USALMETc was statistically similar 
between them. The USAL0.5C amount of Airo+AERO was greater than Airo alone by a 
factor of 2.2. 
The charcoal block effect is compared in Table 7.3.6 and Figure 7.3.7. Data reveals 
significant differences between these parameters except for USAL0.5 which was 
statistically bioequivalent between the two legs of the study.  
 
Table 7.3.1. Mean salbutamol excretion in urine post-inhalation from Airomir without and 
with AeroChamber Plus. 
Treatment 
Method 
(n = 13) 
USAL0.5 USAL24† USAL24Pre USAL24Post USALMET 
µg SD µg SD µg SD µg SD µg SD 
Part 1 Study (without charcoal blockade) 
Airomir 7.1 2.1 84.2 13.1 47.4 7.6 77.1 12.7 29.8 8.3 
Airo+AERO 15.1 4.2 83.9 8.1 56.9 6.6 68.8 5.4 11.9 4.7 
Part 2 Study (with charcoal blockade) 
Airomir 6.7 2.2 48.5 11.9 29.7 9.0 41.8 10.8 12.2 3.9 
Airo+AERO 14.3 4.0 62.3 11.1 39.2 7.8 48.0 8.2 8.7 4.2 
† TRD = USAL24; SD = Standard Deviation 
 
Table 7.3.2. Mean salbutamol excretion in urine post-inhalation from Airomir without and 
with AeroChamber Plus, expressed as % of Nominal Dose. 
Treatment 
Method 
(n = 13) 
USAL0.5 USAL24† USAL24Pre USAL24Post USALMET 
% SD % SD % SD % SD % SD 
Part 1 Study (without charcoal blockade) 
Airomir 3.6 1.0 42.1 6.5 23.7 3.8 38.6 6.4 14.9 4.2 
Airo+AERO 7.5 2.1 42.0 4.0 28.5 3.3 34.4 2.7 6.0 2.4 
Part 2 Study (with charcoal blockade) 
Airomir 3.3 1.1 24.3 5.9 14.8 4.5 20.9 5.4 6.1 1.9 
Airo+AERO 7.1 2.0 31.1 5.5 19.6 3.9 24.0 4.1 4.4 2.1 
† TRD = USAL24; SD = Standard Deviation 
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Table 7.3.3. Mean salbutamol excretion in urine post-inhalation from Airomir without and 
with AeroChamber Plus, expressed as % of Delivered Dose. 
Treatment 
Method 
(n = 13) 
USAL0.5 USAL24† USAL24Pre USAL24Post USALMET 
% SD % SD % SD % SD % SD 
Part 1 Study (without charcoal blockade) 
Airomir 4.0 1.1 47.7 7.5 26.8 4.4 43.7 7.3 16.8 4.7 
Airo+AERO 14.9 3.7 83.4 5.4 56.6 5.0 68.5 3.9 11.9 4.7 
Part 2 Study (with charcoal blockade) 
Airomir 3.8 1.3 27.6 6.9 16.9 5.2 23.8 6.2 6.9 2.2 
Airo+AERO 14.2 4.3 61.7 12.0 38.9 8.5 47.5 8.7 8.6 4.0 
† TRD = USAL24; SD = Standard Deviation 
 
Table 7.3.4. Mean salbutamol excretion in urine post-inhalation from Airomir without and 
with AeroChamber Plus, expressed as % of Recovered Dose. 
Treatment 
Method 
(n = 13) 
USAL0.5 USAL24† USAL24Pre USAL24Post USALMET 
% SD % SD % SD % SD % SD 
Part 1 Study (without charcoal blockade) 
Airomir 8.5 2.3 - - 56.5 6.2 91.5 2.3 35.0 6.4 
Airo+AERO 17.8 3.7 - - 67.8 3.8 82.2 3.7 14.4 6.0 
Part 2 Study (with charcoal blockade) 
Airomir 14.0 4.0 - - 60.5 6.2 86.0 4.0 25.5 6.9 
Airo+AERO 22.8 3.7 - - 63.0 4.6 77.2 3.7 14.3 6.9 
† TRD = USAL24; SD = Standard Deviation 
 
 
Figure 7.3.1. Comparative salbutamol urinary excretion at 0.5h post-inhalation of Airomir without and 
with AeroChamber Plus. 
Numerals represent individual volunteers. nc = no charcoal ingestion; +c = with charcoal ingestion. 
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Figure 7.3.2. Comparative total salbutamol urinary excretion during 24h post-inhalation of Airomir 
without and with AeroChamber Plus. 
 
 
 
Figure 7.3.3. Comparative unchanged salbutamol urinary excretion during 0.5-24h post-inhalation of 
Airomir without and with AeroChamber Plus. 
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Figure 7.3.4. Comparative total salbutamol urinary excretion during 0.5-24h post-inhalation of 
Airomir without and with AeroChamber Plus. 
 
 
 
Figure 7.3.5. Comparative salbutamol metabolites urinary excretion during 0.5-24h post-inhalation of 
Airomir without and with AeroChamber Plus. 
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Figure 7.3.6. Comparative salbutamol urinary recovery profiles obtained post-inhalation of 
Airomir without and with AeroChamber Plus. 
Numerals represent individual volunteers. nc = no charcoal ingestion; +c = with charcoal 
ingestion. 
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Table 7.3.5. In-Vivo Equivalence and Statistical Significance of Airomir without and with AeroChamber Plus. 
Parameter 
Mean 
Ratio 
90% CI 
p value 
In-Vivo Equivalence Mean 
Difference 
(µg) 
95% CI 
p value 
Statistical 
Similarity LL UL 0.80-1.25
a
 0.67-1.50
b
 LL UL 
Airo+AERO Vs Airomir: Part 1 Study (without charcoal blockade) 
USAL0.5NC 2.12 1.72 2.61 <0.0001 No No 7.98 5.04 10.91 <0.0001 No 
USAL24NC 1.00 0.91 1.11 0.950 Yes Yes -0.29 -10.72 10.14 0.953 Yes 
USAL24PreNC 1.21 1.08 1.36 0.013 No Yes 9.59 2.47 16.71 0.013 No 
USAL24PostNC 0.90 0.81 1.00 0.098 Yes Yes -8.27 -17.66 1.12 0.079 Yes 
USALMETnc 0.39 0.31 0.49 <0.0001 No No -17.86 -23.74 -11.97 <0.0001 No 
Airo+AERO Vs Airomir: Part 2 Study (with charcoal blockade) 
USAL0.5C 2.16: 1.92 2.43 <0.0001 No No 7.61 5.91 9.31 <0.0001 No 
USAL24C 1.30 1.16 1.47 0.002 No Yes 13.76 7.15 20.37 0.001 No 
USAL24PreC 1.36 1.17 1.59 0.004 No No 9.60 4.08 15.11 0.003 No 
USAL24PostC 1.17 1.02 1.35 0.071 No Yes 6.15 -0.44 12.74 0.065 Yes 
USALMETc 0.70 0.54 0.90 0.027 No No -3.45 -6.93 0.03 0.052 Yes 
a
 EMA, 2009; 
b
 Parameswaran, 1999; CI = Confidence Interval; LL = Lower limit; UL = Upper Limit 
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Table 7.3.6. Statistical comparison of salbutamol post-inhalation urinary excretion between Part 
1 and Part 2 studies of Airomir without and with AeroChamber Plus. 
Parameter 
[nc Vs (+c) 
Treatment 
Mean 
paired 
Difference 
95% CI 
t value p value 
Statistical 
Similarity LL UL 
USAL0.5 
Airomir 0.44 -0.56 1.43 0.957 0.358 Yes 
Airo+AERO 0.80 -2.94 4.54 0.467 0.649 Yes 
USAL24 
Airomir 35.71 28.67 42.74 11.058 <0.0001 No 
Airo+AERO 21.66 12.30 31.01 5.045 <0.0001 No 
USAL24Pre 
Airomir 17.71 13.16 22.25 8.483 <0.0001 No 
Airo+AERO 17.70 11.11 24.28 5.856 <0.0001 No 
USAL24Post 
Airomir 35.27 28.49 42.05 11.332 <0.0001 No 
Airo+AERO 20.86 14.83 26.89 7.536 <0.0001 No 
USALMET 
Airomir 17.57 12.29 22.84 7.257 <0.0001 No 
Airo+AERO 3.16 1.49 4.83 4.118 0.001 No 
CI = Confidence Interval; LL = Lower limit; UL = Upper Limit 
 
 
 
 
Figure 7.3.7. Comparison of salbutamol post-inhalation urinary excretion of Airomir without 
and with AeroChamber Plus between Part 1 and Part 2 studies. 
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7.3.5 Discussion: In-Vivo Equivalence of Airomir Without and With 
AeroChamber Plus 
Part 1 Study revealed that AeroChamber Plus used with Airomir significantly increased 
relative lung deposition (USAL0.5NC); this increase being ≥2-fold (Table 7.3.1 ). The 
two treatment methods therefore did not meet the EMA (2009) in-vivo equivalence 
criterion for USAL0.5NC (Table 7.3.5). These findings may have implications for 
efficacy. 
On the other hand, total systemic bioavailability (USAL24NC) was statistically similar 
and bioequivalent, indicating that the total systemic delivery from either Airomir alone 
or with AERO was not affected by the treatment method. This suggests that both 
treatment methods may have similar pattern of systemic effects. This is perhaps 
surprising given that AERO retained a large proportion of the dispensed dose (40% ND; 
44% TED) that would otherwise additionally contribute to systemic effects via GI 
absorption. However, significantly greater active salbutamol was excreted in the first 
0.5h and during 0.5-24h (USAL24PreNC) post-inhalation of Airo+AERO, suggesting 
that the two treatment methods may have similar systemic effects. This is further 
supported by the findings that USAL24PreNC formed 29% and 68% of ND and TRD, 
respectively, for Airo+AERO as compared to corresponding 24% and 57% for Airomir 
alone (Table 7.3.2 & Table 7.3.4). Nevertheless, it has been shown that the side effects 
from cumulative doses of 100 to 4000 µg of salbutamol MDI were well tolerated and 
infrequent in asthmatics (Lipworth et al., 1988b). Hence, it is unlikely that a total 
systemic exposure of 84 µg over 24 hours (USAL24NC) may be of concern.  
In Part 2 Study with charcoal blockade, the increase in Airomir dose delivery to the 
lungs with AERO as compared to the MDI alone was similar to that in the first leg of 
the study, i.e., without charcoal blockade. This reaffirms that the urinary excretion of 
inhaled salbutamol in the first 0.5h was mainly derived from the proportion of the dose 
deposited in the lungs. This is reflected in the significant differences in total systemic 
bioavailability (USAL24C) of the two treatment methods (Table 7.3.1 and Table 7.3.5). 
The ratio of USAL24C to USAL24NC suggests that ~58% and ~74% of total systemic 
bioavailability of Airomir and Airo+AERO, respectively, was from their lung 
deposition (Table 7.3.1). For Airomir, USAL24C was ~28% of the total delivered dose 
as compared to ~48% of USAL24NC suggesting that ~20% of the delivered dose may 
have been swallowed (Table 7.3.3). For Airo+AERO, these figures were   
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respectively ≤62%, ≥83% and ~22%. Similarity of swallowed proportion of inhaled 
salbutamol from the two treatment methods suggest that charcoal block was consistent. 
This also shows that when Airomir is used with AERO, relatively lesser amount of the 
dispensed dose is swallowed. Further, the ratio of the active salbutamol excretion over 
0.5-24h post-inhalation (USAL24PreC Vs USAL24PreNC) as %TDD shows that ~63% 
and 68% was derived from the lung deposition of the two respective treatment methods 
(Table 7.3.3). Also, USAL24PreNC and USAL24PreC, respectively, constituted ~57% 
and ~61% of the total systemic bioavailability for Airomir alone and ~68% and ~63% 
for Airo+AERO (Table 7.3.4). These results suggest that higher lung deposition of 
Airomir with AERO in 0.5h post inhalation resulted in higher active salbutamol over 
0.5-24h post-inhalation as is evident from the charcoal blockade of the GI 
absorption.The metabolised salbutamol (USALMETc) recovery in Part 2 Study was 
statistically similar between the two treatment methods (Table 7.3.5). However, 
USALMETnc was 2.5-fold more with Airomir alone than Airo+AERO in Part 1 Study 
(Table 7.3.1). This finding reflects on higher proportion of swallowed salbutamol that 
undergoes consequent enterohepatic metabolism and is consistent with the role of 
spacers in reducing the swallowed proportion of the inhaled salbutamol. Interestingly, 
the proportion of metabolised salbutamol in total systemic bioavailability (USAL24) 
was the same at 14% for Airo+AERO in both legs of the study (Table 7.3.4) and 
highlights consistency in Airomir dose delivery when used with AERO. This finding 
also reflects on the similarity of swallowed portion of salbutamol from the two 
treatment methods as mentioned above. 
The current study shows that lung deposition was increased when AERO was attached 
to Airo as compared to the MDI alone. This finding reaffirms that spacer improve lung 
depositions while reducing total systemic bioavailability (Newman et al., 1991a). This 
is consistent with previous reports for Ventolin CFC (Hindle and Chrystyn, 1994), 
Ventolin Evohaler (Mazhar and Chrystyn, 2008), Intal MDI (sodium cromoglycate) 
(Aswania et al., 1999), Cromogen MDI (sodium cromoglycate) (Aswania and Chrystyn, 
2001) and Bricanyl MDI (terbutaline) (Abdelrahim, 2009). In contrast, a study using 
plasma salbutamol as a surrogate marker of lung deposition found no significant 
difference between AeroChamber attached to Airomir and when the MDI was used 
alone even though plasma salbutamol peak (Cmax) and average (Cav) were higher with 
the spacer treatment method (Lipworth and Clark, 1998). AeroChamber is the earlier   
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version of AeroChamber Plus and has relatively smaller volume (145 mL) than that of 
the latter (149 mL). These investigators, however, did not elaborate on as to how much 
dose remained in AeroChamber and the dose that was available for inhalation. 
Electrostatic charge on a static spacer can significantly reduce dose delivery of an MDI 
by electrostatistically pulling away emitted particles of the aerosol cloud from the 
mainstream (Mitchell and Nagel, 2007; Nikander et al., 2014). However, pre-washing a 
spacer with detergent liquid minimises this interaction (Section 2.4). Since 
AeroChamber was not subjected to such pre-treatment in their study, it is likely that a 
larger proportion of the emitted dose may have been retained in it due to electrostatic 
forces on the spacer walls with consequences in low dose available for inhalation. This 
may have masked the differences in plasma salbutamol pharmacokinetics of the two 
treatment methods. In a later study by the same group (Fowler et al., 2001), 
AeroChamber was prewashed with detergent and primed with 50 puffs. This resulted in 
increase in Cmax and Cav which was 1.48-fold (32%) and 1.42-fold (30%) greater than 
those of the MDI alone. This is in line with the result of current study. 
The results show that the total systemic bioavailability of Airomir alone and when used 
with AERO was similar and bioequivalent (Table 7.3.1Table 7.3.1 & Table 7.3.5). This 
finding is consistent with the results of Ventolin Evohaler used alone and when attached 
to AERO (Mazhar and Chrystyn, 2008; Table 6.3.9). These results apparently may look 
contradicting given that larger proportion of dose (88% of ND) was available for 
inhalation when Airomir was used alone as compared to when used with AERO (50% 
of ND). However, in Part 2 Study with charcoal blockade (Table 7.3.1 to Table 7.3.5), 
the total systemic bioavailability (USAL24C) of Airomir alone was significantly lower 
than that of Airo+AERO, constituting 24% and 31% of the nominal dose respectively, 
despite being bioequivalent as per limits suggested by Parameswaran (1999). It is 
therefore clear that this difference in total systemic bioavailability is due the significant 
and bio-inequivalent differences in their relative lung deposition (USAL0.5C). With the 
coadministration of activated charcoal, the GI absorption of swallowed portion of 
Airomir dose was prevented and consequently USAL24C originated from USAL0.5C. 
Since USAL0.5C of Airomir was less than half of Airo+AERO, this was reflected in its 
relatively lower USAL24C. Further, USAL0.5 as % of TRD reflected on the urinary 
excretion of active salbutamol over 0.5-24h (USAL24Pre) of the two treatment methods 
in both legs of the study, suggesting that higher lung deposition resulted in higher 
systemic bioavailability of active salbutamol. Hence, it can be concluded that   
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statistically similar and bioequivalent total systemic bioavailability in Part 1 Study was 
due to significantly greater lung deposition from Airo+AERO.  
USAL24Pre in both legs of study broadly reflect on the trend (Airo+AERO > Airo) of 
in-vitro deposition on the impactor plates (S0toF) (Airo+AERO ≥ Airo), the latter 
mimics the dose delivery to the respiratory tract (Table 3.3.2; Figure 2.3.1). This is in 
line with the significantly smaller IP (throat) deposition with Airo+AERO and shows 
that the non-respirable fraction of the emitted dose was removed by AERO. The ratios 
of FPD/IP were 1.3 and 19.7 for Airo and Airo+AERO respectively and highlight the 
significantly greater in-vitro dose delivery efficiency of the latter treatment method. In 
Part 2 Study, USAL24C also followed this trend reconciling to the above assertion that 
in the presence of charcoal blockade of GI absorption, salbutamol entered systemic 
circulation via the lung route. This is substantiated by significantly higher in-vitro FPF 
of 52% and 86% of these treatment methods, respectively. However, this trend was 
marginally reversed with USAL24NC in Part 1 Study (Airo ≥ Airo+AERO). 
Nevertheless, both USAL24NC and S0toF were statistically similar and equivalent 
between the two treatment methods in their respective in-vivo and in-vitro studies. 
The FPD and FPF of the dispensed dose represent the respirable amount and fraction 
that can reach the lungs which account for the amount excreted 0.5h post-inhalation 
(USAL0.5). The in-vitro finding that Airo+AERO was more efficient than Airo alone in 
delivering the FPD is reflected in higher relative lung bioavailability (USAL0.5) with 
the former albeit with a smaller magnitude (Table 7.2.8 & Table 7.3.1). The increase in 
FPD could not reach statistical significance while the increase in USAL0.5NC did 
achieve this level between the two treatment methods (Table 7.2.9 & Table 7.3.5). 
However, %FPF (%TDD) of Airo+AERO was 1.7-fold greater than that of MDI alone 
(Table 7.2.6) and mirrors the 2.1-fold greater USAL0.5NC (Table 7.3.1) and its fraction 
in the total systemic recovery (USAL24NC) (Table 7.3.4). This is consistent with the 
in-vitro higher FPD delivery efficiency with Airo+AERO (Table 7.2.8). The ratio of 
respirable (FPD) to non-respirable (IP+CPM) dose with Airo+AERO was 5.7-fold 
greater than that of MDI alone which is greater than the ratio of USAL0.5NC between 
the two treatment methods.  
The large improvement in the relative lung deposition with Airo+AERO over Airo 
alone has been obtained in subjects who have been trained and demonstrated good  
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inhalation technique. Besides, the inhalation manoeuvre was completed within 30 
seconds of an actuation. However, many patients do not inhale correctly (Molimard et 
al., 2003; Brennan et al., 2005; Crompton et al., 2006; Chrystyn and Price, 2009; Laube 
et al., 2011; Levy et al., 2013 & 2016; Aggarwal and Gogtay, 2014; Bonini and Usmani 
2015; Sanchis et al., 2016), and this has been observed even after training (Hardwel et 
al., 2009). Liu et al. (2017) have recently reported a significant difference between in-
vitro TED, FPD, FPF for Proventil HFA (USA equivalent of Airomir) without and with 
AERO. They also reported that for Proventil+AERO, these MDI performance metrics 
were significantly influenced by patient handling and compliance parameters mimicked 
by inhalation delay between actuation and inhalation, and variable inhalation flow rates. 
Given that relative lung bioavailability (USAL0.5) of Airomir with AERO was 2-fold 
greater than the MDI alone, this could compensate for the small errors in inhalation 
manoeuvres without adversely affecting the effective lung dose.  
Gunawardena et al. (1997) compared the efficacy of 2 puffs (100 µg each) of 
salbutamol CFC MDI (Baker Norton, UK) administered to asthmatics using two types 
of spacers. They found that the lowest available salbutamol dose was 50 µg and that the 
dose response (measured as FEV1, FVC & PEF) tended to be flat above 200 µg. 
However, Clark and Lipworth (1997) found in asthmatics that 400 µg dose represented 
the steep part of the dose-response curve for bronchodilatation and that dose-related 
systemic effects of salbutamol occurred at higher doses (>500 μg). Nevertheless, 
Lipworth and McDevitt (1989) reported that in normal subject airways a plateau in 
bronchodilatation occurs with much lower doses of inhaled salbutamol. Further, 
Fishwick et al. (2001) found no difference in the bronchodilating response to single 
doses of 50, 100, or 400 µg of salbutamol administered via Turbuhaler after either 5 or 
25 min indicating that 50 µg of salbutamol produced a bronchodilation close to the 
maximum administration and that there was no FEV1 dose–response relationship 
associated with single doses of salbutamol within this range. These researchers 
concluded that the inhaled dose from the inhaler devices therefore may be higher than 
that required by most patients with asthma. Given that Airomir is effective and safe at 
the recommended dosage (Dockhorn et al., 1995 & 1997; Bleecker et al., 1998; PIL), 
the greater relative lung bioavailability of Airo+AERO found in the current study would 
be beneficial and may not raise safety concerns even though pharmacodynamics study 
may be required to prove this. 
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Singh et al. (2011) using plasma profiles determined lung bioavailability and total 
systemic exposure of Foster (Chiesi) without and with AERO. They found increased 
peak plasma concentrations (Cmax) and the AUC(0,30 min) of beclomethasone 
dipropionate, its active metabolite beclometasone 17-monopropionate (17-BMP) and 
formoterol with AERO as compared to the MDI alone. The increases in the AUC(0,30 
min), indicative of lung deposition, for 17-BMP and formoterol were 41% and 45% 
respectively, while the total systemic exposure measured as AUC(0,t last) remained the 
same between the two treatment methods. They also evaluated the lung deposition using 
the charcoal blockade without AERO and found that plasma concentrations were not 
influenced by charcoal ingestion, and that systemic exposure to Foster actives was from 
lung absorption. They reported that more than 30% of the inhaled dose of Foster was 
delivered to the lung using the MDI alone after ingestion of charcoal which confirmed 
AUC(0,30 min) as an index of lung bioavailability. Although the contribution of AERO in 
relative lung deposition (USAL0.5) of Airomir is significantly greater than that found 
with Foster, the results of their study in general support the findings of the current 
study.  
7.3.6 Conclusion  
Applying bioequivalence limits suggested by Parameswaran (1999), the results of 
current study show that relative lung delivery of Airomir alone was not in-vivo 
equivalent to when it was attached to AeroChamber Plus. However, total systemic 
delivery was in-vivo equivalent between the two treatment methods. Since 
AeroChamber Plus removed a large proportion of the non-respirable dose and delivered 
more dose to the lungs, therefore it could be used with Airomir. These results are MDI 
and spacer specific and hence cannot be extrapolated to other treatment methods. 
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8 Chapter 8: In-Vitro and In-Vivo Equivalence of Salamol 
Without and With Spacer 
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8.1 Overview 
Salamol HFA is one of the salbutamol MDIs available in the UK. Little is known about 
its in-vitro performance characteristics while in-vivo studies are hard to find. Further, in-
vitro studies complemented with in-vivo studies of Salamol with spacers have not been 
reported to-date. Hence, these studies have been conducted to compare Salamol when 
used alone and with two spacers, vis-à-vis: Volumatic and AeroChamber Plus. 
Volumatic is the recommended spacer for Salamol to overcome issues of inadequate 
inhalation technique (Teva, 2016). AeroChamber Plus is promoted as universal spacer 
and therefore has been included in this study. 
This chapter is structured into separate sections of in-vitro and in-vivo equivalence 
studies on Salamol without and with spacers. 
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8.2 In-Vitro Equivalence of Salamol Without and With Spacer-
Aerodynamic Particle size Characterisation 
The objectives of this study are to: 
a) determine APSD of Salamol without and with spacer using ACI 
b) investigate in-vitro equivalence between Salamol alone and with Volumatic and 
AeroChamber Plus. 
8.2.1 Materials and Methods 
8.2.1.1 Materials and Equipments 
Details are provided in Chapter 3 (Section 3.3.1.1).  
8.2.1.2 Test MDI 
Salamol™ (Sala). 
8.2.1.3 Test Spacers 
Volumatic™ (VOL) and AeroChamber Plus™ (AERO) (Figure 3.3.1). 
8.2.2 Study Design 
Salamol MDI, spacers and ACI equipment were prepared and studies conducted as 
detailed in Protocols 3.3.1 and 3.3.2 (Sections 3.3.2.3 & 3.3.2.4; Chapter 3). In 
summary, two puffs of the primed Salamol were fired into ACI separately with a gap of 
30 seconds. ACI was operated at a flow rate of 28.3 L/min for 8.5 seconds for each puff 
allowing 4 L of air to pass through it. Salbutamol was recovered from the MDI 
components, spacer and ACI assembly, and quantified by HPLC (Chapter 4). 
Each of the three Salamol treatment methods (MDI alone, Sala+VOL and Sala+AERO) 
was selected randomly. The two spacers were pre-treated with lukewarm soapy water, 
rinsed with clean water and drip dried before use (Section 2.4). 
8.2.3 Deposition Profiles, CQAs and Data Analysis 
The details are provided in Chapter 3 (Section 3.3.3). 
8.2.4 APSD and ACI Stage Grouping 
These are defined in Chapter 3 (Section 3.3.4). 
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8.2.5 Statistical Analysis 
Data analysed as described in Chapter 3 (Section 3.3.5). 
8.2.6 Results: In-Vitro Equivalence of Salamol Without and With Spacer 
The recovery of salbutamol from Salamol MDI, spacers and ACI is given in Table 
8.2.1. APSD and cumulative particle size deposition profiles are shown in Figure 8.2.1 
and Figure 8.2.2. Comparison of CQAs is provided in Figure 8.2.3 and Figure 8.2.4. 
Table 8.2.2 to Table 8.2.7 show comparative data on CQAs while Table 8.2.8 provides 
an insight into the dose delivery efficiency of the three treatment methods. Data for 
individual ACI experiments for Salamol, Sala+VOL and Sala+AERO are given in 
Appendices 5.2.3.3, 8.2.6.1 and 8.2.6.2, respectively. 
Table 8.2.1 shows that mass balance and TED of the three treatment methods were 
within 5% (RSD ≤3.0) and 25% (RSD <3.0), respectively, of labelled metered dose. 
Therefore, APSD results are valid, accurate and precise (Christopher et al., 2003). 
The results show that TED (ex-actuator), FPD and FPF (%TED) were in-vitro 
equivalent and statistically similar between the three Salamol treatment methods (Table 
8.2.2, Table 8.2.4 to Table 8.2.6, Table 8.2.8 & Table 8.2.8). TDD of the two spacer 
treatment methods was also in-vitro equivalent and statistically similar between them. 
However, TDD (ex-spacer) was in-vitro inequivalent and statistically significantly 
different from the TDD (=TED ex-actuator) of the MDI. FPF as %TDD was 
significantly higher with VOL (32%) and AERO (40%) than Salamol alone, hence 
resulting in their in-vitro inequivalence. Nevertheless, FPF as %TDD was in-vitro 
equivalent between the two spacer treatment methods albeit having significant statistical 
difference.  
VOL retained ~8.6% less Salamol than AERO (Table 8.2.2 & Table 8.2.3; Figure 
8.2.3). The IP deposition of Salamol MDI alone was significantly more than the two 
spacer treatment methods and this translated into their in-vitro inequivalence (Table 
8.2.11). 
Impactor mass (S0toF) of the three treatment methods was statistically similar and in-
vitro equivalent except that it was not in-vitro equivalent between the MDI and 
Sala+AERO (Table 8.2.9). Further, S0toF as %TED was within 5% of each other   
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(Table 8.2.3). However, when assessed as % TDD, S0toF was over 39% greater with 
the two spacers than the MDI alone. 
 
Table 8.2.1. APSD of Salamol alone and with spacers. 
Identity 
Salamol Sala+VOL Sala+AERO 
µg SD RSD µg SD RSD µg SD RSD 
MDI Canister Valve 20.0 2.2 10.8 7.5 1.1 15.2 12.6 1.4 11.4 
MDI Actuator 28.8 5.3 18.4 19.9 2.1 10.6 21.2 2.0 9.6 
Spacer - - - 77.7 5.7 7.3 84.3 6.9 8.1 
ACI IP (Throat) 80.1 3.1 3.8 5.9 1.3 21.3 4.4 0.5 10.8 
ACI S-0 2.7 0.6 22.4 2.4 0.2 10.4 1.1 0.2 21.1 
ACI S-1 3.8 0.8 21.3 4.5 0.5 11.5 1.4 0.2 17.3 
ACI S-2 4.1 0.5 11.9 6.7 0.8 12.6 2.7 0.5 18.9 
ACI S-3 18.9 2.5 13.4 21.9 2.6 11.8 20.6 5.1 24.6 
ACI S-4 35.8 4.3 12.1 32.7 2.4 7.3 34.2 2.9 8.5 
ACI S-5 24.0 3.8 15.8 19.6 1.6 8.2 21.5 5.1 23.7 
ACI S-6 5.8 1.0 16.9 4.9 1.5 30.6 5.1 1.5 29.9 
ACI S-7 2.3 0.5 21.5 2.1 0.4 19.6 2.0 0.3 14.4 
ACI Filter 2.6 0.8 31.7 2.4 0.1 3.5 2.3 0.3 13.9 
Total Recovery (µg) 228.9 7.4 3.2 208.1 4.8 2.3 213.4 2.3 1.1 
% Recovery
a
 114.4 3.7 3.2 104.1 2.4 2.3 106.7 1.1 1.1 
Mass Balance
b
 (µg) 208.8 6.2 3.0 200.7 3.7 1.8 200.7 2.4 1.2 
% Recovery  104.4 3.1 3.0 100.3 1.9 1.8 100.4 1.2 1.2 
TED
c
 (µg) 180.0 5.2 2.9 180.7 2.3 1.3 179.6 2.8 1.6 
% TED 90.0 2.6 2.9 90.4 1.1 1.3 89.8 1.4 1.6 
TDD
d
 (µg) - - - 103.0 5.1 4.9 95.2 5.6 5.8 
% TDD - - - 51.5 2.5 4.9 47.6 2.8 5.8 
a = % Recovery calculated with respect to Nominal Dose (ND), i.e., two actuations of 100 µg per puff 
b = Mass Balance = Ex-Canister Valve recovery. Recovery calculated with respect to Nominal Dose 
(ND) excluding deposition on Canister Valve but including deposition on Actuator (mouth piece). 
c = TED (Total Emitted Dose Ex-Actuator); Recovery calculated with respect to Nominal Dose (ND) 
excluding deposition on Canister Valve and Actuator (mouth piece). 
d = TDD (Total Delivered Dose Ex-Spacer); Recovery calculated with respect to Nominal Dose (ND) 
and excludes deposition on Canister Valve, Actuator (mouth piece) and spacer. 
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Figure 8.2.1. Complete mean APSD profiles of Salamol alone and with spacers. 
Actu = Actuator; S = Stage of ACI 
 
 
 
 
Figure 8.2.2. Mean percent cumulative particle size deposition profiles of 
Salamol alone and with spacers. 
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Figure 8.2.3. Dose delivery characteristics of Salamol alone and with spacers. 
 
 
 
Figure 8.2.4. Stage group deposition of Salamol alone and with 
spacers. 
 
FPM was statistically similar and in-vitro equivalent between the three treatment 
methods while EPM was only statistically similar (Table 8.2.4 to Table 8.2.6 & Table 
8.2.11; Figure 8.2.4). On the other hand, CPM showed significant differences between 
them and was therefore in-vitro equivalent.  
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The MMAD and GSD were in-vitro equivalent between the three treatment methods 
(Table 8.2.4 & Table 8.2.10). However, statistical similarity was observed only between 
Salamol Vs Sala+AERO for MMAD and between Salamol Vs Sala+VOL for GSD. 
VOL and AERO were 15 and 20 times more efficient than Salamol alone in delivering 
FPD to the impactor (Table 8.2.8; Figure 8.2.3). However, the ratio of FPD to the 
combined deposition of emitted dose in the spacer and IP was relatively smaller than the 
ratio of FPD to IP of the MDI alone. Similar trend was observed when FPD was 
compared with the non-respirable fraction of the TED, i.e., the combined deposition in 
IP+CPM and SP+IP+CPM.  
Summary of Results 
The TED, FPD, FPF (%TED) were statistically similar and in-vitro equivalent between 
the three Salamol treatment methods (MDI alone, Sala+VOL and Sala+AERO). Their 
MMAD and GSD were also in-vitro equivalent. The TDD and FPF (%TDD) were in-
vitro equivalent between the two spacer treatment methods. 
 
Table 8.2.2. Dose delivery and deposition in ACI of Salamol alone and with spacers. 
Treatment 
Method 
TED TDD SP IP SP+IP S0toF 
µg SD µg SD µg SD µg SD µg SD µg SD 
Salamol 180.3 5.2 180.0 5.2 - - 80.1 3.1 - - 99.96 7.1 
Sala+VOL 180.7 2.3 103.1 5.1 77.7 5.7 5.9 1.3 83.6 5.8 97.17 4.9 
Sala+AERO 179.6 2.8 95.2 5.6 84.3 6.9 4.4 0.5 88.7 6.8 90.84 5.7 
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Table 8.2.3. Dose delivery and deposition in ACI as %TED and %TDD of Salamol alone and with spacers. 
Treatment 
Method 
TDD SP IP SP+IP S0toF IP_TDD S0toF_TDD 
%TED SD %TED SD %TED SD %TED SD %TED SD %TDD SD %TDD SD 
Salamol 100.00 - - - 44.52 2.54 - - 55.48 2.54 44.52 2.54 55.48 2.54 
Sala+VOL 57.02 2.94 42.98 2.94 3.25 0.67 46.22 2.93 53.78 2.93 5.70 1.13 94.30 1.13 
Sala+AERO 53.05 3.41 46.95 3.41 2.44 0.28 49.39 3.41 50.61 3.41 4.62 0.63 95.38 0.63 
 
Table 8.2.4. FPD, Stage groups, MMAD and GSD of Salamol alone and with spacers. 
Treatment 
Method 
FPD FPM EPM CPM MMAD GSD 
µg SD µg SD µg SD µg SD µm SD 
 
SD 
Salamol 89.41 6.58 78.71 7.10 10.70 1.74 10.55 1.60 2.56 0.07 1.62 0.05 
Sala+VOL 83.56 4.44 74.18 2.96 9.38 1.87 13.62 1.16 2.76 0.09 1.65 0.05 
Sala+AERO 85.65 5.33 76.29 4.47 9.37 1.96 5.19 0.48 2.54 0.14 1.50 0.05 
 
Table 8.2.5. FPD and stage groups as %TED of Salamol alone and with spacers. 
Treatment 
Method 
FPF (%) FPM_ED EPM_ED CPM_ED 
%TED SD %TED SD %TED SD %TED SD 
Salamol 49.62 2.36 43.67 2.84 5.95 1.05 5.86 0.88 
Sala+VOL 46.24 2.60 41.05 1.66 5.20 1.07 7.54 0.68 
Sala+AERO 47.72 3.19 42.50 2.70 5.22 1.09 2.89 0.29 
ED = TED 
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Table 8.2.6. FPD and stage groups as %TDD of Salamol alone and with spacers. 
Treatment 
Method 
FPF (%) FPM_DD EPM_DD CPM_DD 
%DD SD %DD SD %DD SD %DD SD 
Salamol 49.62 2.36 43.67 2.84 5.95 1.05 5.86 0.88 
Sala+VOL 81.08 1.31 72.02 1.42 9.06 1.44 13.22 1.04 
Sala+AERO 89.94 0.88 80.13 2.14 9.80 1.68 5.45 0.33 
DD = TDD 
 
Table 8.2.7. FPD and stage groups as %S0toF of Salamol alone and with spacers. 
Treatment 
Method 
FPD_S0toF
a
 FPM_S0toF
a
 EPM_S0toF
a
 CPM_S0toF
a
 
% S0toF SD % S0toF SD % S0toF SD % S0toF SD 
Salamol 89.44 1.52 78.70 3.37 10.74 2.02 10.56 1.52 
Sala+VOL 85.98 1.07 76.38 1.82 9.60 1.44 14.02 1.07 
Sala+AERO 94.29 0.37 84.01 2.02 10.28 1.77 5.71 0.37 
a 
S0toF = Impactor mass (deposition on ACI stages S0 to S7 & F) 
 
Table 8.2.8. FPD and S0toF delivery efficiency of Salamol alone and with spacers. 
Treatment 
Method 
FPD / IP FPD / SP+IP FPD / IP+CPM
a
 FPD / SP+IP+CPM
a
 S0toF / IP S0toF / SP+IP 
Ratio SD Ratio SD Ratio SD Ratio SD Ratio SD Ratio SD 
Salamol 1.12 0.12 - - 0.99 0.09 - - 1.25 0.13 - - 
Sala+VOL 14.69 2.94 1.01 0.12 4.31 0.38 0.86 0.09 17.08 3.43 1.17 0.14 
Sala+AERO 19.79 2.93 0.97 0.13 9.00 0.94 0.92 0.12 20.98 3.03 1.03 0.14 
a 
CPM = S0+S1+S2 
  
  
2
2
3
 
Table 8.2.9. In-Vitro Equivalence and Statistical Significance of CQAs of Salamol alone and with spacers. 
Parameter Multiple Comparisons 
Mean 
Ratio 
90% CI 
p value 
In-Vitro 
Equivalence 
(0.85-1.18) 
Mean 
Difference
c
 
95% CI 
p value 
Statistical 
Similarity LL UL LL UL 
TED
a
 
Salamol 
Sala+VOL 0.99 0.96 1.03 1.000 Yes -0.35 -3.56 2.87 1.000 Yes 
Sala+AERO 1.00 0.97 1.03 1.000 Yes 0.23 -2.99 3.46 1.000 Yes 
Sala+VOL Sala+AERO 1.01 0.98 1.04 1.000 Yes 0.59 -2.64 3.81 1.000 Yes 
TDD
b
 
Salamol 
Sala+VOL 1.75 1.63 1.88 <0.0001 No 38.49 33.85 43.13 <0.0001 No 
Sala+AERO 1.89 1.76 2.03 <0.0001 No 42.40 37.76 47.04 <0.0001 No 
Sala+VOL Sala+AERO 1.08 1.01 1.16 0.062 Yes 3.91 -0.73 8.55 0.112 Yes 
FPD 
Salamol 
Sala+VOL 1.07 0.97 1.18 0.375 Yes 2.93 -1.93 7.78 0.359 Yes 
Sala+AERO 1.04 0.95 1.15 0.947 Yes 1.88 -2.98 6.73 0.910 Yes 
Sala+VOL Sala+AERO 0.98 0.89 1.08 1.000 Yes -1.05 -5.90 3.81 1.000 Yes 
% FPF 
(%TED) 
Salamol 
Sala+VOL 1.07 0.98 1.17 0.227 Yes 3.38 -1.44 8.18 0.225 Yes 
Sala+AERO 1.04 0.95 1.14 0.883 Yes 1.90 -2.91 6.71 0.882 Yes 
Sala+VOL Sala+AERO 0.97 0.89 1.06 1.000 Yes -1.48 -6.29 3.33 1.000 Yes 
% FPF 
(%TDD) 
Salamol 
Sala+VOL 0.61 0.58 0.64 <0.0001 No -31.47 -34.35 -28.59 <0.0001 No 
Sala+AERO 0.55 0.53 0.58 <0.0001 No -40.32 -43.20 -37.44 <0.0001 No 
Sala+VOL Sala+AERO 0.90 0.86 0.94 <0.0001 Yes -8.85 -11.73 -5.97 <0.0001 No 
S0toF 
Salamol 
Sala+VOL 1.03 0.94 1.13 1.000 Yes 1.39 -3.85 6.64 1.000 Yes 
Sala+AERO 1.10 1.00 1.21 0.095 No 4.56 -0.69 9.80 0.098 Yes 
Sala+VOL Sala+AERO 1.07 0.97 1.18 0.325 Yes 3.17 -2.08 8.41 0.358 Yes 
CQA = Critical Quality Attribute; 
a
 TED = Ex-Actuator; 
b
 TDD = Dose delivered into ACI Throat (ex-spacer, for MDI TDD = TED); 
c
 µg except for %FPF. 
CI = Confidence Interval; LL = Lower limit; UL = Upper Limit 
  
  
2
2
4
 
 
 
 
 
 
 
Table 8.2.10. In-Vitro Equivalence and Statistical Significance of MMAD and GSD of Salamol alone and with spacers. 
Parameter Multiple Comparisons 
Mean 
Ratio 
90% CI 
p value 
In-Vitro 
Equivalence 
(0.85-1.18) 
Mean 
Difference
a
 
95% CI 
p value 
Statistical 
Similarity LL UL LL UL 
MMAD 
Salamol 
Sala+VOL 0.93 0.87 0.98 0.030 Yes -0.20 -0.38 -0.02 0.027 No 
Sala+AERO 1.01 0.95 1.07 1.000 Yes 0.02 -0.17 0.19 1.000 Yes 
Sala+VOL Sala+AERO 1.09 1.02 1.15 0.018 Yes 0.22 0.04 0.40 0.017 No 
GSD 
Salamol 
Sala+VOL 0.98 0.94 1.03 1.000 Yes -0.03 -0.12 0.06 1.000 Yes 
Sala+AERO 1.08 1.03 1.13 0.004 Yes 0.12 0.04 0.21 0.005 No 
Sala+VOL Sala+AERO 1.10 1.05 1.15 0.001 Yes 0.15 0.07 0.24 0.001 No 
a
 µm for MMAD, no units for GSD; CI = Confidence Interval; LL = Lower limit; UL = Upper Limit 
 
  
  
2
2
5
 
 
Table 8.2.11. In-Vitro Equivalence and Statistical Significance of Stage group deposition of Salamol alone and with spacers. 
Parameter Multiple Comparisons 
Mean 
Ratio 
90% CI 
p value 
In-Vitro 
Equivalence 
(0.85-1.18) 
Mean 
Difference
f
 
95% CI 
p value 
Statistical 
Similarity LL UL LL UL 
SP+IP
a
 
Salamol 
Sala+VOL 0.96 0.87 1.06 0.990 Yes -1.75 -6.56 3.07 1.000 Yes 
Sala+AERO 0.90 0.82 1.00 0.088 No -4.33 -9.14 0.49 0.084 Yes 
Sala+VOL Sala+AERO 0.94 0.85 1.04 0.510 Yes -2.58 -7.40 2.24 0.488 Yes 
IP (Throat) 
Salamol 
Sala+VOL 13.85 11.31 16.97 <0.0001 No 37.10 35.40 38.80 <0.0001 No 
Sala+AERO 18.36 14.99 22.49 <0.0001 No 37.84 36.15 39.54 <0.0001 No 
Sala+VOL Sala+AERO 1.33 1.08 1.62 0.018 No 0.75 -0.95 2.44 0.736 Yes 
Group 1
b, e
 
(CPM) 
Salamol 
Sala+VOL 0.77 0.64 0.92 0.013 No -1.53 -2.57 -0.50 0.004 No 
Sala+AERO 2.02 1.69 2.42 <0.0001 No 2.68 1.65 3.72 <0.0001 No 
Sala+VOL Sala+AERO 2.63 2.19 3.14 <0.0001 No 4.21 3.18 5.25 <0.0001 No 
Group 2
c, e
 
(FPM) 
Salamol 
Sala+VOL 1.06 0.95 1.17 0.637 Yes 2.27 -2.25 6.78 0.564 Yes 
Sala+AERO 1.03 0.93 1.14 1.000 Yes 1.21 -3.30 5.73 1.000 Yes 
Sala+VOL Sala+AERO 0.97 0.88 1.08 1.000 Yes -1.05 -5.57 3.46 1.000 Yes 
Group 3
d, e
 
(EPM) 
Salamol 
Sala+VOL 1.15 0.87 1.51 0.784 No 0.66 -0.98 2.29 0.854 Yes 
Sala+AERO 1.15 0.87 1.51 0.760 No 0.67 -0.97 2.30 0.841 Yes 
Sala+VOL Sala+AERO 1.00 0.76 1.32 1.000 No 0.01 -1.63 1.64 1.000 Yes 
a
 Spacer + Throat (For MDI, SP+IP = IP); 
b
 Group 1 = S0+S1+S2; 
c
 Group 2 = S3+S4+S5; 
d
 Group 3 =S6+S7+Filter; 
e
 See Table 3.3.2 (Chapter 3); 
f
µg. 
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8.2.7 Discussion: In-Vitro Equivalence of Salamol Without and With Spacer 
The CQAs of Salamol (Sala) used alone and with Volumatic (VOL) and AeroChamber 
Plus (AERO) have been discussed separately. 
8.2.7.1 TED, TDD and Deposition in IP and SP+IP 
The TED of the three treatment methods showed statistical similarity and in-vitro 
equivalence. However, the TDD of Salamol was significantly different than that of the 
two spacer treatment methods. This is because TDD = TED for the MDI while TDD 
was 57% and 53% of TED, respectively, for VOL and AERO. Hence, in-vitro 
equivalence was not expected. Both spacers respectively retained 43% and 47% of TED 
which significantly reduced the proportion of emitted dose entering ACI. This in turn 
significantly reduced deposition in IP as compared to the MDI. This IP deposition was 
reduced by 13.6 and 18.3 folds respectively by VOL and AERO, representing 7.3% and 
5.5% of IP deposition observed with Salamol MDI alone. This indicates efficient 
filtration of large particle mass from the emitted dose by the two spacers.  
Deposition in IP was statistically similar only between the two spacer treatment 
methods albeit not being in-vitro equivalent (Table 8.2.11). Interestingly, the combined 
spacer and IP deposition was statistically similar and in-vitro equivalent between the 
three treatment methods, except Salamol Vs Sala+AERO only being in-vitro 
inequivalent. The SP+IP deposition of latter treatment method was slightly higher (~4 
µg) even though statistically similar with the MDI and therefore the difference may not 
be clinically significant. Also, the SP+IP deposition was similar and in-vitro equivalent 
between the two spacer treatment methods. Hence both add-on devices were effective in 
reducing IP deposition. This is important clinically as it may reduce the incidence of 
salbutamol related systemic effects in sensitive patients. 
8.2.7.2 Spacer Volume and Deposition 
VOL and AERO have significantly different internal volumes and dimensions (Table 
6.2.13; Section 6.2.7.2). Although about 4% more TED was retained in AERO than 
VOL, yet TED deposition within them was statistically similar albeit not being in-vitro 
equivalent. Besides, TDD from both of them was in-vitro equivalent. This suggests that 
the spacer with larger volume, dimensions and internal axial distance may not be 
required for use with Salamol MDI. This assessment is further supported by similar   
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impactor mass (S0toF) and FPD obtained from both spacers. These outcomes are more 
likely linked to the formulation of Salamol MDI, which contains ethanol as co-solvent. 
Since ethanol slows down evaporation (Barry and O’Calaghan, 1997; Ross and Gabrio, 
1999; Stein and Myrdal, 2006), it may have reduced the velocity of the emitted plume 
thereby may also have reduced its cone angle (Hautmann et al., 2013; Johnson et al., 
2016; Kunda et al., 2017). The relatively smaller deposition of the emitted dose in VOL 
than AERO is more likely due to its diamond shape which accounted for the cone angle 
of the discharged aerosol spray. As a consequence, TDD of VOL was greater than 
AERO. Nevertheless, similar deposition was found within the two spacers. Hence, the 
cylindrical dimensions of AERO were equally effective as the diamond shaped VOL in 
providing adequate space for evaporation of the initial emitted droplets (Figure 2.4.1). 
Similar findings have been reported for Airomir MDI when attached to VOL and 
AeroChamber (Mitchell et al., 1999). However, it was also found that FPD, FPF as 
%TED and FPF as % TDD for Sala+AERO were greater than those obtained from 
Sala+VOL. These findings indicate that AERO may be a better add-on device for 
Salamol MDI than VOL. It has been reported that the distance between the MDI 
mouthpiece placed in the lips and the throat of human adult is up to 10 cm (Brambilla et 
al., 2011; Hautmann et al., 2013). The internal axial distance of AERO measured in this 
lab is 9.3 cm. This suggests that an internal axial distance of 9.3 cm should be adequate 
for the optimal performance of Salamol.  
8.2.7.3 Impactor Mass 
The impactor mass (S0toF) was in the decreasing rank order of Salamol MDI > 
Sala+VOL > Sala+AERO. Hence, slightly more dose was delivered to the ACI stages 
with Salamol alone than with the two spacer treatment methods. However, this 
difference may not be of clinical significance since their FPD and FPM were 
statistically similar and in-vitro equivalent. 
8.2.7.4 Respirable Dose (FPD) 
The respirable dose (FPD) was in the decreasing rank order of Sala MDI > Sala+AERO 
> Sala+VOL. This suggests that where appropriate, Salamol MDI alone could be a 
better choice for the desired treatment. However, the TDD that entered ACI with the 
attached spacer constituted over 81% of particles in the FPD range with less than 6% 
deposition in IP as compared to ~50% and ~45%, respectively, with Salamol alone. This 
may have significance for efficacy and safety of the chosen treatment method.  
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The FPD for Salamol is greater than that of Sala+VOL and Sala+AERO. This is in 
conflict with findings where spacer device attached to an MDI produced higher FPD. 
Mitchell et al. (1999) reported higher FPD of Airomir with these spacers than that of the 
MDI. However, von Hollen et al. (2011a & b) and Hatley et al. (2014) reported similar 
FPD of ProAir HFA without and with AERO. Further, Johnson et al. (2016) reported 
higher FPD for ProAir HFA than when the MDI was used with LiteAire. These varied 
and differing results for the FPD obtained without and with the spacer preclude 
suggestions that the use of a spacer should predispose higher FPD. On the contrary, a 
higher FPD and a differing APSD profile may raise concerns for efficacy and safety, in 
particular if these differences are more than 15% (Kelly et al., 2001). 
8.2.7.5 FPF %TED and FPF %TDD 
The FPF as %TED was in the decreasing rank order of Salamol > Sala+AERO > 
Sala+VOL. Since TED is similar for these treatment methods, the FPF is reflective of 
the variability in FPD. However, when FPF was assessed as %TDD, the decreasing 
ranking order changed to Sala+AERO > Sala+VOL > Salamol. The FPF as %TDD of 
Salamol is the lowest because for an MDI the TED = TDD which is, respectively, 43% 
to 47% greater than the spacer treatment methods. This might suggest poor delivery of 
FPD from Salamol when used without these spacers. Nevertheless, the FPD of the MDI 
was higher than the two spacer treatment methods. Further, the FPF as %TDD of 
Sala+AERO was better than Sala+VOL. However, this may not be correct. The data 
shows that more dose (~4 µg) was delivered from VOL than from AERO while the FPD 
was only ~1 µg lesser with VOL treatment method. Consequently, this disproportionate 
relationship resulted in a difference of ~9% in the dose delivery characteristics which is 
suggestive of Sala+AERO being better of the two spacer treatment methods. This is 
however misleading given that the two spacer treatment methods were in-vitro 
equivalent even though being statistically different. Therefore, the derived metric of 
FPF as %TDD would mask the actual performance of a given treatment method (also 
see Section 6.2.7.5).  
Nevertheless, FPF as %TDD may be used as a tool to assess the proportion of the FPD 
contained in the TDD, proportion of deposition in the spacer and to identify the problem 
area where improvement would be needed. Therefore, this metric could be used in new 
product development, problem identification and solving to assist in product 
improvement.   
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8.2.7.6 Respirable dose delivery efficiency 
The FPD to IP ratio for Sala+VOL and Sala+AERO were respectively ~13 and ~18 
times larger than that of the MDI. Also, their ratios of FPD to IP+CPM were ~4 and ~9 
times higher than Salamol. This suggests that AERO was relatively more efficient than 
VOL in removing the coarser portion of the TED. However, the ratio of respirable to 
non-respirable dose (IP+CPM Vs SP+IP+CPM) suggest that more respirable fraction 
was delivered with Salamol alone than with VOL or AERO. Similar trend was observed 
when the ratio of impactor mass (S0toF) to IP and SP+IP were compared with. 
Although these spacers retained most of the coarse mass and are beneficial in this 
respect, these findings are suggestive of Salamol being more efficient in FPD delivery 
as compared to the two spacer treatment methods. The ratio of respirable to non-
respirable dose was in the decreasing rank order of Sala > Sala+AERO > Sala+VOL. 
8.2.7.7 MMAD and GSD 
The MMAD of the three treatment methods was within 2.5 µm to 2.8 µm which shows 
that salbutamol was delivered in the desired particle size range. The dispersion of these 
particles was less than 1.7 which indicates consistency of these treatment methods in 
producing similar MMAD. It is therefore highly likely that the inhaled dose will be 
delivered to the bronchi and bronchioles to relieve bronchospasm. The in-vitro 
equivalence of FPD is suggestive of their similar efficacy.  
The MMAD and GSD were in decreasing rank order of Sala+VOL > Salamol > 
Sala+AERO. Significantly smaller CPM of Sala+AERO seems to have influenced 
APSD profile resulting in the lowest MMAD and GSD. The largest MMAD and GSD 
with Sala+VOL could be due to higher CPM as compared to the other two treatment 
methods. These findings indicate a possible link between CPM and the two metrics. 
8.2.7.8 APSD Stage Groups 
The APSD profiles (Figure 8.2.1 & Figure 8.2.4) of the three treatment methods depict 
that these are centred and nearly running parallel at stages 3-5 while showing similar 
tailing on stages 6-7 & F. However, the fronting is variable due to variability found on 
stages 0-2 deposition. These profiles therefore reflect on the statistical and in-vitro 
results with respect to these stage groups. 
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The FPM similarity and in-vitro equivalence suggest that the three treatment methods 
are more likely to be equally effective in the clinical setting. On the other hand, the 
significant differences in their CPM may highlight the possibility of varying side effects 
which may be fewer with AERO. EPM statistical similarity suggests that these 
treatment methods may equally contribute to systemic effects.  
8.2.7.9 Salamol spacer treatment methods 
The TED, TDD, FPD, FPF (%TED), FPF (%TDD), S0toF, MMAD and GSD were in-
vitro equivalent between Sala+VOL and Sala+AERO. The two spacers have shown 
comparability between them with respect to these CQAs. This study has shown that 
both of them can be used as an add-on device with Salamol MDI. Whether one can be 
substituted for the other would be a matter of suitability, choice and convenience. This 
selection should be supported by pharmacokinetic study and where appropriate with the 
clinical evidence. 
8.2.8 Conclusions: In-Vitro Equivalence of Salamol Without and With Spacer 
The similarity and in-vitro equivalence of FPD of the three treatment methods (Salamol 
alone, Sala+VOL and Sala+AERO) is suggestive of their equal clinical effects. The 
FPD, FPM and S0toF (impactor mass) of Salamol MDI alone were greater than the two 
spacer treatment methods. This indicates that Salamol MDI alone could be used where 
appropriate. 
Large and small volume spacers were equally effective in delivering in-vitro equivalent 
FPD of Salamol. 
The results revealed that TED, FPD, FPF (%TED), MMAD and GSD of Salamol used 
with VOL and AERO were in-vitro equivalent between them. Therefore, these two 
spacers can be considered as suitable add-on devices for Salamol MDI. 
The APSD profiles of the three treatment methods do not meet stage-wise in-vitro 
comparison criteria of EMA (2009) except for FPM. 
Findings of this study cannot be extrapolated to other salbutamol MDIs or/and spacers. 
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8.3 In-Vivo Equivalence of Salamol Without and With Spacer-
Urinary Pharmacokinetic Studies 
The objectives of this study are to investigate in-vivo equivalence between Salamol 
alone and with Volumatic and AeroChamber Plus using urinary pharmacokinetic 
method developed by Hindle and Chrystyn (1992). 
8.3.1 Study Design 
Study design is enumerated in Chapter 3 (Sections 3.4.5 & Sub-section 3.4.5.4). 
Subjects were selected and trained as detailed in Sections 3.4.3 & 3.4.4, respectively. 
This chapter has adopted similar study design as described in Chapters 5 (Section 
5.3.1), 6 (Section 6.3.1) and 7 (Section 7.3.1). 
In summary, this study comprised two parts. In Part 1 on a given study day, the subjects 
inhaled two puffs of primed Salamol, 30 seconds apart, from one of the three treatment 
methods, vis-à-vis: Salamol alone, Sala+VOL and Sala+AERO. In Part 2, these subjects 
repeated inhaling salbutamol from one of these treatment methods with the ingestion of 
charcoal. Each study was separated by 7 days and all subjects inhaled from each of the 
three Salamol treatment methods on a different study day. All subjects provided blank 
urine sample 0.5h before inhaling salbutamol dose and then 0.5h post-dose. Thereafter, 
all urine was pooled for 24 hours. 
The pH and volume of samples were recorded which were stored at –20◦C before 
analysis. Post-dose residual salbutamol was recovered from MDI components and 
spacers. 
8.3.2 Sample Analysis 
Urine and aqueous samples were processed and assayed for salbutamol using validated 
HPLC methods described in Chapter 4. 
8.3.3 Statistical Analysis 
Statistical analysis approach is elaborated in Chapter 3 (Section 3.4.7). 
8.3.4 Results: In-Vivo Equivalence of Salamol Without and With Spacer 
Demographic characteristics of volunteers are given in Table 5.3.1 and Appendix 
5.3.4.1 (Chapter 5). Table 8.3.1 to Table 8.3.4  provide summaries of PK metrics   
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(USAL0.5, USAL24, USAL24Pre, USAL24Post and USALMET) as amounts, % 
nominal, % delivered and % recovered dose of salbutamol, respectively, for both parts 
of the study. In-vivo equivalence and comparative bioavailability data of these metrics 
for the three treatment methods are provided in Table 8.3.5 and Table 8.3.6 for Parts 1 
and 2 of the study, respectively. These metrics are respectively shown in Figure 8.3.1 to 
Figure 8.3.5 while their comparative recovery profiles are presented in Figure 8.3.6.  
Urinary excretion data of Salamol (MDI alone) for individual subjects is given in 
Appendices 5.3.4.4 and 5.3.4.7. These data for Sala+VOL and Sala+AERO are shown 
in Appendices 8.3.4.1 to 8.3.4.4.  
Relative lung bioavailability (USAL0.5) of Sala was not in-vivo equivalent to any of the 
two spacer treatment methods (Sala+SP) in both parts of the study (Table 8.3.5 & Table 
8.3.6). Although being statistically similar in both parts, these spacer treatment methods 
were nevertheless only in-vivo equivalent to each other when assessed using limits 
suggested by Parameswaran (1999). USAL0.5 of Sala+SP was about 3 and 2.5 times 
greater than that of Sala alone in 1
st
 and 2
nd
 Parts of the study, respectively, and hence 
statistically significant.  
Total systemic bioavailability (USAL24NC) in Part 1 of the study was in-vivo 
equivalent as per EMA (2009) criteria and statistically similar between Sala and 
Sala+SP. However, this was not replicated in Part 2 of the study where USAL24C was 
in-vivo equivalent only between Sala and Sala+AERO as per specifications put forward 
by Parameswaran (1999). Interestingly, the two spacer treatment methods met EMA 
(2009) in-vivo equivalence criteria between them for total systemic bioavailability in 
both legs of the study which was also statistically similar.  
In Part 1 of the study, the recovery of active (USAL24PreNC) and total salbutamol 
[(USAL24PostNC) (inclusive of metabolites)] were in-vivo equivalent between Sala and 
Sala+SP to the Parameswaran (1999) criteria. These recoveries were, however, not 
statistically similar. In Part 2 of the study, the recovery of active salbutamol 
(USAL24PreC) was neither in-vivo equivalent nor statistically similar between Sala and 
Sala+SP. In contrast, total salbutamol [(USAL24PostC) (inclusive of metabolites)] met 
in-vivo equivalence criteria of Parameswaran (1999) for Sala Vs Sala+SP. The three 
treatment methods were also statistically similar. Nevertheless, the recovery of 
salbutamol metabolites (USALMET) in both legs of study was in-vivo inequivalent and 
statistically different between Sala and Sala+SP.  
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Interestingly, the recoveries of USAL0.5, USAL24, USAL24Pre, USAL24Post and 
USALMET (except in Part 2) were in-vivo equivalent to Parameswaran (1999) criteria 
and statistically similar between the two spacer treatment methods in both parts of the 
study (Table 8.3.5 & Table 8.3.6). Further, USAL24NC, USAL24PreNC and 
USAL24PostNC also conformed to EMA (2009) in-vivo equivalence criteria in Part 1 
of the study while this was only observed with USAL24C in Part 2 of the study. 
Table 8.3.7 and Figure 8.3.7 show the effect of charcoal blockade on each PK parameter 
of the three treatment methods between Parts 1 and 2 of the study. The results show 
significant differences between these parameters except for USAL0.5 which was not 
affected by charcoal intake. The results further reveal that the recovery of salbutamol 
metabolites (USALMET) was similar between the two parts of the study for the spacer 
treatment methods even in the presence of charcoal. Table 8.3.8 shows in-vitro and in-
vivo trends of the three Salamol treatment methods. 
 
 
Table 8.3.1. Mean salbutamol excreted in urine post-inhalation from Salamol without and 
with spacers. 
Treatment 
Method 
(n = 13) 
USAL0.5 USAL24† USAL24Pre USAL24Post USALMET 
µg SD µg SD µg SD µg SD µg SD 
Part 1 Study (without charcoal blockade) 
Salamol 6.7 3.2 94.3 19.4 42.9 11.2 87.6 18.4 44.8 12.9 
Sala+VOL 19.5 6.2 85.6 10.1 57.5 9.7 66.1 9.7 8.6 5.2 
Sala+AERO 17.6 5.9 86.5 13.3 57.4 11.2 68.9 7.7 11.5 5.1 
Part 2 Study (with charcoal blockade) 
Salamol 7.2 3.4 50.2 13.1 27.2 11.6 43.0 13.5 15.7 8.9 
Sala+VOL 17.5 3.0 66.1 9.6 40.0 7.0 48.6 7.0 8.6 2.3 
Sala+AERO 16.6 4.7 62.1 10.2 36.8 7.1 45.5 5.9 8.7 3.6 
† TRD = USAL24; SD = Standard Deviation 
 
  
  234 
Table 8.3.2. Mean salbutamol excretion in urine post-inhalation from Salamol without and 
with spacers, expressed as % of Nominal Dose. 
Treatment 
Method 
(n = 13) 
USAL0.5 USAL24† USAL24Pre USAL24Post USALMET 
% SD % SD % SD % SD % SD 
Part 1 Study (without charcoal blockade) 
Salamol 3.4 1.6 47.2 9.7 21.4 5.6 43.8 9.2 22.4 6.5 
Sala+VOL 9.7 3.1 42.8 5.0 28.8 4.8 33.1 4.8 4.3 2.6 
Sala+AERO 8.8 3.0 43.2 6.7 28.7 5.6 34.5 3.8 5.8 2.5 
Part 2 Study (with charcoal blockade) 
Salamol 3.6 1.7 25.1 6.5 13.6 5.8 21.5 6.8 7.9 4.5 
Sala+VOL 8.8 1.5 33.1 4.8 20.0 3.5 24.3 3.5 4.3 1.1 
Sala+AERO 8.3 2.3 31.0 5.1 18.4 3.5 22.8 2.9 4.3 1.8 
† TRD = USAL24; SD = Standard Deviation 
 
 
Table 8.3.3. Mean salbutamol excretion urine post-inhalation from Salamol without and 
with spacers, expressed as % of estimated Delivered Dose. 
Treatment 
Method 
(n = 13) 
USAL0.5 USAL24† USAL24Pre USAL24Post USALMET 
% SD % SD % SD % SD % SD 
Part 1 Study (without charcoal blockade) 
Salamol 3.9 1.9 54.2 11.4 24.6 6.4 50.3 10.8 25.7 7.5 
Sala+VOL 18.1 5.7 79.3 6.9 53.3 8.3 61.2 7.3 7.9 4.8 
Sala+AERO 17.4 4.0 86.9 4.1 57.5 6.1 69.5 2.0 12.0 6.2 
Part 2 Study (with charcoal blockade) 
Salamol 4.2 2.0 29.0 7.8 15.7 6.6 24.8 8.0 9.1 5.3 
Sala+VOL 16.6 2.5 62.8 7.9 37.9 5.9 46.1 5.9 8.2 2.2 
Sala+AERO 17.5 4.2 66.0 8.1 39.1 5.8 48.5 4.4 9.4 4.0 
† TRD = USAL24; SD = Standard Deviation 
 
Table 8.3.4. Mean salbutamol excretion in urine post-inhalation from 
Salamol without and with spacers, expressed as % of Recovered Dose. 
Treatment 
Method 
(n = 13) 
USAL0.5 USAL24Pre USAL24Post USALMET 
% SD % SD % SD % SD 
Part 1 Study (without charcoal blockade) 
Salamol 7.1 3.1 45.4 9.4 92.9 3.1 47.5 8.7 
Sala+VOL 22.8 6.8 67.1 7.2 77.2 6.8 10.2 6.5 
Sala+AERO 19.8 3.8 66.1 5.4 80.2 3.8 14.1 7.7 
Part 2 Study (with charcoal blockade) 
Salamol 15.8 11.3 53.2 16.0 84.2 11.3 31.0 14.3 
Sala+VOL 26.5 2.1 60.3 3.3 73.5 2.1 13.2 3.6 
Sala+AERO 26.3 3.3 59.3 4.9 73.7 3.3 14.5 6.7 
TRD = USAL24; SD = Standard Deviation 
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Figure 8.3.1. Comparative salbutamol urinary excretion at 0.5h post-inhalation of Salamol without 
and with spacers. 
Numerals represent individual volunteers. nc = no charcoal ingestion; +c = with charcoal ingestion. 
 
 
 
Figure 8.3.2. Comparative total salbutamol urinary excretion during 24h post-inhalation of Salamol 
without and with spacers. 
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Figure 8.3.3. Comparative unchanged salbutamol urinary excretion during 0.5-24h post-inhalation of 
Salamol without and with spacers. 
 
 
 
Figure 8.3.4. Comparative total salbutamol urinary excretion during 0.5-24h post-inhalation of 
Salamol without and with spacers. 
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Figure 8.3.5. Comparative salbutamol metabolites urinary excretion during 0.5-24h post-inhalation of 
Salamol without and with spacers. 
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Figure 8.3.6. Comparative salbutamol urinary recovery profiles obtained post-inhalation of Salamol without and with spacers. 
Numerals represent individual volunteers. nc = no charcoal ingestion; +c = with charcoal ingestion. 
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Table 8.3.5. In-Vivo Equivalence and Statistical Significance of Salamol without and with spacers (Part 1 Study). 
Parameter Multiple Comparisons 
Mean 
Ratio 
90% CI 
p value 
In-Vivo Equivalence Mean 
Difference
c
 
95% CI 
p value 
Statistical 
Similarity LL UL 0.80-1.25
a
 0.67-1.50
b
 LL UL 
USAL0.5NC 
Salamol 
Sala+VOL 0.32 0.24 0.43 <0.0001 No No -12.77 -17.30 -8.24 <0.0001 No 
Sala+AERO 0.35 0.26 0.48 <0.0001 No No -10.89 -15.42 -6.36 <0.0001 No 
Sala+VOL Sala+AERO 1.11 0.83 1.50 0.541 No Yes 1.89 -2.64 6.42 0.398 Yes 
USAL24NC 
Salamol 
Sala+VOL 1.09 0.97 1.21 0.205 Yes Yes 8.75 -3.16 20.66 0.142 Yes 
Sala+AERO 1.08 0.97 1.21 0.239 Yes Yes 7.85 -4.06 19.76 0.186 Yes 
Sala+VOL Sala+AERO 0.99 0.89 1.11 0.925 Yes Yes -0.90 -12.81 11.01 0.877 Yes 
USAL24PreNC 
Salamol 
Sala+VOL 0.80 0.69 0.91 0.008 No Yes -11.55 -20.19 -2.91 0.011 No 
Sala+AERO 0.80 0.70 0.92 0.010 No Yes -11.44 -20.08 -2.79 0.012 No 
Sala+VOL Sala+AERO 1.01 0.88 1.15 0.933 Yes Yes 0.12 -8.53 8.76 0.978 Yes 
USAL24PostNC 
Salamol 
Sala+VOL 1.31 1.18 1.46 0.000 No Yes 21.53 11.83 31.23 <0.0001 No 
Sala+AERO 1.25 1.13 1.39 0.001 No Yes 18.74 9.04 28.44 0.001 No 
Sala+VOL Sala+AERO 0.96 0.86 1.06 0.461 Yes Yes -2.79 -12.49 6.91 0.558 Yes 
USALMETnc 
Salamol 
Sala+VOL 5.52 3.82 7.99 <0.0001 No No 33.08 24.80 41.36 <0.0001 No 
Sala+AERO 3.79 2.62 5.48 <0.0001 No No 30.18 21.90 38.45 <0.0001 No 
Sala+VOL Sala+AERO 0.69 0.47 0.99 0.093 No No -2.91 -11.18 5.37 0.476 Yes 
a 
EMA, 2009; 
b 
Parameswaran, 1999; 
c
 µg; CI = Confidence Interval; LL = Lower limit; UL = Upper Limit 
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Table 8.3.6. In-Vivo Equivalence and Statistical Significance of Salamol without and with spacers (Part 2 Study). 
Parameter Multiple Comparisons 
Mean 
Ratio 
90% CI 
p value 
In-Vivo Equivalence Mean 
Difference
c
 
95% CI 
p value 
Statistical 
Similarity LL UL 0.80-1.25
a
 0.67-1.50
b
 LL UL 
USAL0.5C 
Salamol 
Sala+VOL 0.38 0.31 0.47 <0.0001 No No -10.33 -13.39 -7.28 <0.0001 No 
Sala+AERO 0.41 0.33 0.51 <0.0001 No No -9.35 -12.40 -6.30 <0.0001 No 
Sala+VOL Sala+AERO 1.08 0.87 1.35 0.541 No Yes 0.98 -2.07 4.03 0.514 Yes 
USAL24C 
Salamol 
Sala+VOL 0.73 0.63 0.84 0.001 No No -16.96 -25.84 -8.08 0.001 No 
Sala+AERO 0.79 0.68 0.91 0.009 No Yes -11.91 -20.79 -3.03 0.011 No 
Sala+VOL Sala+AERO 1.08 0.94 1.25 0.346 Yes Yes 5.05 -3.83 13.93 0.252 Yes 
USAL24PreC 
Salamol 
Sala+VOL 0.63 0.50 0.78 0.002 No No -12.76 -20.18 -5.33 0.002 No 
Sala+AERO 0.68 0.54 0.85 0.007 No No -9.62 -17.05 -2.19 0.013 No 
Sala+VOL Sala+AERO 1.09 0.87 1.36 0.527 No Yes 3.14 -4.29 10.56 0.392 Yes 
USAL24PostC 
Salamol 
Sala+VOL 0.84 0.70 1.00 0.104 No Yes -5.63 -13.35 2.10 0.146 Yes 
Sala+AERO 0.89 0.74 1.07 0.287 No Yes -2.56 -10.29 5.17 0.501 Yes 
Sala+VOL Sala+AERO 1.07 0.89 1.28 0.555 No Yes 3.07 -4.66 10.80 0.421 Yes 
USALMETc 
Salamol 
Sala+VOL 1.58 1.16 2.17 0.020 No No 7.13 2.61 11.65 0.003 No 
Sala+AERO 1.65 1.21 2.26 0.012 No No 7.06 2.54 11.59 0.004 No 
Sala+VOL Sala+AERO 1.04 0.76 1.43 0.822 No Yes -0.07 -4.59 4.45 0.975 Yes 
a 
EMA, 2009; 
b 
Parameswaran, 1999; 
c
 µg; CI = Confidence Interval; LL = Lower limit; UL = Upper Limit 
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Table 8.3.7. Statistical comparison of salbutamol post-inhalation urinary excretion between Part 1 
and Part 2 studies of Salamol without and with spacers. 
Parameter
1
 
[nc Vs (+c)] 
Treatment 
Mean 
paired 
Difference
2
 
95% CI 
t value p value 
Statistical 
Similarity LL UL 
USAL0.5 
Salamol -0.50 -2.22 1.21 -0.640 0.534 Yes 
Sala+VOL 1.94 -2.84 6.72 0.884 0.394 Yes 
Sala+AERO 1.04 -2.51 4.59 0.636 0.537 Yes 
USAL24 
Salamol 44.18 28.76 59.60 6.243 <0.0001 No 
Sala+VOL 18.47 10.12 26.82 4.819 <0.0001 No 
Sala+AERO 24.42 17.10 31.75 7.264 <0.0001 No 
USAL24Pre 
Salamol 15.66 5.91 25.42 3.500 0.004 No 
Sala+VOL 17.54 12.34 22.73 7.358 <0.0001 No 
Sala+AERO 20.56 13.28 27.83 6.158 <0.0001 No 
USAL24Post 
Salamol 44.68 29.27 60.09 6.318 <0.0001 No 
Sala+VOL 17.53 11.69 23.37 6.542 <0.0001 No 
Sala+AERO 23.39 19.43 27.34 12.893 <0.0001 No 
USALMET 
Salamol 29.02 18.57 39.47 6.052 <0.0001 No 
Sala+VOL -0.01 -3.04 3.02 -0.008 0.994 Yes 
Sala+AERO 2.83 -1.18 6.84 1.538 0.150 Yes 
1
 nc = no charcoal; +c = with charcoal; 
2
 µg 
 
 
Figure 8.3.7. Comparison of salbutamol post-inhalation urinary excretion of Salamol without and with 
spacers between Part 1 and Part 2 (with charcoal blockade) studies. 
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Table 8.3.8. In-vitro and in-vivo trends between APSD performance metrics and salbutamol post-
inhalation urinary excretion of Salamol without and with spacers. 
Parameter 
Salamol Sala+VOL Sala+AERO Trend 
(in decreasing order) µg µg µg 
FPD 89.4 83.6 85.7 Sala > Sala+AERO > Sala+VOL 
%FPF (%TDD) 49.6% 81.1% 89.9% Sala+AERO > Sala+VOL > Sala 
S0toF 100.0 97.2 90.8 Sala > Sala+VOL > Sala+AERO 
USAL0.5NC 6.7 19.5 17.6 Sala+VOL > Sala+AERO > Sala 
USAL0.5C 7.2 17.5 16.6 Sala+VOL > Sala+AERO > Sala 
IP+CPM 90.6 19.5 9.6 Sala > Sala+VOL > Sala+AERO 
IP 80.1 5.9 4.4 Sala > Sala+VOL > Sala+AERO 
USAL24PreNC 42.9 57.5 57.4 Sala+VOL > Sala+AERO > Sala 
USAL24PreC 27.2 40.0 36.8 Sala+VOL > Sala+AERO > Sala 
USAL24PostNC 87.6 66.1 68.9 Sala > Sala+AERO > Sala+VOL 
USAL24PostC 43.0 48.6 45.5 Sala+VOL > Sala+AERO > Sala 
TDD (ACI) 180.0 103.2 95.2 Sala > Sala+VOL > Sala+AERO 
TDD (NC) 174.2 107.9 99.2 Sala > Sala+VOL > Sala+AERO 
TDD (C) 173.6 105.2 93.7 Sala > Sala+VOL > Sala+AERO 
USAL24NC 94.3 85.6 86.5 Sala > Sala+AERO > Sala+VOL 
USAL24C 50.2 66.1 62.1 Sala > Sala+VOL > Sala+AERO 
 
8.3.5 Discussion: In-Vivo Equivalence of Salamol Without and With Spacer 
Volumatic (VOL) is the recommended spacer for Salamol (Teva, 2016) while 
AeroChamber Plus (AERO) is promoted for use with it. The urinary PK data indicate 
that the two spacers significantly increased the relative lung bioavailability of 
salbutamol (USAL0.5) from Salamol as compared to the MDI alone. This rendered the 
two treatment methods (Sala Vs Sala+SP) in-vivo inequivalent. However, the increase 
in lung bioavailability may be of concern for safety in hypersensitive patients. 
Nevertheless, Lipworth et al. (1988) have shown in asthmatics that the side effects of 
salbutamol MDI were well tolerated and infrequent with cumulative doses from 100 to 
4000 µg. Hence, spacer mediated increase in salbutamol bioavailability may be 
beneficial in relieving the acute asthma attack, in particular in patients who have 
difficulty in inhaling salbutamol from the MDI alone. 
Intriguingly, the in-vivo relative lung deposition (USAL0.5) in healthy volunteers is in 
conflict with that of in-vitro FPD (respirable dose) obtained with ACI for the MDI and 
the two spacer treatment methods (Table 8.2.4 & Table 8.2.9). FPD is considered as the 
proportion of the inhaled puff that is highly likely to deposit in the lungs (Newman, 
1998; Chrystyn et al., 2015) and was in-vitro equivalent and statistically similar for the   
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three Salamol treatment methods. The conflicting results are more likely due to 
differences in the two systems (in-vitro Vs in-vivo), having different aerodynamics and 
environments.  
In ACI, the airflow is constant and maintained at 28.3 L/min under controlled 
conditions. In human respiratory tract (HRT), however, the inhalation manoeuvre is 
affected by aerosol impaction in the oropharyngeal cavity such as reflexive cessation of 
inhalation (Crompton, 1982). Besides, the anatomy and physiology play a significant 
role in this mechanism (Labiris and Dolovich, 2003). It is also likely that spacers may 
have comforted volunteers with their inhalation technique besides eliminating the reflex 
cessation of inhalation. The increased relative lung deposition with spacers, therefore, 
highlights the importance of their use. 
The increase in relative lung deposition (USAL0.5NC) was of greater magnitude with 
Volumatic (2.9 fold) than with AeroChamber Plus (2.6 fold). However, USAL0.5NC 
was statistically similar between the two spacers. Further, USAL0.5 with VOL differed 
by <1 µg than that of AERO in both parts of the study and, therefore, may not be 
clinically significant. Hence, it can be concluded that spacer dimension or volume did 
not affect lung deposition of Salamol. This is consistent with the in-vitro results 
(Sections 8.2.7.2 & 8.2.7.9). These results are also in line with those observed with 
Ventolin Evohaler for the two spacers (Table 6.3.1, Table 6.3.9 & Table 6.3.10). 
On another note, it is clear that the treatment method using Salamol alone is not in-vivo 
equivalent to the two treatment methods using VOL and AERO. This may have clinical 
implications. Further, there was little difference between the two Salamol spacer 
treatment methods. 
The relative lung deposition (USAL0.5C) patterns were reproducible in Part 2 Study 
(charcoal blockade) for three Salamol treatment methods (Table 8.3.1 & Table 8.3.6). 
Further, the comparative relative lung deposition of these treatment methods was 
statistically similar between the two parts of the study (Table 8.3.7, Figure 8.3.7). 
Interestingly, these results also reflect on the trend found with Ventolin Evohaler with 
the two spacers (Table 6.3.1 & Table 6.3.10). These findings clearly re-inforce that the 
excretion of inhaled salbutamol in the first 0.5h mainly comes from the dose deposited 
in the lungs.  
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The total systemic bioavailability (USAL24NC) was in-vivo equivalent and statistically 
similar between the three treatment methods in Part 1 of the study (Table 8.3.1 & Table 
8.3.5). This suggests that USAL24NC was indifferent to the method of salbutamol 
delivery from Salamol. However, in Part 2 study (charcoal blockade), greater total 
systemic recoveries (USAL24C) from Sala+VOL and Sala+AERO indicate that spacer 
method of delivery was more efficient than the MDI alone (Table 8.3.2 & Table 8.3.3). 
This also pinpoints that the systemic delivery (USAL24C) in the presence of charcoal 
blockade of GIT absorption was mainly from the lung deposition and that the greater 
lung deposition with the two spacers (USAL0.5C) was responsible for greater total 
systemic bioavailability (Table 8.3.1). This is further evident from the higher 
contribution of lung deposition when assessed as % estimated delivered dose (Table 
8.3.3) and its proportion in the total systemic bioavailability (Table 8.3.4). 
The total systemic bioavailability with charcoal blockade (USAL24C) was about 53%, 
77% and 72% for Salamol, Sal+VOL and Sala+AERO, respectively, to that without 
charcoal ingestion (Table 8.3.1). This indicates that about half of the inhaled dose was 
swallowed with the MDI while this swallowed proportion was less than 28% when 
spacers were used. The two spacers therefore effectively reduced oropharyngeal 
deposition. The total systemic bioavailability with charcoal blockade has been mainly 
derived from the lung deposition (USAL0.5C). USAL24C represented 29%, 63% and 
66%, respectively, of the estimated delivered dose (TDD) which was predominantly 
derived from USAL0.5C constituting 4%, 17% and 18% of TDD. 
The in-vitro TDD and in-vivo estimated TDD (ND-UDD) reflect on differences of 
USAL24 between the two parts of the study (Table 8.3.8). However, USAL24NC is 
similar to in-vitro S0toF (impactor mass) which is the dose that reached to the ACI, a 
surrogate for the human respiratory system. This indicates that oropharyngeal 
deposition may have removed a large proportion of the dispensed dose when Salamol 
alone was used. This is evident from the 45% in-vitro recovery of the TED from IP 
(Table 8.2.3). On the other hand, similar %TED is retained by the two spacers while 
significantly reducing IP deposition. This may have allowed more of the dispensed dose 
in the fine particle range (FPD) to reach lungs. Indeed, in-vitro studies indicated that 
Salamol had 50% FPF as compared to 81% and 90% for Sala+VOL and Sala+AERO, 
respectively (Table 8.2.6). Further, in-vitro S0toF made 56%, 94% and 95%, 
respectively, of the TDD for these treatment methods (Table 8.2.3) and reflects on   
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greater systemic bioavailability (USAL24C) observed in charcoal blockade study. These 
findings highlight the predictive value of in-vitro studies for in-vivo metrics. 
In Part 1 Study, in-vivo equivalence to Parameswaran’s (1999) criteria was observed for 
unchanged active salbutamol (USAL24PreNC) between Salamol and the two spacer 
treatment methods (Sala+SP). However, this was not observed with USAL24PreC in 
Part 2 Study. Further, USAL24Pre was statistically different in both parts of the study 
between them. Unchanged salbutamol is mainly derived from lung deposition 
(Shenfield et al., 1976; Tomlinson et al., 1995; Ward et al., 2000). Greater lung 
deposition (USAL0.5) reflected on higher amounts of unchanged salbutamol excreted in 
urine over 24 hours in both parts of the study (Table 8.3.1 to Table 8.3.4). USAL24PreC 
formed 63%, 70% and 64% of USAL24PreNC for Salamol, Sala+VOL and 
Sala+AERO, respectively. This indicates that these proportions of the unchanged 
salbutamol were mainly derived from the lung deposition since absorption from GIT 
was blocked with the ingestion of activated charcoal. Hence, in Part 1 Study, the 
remaining proportion of salbutamol may have escaped biotransformation, entered 
systemic circulation and was excreted in urine as unchanged salbutamol ( 
Figure 2.3.4, Chapter 2) (Chrystyn, 2000; Ward et al., 2000). 
The results suggest that urinary excretion of unchanged salbutamol over 24 hour 
(USAL24Pre) can be anticipated from lung deposition (USAL0.5). In Part 1 Study, 
USAL0.5NC formed 16%, 34% and 31% of USAL24PreNC, respectively, of the three 
treatment methods. In Part 2 Study, 27%, 44% and 45% of USAL24PreC may have 
originated from USAL0.5C. The urinary excretion of unchanged salbutamol from 
Salamol used with the two spacers is statistically similar within each part of the study 
(Table 8.3.5 & Table 8.3.6). Interestingly, this phenomenon is consistent across the two 
parts of the study for each of the three treatment methods when their respective relative 
proportions of USAL24PreNC (63%, 70% and 64%) are taken into account.  
The presence of unchanged pharmacologically active salbutamol (USAL24Pre) would 
reflect on the effectiveness of the responsive bronchodilatory treatment for the duration 
of dosing interval. Larger bioavailability of USAL24Pre may also predispose 
salbutamol related systemic effects in some hypersensitive patients. Further, the results 
suggest that Salamol when used with VOL and AERO may provide better and 
consistent effects than the MDI alone.  
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The urinary excretion of metabolised salbutamol from Salamol in Part 1 Study was 2.9 
folds more than that found in Part 2 Study. Salbutamol is primarily metabolised in the 
liver (Ward et al., 2000) and a large proportion of the orally absorbed drug undergoes 
first pass degradation. The co-administration of charcoal prevents GIT absorption, 
hence, a larger and significant difference in the recovery of salbutamol metabolites was 
observed between the two parts of the study. The recovery of metabolites with charcoal 
ingestion also indicates that about 35% of salbutamol absorbed from the lungs was 
metabolised over 24 hours. This may have occurred mainly in the liver since first-pass 
conjugation has not been reported in the lungs (Shenfield et al., 1976; Olsson et al., 
2011). About 8% of salbutamol is also protein bound (Martin et al., 1971; Goldstein et 
al., 1987) which may also have been metabolised and contributed to the total recovery 
of metabolites.  
On the other hand, USALMET was statistically similar for Sala+SP between the two 
parts of the study. This indicates that with the spacer treatment method, the metabolites 
excreted in urine from systemic circulation originated mainly from the lungs deposition. 
This is evident from their in-vivo equivalence to Parameswaran’s (1999) criteria in the 
charcoal blockade which was not observed in the 1
st
 part of the study and is more likely 
due to individual variation in GIT absorption of the swallowed salbutamol.  
The two spacers significantly reduced the systemic availability of Salamol dose; VOL 
and AERO respectively retained 40% and 45% of the TED in Part 1 Study. These 
values were 42% and 48% in Part 2 Study. This dose retention in spacers is reflective of 
their volumes and is similar to those reported for in-vitro studies (Table 8.2.2 & Table 
8.2.3). Interestingly, similar fraction of dose was retained when VOL was attached to 
Ventolin Evohaler which was at 42% and 41% of TED in Parts 1 and 2 of the study, 
respectively. However, more TED of Ventolin Evohaler was retained in AERO and 
these values were 50% and 51%. This is more likely due to the fast spray speed and 
greater ballistic force of Evo resulting in higher deposition in AERO (Brambilla et al., 
2011; Hautmann et al., 2013; Johnson et al., 2016; Kunda et al., 2017). On the other 
hand, 44% of Airomir TED was retained in AERO in both parts of the study which is 
lower than that of Sala+AERO. These differences reflect on the differences in 
formulation and device design of the three MDIs which produce emitted dose with 
differing ballistic characteristics of their sprays (Brambilla et al., 2011; Hautmann et al., 
2013; Johnson et al., 2016; Kunda et al., 2017).   
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The co-administration of charcoal significantly blocked the absorption of the swallowed 
portion of salbutamol dose of the three Salamol treatment methods (Table 8.3.7). 
However, urinary excretion of salbutamol in 0.5 hour (USAL0.5), a surrogate for the 
delivery to the lungs, was statistically similar in both parts of the study. This re-affirms 
that USAL0.5 is an index of lung deposition which is unaffected by charcoal ingestion. 
These results also confirm the findings with Ventolin Evohaler (Table 6.3.9) and 
Airomir (Table 7.3.6). Further, these observations also re-affirm that charcoal co-
administration effectively differentiates between the lung and systemic absorption of 
inhaled drugs (Borgström and Nilsson, 1990). 
8.3.5.1 In-Vitro and In-Vivo trends 
FPD of Salamol did not reflect on the USAL0.5 (Table 8.3.8). FPD was in-vitro 
equivalent and statistically similar between the MDI and the two spacer treatment 
methods while this was not observed with in-vivo studies for USAL0.5. Although lung 
deposition (USAL0.5) with the two spacer treatment methods was in-vivo equivalent 
and statistically similar between them, yet this was significantly greater than the MDI in 
both parts of the study. Nevertheless, FPD as a fraction of delivered dose (%FPF) 
broadly represented the differences of USAL0.5 between the MDI and spacer treatment 
methods. As pointed out earlier, the significant increase in USAL0.5 with the spacer 
treatment method may have been partly due to the good control of inhalation 
manoeuvre. Moreover, the absence of throat impaction effect, causing reflexive 
cessation of inhalation manoeuvre, may have contributed to this difference, which is 
evident from the significantly reduced IP deposition with the two spacers. The 
significant decrease in IP deposition and non-respirable dose (IP+CPM) with spacer 
treatment methods as compared to the MDI is reflected in significant increase in active 
salbutamol (USAL24Pre) and decrease in metabolites (USALMET) over 24 hours. 
The spacer removes a significant amount of the TED; hence, TDD is expected to be 
significantly different than that of the MDI alone. This was observed in-vitro. However, 
their total systemic bioavailability (USAL24NC) in Part 1 Study was in-vivo equivalent 
and statistically similar. Given that a spacer removes large proportion of the TED, it is 
rationale to compare the impactor mass (S0toF) to USAL24NC. This comparison 
reveals similarity of in-vitro trend to that of in-vivo. Nonetheless, due to the blockade of 
salbutamol absorption in Part 2 Study, significant increase was observed in USAL24C   
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with the two spacers as compared to the MDI alone. Although being in contrast to TDD, 
this mimics the trend observed with the lung deposition (USAL0.5C) which is the main 
source of systemic bioavailability when GIT absorption is prevented with charcoal co-
administration. 
8.3.6 Conclusions: In-Vivo Equivalence of Salamol Without and With Spacer 
The relative lung deposition of Salamol with VOL and AERO was significantly greater 
than that obtained with the MDI alone. The two delivery systems (MDI Vs MDI+SP) 
were bio-inequivalent and therefore can have clinical implications. However, the 
USAL0.5 was bioequivalent between the two spacer treatment methods despite their 
significantly different volumes.  
The total systemic bioavailability (USAL24NC) of the two delivery systems (three 
treatment methods) was equivalent and statistically similar. It is therefore highly likely 
that these will have similar salbutamol related systemic effects. Further, USAL24NC 
between the two spacer treatment methods is bioequivalent and statistically similar 
which may indicate a similar pattern of systemic effects. 
Although FPD is suggestive of in-vitro equivalence of the three treatment methods, this 
could not be observed with in-vivo relative lung deposition. Hence, caution should be 
exercised in relating in-vitro and in-vivo results. 
The relative lung deposition (USAL0.5), total systemic bioavailability (USAL24) and 
bioavailability of active salbutamol (USAL24Pre) were in-vivo equivalent and 
statistically similar between the two Salamol spacer treatment methods in both legs of 
the study. These findings suggest that both VOL and AERO should provide equally 
effective and similarly tolerated relief from bronchoconstriction. Whether one of these 
spacers could be exchanged for the other with Salamol would be at the discretion of the 
prescriber and the patient.  
The co-administration of activated charcoal clearly differentiated between the amount of 
Salamol that was deposited in the lungs and that which was absorbed through the GIT 
after swallowing. 
The results of this study should not be interpolated to either other salbutamol MDIs or 
spacers.  
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9 Chapter 9: Summary, General Conclusions and Future 
work 
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9.1 Summary and General Conclusions 
The in-vitro dose delivery characteristics of salbutamol HFA MDIs, Ventolin Evohaler 
(Evo), Airomir (Airo) and Salamol (Sala) have been assessed and complemented with 
in-vivo evaluation in humans. These studies included comparisons of the MDIs with 
each other and between the MDI alone and when attached to the spacer. The in-vitro 
studies were carried out using Andersen Cascade Impactor (ACI) (BP, 2005; USP28-
NF23, 2005; Ph. Eur., 2011) while urinary pharmacokinetic (PK) method of Hindle and 
Chrystyn (1992) was applied for in-vivo assessment. The PK studies were also 
complemented by charcoal block studies (EMA, 2009).  
9.1.1 Salbutamol MDIs 
Evo, Airo and Sala had in-vitro equivalent and statistically similar emitted dose (Table 
5.2.7). However, the FPD (and FPM) was only in-vitro equivalent and statistically 
similar between Airo and Sala. Further, Induction Port (IP) deposition was in-vitro 
inequivalent between these MDIs, while only being marginally similar between Evo and 
Sala (p = 0.055). This was expected. Evo is formulated in HFA134a propellant only, has 
larger metered dose volume and actuator orifice diameter (Table 2.2.1); hence releases 
relatively more ballistic spray than the other MDIs (Barry and O’Calaghan, 1997; 
Gabrio et al. 1999; Brambilla et al., 2011; Hautmann et al., 2013; Johnson et al., 2016; 
Kunda et al., 2017). Airo and Sala contain ethanol which slows down their spray speed 
and evaporation of the propellant (Stein and Myrdal, 2006). It is therefore clear that 
their differences in the dose emission characteristics have origin in formulation and 
device design. 
Although statistically similar, the relative lung deposition (USAL0.5) was not in-vivo 
equivalent amongst the MDIs in both parts of the study (without and with charcoal 
block). While statistically similar total systemic bioavailability (USAL24) was also 
observed between them, only paired comparison of Evo Vs Sala and Airo Vs Sala were 
in-vivo equivalent to Parameswaran (1999) limits.  
In Part 2 Study, with concomitant charcoal intake, USAL0.5C reproduced similar trend 
as that of USAL0.5NC, which re-affirms that urinary excretion of salbutamol in the first 
half an hour post-inhalation is derived from the lung deposition (Hindle and Chrystyn, 
1992). Nevertheless, total systemic bioavailability (USAL24C) was in-vivo inequivalent 
with significant statistical difference. This was anticipated since GIT absorption of the   
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swallowed dose was prevented by charcoal. The co-administration of charcoal clearly 
differentiated between the systemic salbutamol derived from the lungs and absorbed 
from the GIT (Table 5.3.9). 
The results of the urinary PK study suggest that Evo, Airo and Sala were not in-vivo 
equivalent in healthy subjects. Hence, caution should be exercised if a change of 
salbutamol MDI brand is desired. Indeed, MHRA (Chrystyn and Price, 2009) and health 
authorities (NHS Gloucestershire, 2017) have instructed physicians to prescribe MDIs 
by brand names.  
9.1.2 Salbutamol MDI with spacer 
A general tendency of significantly greater lung deposition (USAL0.5) with spacer use 
was observed irrespective of the MDI and spacer brands. However, this increase was 
not seen with in-vitro respirable dose (FPD). Differences in FPD of the two treatment 
methods (MDI and MDI+SP) were not significant and, instead, were in-vitro equivalent. 
Although unexpected and is in conflict with previous findings for Airomir (Barry and 
O’Callaghan, 1997; Ross and Gabrio, 1999; Mitchell et al., 1999), this phenomenon is 
understandable since in-vitro findings are not always replicated in humans (Dompeling 
et al., 2001; Barben et al., 2003; Dubus et al., 2003). Further, in contrast to dynamic 
human respiratory tract physiology and anatomy, the in-vitro experiments are conducted 
under controlled conditions in rigid systems. The constant flow in ACI may have 
masked the differences between the MDI alone and with the spacer (Table 6.2.9, Table 
7.2.9 & Table 8.2.9). The airflow effectively carried away the emitted dose of the two 
treatment methods into ACI. This is in line with the findings for Ventolin Evohaler 
(Cripps et al., 2000) and ProAir HFA (von Hollen et al., 2011a & b; Hatley et al., 2014). 
Nevertheless, the significant differences of note between the two aerosol delivery 
systems (MDI Vs MDI+SP) were the composition of delivered dose containing the 
relative proportions of FPD [%FPF (%TDD)] and the deposition in the IP. This was 
predictable as spacer retains a large proportion of the emitted dose containing large 
particles, possessing greater impaction force, ballistic speed and larger spray cone while 
simultaneously providing space to them to evaporate into finer particles and slowing 
their speed (Terzano, 2001; Hess, 2008; Nikander et al., 2014). Consequently, the 
delivered dose contained particles mainly in the size range of FPD. On the contrary, 
when the MDI is used alone, a large proportion of the emitted dose is deposited in IP.  
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There is less space to slow down the emitted dose and therefore a large proportion of the 
ballistic dose deposits in IP. These in-vitro findings indicate the role of spacer in 
significantly reducing the IP deposition. This benefit was obvious in humans where the 
lung deposition was significantly greater with the spacer than without it. This is partly 
due to the more effective and consistent inhalation manoeuvre with the spacer use and 
partly due to the absence of reflexive cessation observed with the impaction of emitted 
dose on the throat from an MDI. 
The only out of trend in-vitro result observed was between Evo Vs Evo+AERO where 
FPD of Evo with AERO was significantly lower than the MDI. This is more likely due 
to the ballistic emitted dose with large spray cone, eventually resulting in larger spacer 
deposition (52% of TED) and smaller TDD. Cripps et al. (2000) also reported similar 
findings for Evo with Babyhaler and VOL. Further, the current results indicate that the 
volume of the spacer may not have played a significant role. This finding is in conflict 
with the reported significant increase in FPD with increase in spacer volume for 
Airomir (Mitchell et al., 1999; Ross and Gabrio, 1999), which however, did not reach 
significance for Evo (Cripps et al., 2000; Hall et al., 2011). Although spacer and MDI 
specific differences are often observed (Barry and O’Calaghan, 1997; Ross and Gabrio, 
1999; Dubus et al., 2001), as with Evo+AERO in the current study (Table 6.2.4, Table 
6.3.9 and Table 6.3.10), it is highly unlikely that small differences in FPD between the 
two treatment methods (MDI and MDI+SP) may be of clinical significance.  
Intriguingly, Salamol MDI alone had greater FPD than with VOL and AERO (Table 
8.2.4). This suggests that Salamol alone maybe a better choice than the spacer treatment 
method. Also, albeit being lower by only <2 µg, FPD of Airomir was statistically 
similar and in-vitro equivalent to that with AERO (Table 7.2.8 & Table 7.2.9). 
However, in-vivo results do not support these assessments since spacers had 
significantly greater lung deposition than the MDI in healthy humans (Table 8.3.1, 
Table 8.3.5, Table 8.3.6, Table 7.3.1 & Table 7.3.5). Given that patients have reduced 
airway calibre (Lipworth and Clark, 1997) and poor inhalation technique (Laube et al., 
2011; Lavorini, 2013, 2014; Lavorini et al., 2014), the observed increase in lung 
deposition with spacer treatment methods may be beneficial.  
The significant decrease in the in-vitro delivered dose with the spacer as compared to 
the MDI did not reflect on total systemic bioavailability (USAL24NC). USAL24NC of  
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the MDIs was in-vivo equivalent and statistically similar to the spacer treatment 
methods.  
Interestingly, this was also observed between the MDI alone treatment methods, except 
that Evo was not in-vivo equivalent to Airo. 
In contrast, the USAL24C increased significantly with the spacer treatment methods as 
compared to the MDI. This is more likely due to the greater lung deposition with the 
spacer. Interestingly, with AERO, the treatment methods of Airo and Sala showed in-
vivo equivalent USAL24C to their respective MDIs. This out of trend finding highlights 
that each spacer influences the dose delivery of a given salbutamol MDI differently 
(Barry and O’Calaghan, 1997; Ross and Gabrio, 1999; Dubus et al., 2001). Further, 
these results re-inforce that outcomes of one spacer study cannot be extrapolated to 
other spacers and salbutamol MDIs or an MDI of a different drug (Mitchell and Nagel, 
2007; Laube et al., 2011; Nikander et al., 2014). 
The comparative in-vitro and in-vivo results of salbutamol MDIs without and with 
spacers do not reflect on each other. The statistical similarity of FPD is not reproduced 
in significantly increased lung deposition. On the other hand, the significant decrease in 
in-vitro delivered dose did not represent the in-vivo statistical similarity of total 
systemic bioavailability in Part 1 Study and to latter’s significant increase in Part 2 
Study. These results clearly show that in-vitro results may not always mimic the in-vivo 
findings. Hence, caution should be exercised in making decisions based on the in-vitro 
data only. 
Overall, the results highlight that the MDI delivers FPD inefficiently as compared to the 
spacer treatment methods as evident from significantly greater FPF (%TDD) (Table 
6.2.6 & Table 6.2.9, Table 7.2.6 & Table 7.2.9, Table 8.2.6 & Table 8.2.9). This is 
clearly reflected in greater lung deposition (Table 6.3.1 & Table 6.3.2, Table 7.3.1 & 
Table 7.3.5, Table 8.3.1 & Table 8.3.6). The spacer therefore removes non-respirable 
dose that otherwise would deposit in the throat.  
9.2 Future work 
The current work assessed in-vitro particle size characteristics of salbutamol HFA MDIs 
as stipulated by the regulatory authorities which is a standard practice in the 
pharmaceutical companies. Therefore, this work can be extended to other areas to 
further explore dose delivery characteristics of salbutamol HFA MDIs and to identify   
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their link to the in-vivo studies in humans. Hence, in-vitro research using ACI or NGI 
can include the following areas:  
1. The current in-vivo studies in humans revealed prolonged excretion of salbutamol 
post-inhalation, both as active and metabolised moieties (Silkstone et al., 2000, 
2002a). This was reproduced in charcoal block studies indicating that the 
absorption of salbutamol from the lungs may have been taking place over extended 
time period. Hence, it would be interesting to explore and differentiate in-vitro 
whether this prolonged excretion is due to the dissolution of inhaled salbutamol 
particles or is an intrinsic characteristic of the molecule. The dynamics of total 
delivered (TDD) and respirable (FPD) doses, collected on filters, can be explored 
with in-vitro dissolution studies (May et al., 2012, 2014, 2015; Riley et al., 2012; 
Son et al., 2010). The dose-laden filters are then to undergo dissolution to generate 
profiles. The following methods could be adopted to collect doses: 
a) Filtration unit for TDD. 
b) Filters placed in glass twin impinger and/or abbreviated impactors (AIM) 
for FPD and non-respirable dose. Modifications in AIM can also be used for 
stage group segregation. 
c) Filter on each stage of the impactor (ACI or NGI) for Individual stage 
depositions. This can pose HPLC method sensitivity challenges. 
2. The extent of deposition in the throat can affect the FPD (Golshahi and Finlay, 
2012; Borgström et al., 2006). USP throat has been shown to have different 
deposition patterns than those of mouth-throat models and casts (Zhang et al., 2007; 
Zhou et al., 2011). Hence, it would be interesting to discover any impact on FPD 
and stage group deposition of salbutamol MDIs. In-vitro studies using Alberta 
Idealized Throats (Copley et al., 2011; Copley, 2015), throat geometry models and 
replicas (Fadl et al., 2007; Zhou et al., 2011; Olsson et al., 2013) can provide useful 
insight into APSD profiles that could then be compared with in-vivo lung 
deposition in humans using urinary PK studies.  
3. The flow rate through the impactors can also affect the inhaled dose (von Hollen et 
al., 2013; Slator et al., 2014; Liu et al., 2017). Hence these throat models should be 
compared using the following flow rates 
a) standard flow rate 28.3 (ACI) or 30 (NGI) L/min 
b) simulated flow rate 
c) breathing simulation  
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d)  respiratory profiles of volunteers / patients (Chrystyn et al., 2015) 
4. Extended comparison should be carried out to include newly marketed and existing 
spacers. Spacer studies should be conducted on the above mentioned flow rates 
(No. 3). Tidal breathing patterns should also be explored with the spacers. 
Moreover, these studies can also include spacer with mask. 
5. The experimental conditions of the current in-vitro work reflect on the adult 
population. This work can, therefore, be expanded to conditions that mimic child 
population. Hence, flow rate of 15 L/min can be used with all the experiments listed 
above [Nos. 2 & 3].  
6. In-vitro and in-vivo studies should be carried out to other salbutamol MDIs 
(Asmavent, Asthalin, AirSalb, Apo-salbutamol; Respigen, Ratio-salbutamol) with 
and without spacer. 
7. In-vitro and in-vivo studies should be conducted to compare breath-actuated 
salbutamol MDIs (Airomir Autohaler, Salamol Easi-Breathe) with: 
a) their standard versions without and with spacer 
b) other standard MDIs without and with spacer. 
8. Further expansion of studies in Nos. 6 & 7 could include those enumerated in Nos. 
1-5. 
9. Differing CQAs results have been observed for salbutamol MDIs across regions 
(Table 2.5.1, Table 2.5.2 & Table 2.5.3). It would be interesting to compare these 
MDIs marketed in different regions if manufactured at different sites. This is to 
identify if these differences are related to laboratories or multiple manufacturing 
sites or are due to batch to batch variability.  
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Appendix 5.2.3.1: APSD of two puffs (200 µg) of Ventolin Evohaler MDI obtained with ACI at 28.3 ± 1.5 L/min 
Identity Run 1 Run 2 Run 3 Run 4 Run 5 Mean SD RSD Median 
MDI Canister Valve 4.85 4.71 5.80 4.53 4.97 4.97 0.49 9.91 4.85 
MDI Actuator 30.95 37.01 37.55 37.92 37.55 36.20 2.95 8.15 37.55 
ACI Throat 96.98 88.47 89.33 77.03 92.08 88.78 7.36 8.29 89.33 
ACI S-0 1.84 2.28 2.18 1.92 2.05 2.06 0.18 8.83 2.05 
ACI S-1 3.21 2.60 3.03 2.39 2.56 2.76 0.35 12.52 2.60 
ACI S-2 3.72 4.94 5.21 4.61 4.62 4.62 0.56 12.15 4.62 
ACI S-3 14.91 21.09 19.05 18.48 18.38 18.38 2.23 12.13 18.48 
ACI S-4 30.64 35.63 36.76 36.08 36.76 35.17 2.58 7.33 36.08 
ACI S-5 16.56 20.93 21.08 20.03 21.08 19.94 1.94 9.72 20.93 
ACI S-6 3.50 3.24 3.80 3.05 3.40 3.40 0.28 8.29 3.40 
ACI S-7 0.70 0.54 0.73 0.55 0.63 0.63 0.08 13.23 0.63 
ACI Filter 1.14 0.69 1.00 0.77 0.90 0.90 0.18 19.94 0.90 
Total Recovery (µg) 208.99 222.14 225.51 207.36 224.98 217.80 8.89 4.08 222.14 
% Recovery
a
 104.50 111.07 112.76 103.68 112.49 108.90 4.45 4.08 111.07 
Mass Balance
b
 (µg) 204.14 217.43 219.71 202.83 220.01 212.82 8.59 4.04 217.43 
% Recovery  102.07 108.71 109.85 101.42 110.00 106.41 4.30 4.04 108.71 
a = % Recovery calculated with respect to Nominal Dose (ND), i.e., two actuations of 100 µg per puff 
b = Mass Balance = Ex-Canister Valve recovery. Recovery calculated with respect to Nominal Dose 
(ND) excluding deposition on Canister Valve but including deposition on Actuator (mouth piece). 
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Appendix 5.2.3.2: APSD of two puffs (200 µg) of Airomir MDI obtained with ACI at 28.3 ± 1.5 L/min 
Identity Run 1 Run 2 Run 3 Run 4 Run 5 Mean SD RSD Median 
MDI Canister Valve 22.90 20.49 19.58 15.42 19.58 19.60 2.70 13.77 19.58 
MDI Actuator 19.07 18.93 22.82 21.36 22.82 21.00 1.92 9.13 21.36 
ACI Throat 73.15 68.95 68.11 70.08 68.11 69.68 2.10 3.02 68.95 
ACI S-0 2.73 2.79 4.36 3.01 4.36 3.45 0.84 24.29 3.01 
ACI S-1 2.53 3.15 4.70 5.00 4.70 4.01 1.10 27.48 4.70 
ACI S-2 3.76 5.51 7.07 5.58 7.07 5.80 1.37 23.67 5.58 
ACI S-3 20.01 25.65 25.22 29.52 25.22 25.12 3.38 13.47 25.22 
ACI S-4 38.55 35.18 34.16 34.53 36.08 35.70 1.75 4.90 35.18 
ACI S-5 22.56 21.05 21.46 18.70 21.46 21.04 1.43 6.77 21.46 
ACI S-6 5.22 5.21 5.54 4.43 5.54 5.19 0.45 8.72 5.22 
ACI S-7 2.05 2.08 2.02 2.08 2.02 2.05 0.03 1.46 2.05 
ACI Filter 2.72 2.65 2.14 1.74 2.14 2.28 0.41 17.82 2.14 
Total Recovery (µg) 215.25 211.64 217.17 211.46 219.08 214.92 3.36 1.56 215.25 
% Recovery
a
 107.62 105.82 108.59 105.73 109.54 107.46 1.68 1.56 107.62 
Mass Balance
b
 (µg) 192.35 191.15 197.59 196.04 199.50 195.32 3.51 1.80 196.04 
% Recovery  96.17 95.57 98.79 98.02 99.75 97.66 1.76 1.80 98.02 
a = % Recovery calculated with respect to Nominal Dose (ND), i.e., two actuations of 100 µg per puff 
b = Mass Balance = Ex-Canister Valve recovery. Recovery calculated with respect to Nominal Dose 
(ND) excluding deposition on Canister Valve but including deposition on Actuator (mouth piece). 
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Appendix 5.2.3.3: APSD of two puffs (200 µg) of Salamol MDI obtained with ACI at 28.3 ± 1.5 L/min 
Identity Run 1 Run 2 Run 3 Run 4 Run 5 Mean SD RSD Median 
MDI Canister Valve 23.24 20.02 17.35 20.56 19.04 20.04 2.17 10.80 20.02 
MDI Actuator 34.83 33.25 28.29 22.13 25.50 28.80 5.29 18.36 28.29 
ACI Throat 82.55 79.64 80.56 82.52 75.07 80.07 3.07 3.83 80.56 
ACI S-0 1.81 2.56 3.43 2.70 3.05 2.71 0.61 22.37 2.70 
ACI S-1 2.80 3.57 4.14 3.42 4.93 3.77 0.80 21.32 3.57 
ACI S-2 3.49 3.82 4.06 4.79 4.18 4.07 0.48 11.88 4.06 
ACI S-3 18.15 22.48 20.23 18.13 15.74 18.95 2.53 13.38 18.15 
ACI S-4 35.37 36.89 28.70 37.75 40.25 35.79 4.34 12.13 36.89 
ACI S-5 23.06 24.85 18.72 23.94 29.29 23.97 3.79 15.81 23.94 
ACI S-6 4.75 5.72 6.41 4.99 7.10 5.80 0.98 16.92 5.72 
ACI S-7 1.83 2.11 2.96 1.91 2.66 2.30 0.49 21.51 2.11 
ACI Filter 2.10 2.81 3.82 2.67 1.63 2.60 0.82 31.65 2.67 
Total Recovery (µg) 233.97 237.73 218.67 225.51 228.45 228.87 7.42 3.24 228.45 
% Recovery
a
 116.99 118.87 109.34 112.75 114.22 114.43 3.71 3.24 114.22 
Mass Balance
b
 (µg) 210.73 217.71 201.32 204.94 209.41 208.82 6.21 2.98 209.41 
% Recovery  105.37 108.86 100.66 102.47 104.71 104.41 3.11 2.98 104.71 
a = % Recovery calculated with respect to Nominal Dose (ND), i.e., two actuations of 100 µg per puff 
b = Mass Balance = Ex-Canister Valve recovery. Recovery calculated with respect to Nominal Dose 
(ND) excluding deposition on Canister Valve but including deposition on Actuator (mouth piece). 
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Appendix 5.3.4.1: Volunteer’s demographic data 
Volunteer 
Id 
 
Sex Age Heights Weight BMI 
 
M/F (years) (m) (Kg) (Kg/m
2
) 
1 
 
F 27 1.70 72 24.91 
2 
 
M 38 1.73 81 27.06 
3 
 
F 31 1.58 50 20.03 
4 
 
M 38 1.68 69 24.45 
5 
 
F 27 1.65 61 22.41 
6 
 
F 25 1.65 68 24.98 
7 
 
M 48 1.82 82 24.76 
8 
 
F 26 1.57 55 22.31 
9 
 
F 25 1.62 48 18.29 
10 
 
M 39 1.64 54 20.08 
11 
 
M 33 1.79 71 22.16 
12 
 
F 23 1.68 65 23.03 
13 
 
M 25 1.70 67 23.18 
Mean 
 
 31.15 1.68 64.85 22.90 
SD 
 
 7.55 0.07 10.84 2.42 
Median 
 
 27 1.68 67 10.57 
M = male; F = female; BMI = Body Mass Index 
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Appendix 5.3.4.2: Ventolin Evohaler Part 1 Study (without charcoal blockade) 
Salbutamol urinary excretion of individual healthy volunteers Dose retained in MDI device components 
TDD-TRD 
Subj USAL0.5 USAL24
a
 USAL24Pre USAL24Post USALMET Canister Actuator TDD TDD %ND 
1 4.0 110.8 45.0 108.6 63.6 4.1 30.7 169.3 84.6 58.4 
2 6.6 92.9 32.3 88.6 56.3 4.3 42.3 157.7 78.9 64.9 
3 4.8 74.4 41.8 71.8 29.9 4.7 39.9 160.1 80.1 85.8 
4 4.2 114.6 64.4 111.7 47.3 6.0 47.0 153.0 76.5 38.4 
5 7.1 97.1 72.6 87.8 15.2 5.8 34.3 165.7 82.8 68.6 
6 2.5 118.1 94.5 114.8 20.3 5.0 34.0 166.0 83.0 47.9 
7 8.0 103.2 55.7 96.4 40.7 5.4 33.3 166.7 83.3 63.4 
8 8.4 79.6 33.0 75.7 42.8 7.0 46.4 153.6 76.8 74.0 
9 6.9 107.4 77.2 97.7 20.5 3.9 39.8 160.2 80.1 52.8 
10 4.1 86.3 49.9 81.3 31.4 4.5 38.2 161.8 80.9 75.6 
11 4.3 116.9 63.2 108.9 45.8 5.7 44.3 155.7 77.9 38.8 
12 5.6 123.7 73.1 118.7 45.6 3.9 36.7 163.3 81.7 39.6 
13 7.8 78.5 56.2 72.6 16.4 3.9 45.5 154.5 77.2 76.0 
Mean 5.7 100.26 58.4 95.0 36.6 4.94 39.41 160.6 80.3 60.3 
SD 1.9 16.72 18.3 16.6 15.6 0.97 5.43 5.4 2.7 15.8 
RSD 32.5 16.68 31.3 17.5 42.6 19.60 13.77 3.4 3.4 26.2 
a 
TRD 
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Appendix 5.3.4.3: Airomir Part 1 Study (without charcoal blockade) 
Salbutamol urinary excretion of individual healthy volunteers Dose retained in MDI device components 
TDD-TRD 
Subj USAL0.5 USAL24
a
 USAL24Pre USAL24Post USALMET Canister Actuator TDD TDD %ND 
1 9.7 95.0 53.9 85.4 31.4 15.1 21.6 178.4 89.2 83.4 
2 4.9 77.5 44.9 72.5 27.7 17.4 24.8 175.2 87.6 97.7 
3 5.5 68.7 44.8 63.3 18.5 18.9 25.5 174.5 87.2 105.7 
4 6.2 67.9 43.8 61.7 17.9 17.1 23.3 176.7 88.4 108.8 
5 6.2 75.4 46.3 69.2 22.9 13.6 18.9 181.1 90.5 105.7 
6 7.8 72.9 32.8 65.1 32.3 12.9 23.6 176.4 88.2 103.5 
7 5.7 96.6 59.2 90.9 31.7 13.9 25.4 174.6 87.3 78.0 
8 8.6 97.6 55.9 89.1 33.1 18.2 23.4 176.6 88.3 79.0 
9 10.0 95.1 56.1 85.1 29.0 14.6 26.7 173.3 86.6 78.2 
10 5.3 96.6 48.0 91.3 43.3 16.7 22.6 177.4 88.7 80.8 
11 5.1 100.0 49.6 94.9 45.3 13.1 24.0 176.0 88.0 76.0 
12 6.6 66.5 37.8 59.9 22.1 13.7 25.0 175.0 87.5 108.5 
13 10.9 84.9 42.2 74.1 31.8 16.2 19.6 180.4 90.2 95.5 
Mean 7.11 84.22 47.36 77.11 29.76 15.49 23.41 176.59 88.30 92.37 
SD 2.05 13.06 7.61 12.74 8.34 2.04 2.29 2.29 1.15 13.29 
RSD 28.88 15.50 16.06 16.52 28.02 13.17 9.80 1.30 1.30 14.39 
a 
TRD 
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Appendix 5.3.4.4: Salamol Part 1 Study (without charcoal blockade) 
Salbutamol urinary excretion of individual healthy volunteers Dose retained in MDI device components 
TDD-TRD 
Subj USAL0.5 USAL24
a
 USAL24Pre USAL24Post USALMET Canister Actuator TDD TDD %ND 
1 6.7 87.8 46.7 81.2 34.4 16.8 23.9 176.1 88.0 88.2 
2 6.1 102.6 57.6 96.4 38.8 15.7 28.3 171.7 85.9 69.2 
3 5.9 75.7 33.6 69.8 36.1 14.9 26.0 174.0 87.0 98.3 
4 10.7 101.1 46.9 90.5 43.6 18.1 28.1 171.9 86.0 70.8 
5 6.9 62.4 14.9 55.5 40.6 20.3 26.4 173.6 86.8 111.2 
6 1.9 81.8 37.1 79.8 42.7 17.4 19.6 180.4 90.2 98.6 
7 5.6 111.2 42.2 105.6 63.4 17.6 29.7 170.3 85.2 59.1 
8 5.0 128.1 47.8 123.0 75.2 15.6 26.0 174.0 87.0 46.0 
9 12.9 124.6 56.7 111.6 55.0 22.8 27.0 173.0 86.5 48.4 
10 7.0 81.3 36.3 74.3 37.9 15.2 29.3 170.7 85.3 89.3 
11 2.1 86.7 52.4 84.6 32.2 18.6 19.9 180.1 90.0 93.4 
12 5.2 80.0 42.6 74.8 32.2 15.7 30.0 170.0 85.0 90.0 
13 11.0 103.3 42.7 92.3 49.6 28.9 21.2 178.8 89.4 75.5 
Mean 6.70 94.35 42.89 87.65 44.75 18.29 25.80 174.20 87.10 79.85 
SD 3.22 19.44 11.17 18.41 12.92 3.89 3.61 3.61 1.80 20.21 
RSD 48.11 20.60 26.05 21.00 28.86 21.26 13.99 2.07 2.07 25.31 
a 
TRD 
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Appendix 5.3.4.5: Ventolin Evohaler Part 2 Study (with charcoal blockade) 
Salbutamol urinary excretion of individual healthy volunteers Dose retained in MDI device components 
TDD-TRD 
Subj USAL0.5 USAL24
a
 USAL24Pre USAL24Post USALMET Canister Actuator TDD TDD %ND 
1 2.2 22.5 13.6 20.3 6.7 5.4 38.3 161.7 80.9 139.2 
2 4.3 31.9 15.6 27.7 12.0 4.7 42.6 157.4 78.7 125.5 
3 2.6 34.2 16.3 31.6 15.3 4.9 45.1 154.9 77.4 120.7 
4 2.8 32.0 20.6 29.2 8.6 5.3 44.8 155.2 77.6 123.3 
5 9.3 36.9 21.4 27.6 6.2 4.7 35.1 164.9 82.4 128.0 
6 3.4 18.7 10.0 15.3 5.3 5.3 37.1 162.9 81.4 144.2 
7 6.8 30.7 12.6 23.9 11.3 4.9 37.8 162.2 81.1 131.4 
8 3.8 30.2 8.0 26.4 18.4 5.2 38.8 161.2 80.6 131.0 
9 9.7 33.1 7.6 23.4 15.8 4.8 37.8 162.2 81.1 129.1 
10 5.0 25.8 15.2 20.8 5.5 5.8 38.5 161.5 80.8 135.7 
11 8.0 31.8 6.8 23.8 17.0 6.3 45.9 154.1 77.0 122.3 
12 5.0 34.8 23.4 29.8 6.4 4.7 42.0 158.0 79.0 123.2 
13 5.9 24.6 15.0 18.8 3.7 4.5 46.4 153.6 76.8 129.0 
Mean 5.29 29.79 14.3 24.5 10.2 5.11 40.78 159.22 79.61 129.43 
SD 2.50 5.31 5.3 4.8 5.1 0.51 3.83 3.83 1.91 6.96 
RSD 47.28 17.83 37.2 19.5 49.7 9.88 9.38 2.40 2.40 5.38 
a 
TRD 
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Appendix 5.3.4.6: Airomir Part 2 Study (with charcoal blockade) 
Salbutamol urinary excretion of individual healthy volunteers Dose retained in MDI device components 
TDD-TRD 
Subj USAL0.5 USAL24
a
 USAL24Pre USAL24Post USALMET Canister Actuator TDD TDD %ND 
1 6.6 55.5 36.1 48.9 12.8 16.5 25.2 174.8 87.4 119.3 
2 5.5 36.2 18.8 30.7 11.9 15.6 19.5 180.5 90.3 144.3 
3 4.6 39.0 21.1 34.4 13.3 14.6 26.8 173.2 86.6 134.2 
4 8.4 55.6 36.0 47.3 11.3 16.6 23.3 176.7 88.4 121.1 
5 4.7 29.0 16.0 24.3 8.3 13.1 18.0 182.0 91.0 153.0 
6 5.8 29.3 18.4 23.5 5.1 13.6 24.9 175.1 87.6 145.8 
7 8.2 62.2 42.9 54.0 11.1 14.0 25.6 174.4 87.2 112.1 
8 6.8 57.2 29.0 50.3 21.3 16.1 26.4 173.6 86.8 116.4 
9 9.2 66.6 42.8 57.3 14.6 15.8 21.9 178.1 89.0 111.5 
10 5.2 47.1 26.4 41.9 15.5 14.8 24.1 175.9 88.0 128.8 
11 4.5 51.2 35.4 46.7 11.3 14.6 26.7 173.3 86.6 122.1 
12 5.1 50.1 31.8 45.0 13.2 14.2 25.9 174.1 87.0 123.9 
13 11.9 51.6 30.8 39.6 8.9 13.7 25.1 174.9 87.4 123.3 
Mean 6.67 48.52 29.65 41.84 12.19 14.87 24.11 175.89 87.95 127.38 
SD 2.22 11.90 9.04 10.80 3.88 1.14 2.76 2.76 1.38 13.21 
RSD 33.21 24.52 30.47 25.81 31.86 7.67 11.46 1.57 1.57 10.37 
a 
TRD 
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Appendix 5.3.4.7: Salamol Part 2 Study (with charcoal blockade) 
Salbutamol urinary excretion of individual healthy volunteers Dose retained in MDI device components 
TDD-TRD 
Subj USAL0.5 USAL24
a
 USAL24Pre USAL24Post USALMET Canister Actuator TDD TDD %ND 
1 6.2 25.9 12.6 19.7 7.2 18.2 19.7 180.3 90.1 154.4 
2 4.1 37.9 18.0 33.8 15.8 12.8 25.6 174.4 87.2 136.5 
3 2.8 48.5 20.2 45.6 25.4 11.8 26.6 173.4 86.7 125.0 
4 11.8 69.1 32.5 57.3 24.8 12.7 29.6 170.4 85.2 101.4 
5 8.5 61.5 22.3 53.0 30.7 12.0 30.4 169.6 84.8 108.0 
6 7.9 42.5 25.1 34.5 9.4 25.3 31.0 169.0 84.5 126.5 
7 6.3 62.7 38.1 56.4 18.4 13.4 31.4 168.6 84.3 105.9 
8 5.6 48.4 32.6 42.8 10.2 11.8 25.5 174.5 87.2 126.1 
9 15.5 30.8 8.7 15.4 6.7 12.2 26.8 173.2 86.6 142.4 
10 5.5 51.4 20.7 45.9 25.2 13.3 27.1 172.9 86.5 121.5 
11 4.8 52.8 42.4 48.0 5.7 25.5 19.3 180.7 90.3 127.9 
12 8.2 62.2 33.8 54.0 20.3 13.6 27.9 172.1 86.0 109.8 
13 6.6 58.6 47.0 52.0 5.0 26.1 22.7 177.3 88.6 118.7 
Mean 7.20 50.17 27.23 42.96 15.74 16.04 26.43 173.57 86.78 123.40 
SD 3.36 13.06 11.55 13.50 8.93 5.70 3.92 3.92 1.96 15.18 
RSD 46.60 26.03 42.43 31.43 56.77 35.55 14.83 2.26 2.26 12.30 
a 
TRD 
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Appendix 6.2.6.1: APSD of two puffs (200 µg) of Ventolin Evohaler + Volumatic obtained with ACI at 28.3 ± 1.5 L/min 
Identity Run 1 Run 2 Run 3 Run 4 Run 5 Mean SD RSD Median 
MDI Canister Valve 5.43 6.14 5.15 6.99 7.11 6.17 0.89 14.36 6.14 
MDI Actuator 22.52 21.28 23.79 24.84 23.28 23.14 1.34 5.79 23.28 
Spacer 82.59 78.34 66.36 74.77 72.40 74.89 6.13 8.18 74.77 
ACI Throat 6.44 7.15 5.97 2.26 5.71 5.51 1.90 34.42 5.97 
ACI S-0 1.65 1.95 1.38 2.05 2.63 1.93 0.47 24.36 1.95 
ACI S-1 4.51 3.22 4.51 3.92 3.05 3.84 0.69 18.00 3.92 
ACI S-2 6.14 3.75 7.26 5.16 5.32 5.53 1.30 23.45 5.32 
ACI S-3 15.18 18.25 20.50 22.84 23.62 20.08 3.45 17.20 20.50 
ACI S-4 32.23 33.45 30.56 34.45 35.42 33.22 1.90 5.72 33.45 
ACI S-5 17.29 18.95 19.80 21.30 17.58 18.98 1.65 8.68 18.95 
ACI S-6 5.25 4.14 3.24 2.96 4.32 3.98 0.91 22.95 4.14 
ACI S-7 0.82 0.97 1.05 0.72 0.91 0.89 0.13 14.38 0.91 
ACI Filter 0.95 0.82 1.15 0.65 1.03 0.92 0.19 20.96 0.95 
Total Recovery (µg) 201.00 198.42 190.73 202.91 202.38 199.09 4.99 2.50 201.00 
% Recovery
a
 100.50 99.21 95.36 101.45 101.19 99.54 2.49 2.50 100.50 
Mass Balance
b
 (µg) 195.57 192.27 185.57 195.92 195.27 192.92 4.36 2.26 195.27 
% Recovery  97.79 96.14 92.79 97.96 97.63 96.46 2.18 2.26 97.63 
a = % Recovery calculated with respect to Nominal Dose (ND), i.e., two actuations of 100 µg per puff 
b = Mass Balance = Ex-Canister Valve recovery. Recovery calculated with respect to Nominal Dose (ND) excluding deposition 
on Canister Valve but including deposition on Actuator (mouth piece). 
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Appendix 6.2.6.2: APSD of two puffs (200 µg) of Ventolin Evohaler + AeroChamber Plus obtained with ACI at 28.3 ± 1.5 
L/min 
Identity Run 1 Run 2 Run 3 Run 4 Run 5 Mean SD RSD Median 
MDI Canister Valve 6.73 5.15 7.18 4.09 5.63 5.76 1.24 21.52 5.63 
MDI Actuator 22.90 24.66 25.30 26.18 21.56 24.12 1.87 7.75 24.66 
Spacer 86.55 96.56 98.99 87.41 83.61 90.62 6.73 7.43 87.41 
ACI Throat 4.79 5.65 3.86 6.62 4.17 5.02 1.13 22.45 4.79 
ACI S-0 2.11 1.45 1.92 2.99 3.05 2.30 0.70 30.24 2.11 
ACI S-1 5.14 3.95 3.33 4.62 5.05 4.42 0.77 17.40 4.62 
ACI S-2 7.25 4.92 5.69 6.61 6.12 6.12 0.89 14.49 6.12 
ACI S-3 21.33 17.63 15.26 20.48 19.66 18.87 2.44 12.94 19.66 
ACI S-4 25.23 31.13 28.66 30.52 27.87 28.68 2.34 8.17 28.66 
ACI S-5 15.11 13.54 17.05 16.25 14.84 15.36 1.35 8.79 15.11 
ACI S-6 3.62 2.82 1.85 2.22 2.88 2.68 0.68 25.35 2.82 
ACI S-7 1.44 0.82 0.77 0.69 0.84 0.91 0.30 32.98 0.82 
ACI Filter 1.26 0.94 0.82 0.87 0.98 0.97 0.17 17.60 0.94 
Total Recovery (µg) 203.46 209.22 210.67 209.55 196.26 205.83 6.04 2.94 209.22 
% Recovery
a
 101.73 104.61 105.34 104.78 98.13 102.92 3.02 2.94 104.61 
Mass Balance
b
 (µg) 196.72 204.07 203.50 205.46 190.63 200.08 6.27 3.13 203.50 
% Recovery  98.36 102.03 101.75 102.73 95.32 100.04 3.13 3.13 101.75 
a = % Recovery calculated with respect to Nominal Dose (ND), i.e., two actuations of 100 µg per puff 
b = Mass Balance = Ex-Canister Valve recovery. Recovery calculated with respect to Nominal Dose 
(ND) excluding deposition on Canister Valve but including deposition on Actuator (mouth piece). 
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Appendix 6.2.6.3: APSD of two puffs (200 µg) of Ventolin Evohaler + Able obtained with ACI at 28.3 ± 1.5 L/min 
Identity Run 1 Run 2 Run 3 Run 4 Run 5 Mean SD RSD Median 
MDI Canister Valve 8.69 5.00 4.23 7.61 8.16 6.74 1.99 29.58 7.61 
MDI Actuator 17.29 22.43 18.21 23.36 18.82 20.02 2.70 13.48 18.82 
Spacer 92.59 86.87 91.43 84.97 82.10 87.59 4.40 5.02 86.87 
ACI Throat 4.12 4.92 6.45 4.50 5.64 5.13 0.93 18.15 4.92 
ACI S-0 2.19 2.80 2.46 2.46 1.73 2.33 0.40 17.03 2.46 
ACI S-1 4.12 4.52 3.84 4.73 5.20 4.48 0.53 11.81 4.52 
ACI S-2 5.47 7.53 5.39 6.43 6.64 6.29 0.89 14.12 6.43 
ACI S-3 16.18 23.63 20.22 16.65 22.58 19.85 3.38 17.00 20.22 
ACI S-4 31.16 22.93 23.53 33.11 28.92 27.93 4.55 16.28 28.92 
ACI S-5 14.62 16.73 20.07 16.39 18.84 17.33 2.14 12.36 16.73 
ACI S-6 6.07 6.13 3.73 5.02 4.23 5.04 1.08 21.34 5.02 
ACI S-7 2.10 2.27 1.50 1.71 1.89 1.89 0.31 16.17 1.89 
ACI Filter 1.76 1.89 2.36 2.13 1.73 1.97 0.27 13.53 1.89 
Total Recovery (µg) 206.35 207.66 203.41 209.06 206.48 206.59 2.09 1.01 206.48 
% Recovery
a
 103.18 103.83 101.71 104.53 103.24 103.30 1.04 1.01 103.24 
Mass Balance
b
 (µg) 197.67 202.67 199.18 201.46 198.32 199.86 2.13 1.06 199.18 
% Recovery  98.83 101.33 99.59 100.73 99.16 99.93 1.06 1.06 99.59 
a = % Recovery calculated with respect to Nominal Dose (ND), i.e., two actuations of 100 µg per puff 
b = Mass Balance = Ex-Canister Valve recovery. Recovery calculated with respect to Nominal Dose 
(ND) excluding deposition on Canister Valve but including deposition on Actuator (mouth piece). 
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Appendix 6.3.4.1: Ventolin Evohaler+Volumatic Part 1 Study (without charcoal blockade) 
Salbutamol urinary excretion of individual healthy volunteers Dose retained in MDI device components and spacer 
TDD-TRD 
Subj USAL0.5 USAL24
a
 USAL24Pre USAL24Post USALMET Canister Actuator SP TED TDD TDD %ND 
1 20.0 104.5 54.7 95.7 40.9 4.1 19.2 67.8 180.8 113.0 56.5 8.5 
2 4.1 98.8 61.7 92.7 31.0 4.3 19.4 71.7 180.6 108.9 54.4 10.1 
3 25.7 107.4 77.0 92.6 15.6 4.7 19.1 67.7 180.9 113.2 56.6 5.7 
4 4.8 112.5 65.4 100.7 35.2 6.0 16.4 65.9 183.6 117.7 58.8 5.2 
5 24.7 74.8 45.2 64.4 19.2 5.8 24.4 91.8 175.6 83.8 41.9 9.0 
6 10.4 91.4 58.8 75.5 16.7 5.0 25.7 77.7 174.3 96.6 48.3 5.2 
7 26.4 93.5 68.8 86.0 17.3 5.4 22.3 77.3 177.7 100.4 50.2 6.9 
8 19.3 82.4 60.8 76.9 16.1 7.0 25.3 85.5 174.7 89.2 44.6 6.8 
9 24.9 102.4 81.9 96.8 14.9 3.9 22.0 68.0 178.0 110.1 55.0 7.7 
10 12.1 80.5 44.9 61.0 16.2 4.5 23.4 88.0 176.6 88.6 44.3 8.1 
11 10.5 93.8 60.6 83.4 22.7 5.7 23.8 75.2 176.2 101.0 50.5 7.3 
12 20.9 114.8 79.9 95.2 15.3 3.9 17.7 62.7 182.3 119.6 59.8 4.8 
13 8.9 108.8 57.1 88.0 30.9 3.9 16.5 69.6 183.5 113.9 57.0 5.1 
Mean 16.36 97.35 62.84 85.29 22.45 4.94 21.17 74.52 178.83 104.30 52.15 6.95 
SD 8.18 12.67 11.76 12.54 8.93 0.97 3.28 9.13 3.28 11.89 5.94 1.69 
RSD 49.99 13.01 18.71 14.71 39.75 19.60 15.49 12.25 1.83 11.40 11.40 24.29 
a 
TRD 
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Appendix 6.3.4.2. Ventolin Evohaler+AeroChamber Plus Part 1 Study (without charcoal blockade) 
Salbutamol urinary excretion of individual healthy volunteers Dose retained in MDI device components and spacer 
TDD-TRD 
Subj USAL0.5 USAL24
a
 USAL24Pre USAL24Post USALMET Canister Actuator SP TED TDD TDD %ND 
1 23.9 104.4 64.8 80.5 15.6 4.6 17.1 75.4 182.9 107.5 53.8 3.1 
2 5.0 101.5 75.1 95.8 20.7 4.5 17.2 76.4 182.8 106.5 53.2 5.0 
3 15.6 86.5 48.7 65.6 16.9 5.0 21.1 88.5 178.9 90.4 45.2 3.9 
4 5.1 83.8 71.7 80.9 9.2 6.6 25.2 86.0 174.8 88.7 44.4 5.0 
5 22.5 105.2 69.2 82.8 13.5 4.5 19.6 71.7 180.4 108.7 54.4 3.5 
6 7.4 30.7 17.3 27.3 10.0 6.8 28.6 128.9 171.4 42.5 21.3 11.8 
7 24.0 84.5 65.8 71.5 5.7 4.2 20.5 91.5 179.5 87.9 44.0 3.4 
8 17.5 119.2 82.4 100.6 18.2 4.2 13.2 64.5 186.8 122.3 61.2 3.2 
9 14.1 78.6 52.3 68.2 15.9 5.5 19.9 97.7 180.1 82.5 41.2 3.8 
10 9.2 115.5 75.2 97.4 22.2 4.6 14.2 67.0 185.8 118.8 59.4 3.3 
11 14.3 74.9 44.9 60.7 15.7 6.2 23.9 95.8 176.1 80.3 40.2 5.5 
12 25.2 47.4 27.1 40.9 13.8 4.4 28.5 119.9 171.5 51.6 25.8 4.2 
13 8.8 67.7 47.9 62.7 14.8 4.4 25.8 100.9 174.2 73.3 36.6 5.6 
Mean 14.82 84.60 57.10 71.90 14.80 5.05 21.14 89.54 178.86 89.31 44.66 4.72 
SD 7.39 25.77 19.57 21.48 4.54 0.92 5.03 19.48 5.03 24.09 12.04 2.31 
RSD 49.85 30.46 34.28 29.88 30.66 18.29 23.77 21.76 2.81 26.97 26.97 48.98 
a 
TRD 
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Appendix 6.3.4.3: Ventolin Evohaler+Able spacer Part 1 Study (without charcoal blockade) 
Salbutamol urinary excretion of individual healthy volunteers Dose retained in MDI device components and spacer 
TDD-TRD 
Subj USAL0.5 USAL24
a
 USAL24Pre USAL24Post USALMET Canister Actuator SP TED TDD TDD %ND 
1 8.4 72.4 46.0 64.1 18.1 5.9 15.8 100.8 184.2 83.4 41.7 11.0 
2 13.3 81.7 54.0 68.4 14.4 5.2 21.3 89.8 178.7 88.9 44.5 7.2 
3 15.8 98.7 64.2 82.8 18.7 5.1 16.3 80.5 183.7 103.2 51.6 4.5 
4 6.2 63.4 42.2 57.2 15.0 4.5 21.9 107.4 178.1 70.6 35.3 7.2 
5 21.4 89.9 58.1 68.5 10.4 5.1 16.6 87.8 183.4 95.6 47.8 5.7 
6 6.3 53.6 44.1 47.3 3.2 5.9 25.5 110.5 174.5 64.0 32.0 10.4 
7 14.9 84.5 53.3 69.5 16.2 5.1 17.4 92.4 182.6 90.2 45.1 5.7 
8 20.4 123.2 86.6 102.8 16.2 3.5 13.7 58.5 186.3 127.8 63.9 4.7 
9 18.5 102.9 72.1 84.4 12.3 5.1 18.4 73.5 181.6 108.1 54.1 5.2 
10 12.0 82.3 65.5 70.3 4.8 6.3 21.2 92.3 178.8 86.5 43.2 4.2 
11 17.4 97.4 66.7 80.0 13.3 6.5 20.6 77.8 179.4 101.6 50.8 4.1 
12 21.5 127.2 92.4 105.7 13.3 4.7 16.3 52.2 183.7 131.4 65.7 4.2 
13 11.5 89.0 59.7 77.5 17.8 5.5 12.3 92.9 187.7 94.8 47.4 5.8 
Mean 14.43 89.70 61.91 75.27 13.36 5.25 18.26 85.88 181.74 95.86 47.93 6.16 
SD 5.39 20.98 15.27 16.42 4.79 0.78 3.68 17.26 3.68 19.36 9.68 2.28 
RSD 37.36 23.39 24.67 21.81 35.84 14.88 20.14 20.10 2.02 20.19 20.19 37.01 
a 
TRD 
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Appendix 6.3.4.4: Ventolin Evohaler+Volumatic Part 2 Study (with charcoal blockade) 
Salbutamol urinary excretion of individual healthy volunteers Dose retained in MDI device components and spacer 
TDD-TRD 
Subj USAL0.5 USAL24
a
 USAL24Pre USAL24Post USALMET Canister Actuator SP TED TDD TDD %ND 
1 8.8 64.5 35.5 55.7 20.2 5.4 18.8 71.1 181.2 110.1 55.0 45.5 
2 6.1 49.1 29.6 43.0 13.4 4.7 22.0 73.2 178.0 104.9 52.4 55.8 
3 17.9 71.6 42.5 53.8 11.2 4.9 19.8 69.5 180.2 110.7 55.4 39.1 
4 11.8 55.9 26.3 44.1 17.8 5.3 24.5 76.9 175.5 98.6 49.3 42.7 
5 19.4 84.1 50.1 64.6 14.5 4.7 24.0 71.2 176.0 104.8 52.4 20.8 
6 15.9 58.4 25.8 42.4 16.7 5.3 23.1 79.1 176.9 97.8 48.9 39.4 
7 17.5 87.3 51.1 69.8 18.8 4.9 20.7 69.8 179.3 109.5 54.8 22.2 
8 19.6 94.7 57.8 75.1 17.3 5.2 22.1 68.8 177.9 109.2 54.6 14.5 
9 15.6 83.7 38.0 68.2 30.2 4.8 23.6 70.2 176.4 106.1 53.1 22.4 
10 9.4 54.0 36.7 44.6 8.0 5.8 25.2 77.3 174.8 97.5 48.8 43.5 
11 10.4 50.4 31.3 40.1 8.8 6.3 24.1 75.7 175.9 100.1 50.1 49.7 
12 19.6 69.2 36.1 49.6 13.5 4.7 22.9 73.6 177.1 103.5 51.7 34.3 
13 20.8 73.1 46.4 52.3 5.9 4.5 25.1 76.3 174.9 98.6 49.3 25.4 
Mean 14.83 68.93 39.01 54.10 15.09 5.11 22.76 73.29 177.24 103.96 51.98 35.03 
SD 4.92 15.09 9.99 11.80 6.31 0.51 2.02 3.45 2.02 4.99 2.50 12.79 
RSD 33.21 21.89 25.61 21.81 41.83 9.88 8.88 4.71 1.14 4.80 4.80 36.52 
a 
TRD 
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Appendix 6.3.4.5: Ventolin Evohaler+AeroChamber Plus Part 2 Study (with charcoal blockade) 
Salbutamol urinary excretion of individual healthy volunteers Dose retained in MDI device components and spacer 
TDD-TRD 
Subj USAL0.5 USAL24
a
 USAL24Pre USAL24Post USALMET Canister Actuator SP TED TDD TDD %ND 
1 6.5 43.6 25.4 37.1 11.6 4.2 22.3 96.4 177.7 81.2 40.6 37.7 
2 5.7 53.5 31.6 47.8 16.2 4.8 23.2 92.5 176.8 84.3 42.1 30.8 
3 20.9 73.4 39.3 52.6 13.2 4.2 23.3 88.0 176.7 88.7 44.4 15.3 
4 6.9 36.6 17.7 29.7 11.9 5.9 25.8 98.2 174.2 76.0 38.0 39.5 
5 10.7 48.1 32.2 37.4 5.2 5.1 22.1 92.3 177.9 85.6 42.8 37.5 
6 8.4 49.6 35.8 41.2 5.4 5.4 23.4 93.1 176.6 83.5 41.7 33.9 
7 21.0 81.6 50.7 60.6 9.9 5.5 23.3 83.7 176.7 92.9 46.5 11.3 
8 18.6 78.2 45.0 59.7 14.6 5.5 22.4 86.1 177.6 91.5 45.8 13.3 
9 19.4 87.1 46.8 67.6 20.9 4.2 20.1 82.5 179.9 97.3 48.7 10.3 
10 18.1 75.7 49.6 57.6 8.0 4.3 21.3 84.8 178.7 93.9 47.0 18.2 
11 24.9 90.3 54.7 65.5 10.8 5.5 19.1 80.5 180.9 100.4 50.2 10.1 
12 9.5 65.0 45.0 55.4 10.4 4.9 21.1 93.3 178.9 85.6 42.8 20.6 
13 9.0 57.7 41.6 48.7 7.1 5.0 23.7 95.7 176.3 80.6 40.3 22.9 
Mean 13.81 64.65 39.65 50.83 11.18 4.96 22.40 89.78 177.60 87.82 43.91 23.17 
SD 6.72 17.64 10.71 11.78 4.42 0.60 1.71 5.81 1.71 7.09 3.54 11.26 
RSD 48.69 27.29 27.02 23.17 39.52 12.02 7.64 6.47 0.96 8.07 8.07 48.59 
a 
TRD 
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Appendix 6.3.4.6: Ventolin Evohaler+Able spacer Part 2 Study (with charcoal blockade) 
Salbutamol urinary excretion of individual healthy volunteers Dose retained in MDI device components and spacer 
TDD-TRD 
Subj USAL0.5 USAL24
a
 USAL24Pre USAL24Post USALMET Canister Actuator SP TED TDD TDD %ND 
1 5.4 42.0 30.9 36.7 5.8 5.4 21.3 90.1 178.7 88.6 44.3 46.5 
2 6.5 38.7 23.2 32.2 9.0 6.5 20.3 104.2 179.7 75.6 37.8 36.8 
3 18.8 86.9 49.0 68.1 19.2 4.1 17.4 74.1 182.6 108.5 54.2 21.6 
4 15.3 66.2 42.4 50.8 8.4 5.1 22.2 90.1 177.8 87.7 43.8 21.5 
5 7.7 39.3 24.0 31.6 7.6 5.8 21.3 89.7 178.7 89.0 44.5 49.7 
6 16.4 74.3 42.6 57.9 15.3 4.7 18.8 82.1 181.2 99.1 49.5 24.8 
7 11.4 50.8 26.7 39.3 12.6 6.3 19.4 93.1 180.6 87.5 43.7 36.7 
8 23.8 93.5 51.9 69.8 17.9 4.2 17.6 76.2 182.4 106.2 53.1 12.7 
9 19.2 77.8 34.8 58.6 23.8 6.2 19.1 78.7 180.9 102.2 51.1 24.4 
10 16.3 63.3 38.4 47.0 8.5 5.3 19.5 86.5 180.5 94.0 47.0 30.7 
11 7.7 33.5 13.0 25.8 12.8 5.6 23.1 98.3 176.9 78.6 39.3 45.1 
12 15.4 63.3 40.4 47.9 7.5 5.4 18.7 81.7 181.3 99.6 49.8 36.3 
13 18.9 76.0 37.9 57.1 19.2 6.3 19.1 79.5 180.9 101.4 50.7 25.4 
Mean 14.06 61.97 35.01 47.91 12.89 5.45 19.83 86.49 180.17 93.68 46.84 31.71 
SD 5.78 19.63 11.08 14.12 5.70 0.77 1.72 8.87 1.72 10.21 5.10 11.20 
RSD 41.11 31.68 31.64 29.48 44.23 14.10 8.68 10.25 0.95 10.90 10.90 35.33 
a 
TRD 
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Appendix 7.2.6.1: APSD of two puffs (200 µg) of Airomir + AeroChamber Plus obtained with ACI at 28.3 ± 1.5 L/min 
Identity Run 1 Run 2 Run 3 Run 4 Run 5 Mean SD RSD Median 
MDI Canister Valve 14.28 13.48 12.54 15.85 15.40 14.31 1.36 9.49 14.28 
MDI Actuator 21.32 18.73 20.40 19.35 18.88 19.74 1.10 5.58 19.35 
Spacer 67.50 72.30 70.25 69.65 74.40 70.82 2.63 3.72 70.25 
ACI Throat 5.24 4.14 4.44 5.11 5.33 4.85 0.53 10.88 5.11 
ACI S-0 2.20 1.80 2.15 2.29 1.94 2.08 0.20 9.66 2.15 
ACI S-1 1.40 1.77 1.96 1.81 1.25 1.64 0.30 18.13 1.77 
ACI S-2 5.19 6.68 7.24 7.13 6.28 6.50 0.83 12.74 6.68 
ACI S-3 18.46 22.23 16.41 19.80 21.48 19.68 2.34 11.89 19.80 
ACI S-4 42.01 36.69 37.05 43.90 40.52 40.04 3.13 7.81 40.52 
ACI S-5 21.54 26.40 26.32 23.67 18.84 23.36 3.23 13.84 23.67 
ACI S-6 7.61 9.24 5.99 6.15 8.30 7.46 1.40 18.71 7.61 
ACI S-7 2.62 1.89 2.27 2.13 1.96 2.17 0.29 13.28 2.13 
ACI Filter 1.71 2.25 2.43 1.82 1.86 2.01 0.31 15.37 1.86 
Total Recovery (µg) 211.08 217.60 209.46 218.68 216.45 214.66 4.12 1.92 216.45 
% Recovery
a
 105.54 108.80 104.73 109.34 108.23 107.33 2.06 1.92 108.23 
Mass Balance
b
 (µg) 196.80 204.12 196.92 202.83 201.05 200.34 3.36 1.68 201.05 
% Recovery  98.40 102.06 98.46 101.42 100.53 100.17 1.68 1.68 100.53 
a = % Recovery calculated with respect to Nominal Dose (ND), i.e., two actuations of 100 µg per puff 
b = Mass Balance = Ex-Canister Valve recovery. Recovery calculated with respect to Nominal Dose 
(ND) excluding deposition on Canister Valve but including deposition on Actuator (mouth piece). 
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Appendix 7.3.4.1: Airomir+AeroChamber Plus Part 1 Study (without charcoal blockade) 
Salbutamol urinary excretion of individual healthy volunteers Dose retained in MDI device components and spacer 
TDD-TRD 
Subj USAL0.5 USAL24
a
 USAL24Pre USAL24Post USALMET Canister Actuator SP TED TDD TDD %ND 
1 8.3 70.3 48.9 62.1 13.2 16.0 21.7 78.2 178.3 100.1 50.0 29.8 
2 9.6 86.5 52.5 76.9 24.4 17.2 20.6 76.5 179.4 103.0 51.5 16.5 
3 13.5 79.3 58.0 65.7 7.8 14.3 19.1 81.1 180.9 99.8 49.9 20.5 
4 17.2 94.5 64.1 77.3 13.2 15.7 15.7 76.0 184.3 108.3 54.1 13.8 
5 21.2 97.7 69.6 76.5 7.0 13.0 15.3 71.4 184.7 113.4 56.7 15.6 
6 20.2 91.6 62.0 71.4 9.4 20.0 19.9 78.2 180.1 101.9 50.9 10.3 
7 14.4 77.1 45.7 62.8 17.1 17.3 20.9 79.1 179.1 100.0 50.0 22.9 
8 15.7 82.0 57.6 66.3 8.7 14.5 18.4 82.4 181.6 99.1 49.6 17.1 
9 17.6 83.1 56.1 65.5 9.4 19.9 19.6 84.3 180.4 96.2 48.1 13.1 
10 12.8 80.6 55.0 67.7 12.7 12.7 22.3 86.0 177.7 91.7 45.9 11.2 
11 20.9 92.4 63.9 71.5 7.6 17.6 19.0 75.3 181.0 105.8 52.9 13.4 
12 12.2 76.7 52.7 64.5 11.8 12.3 21.8 82.4 178.2 95.8 47.9 19.2 
13 12.6 79.4 54.3 66.8 12.5 19.9 22.8 84.6 177.2 92.6 46.3 13.2 
Mean 15.09 83.93 56.94 68.85 11.90 16.17 19.77 79.65 180.23 100.58 50.29 16.65 
SD 4.16 8.07 6.62 5.37 4.74 2.75 2.32 4.28 2.32 6.09 3.04 5.39 
RSD 27.60 9.62 11.63 7.80 39.83 17.00 11.76 5.38 1.29 6.05 6.05 32.35 
a 
TRD 
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Appendix 7.3.4.2: Airomir+AeroChamber Plus Part 2 Study (with charcoal blockade) 
Salbutamol urinary excretion of individual healthy volunteers Dose retained in MDI device components and spacer 
TDD-TRD 
Subj USAL0.5 USAL24
a
 USAL24Pre USAL24Post USALMET Canister Actuator SP TED TDD TDD %ND 
1 13.2 61.2 37.0 48.1 11.0 13.7 18.7 72.4 181.3 109.0 54.5 47.7 
2 8.5 60.6 31.1 52.1 21.1 13.1 19.4 77.0 180.6 103.5 51.8 42.9 
3 11.9 52.7 33.6 40.8 7.2 20.1 17.3 80.0 182.7 102.7 51.4 50.0 
4 14.8 71.2 45.1 56.4 11.3 17.0 21.5 77.0 178.5 101.4 50.7 30.2 
5 13.7 63.4 43.6 49.7 6.2 15.4 18.9 80.8 181.1 100.3 50.1 26.8 
6 9.8 45.3 27.5 35.5 8.1 19.6 17.7 73.6 182.3 108.7 54.4 63.4 
7 21.3 72.6 43.5 51.4 7.9 17.2 22.7 77.9 177.3 99.4 49.7 16.8 
8 15.5 71.4 47.9 55.9 8.0 15.0 20.4 83.7 179.6 96.0 48.0 24.6 
9 16.1 71.6 46.7 55.5 8.8 12.8 16.8 77.5 183.2 105.7 52.9 34.1 
10 13.6 53.6 33.4 40.0 6.6 17.6 20.3 82.0 179.7 97.7 48.9 44.2 
11 9.6 41.7 27.5 32.1 4.6 17.8 24.0 78.9 176.0 97.1 48.5 55.4 
12 16.6 67.3 45.9 50.8 4.8 15.2 20.7 81.1 179.3 98.1 49.1 30.8 
13 21.2 76.7 47.5 55.6 8.1 14.5 19.7 84.0 180.3 96.3 48.2 11.6 
Mean 14.28 62.28 39.25 47.99 8.74 16.08 19.86 78.91 180.14 101.23 50.62 36.80 
SD 3.98 11.09 7.80 8.21 4.20 2.35 2.10 3.52 2.10 4.46 2.23 15.30 
RSD 27.85 17.80 19.88 17.11 47.98 14.64 10.55 4.46 1.16 4.40 4.40 41.57 
a 
TRD 
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Appendix 8.2.6.1: APSD of two puffs (200 µg) of Salamol + Volumatic obtained with ACI at 28.3 ± 1.5 L/min 
Identity Run 1 Run 2 Run 3 Run 4 Run 5 Mean SD RSD Median 
MDI Canister Valve 8.76 7.51 8.24 7.00 5.84 7.47 1.13 15.16 7.51 
MDI Actuator 22.85 21.51 18.87 18.16 18.29 19.94 2.12 10.63 18.87 
Spacer 75.62 70.46 84.93 81.79 75.64 77.69 5.70 7.34 75.64 
ACI Throat 7.99 4.79 5.75 5.10 5.73 5.87 1.25 21.33 5.73 
ACI S-0 2.40 2.55 2.56 1.96 2.31 2.36 0.24 10.39 2.40 
ACI S-1 4.76 4.46 4.25 3.88 5.26 4.52 0.52 11.55 4.46 
ACI S-2 6.08 7.98 7.25 6.01 6.37 6.74 0.85 12.62 6.37 
ACI S-3 21.30 23.79 23.53 23.26 17.61 21.90 2.59 11.83 23.26 
ACI S-4 33.88 34.09 28.81 31.98 34.71 32.69 2.40 7.33 33.88 
ACI S-5 22.05 19.14 18.00 18.55 20.20 19.59 1.60 8.17 19.14 
ACI S-6 4.43 7.32 3.45 4.09 5.00 4.86 1.49 30.61 4.43 
ACI S-7 2.16 2.77 1.63 1.93 2.17 2.13 0.42 19.63 2.16 
ACI Filter 2.35 2.34 2.35 2.54 2.37 2.39 0.08 3.55 2.35 
Total Recovery (µg) 214.64 208.70 209.62 206.24 201.50 208.14 4.81 2.31 208.70 
% Recovery
a
 107.32 104.35 104.81 103.12 100.75 104.07 2.40 2.31 104.35 
Mass Balance
b
 (µg) 205.88 201.19 201.38 199.24 195.66 200.67 3.71 1.85 201.19 
% Recovery  102.94 100.60 100.69 99.62 97.83 100.33 1.85 1.85 100.60 
a = % Recovery calculated with respect to Nominal Dose (ND), i.e., two actuations of 100 µg per puff 
b = Mass Balance = Ex-Canister Valve recovery. Recovery calculated with respect to Nominal Dose 
(ND) excluding deposition on Canister Valve but including deposition on Actuator (mouth piece). 
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Appendix 8.2.6.2: APSD of two puffs (200 µg) of Salamol + Aerochamber Plus obtained with ACI at 28.3 ± 1.5 L/min 
Identity Run 1 Run 2 Run 3 Run 4 Run 5 Mean SD RSD Median 
MDI Canister Valve 11.33 13.57 11.92 14.69 11.67 12.64 1.44 11.36 11.92 
MDI Actuator 19.62 20.96 21.88 24.29 19.22 21.19 2.03 9.58 20.96 
Spacer 88.98 84.69 92.80 76.10 79.10 84.34 6.87 8.14 84.69 
ACI Throat 3.58 4.63 4.79 4.47 4.42 4.38 0.47 10.75 4.47 
ACI S-0 0.84 1.44 0.93 1.13 1.17 1.10 0.23 21.12 1.13 
ACI S-1 1.49 1.49 1.39 1.02 1.68 1.41 0.24 17.32 1.49 
ACI S-2 2.24 2.21 2.59 3.42 2.91 2.67 0.51 18.93 2.59 
ACI S-3 19.16 14.79 17.21 26.10 25.57 20.56 5.06 24.59 19.16 
ACI S-4 30.48 34.71 32.00 36.64 37.15 34.19 2.90 8.47 34.71 
ACI S-5 28.52 24.46 20.60 18.61 15.46 21.53 5.09 23.65 20.60 
ACI S-6 3.86 4.01 4.87 5.00 7.64 5.08 1.52 29.93 4.87 
ACI S-7 1.68 2.17 1.77 1.83 2.33 1.96 0.28 14.37 1.83 
ACI Filter 2.22 1.86 2.31 2.57 2.70 2.33 0.33 13.95 2.31 
Total Recovery (µg) 214.00 210.99 215.06 215.86 211.01 213.38 2.27 1.07 214.00 
% Recovery
a
 107.00 105.49 107.53 107.93 105.51 106.69 1.14 1.07 107.00 
Mass Balance
b
 (µg) 202.67 197.42 203.14 201.17 199.34 200.75 2.38 1.18 201.17 
% Recovery  101.33 98.71 101.57 100.58 99.67 100.37 1.19 1.18 100.58 
a = % Recovery calculated with respect to Nominal Dose (ND), i.e., two actuations of 100 µg per puff 
b = Mass Balance = Ex-Canister Valve recovery. Recovery calculated with respect to Nominal Dose 
(ND) excluding deposition on Canister Valve but including deposition on Actuator (mouth piece). 
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Appendix 8.3.4.1: Salamol+Volumatic Part 1 Study (without charcoal blockade) 
Salbutamol urinary excretion of individual healthy volunteers Dose retained in MDI device components and spacer 
TDD-TRD 
Subj USAL0.5 USAL24
a
 USAL24Pre USAL24Post USALMET Canister Actuator SP TED TDD TDD %ND 
1 15.5 72.7 52.3 57.1 4.9 8.2 17.4 72.5 182.6 110.1 55.1 37.4 
2 17.3 94.7 72.0 77.3 5.3 9.3 19.6 64.2 180.4 116.2 58.1 21.5 
3 26.5 75.4 42.9 48.9 6.0 8.9 18.7 75.3 181.3 106.0 53.0 30.6 
4 16.7 81.0 62.0 64.3 2.3 10.8 22.7 80.1 177.3 97.2 48.6 16.2 
5 24.1 98.0 58.1 73.9 15.9 6.7 14.8 63.9 185.2 121.3 60.6 23.2 
6 26.5 88.3 57.4 61.8 4.4 9.8 21.8 68.5 178.2 109.7 54.8 21.4 
7 16.0 86.4 66.0 70.4 4.4 10.1 21.3 78.1 178.7 100.6 50.3 14.2 
8 12.1 92.2 67.4 80.1 12.6 9.3 19.5 66.0 180.5 114.5 57.2 22.3 
9 27.5 83.3 52.2 55.9 3.6 11.2 23.6 77.3 176.4 99.2 49.6 15.8 
10 12.8 69.9 42.3 57.2 14.9 11.4 24.1 76.2 175.9 99.7 49.8 29.8 
11 14.9 79.0 46.6 64.2 17.5 6.7 15.9 80.2 184.1 103.9 51.9 24.8 
12 14.4 87.7 61.5 73.3 11.8 9.9 20.7 69.2 179.3 110.0 55.0 22.3 
13 28.8 104.0 67.1 75.2 8.1 8.2 18.2 67.6 181.8 114.2 57.1 10.2 
Mean 19.48 85.59 57.52 66.12 8.60 9.26 19.87 72.25 180.13 107.88 53.94 22.29 
SD 6.16 10.07 9.69 9.67 5.24 1.52 2.85 5.97 2.85 7.49 3.74 7.39 
RSD 31.64 11.76 16.85 14.62 60.92 16.42 14.33 8.26 1.58 6.94 6.94 33.15 
a 
TRD 
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Appendix 8.3.4.2: Salamol+AeroChamber Plus Part 1 Study (without charcoal blockade) 
Salbutamol urinary excretion of individual healthy volunteers Dose retained in MDI device components and spacer 
TDD-TRD 
Subj USAL0.5 USAL24
a
 USAL24Pre USAL24Post USALMET Canister Actuator SP TED TDD TDD %ND 
1 17.9 93.1 67.1 75.3 8.2 9.1 15.5 78.7 184.5 105.8 52.9 12.6 
2 10.4 69.1 45.4 58.7 13.2 12.8 21.9 94.6 178.1 83.5 41.7 14.4 
3 27.2 105.1 68.8 77.9 9.2 8.7 14.8 72.3 185.2 112.9 56.4 7.7 
4 12.5 80.4 52.7 67.9 15.2 12.4 21.3 88.1 178.7 90.6 45.3 10.2 
5 11.4 74.1 39.7 62.7 22.9 10.2 18.3 92.8 181.7 88.9 44.5 14.8 
6 18.4 84.9 62.9 66.6 3.6 9.8 16.2 85.8 183.8 98.0 49.0 13.1 
7 25.7 103.5 66.2 77.8 11.6 9.3 15.4 71.1 184.6 113.4 56.7 10.0 
8 26.5 108.0 72.7 81.5 8.8 9.4 15.5 67.0 184.5 117.5 58.7 9.5 
9 11.7 71.1 42.5 59.4 16.9 13.1 25.4 86.8 174.6 87.9 43.9 16.8 
10 20.6 95.7 69.6 75.1 5.5 11.0 21.4 68.7 178.6 109.9 54.9 14.1 
11 18.5 84.4 56.6 65.9 9.3 10.9 19.8 86.2 180.2 94.0 47.0 9.6 
12 13.9 77.4 52.6 63.6 11.0 9.5 17.2 90.2 182.8 92.5 46.3 15.1 
13 14.1 77.6 49.4 63.5 14.1 9.5 16.2 89.2 183.8 94.6 47.3 17.1 
Mean 17.59 86.50 57.40 68.91 11.50 10.44 18.38 82.43 181.62 99.19 49.60 12.70 
SD 5.94 13.32 11.19 7.67 5.08 1.49 3.28 9.61 3.28 11.29 5.64 3.02 
RSD 33.76 15.39 19.50 11.14 44.20 14.26 17.84 11.66 1.81 11.38 11.38 23.78 
a 
TRD 
 
  
  
3
1
3
 
 
 
 
 
Appendix 8.3.4.3: Salamol+Volumatic Part 2 Study (with charcoal blockade) 
Salbutamol urinary excretion of individual healthy volunteers Dose retained in MDI device components and spacer 
TDD-TRD 
Subj USAL0.5 USAL24
a
 USAL24Pre USAL24Post USALMET Canister Actuator SP TED TDD TDD %ND 
1 20.2 67.5 42.7 47.3 4.7 9.9 20.0 69.3 180.0 110.7 55.3 87.5 
2 23.3 83.3 52.1 60.0 7.9 9.7 19.5 72.6 180.5 107.9 53.9 102.8 
3 15.1 60.4 37.7 45.4 7.6 8.5 17.9 81.1 182.1 101.0 50.5 78.4 
4 21.0 78.8 51.3 57.8 6.5 9.8 19.4 77.2 180.6 103.4 51.7 98.1 
5 12.9 56.4 33.9 43.5 9.6 8.7 17.3 82.3 182.7 100.5 50.2 73.7 
6 15.7 63.5 40.6 47.9 7.2 10.2 20.2 71.9 179.8 107.9 53.9 83.7 
7 16.2 62.5 37.7 46.3 8.7 10.3 20.5 75.2 179.5 104.4 52.2 83.0 
8 18.5 76.6 44.4 58.1 13.7 9.2 17.9 74.1 182.1 107.9 54.0 94.5 
9 16.9 65.3 36.6 48.3 11.7 9.6 18.6 83.2 181.4 98.2 49.1 83.9 
10 16.3 62.9 38.7 46.5 7.9 10.4 20.2 72.9 179.8 106.9 53.4 83.1 
11 14.5 49.0 26.2 34.4 8.2 9.3 19.1 86.2 180.9 94.7 47.3 68.0 
12 20.7 73.0 43.2 52.4 9.2 11.3 20.7 64.2 179.3 115.1 57.5 93.8 
13 16.6 60.4 34.7 43.8 9.1 11.6 21.3 69.5 178.7 109.3 54.6 81.7 
Mean 17.54 66.12 39.98 48.59 8.61 9.89 19.43 75.35 180.57 105.22 52.61 85.56 
SD 3.00 9.58 6.99 7.01 2.25 0.91 1.21 6.35 1.21 5.57 2.78 9.75 
RSD 17.12 14.48 17.49 14.43 26.20 9.24 6.24 8.43 0.67 5.29 5.29 11.39 
a 
TRD 
 
  
  
3
1
4
 
 
 
 
 
Appendix 8.3.4.4: Salamol+AeroChamber Plus Part 2 Study (with charcoal blockade) 
Salbutamol urinary excretion of individual healthy volunteers Dose retained in MDI device components and spacer 
TDD-TRD 
Subj USAL0.5 USAL24
a
 USAL24Pre USAL24Post USALMET Canister Actuator SP TED TDD TDD %ND 
1 14.5 61.8 37.9 47.4 9.5 12.7 21.2 81.6 178.8 97.2 48.6 35.4 
2 18.4 63.6 41.0 45.1 4.2 10.7 17.8 80.2 182.2 101.9 51.0 38.4 
3 24.1 77.8 47.2 53.7 6.5 13.3 22.2 79.0 177.8 98.7 49.4 20.9 
4 15.8 64.6 32.9 48.8 15.9 10.5 17.6 85.2 182.4 97.2 48.6 32.6 
5 14.0 54.4 30.1 40.5 10.3 13.7 23.4 87.0 176.6 89.6 44.8 35.1 
6 10.1 49.5 28.3 39.3 11.0 14.4 24.6 88.3 175.4 87.2 43.6 37.7 
7 16.4 64.7 40.8 48.4 7.5 12.9 22.1 82.5 178.0 95.4 47.7 30.7 
8 25.8 81.8 47.7 56.0 8.3 9.8 16.2 83.1 183.8 100.7 50.4 18.9 
9 19.5 67.4 42.0 48.0 6.0 10.4 17.2 90.6 182.8 92.3 46.1 24.8 
10 13.8 55.5 28.2 41.8 13.5 11.7 19.2 94.1 180.8 86.7 43.3 31.1 
11 12.3 53.0 30.1 40.7 10.6 11.3 17.3 95.5 182.7 87.3 43.6 34.3 
12 11.9 47.1 31.0 35.2 4.2 13.3 24.3 86.8 175.8 89.0 44.5 41.9 
13 18.7 65.8 41.9 47.1 5.2 13.9 23.6 81.8 176.4 94.6 47.3 28.8 
Mean 16.55 62.08 36.85 45.52 8.67 12.20 20.52 85.81 179.48 93.67 46.84 31.60 
SD 4.65 10.25 7.06 5.87 3.59 1.53 3.05 5.19 3.05 5.36 2.68 6.79 
RSD 28.11 16.51 19.16 12.90 41.34 12.56 14.86 6.04 1.70 5.72 5.72 21.49 
a 
TRD 
 
 
  
 
